



Pl 1127620



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME;

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office

February 25, 2004


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/431,123

FILING DATE: December 05, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/38815

By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS



  
N. WOODSON  
Certifying Officer

PRIORITY DOCUMENT  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

12/05/02

10931 U.S. PTO

60431123 12/05/02

PTO/SB/H6 (10-01)

Approved for use through 10/31/2002. OMB 0851-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No. ET 657 238 010 US

**INVENTOR(S)**

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Roberto Leah R. Yongming	Macina Turner Sun	San Jose, CA Sunnyvale, CA Redwood City, CA

☐ Additional inventors are being named on the \_\_\_\_\_ separately numbered sheets attached hereto**TITLE OF THE INVENTION (280 characters max)****COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS****CORRESPONDENCE ADDRESS**

Direct all correspondence to:

☐ Customer Number

OR

Type Customer Number here

Place Customer Number  
Bar Code Label here

<input checked="" type="checkbox"/> Firm or Individual Name	Licata & Tyrrell				
Address	66 East Main Street				
Address					
City	Marlton	State	New Jersey	ZIP	08053
Country	USA	Telephone	(805) 810-1515	Fax	(805) 810-1454

**ENCLOSED APPLICATION PARTS (check all that apply)**

- ☒ Specification Total Number of Pages 240 ☐ CD(s), Number
- ☐ Drawing(s) Number of Sheets          ☐ Other (specify)
- ☐ Application Data Sheet. See 37 CFR 1.76

**METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT**

- ☐ Applicant claims small entity status. See 37 CFR 1.27.
- ☐ A check or money order is enclosed to cover the filing fees

FILING FEE  
AMOUNT (\$)

- ☒ The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 50-0434
- ☐ Payment by credit card. Form PTO-2038 is attached.

160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.☐ Yes, the name of the U.S. Government agency and the Government contract number are: \_\_\_\_\_Respectfully submitted,  
SIGNATUREDate: 5 December 2002

TYPED or PRINTED NAME

Nathan P. LettsREGISTRATION NO.  
(if appropriate)36,581

TELEPHONE

(650) 246-6400

Docket Number:

DEX-0360**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C., 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231

DEX - 0360


**CERTIFICATE OF EXPRESS MAILING**

"Express Mail" Label No. ET 657 238 010 US

Date of Deposit: 5 December 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R 1.10 on the date indicated above and is addressed to the "BOX PROVISIONAL", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Provision Application Transmittal Letter, with authorization to charge deposit account 50-0434 \$160.00 for filing fee (2 copies);
- 2) Application consisting of 240 pages including; 234 pages of Specification, 5 pages of Claims, and 1 page of Abstract; and
- 3) Return Post Card.



NATHAN P. LETTS  
Registration No. 36,581

DEX-0360

PATENT

**COMPOSITIONS AND METHODS  
RELATING TO BREAST SPECIFIC GENES AND PROTEINS**

**FIELD OF THE INVENTION**

5       The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, 10 polypeptides, antibodies, post translational modifications (PTMs), variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast, identifying breast tissue and monitoring and identifying and/or designing agonists and antagonists of polypeptides of 15 the invention. The uses also include gene therapy, therapeutic molecules including but limited to antibodies or antisense molecules, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.

**BACKGROUND OF THE INVENTION**

20       Breast cancer, also referred to as mammary tumors, is the second most common cancer among women, accounting for a third of the cancers diagnosed in the United States. One in nine women will develop breast cancer in her lifetime and about 192,000 new cases of breast cancer are diagnosed annually with about 42,000 deaths. Bevers, *Primary Prevention of Breast Cancer*, in Breast Cancer, 20-54 (Kelly K Hunt et al., ed., 2001); Kochanek et al., 49 Nat'l. Vital Statistics Reports 1, 14 (2001). Breast cancer is extremely 25 rare in women younger than 20 and is very rare in women under 30. The incidence of breast cancer rises with age and becomes significant by age 50. White Non-Hispanic women have the highest incidence rate for breast cancer and Korean women have the lowest. Increased prevalence of the genetic mutations BRCA1 and BRCA2 that promote breast and other cancers are found in Ashkenazi Jews. African American women have the 30 highest mortality rate for breast cancer among these same groups (31 per 100,000), while Chinese women have the lowest at 11 per 100,000. Although men can get breast cancer, this is extremely rare. (American Cancer Society Website: <http://www.cancer.org>). With

DEX-0360

2

PATENT

the exception of those cases with associated genetic factors, precise causes of breast cancer are not known.

In the treatment of breast cancer, there is considerable emphasis on detection and risk assessment because early and accurate staging of breast cancer has a significant impact on survival. For example, breast cancer detected at an early stage (stage T0, discussed below) has a five-year survival rate of 92%. Conversely, if the cancer is not detected until a late stage (i.e., stage T4 (IV)), the five-year survival rate is reduced to 13%. AJCC Cancer Staging Handbook pp. 164-65 (Irvin D. Fleming et al. eds., 5<sup>th</sup> ed. 1998). Some detection techniques, such as mammography and biopsy, involve increased discomfort, expense, and/or radiation, and are only prescribed only to patients with an increased risk of breast cancer.

Current methods for predicting or detecting breast cancer risk are not optimal. One method for predicting the relative risk of breast cancer is by examining a patient's risk factors and pursuing aggressive diagnostic and treatment regimens for high risk patients. A patient's risk of breast cancer has been positively associated with increasing age, nulliparity, family history of breast cancer, personal history of breast cancer, early menarche, late menopause, late age of first full term pregnancy, prior proliferative breast disease, irradiation of the breast at an early age and a personal history of malignancy. Lifestyle factors such as fat consumption, alcohol consumption, education, and socioeconomic status have also been associated with an increased incidence of breast cancer although a direct cause and effect relationship has not been established. While these risk factors are statistically significant, their weak association with breast cancer limited their usefulness. Most women who develop breast cancer have none of the risk factors listed above, other than the risk that comes with growing older. NIH Publication No. 00-1556 (2000).

Current screening methods for detecting cancer, such as breast self exam, ultrasound, and mammography have drawbacks that reduce their effectiveness or prevent their widespread adoption. Breast self exams, while useful, are unreliable for the detection of breast cancer in the initial stages where the tumor is small and difficult to detect by palpitation. Ultrasound measurements require skilled operators at an increased expense. Mammography, while sensitive, is subject to over diagnosis in the detection of lesions that have questionable malignant potential. There is also the fear of the radiation used in

DEX-0360

3

PATENT

mammography because prior chest radiation is a factor associated with an increase incidence of breast cancer.

At this time, there are no adequate methods of breast cancer prevention. The current methods of breast cancer prevention involve prophylactic mastectomy  
5 (mastectomy performed before cancer diagnosis) and chemoprevention (chemotherapy before cancer diagnosis) which are drastic measures that limit their adoption even among women with increased risk of breast cancer. Bevers, *supra*.

A number of genetic markers have been associated with breast cancer. Examples of these markers include carcinoembryonic antigen (CEA) (Mughal et al., *JAMA* 249:1881  
10 (1983)), MUC-1 (Frische and Liu, *J. Clin. Ligand* 22:320 (2000)), HER-2/neu (Haris et al., *Proc.Am.Soc.Clin.Oncology* 15:A96 (1996)), uPA, PAI-1, LPA, LPC, RAK and BRCA (Esteve and Fritsche, *Serum and Tissue Markers for Breast Cancer*, in Breast Cancer, 286-308 (2001)). These markers have problems with limited sensitivity, low correlation, and false negatives which limit their use for initial diagnosis. For example,  
15 while the BRCA1 gene mutation is useful as an indicator of an increased risk for breast cancer, it has limited use in cancer diagnosis because only 6.2 % of breast cancers are BRCA1 positive. Malone et al., *JAMA* 279:922 (1998). See also, Mewman et al., *JAMA* 279:915 (1998) (correlation of only 3.3%).

There are four primary classifications of breast cancer varying by the site of origin  
20 and the extent of disease development.

- I. Ductal carcinoma in situ (DCIS): Malignant transformation of ductal epithelial cells that remain in their normal position. DCIS is a purely localized disease, incapable of metastasis.
- 25 II. Invasive ductal carcinoma (IDC): Malignancy of the ductal epithelial cells breaking through the basal membrane and into the supporting tissue of the breast. IDC may eventually spread elsewhere in the body.
- III. Lobular carcinoma in situ (LCIS): Malignancy arising in a single lobule of the breast that fail to extend through the lobule wall, it generally remains localized.
- 30 IV. Infiltrating lobular carcinoma (ILC): Malignancy arising in a single lobule of the breast and invading directly through the lobule wall into adjacent tissues. By virtue of its invasion beyond the lobule wall, ILC may penetrate lymphatics and blood vessels and spread to distant sites.

DEX-0360

4

PATENT

For purpose of determining prognosis and treatment, these four breast cancer types have been staged according to the size of the primary tumor (T), the involvement of lymph nodes (N), and the presence of metastasis (M). Although DCIS by definition represents localized stage I disease, the other forms of breast cancer may range from stage II to stage IV. There are additional prognostic factors that further serve to guide surgical and medical intervention. The most common ones are total number of lymph nodes involved, ER (estrogen receptor) status, Her2/neu receptor status and histologic grades.

Breast cancers are diagnosed into the appropriate stage categories recognizing that different treatments are more effective for different stages of cancer. Stage TX indicates that primary tumor cannot be assessed (i.e., tumor was removed or breast tissue was removed). Stage T0 is characterized by abnormalities such as hyperplasia but with no evidence of primary tumor. Stage Tis is characterized by carcinoma in situ, intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no tumor. Stage T1 (I) is characterized as having a tumor of 2 cm or less in the greatest dimension. Within stage T1, Tmic indicates microinvasion of 0.1 cm or less, T1a indicates a tumor of between 0.1 to 0.5 cm, T1b indicates a tumor of between 0.5 to 1 cm, and T1c indicates tumors of between 1 cm to 2 cm. Stage T2 (II) is characterized by tumors from 2 cm to 5 cm in the greatest dimension. Tumors greater than 5 cm in size are classified as stage T3 (III). Stage T4 (IV) indicates a tumor of any size with extension to the chest wall or skin. Within stage T4, T4a indicates extension of the tumor to the chest wall, T4b indicates edema or ulceration of the skin of the breast or satellite skin nodules confined to the same breast, T4c indicates a combination of T4a and T4b, and T4d indicates inflammatory carcinoma. AJCC Cancer Staging Handbook pp. 159-70 (Irvin D. Fleming et al. eds., 5<sup>th</sup> ed. 1998). In addition to standard staging, breast tumors may be classified according to their estrogen receptor and progesterone receptor protein status. Fisher et al., *Breast Cancer Research and Treatment* 7:147 (1986). Additional pathological status, such as HER2/neu status may also be useful. Thor et al., *J.Nat'l.Cancer Inst.* 90:1346 (1998); Paik et al., *J.Nat'l.Cancer Inst.* 90:1361 (1998); Hutchins et al., *Proc.Am.Soc.Clin.Oncology* 17:A2 (1998).; and Simpson et al., *J.Clin.Oncology* 18:2059 (2000).

In addition to the staging of the primary tumor, breast cancer metastasises to regional lymph nodes may be staged. Stage NX indicates that the lymph nodes cannot be assessed (e.g., previously removed). Stage N0 indicates no regional lymph node

DEX-0360

5

PATENT

metastasis. Stage N1 indicates metastasis to movable ipsilateral axillary lymph nodes. Stage N2 indicates metastasis to ipsilateral axillary lymph nodes fixed to one another or to other structures. Stage N3 indicates metastasis to ipsilateral internal mammary lymph nodes. *Id.*

- 5           Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Simpson et al., *J. Clin. Oncology* 18:2059 (2000). Generally, pathological staging of breast cancer is preferable to clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred if it were as accurate as pathological staging because it does not depend on an invasive procedure to
- 10       obtain tissue for pathological evaluation. Staging of breast cancer would be improved by detecting new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion. Progress in this field will allow more rapid and reliable method for treating breast cancer patients.

- Treatment of breast cancer is generally decided after an accurate staging of the
- 15       primary tumor. Primary treatment options include breast conserving therapy (lumpectomy, breast irradiation, and surgical staging of the axilla), and modified radical mastectomy. Additional treatments include chemotherapy, regional irradiation, and, in extreme cases, terminating estrogen production by ovarian ablation.

- Until recently, the customary treatment for all breast cancer was mastectomy.
- 20       Fonseca et al., *Annals of Internal Medicine* 127:1013 (1997). However, recent data indicate that less radical procedures may be equally effective, in terms of survival, for early stage breast cancer. Fisher et al., *J. of Clinical Oncology* 16:441 (1998). The treatment options for a patient with early stage breast cancer (i.e., stage Tis) may be breast-sparing surgery followed by localized radiation therapy at the breast. Alternatively,
- 25       mastectomy optionally coupled with radiation or breast reconstruction may be employed. These treatment methods are equally effective in the early stages of breast cancer.

- Patients with stage I and stage II breast cancer require surgery with chemotherapy and/or hormonal therapy. Surgery is of limited use in Stage III and stage IV patients. Thus, these patients are better candidates for chemotherapy and radiation therapy with
- 30       surgery limited to biopsy to permit initial staging or subsequent restaging because cancer is rarely curative at this stage of the disease. AJCC Cancer Staging Handbook 84, ¶. 164-65 (Irvin D. Fleming et al. eds., 5<sup>th</sup> ed. 1998).

DEX-0360

6

PATENT

In an effort to provide more treatment options to patients, efforts are underway to define an earlier stage of breast cancer with low recurrence which could be treated with lumpectomy without postoperative radiation treatment. While a number of attempts have been made to classify early stage breast cancer, no consensus recommendation on  
5 postoperative radiation treatment has been obtained from these studies. Page et al., *Cancer* 75:1219 (1995); Fisher et al., *Cancer* 75:1223 (1995); Silverstein et al., *Cancer* 77:2267 (1996).

As discussed above, each of the methods for diagnosing and staging breast cancer is limited by the technology employed. Accordingly, there is need for sensitive molecular  
10 and cellular markers for the detection of breast cancer. There is a need for molecular markers for the accurate staging, including clinical and pathological staging, of breast cancers to optimize treatment methods. Finally, there is a need for sensitive molecular and cellular markers to monitor the progress of cancer treatments, including markers that can detect recurrence of breast cancers following remission.

15 Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention  
20 will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

#### SUMMARY OF THE INVENTION

The present invention solves many needs in the art by providing nucleic acid  
25 molecules, polypeptides and antibodies thereto, variants and derivatives of the nucleic acids and polypeptides, agonists and antagonists that may be used to identify, diagnose, monitor, stage, image and treat breast cancer and non-cancerous disease states in breast; identify and monitor breast tissue; and identify and design agonists and antagonists of polypeptides of the invention. The invention also provides gene therapy, methods for  
30 producing transgenic animals and cells, and methods for producing engineered breast tissue for treatment and research.

One aspect of the present invention relates to nucleic acid molecules that are specific to breast cells, breast tissue and/or the breast organ. These breast specific nucleic

DEX-0360

7

PATENT

acids (BSNAs) may be a naturally occurring cDNA, genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally occurring nucleic acid molecule. If the BSNA is genomic DNA, then the BSNA is a breast specific gene (BSG). If the BSNA is RNA, then it is a breast specific transcript encoded by a BSG. Due to alternative  
5 splicing and transcriptional modification one BSG may encode for multiple breast specific RNAs. In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to breast. More preferred is a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 104-190. In another preferred  
10 embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1-103. For the BSNA sequences listed herein, DEX0360\_001.nt.1 corresponds to SEQ ID NO: 1. For sequences with multiple splice variants, the parent sequence DEX0360\_001.nt.1, will be followed by DEX0360\_001.nt.2, etc. for each splice variant. The sequences off the corresponding peptides are listed as DEX0360\_001.aa.1, etc. For the mapping of all of the nucleotides and peptides, see the table in the Example 1 section  
15 below.

This aspect of the present invention also relates to nucleic acid molecules that selectively hybridize or exhibit substantial sequence similarity to nucleic acid molecules encoding a breast Specific Protein (BSP), or that selectively hybridize or exhibit substantial sequence similarity to a BSNA. In one embodiment of the present invention  
20 the nucleic acid molecule comprises an allelic variant of a nucleic acid molecule encoding a BSP, or an allelic variant of a BSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid sequence that encodes a BSP or a part of a nucleic acid sequence of a BSNA.

In addition, this aspect of the present invention relates to a nucleic acid molecule  
25 further comprising one or more expression control sequences controlling the transcription and/or translation of all or a part of a BSNA or the transcription and/or translation of a nucleic acid molecule that encodes all or a fragment of a BSP.

Another aspect of the present invention relates to vectors and/or host cells comprising a nucleic acid molecule of this invention. In a preferred embodiment, the  
30 nucleic acid molecule of the vector and/or host cell encodes all or a fragment of a BSP. In another preferred embodiment, the nucleic acid molecule of the vector and/or host cell comprises all or a part of a BSNA. Vectors and host cells of the present invention are

useful in the recombinant production of polypeptides, particularly BSPs of the present invention.

Another aspect of the present invention relates to polypeptides encoded by a nucleic acid molecule of this invention. The polypeptide may comprise either a fragment  
5 or a full-length protein. In a preferred embodiment, the polypeptide is a BSP. However, this aspect of the present invention also relates to mutant proteins (muteins) of BSPs, fusion proteins of which a portion is a BSP, and proteins and polypeptides encoded by allelic variants of a BSNA as provided herein.

Another aspect of the present invention relates to antibodies and other binders that  
10 specifically binds to a polypeptide of the instant invention. Accordingly antibodies or binders of the present specifically bind to BSPs, muteins, fusion proteins, and/or homologous proteins or a polypeptides encoded by allelic variants of an BSNA as provided herein.

Another aspect of the present invention relates to agonists and antagonists of the  
15 nucleic acid molecules and polypeptides of this invention. The agonists and antagonists of the instant invention may be used to treat breast cancer and non-cancerous disease states in breast and to produce engineered breast tissue.

Another aspect of the present invention relates to methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical  
20 nucleic acid sequences compared to the nucleic acid molecules described herein. Such methods are useful in identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast. Such methods are also useful in identifying and/or monitoring breast tissue. In addition, measurement of levels of one or more of the nucleic acid molecules of this invention may be useful for diagnostics as part  
25 of panel in combination with known other markers, particularly those described in the breast cancer background section above.

Another aspect of the present invention relates to use of the nucleic acid molecules of this invention in gene therapy, for producing transgenic animals and cells, and for producing engineered breast tissue for treatment and research.

30 Another aspect of the present invention relates to methods for detecting polypeptides this invention, preferably using antibodies thereto. Such methods are useful to identify, diagnose, monitor, stage, image and treat breast cancer and non-cancerous disease states in breast. In addition, measurement of levels of one or more of the

polypeptides of this invention may be useful to identify, diagnose, monitor, stage, image breast cancer in combination with known other markers, particularly those described in the breast cancer background section above. The polypeptides of the present invention can also be used to identify and/or monitor breast tissue, and to produce engineered breast tissue.

Yet another aspect of the present invention relates to a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for comparison, alignment and ordering of the sequences of the invention to other sequences. In addition, the computer records regarding the nucleic acid and/or amino acid sequences and/or measurements of their levels may be used alone or in combination with other markers to diagnose breast related diseases.

#### DETAILED DESCRIPTION OF THE INVENTION

##### Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g.,* Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Press (2001); Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel *et al.*, Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology – 4<sup>th</sup> Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor

DEX-0360

10

PATENT

Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1999).

Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single and double stranded forms of DNA. In addition, a polynucleotide may include either or both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages.

Nucleotides are represented by single letter symbols in nucleic acid molecule sequences. The following table lists symbols identifying nucleotides or groups of nucleotides which may occupy the symbol position on a nucleic acid molecule. See Nomenclature Committee of the International Union of Biochemistry (NC-IUB), Nomenclature for incompletely specified bases in nucleic acid sequences, Recommendations 1984., *Eur J Biochem.* 150(1):1-5 (1985).

Symbol	Meaning	Group/Origin of Designation	Complementary Symbol
a	a	Adenine	t/u
g	g	Guanine	c
c	c	Cytosine	g
t	t	Thymine	a
u	u	Uracil	a
r	g or a	puRine	y
y	t/u or c	pYrimidine	r
m	a or c	aMino	k

DEX-0360

11

PATENT

k	g or t/u	Keto	m
s	g or c	Strong interactions 3H-bonds	w
w	a or t/u	Weak interactions 2H-bonds	s
b	g or c or t/u	not a	v
d	a or g or t/u	not c	h
h	a or c or t/u	not g	d
v	a or g or c	not t, not u	b
n	a or g or c or t/u, unknown, or other	aNy	n

The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids, etc.) The term "nucleic acid molecule" also includes any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

A "gene" is defined as a nucleic acid molecule that comprises a nucleic acid sequence that encodes a polypeptide and the expression control sequences that surround the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well known in the art, eukaryotic genes usually contain both exons and introns. The term "exon" refers to a nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute contiguous sequence to a mature mRNA transcript. The term "intron" refers to a nucleic acid sequence found in genomic DNA that

DEX-0360

12

PATENT

is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be "spliced out" during processing of the transcript.

A nucleic acid molecule or polypeptide is "derived" from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the  
5 nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.

An "isolated" or "substantially pure" nucleic acid or polynucleotide (*e.g.*, an RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell,  
10 *e.g.*, ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature  
15 as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term "isolated" or "substantially pure" also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term "isolated nucleic acid molecule" includes nucleic acid molecules that  
20 are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.

A "part" of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid  
25 molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a  
30 nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA*

DEX-0360

13

PATENT

81:3998-4002 (1984); and U.S. Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule, or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

The term "oligonucleotide" refers to a nucleic acid molecule generally comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single-or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35, 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, *e.g.* for use as probes or primers, or may be double-stranded, *e.g.* for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including in vitro recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as those that employ a kinase and ATP. The 3' end of a chemically synthesized oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other polynucleotide(s) prior to ligation.

DEX-0360

14

PATENT

The term "naturally occurring nucleotide" referred to herein includes naturally occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotide linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. *See e.g.*, LaPlanche *et al. Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al. Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al. Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical Approach, pp. 87-108, Oxford University Press (1991); Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), and U.S. Patent No. 5,151,510, the disclosure of which is hereby incorporated by reference in its entirety.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In addition, the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence. In a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

The term "percent sequence identity" in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or

DEX-0360

15

PATENT

Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*, the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98  
5 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.* 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998)). Unless otherwise specified, default parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the  
10 scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1.

A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, *e.g.*, for antisense  
15 therapy, double stranded RNA (dsRNA) inhibition (RNAi), combination of triplex and antisense, hybridization probes and PCR primers.

In the molecular biology art, researchers use the terms "percent sequence identity", "percent sequence similarity" and "percent sequence homology" interchangeably. In this application, these terms shall have the same meaning with respect to nucleic acid  
20 sequences only.

The term "substantial similarity" or "substantial sequence similarity," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more  
25 preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists between a first and second nucleic acid  
30 sequence when the first nucleic acid sequence or fragment thereof hybridizes to an antisense strand of the second nucleic acid, under selective hybridization conditions. Typically, selective hybridization will occur between the first nucleic acid sequence and an antisense strand of the second nucleic acid sequence when there is at least about 55%

sequence identity between the first and second nucleic acid sequences— preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% — over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

5           Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. “Stringent hybridization conditions” and “stringent wash conditions” in the context  
10 of nucleic acid hybridization experiments depend upon a number of different physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, “stringent hybridization” is performed at about  
15 25°C below the thermal melting point ( $T_m$ ) for the specific DNA hybrid under a particular set of conditions. “Stringent washing” is performed at temperatures about 5°C lower than the  $T_m$  for the specific DNA hybrid under a particular set of conditions. The  $T_m$  is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe. See Sambrook (1989), *supra*, p. 9.51.

20           The  $T_m$  for a particular DNA-DNA hybrid can be estimated by the formula:  
$$T_m = 81.5^{\circ}\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) - 0.63 (\% \text{ formamide}) - (600/l)$$
where  $l$  is the length of the hybrid in base pairs.

          The  $T_m$  for a particular RNA-RNA hybrid can be estimated by the formula:  
$$T_m = 79.8^{\circ}\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$
  
25

          The  $T_m$  for a particular RNA-DNA hybrid can be estimated by the formula:  
$$T_m = 79.8^{\circ}\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$$

          In general, the  $T_m$  decreases by 1-1.5°C for each 1% of mismatch between two  
30 nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C

DEX-0360

17

PATENT

would be subtracted from the calculated  $T_m$  of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art.

An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X SSC at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without formamide for at least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or northern blot or for screening a library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify nucleic acid sequences that are similar but not identical can be identified by experimentally changing the hybridization temperature from 68°C to 42°C while keeping the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (*e.g.* 42°C and 6X SSC) and varying the formamide concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These agents are well known in the art. *See* Sambrook *et al.* (1989), *supra*, pages 8.46 and 9.46-9.58. *See also* Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see* Sambrook (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

DEX-0360

18

PATENT

As defined herein, nucleic acids that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid is created synthetically or recombinantly using a high codon degeneracy as permitted by the redundancy of the genetic code.

Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (*e.g.*, for oligonucleotide probes) may be calculated by the formula:

$$T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/N),$$
 wherein N is change length and the  $[\text{Na}^+]$  is 1 M or less. *See* Sambrook (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the  $T_m$ ) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using mismatched probes, pools of degenerate probes or "guessmers," as well as hybridization solutions and methods for empirically determining hybridization conditions are well known in the art. *See, e.g.*, Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

The term "digestion" or "digestion of DNA" refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques

DEX-0360

19

PATENT

for ligation are well known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon. The single exon probes may contain priming sequences not found in contiguity with the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies. In another aspect, the invention is directed to single exon probes based on the BSNA's disclosed herein.

In one embodiment, the term "microarray" refers to a "nucleic acid microarray" having a substrate-bound plurality of nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). Additionally, these nucleic acid microarrays include substrate-bound plurality of nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000). Examples of nucleic acid microarrays may be found in U.S. Patent Nos. 6,391,623, 6,383,754, 6,383,749, 6,380,377, 6,379,897, 6,376,191, 6,372,431, 6,351,712, 6,344,316, 6,316,193, 6,312,906, 6,309,828, 6,309,824, 6,306,643, 6,300,063, 6,287,850, 6,284,497, 6,284,465, 6,280,954, 6,262,216, 6,251,601, 6,245,518, 6,263,287, 6,251,601,

DEX-0360

20

PATENT

6,238,866, 6,228,575, 6,214,587, 6,203,989, 6,171,797, 6,103,474, 6,083,726, 6,054,274, 6,040,138, 6,083,726, 6,004,755, 6,001,309, 5,958,342, 5,952,180, 5,936,731, 5,843,655, 5,814,454, 5,837,196, 5,436,327, 5,412,087, 5,405,783, the disclosures of which are incorporated herein by reference in their entireties.

5 In an alternative embodiment, a "microarray" may also refer to a "peptide microarray" or "protein microarray" having a substrate-bound collection of plurality of polypeptides, the binding to each of the plurality of bound polypeptides being separately detectable. Alternatively, the peptide microarray may have a plurality of binders, including but not limited to monoclonal antibodies, polyclonal antibodies, phage display  
10 binders, yeast 2 hybrid binders, aptamers, which can specifically detect the binding of the polypeptides of this invention. The array may be based on autoantibody detection to the polypeptides of this invention, see Robinson *et al.*, *Nature Medicine* 8(3):295-301 (2002). Examples of peptide arrays may be found in WO 02/31463, WO 02/25288, WO 01/94946, WO 01/88162, WO 01/68671, WO 01/57259, WO 00/61806, WO 00/54046, WO  
15 00/47774, WO 99/40434, WO 99/39210, WO 97/42507 and U.S. Patent Nos. 6,268,210, 5,766,960, 5,143,854, the disclosures of which are incorporated herein by reference in their entireties.

In addition, determination of the levels of the BSNA or BSP may be made in a multiplex manner using techniques described in WO 02/29109, WO 02/24959, WO  
20 01/83502, WO01/73113, WO 01/59432, WO 01/57269, WO 99/67641, the disclosures of which are incorporated herein by reference in their entireties.

The term "mutant", "mutated", or "mutation" when applied to nucleic acid sequences means that nucleotides in a nucleic acid sequence may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made  
25 at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. In a preferred embodiment of the present invention, the nucleic acid sequence is the wild type nucleic acid sequence encoding a BSP or is a BSNA. The nucleic acid sequence may be mutated by any method known in the art  
30 including those mutagenesis techniques described *infra*.

The term "error-prone PCR" refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g., Leung*

*et al.*, *Technique* 1: 11-15 (1989) and Caldwell *et al.*, *PCR Methods Applic.* 2: 28-33 (1992).

The term "oligonucleotide-directed mutagenesis" refers to a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g.*,  
5 Reidhaar-Olson *et al.*, *Science* 241: 53-57 (1988).

The term "assembly PCR" refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

10 The term "sexual PCR mutagenesis" or "DNA shuffling" refers to a method of error-prone PCR coupled with forced homologous recombination between DNA molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g.*, Stemmer,  
15 *Proc. Natl. Acad. Sci. U.S.A.* 91: 10747-10751 (1994). DNA shuffling can be carried out between several related genes ("Family shuffling").

The term "*in vivo* mutagenesis" refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair pathways.  
20 These "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

The term "cassette mutagenesis" refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide "cassette" that  
25 differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

The term "recursive ensemble mutagenesis" refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This  
30 method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. *See, e.g.*, Arkin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

The term "exponential ensemble mutagenesis" refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein

small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. *See, e.g., Delegrave et al., Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455 (1993).

- 5           “Operatively linked” expression control sequences refers to a linkage in which the expression control sequence is either contiguous with the gene of interest to control the gene of interest, or acts in *trans* or at a distance to control the gene of interest.

          The term “expression control sequence” as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they  
10   are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that  
15   enhance translation efficiency (*e.g.*, ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence. The term “control sequences” is intended to include, at a minimum,  
20   all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

          The term “vector,” as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of  
25   vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain  
30   vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of

DEX-0360

23

PATENT

directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used  
5 interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which a recombinant expression vector has been introduced.  
10 It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

15 As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refers to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

20 As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence is meant to be inclusive of all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to  
25 that translated from the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally occurring and non-naturally occurring proteins and polypeptides, as well as polypeptide fragments and polypeptide mutants, derivatives and analogs thereof. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single  
30 polypeptide each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises a BSP encoded by a nucleic acid molecule of the instant invention, or a fragment, mutant, analog and derivative thereof.

DEX-0360

24

PATENT

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well known in the art.

A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be determined by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a protein sample, followed by visualizing a single polypeptide band upon staining the gel with a stain well known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well known in the art for purification.

The term "fragment" when used herein with respect to polypeptides of the present invention refers to a polypeptide that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length BSP. In a preferred embodiment, the fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally occurring polypeptide. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" when used herein with respect to polypeptides of the present invention refers to a polypeptide which is substantially similar in primary structural sequence to a BSP but which include, *e.g.*, *in vivo* or *in vitro* chemical and biochemical modifications that are not found in the BSP. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin,

DEX-0360

25

PATENT

covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Other modification include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well known in the art, and include radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$  and  $^3\text{H}$ , ligands which bind to labeled antigens (*e.g.*, antibodies), fluorophores, chemiluminescent agents, enzymes, and antigens which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods for labeling polypeptides are well known in the art. *See* Ausubel (1992), *supra*; Ausubel (1999), *supra*.

The term "fusion protein" refers to polypeptides of the present invention coupled to a heterologous amino acid sequences. Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be produced recombinantly by constructing a nucleic acid sequence that encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

The term "analog" refers to both polypeptide analogs and non-peptide analogs. The term "polypeptide analog" as used herein refers to a polypeptide that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue

DEX-0360

26

PATENT

bonds. In a preferred embodiment, the analog has the same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally occurring sequence. Analogous typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally occurring polypeptide.

The term "non-peptide analog" refers to a compound with properties that are analogous to those of a reference polypeptide. A non-peptide compound may also be termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of:  $-\text{CH}_2\text{NH}-$ ,  $-\text{CH}_2\text{S}-$ ,  $-\text{CH}_2\text{-CH}_2-$ ,  $-\text{CH=CH}-$  (cis and trans),  $-\text{COCH}_2-$ ,  $-\text{CH(OH)CH}_2-$ , and  $-\text{CH}_2\text{SO}-$ , by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992)). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

The term "mutant" or "mutein" when referring to a polypeptide of the present invention relates to an amino acid sequence containing substitutions, insertions or deletions of one or more amino acids compared to the amino acid sequence of a BSP. A mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence

DEX-0360

27

PATENT

similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90% sequence similarity to a BSP. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as GAP or BESTFIT or other variation Smith-Waterman alignment. See, T. F. Smith and M. S. Waterman, J. Mol. Biol. 147:195-197 (1981) and W.R. Pearson, Genomics 11:635-650 (1991).

Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid substitutions) may be made in the naturally occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not substantially change the structural characteristics of the parent sequence (*e.g.*, a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H. Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991).

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2<sup>nd</sup> Ed., Sinauer Associates (1991). Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as  $\alpha$ -,  $\alpha$ -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline,  $\gamma$ -carboxyglutamate,  $\epsilon$ -N,N,N-trimethyllysine,  $\epsilon$ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine,

DEX-0360

28

PATENT

5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

- 5 By "homology" or "homologous" when referring to a polypeptide of the present invention it is meant polypeptides from different organisms with a similar sequence to the encoded amino acid sequence of a BSP and a similar biological activity or function. Although two polypeptides are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the polypeptides. Instead, the term
- 10 "homologous" is defined to mean that the two polypeptides have similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous polypeptide is one that exhibits 50% sequence similarity to BSP, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous polypeptides that exhibit 80%, 85% or 90% sequence similarity to a BSP.
- 15 In a yet more preferred embodiment, a homologous polypeptide exhibits 95%, 97%, 98% or 99% sequence similarity.

- When "sequence similarity" is used in reference to polypeptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has "sequence similarity"
- 20 comprises conservative or moderately conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (*e.g.*, charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases
- 25 where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. *See, e.g., Pearson, Methods Mol. Biol.* 24: 307-31 (1994).

- 30 For instance, the following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);

DEX-0360

29

PATENT

- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

5 Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45 (1992). A "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

10 Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as "Gap" and "Bestfit" which can be used with default parameters to determine sequence homology or sequence identity between closely  
15 related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. *See, e.g.*, GCG Version 6.1. Other programs include FASTA, discussed *supra*.

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program  
20 BLAST, especially blastp or tblastn. *See, e.g.*, Altschul *et al.*, *J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al.*, *Nucleic Acids Res.* 25:3389-402 (1997). Preferred parameters for blastp are:

	Expectation value:	10 (default)
	Filter:	seg (default)
25	Cost to open a gap:	11 (default)
	Cost to extend a gap:	1 (default)
	Max. alignments:	100 (default)
	Word size:	11 (default)
	No. of descriptions:	100 (default)
30	Penalty Matrix:	BLOSUM62

The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35

DEX-0360

30

PATENT

residues. When searching a database containing sequences from a large number of different organisms, it is preferable to compare amino acid sequences.

Algorithms other than blastp for database searching using amino acid sequences are known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (1990), *supra*; Pearson (2000), *supra*. For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default or recommended parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1.

An "antibody" refers to an intact immunoglobulin, or to an antigen-binding portion thereof that competes with the intact antibody for specific binding to a molecular species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')<sub>2</sub>, Fv, dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. A Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab')<sub>2</sub> fragment is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consists of the VH and CH1 domains; a Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g.*, Ward *et al.*, *Nature* 341: 544-546 (1989).

By "bind specifically" and "specific binding" as used herein it is meant the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to "recognize" a first molecular species when it can bind specifically to that first molecular species.

A single-chain antibody (scFv) is an antibody in which VL and VH regions are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g.*, Bird *et al.*, *Science* 242: 423-426 (1988); Huston *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but

DEX-0360

31

PATENT

using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak *et al., Structure* 2: 1121-1123 (1994). One or more CDRs  
5 may be incorporated into a molecule either covalently or noncovalently to make it an immunoaderhin. An immunoaderhin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoaderhin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody  
10 that contains one or more regions from one antibody and one or more regions from one or more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally occurring immunoglobulin has two identical binding sites, a single-chain  
15 antibody or Fab fragment has one binding site, while a "bispecific" or "bifunctional" antibody has two different binding sites.

An "isolated antibody" is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a  
20 cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (*e.g.*, BSA) or a chemical such as polyethylene glycol (PEG).

A "neutralizing antibody" or "an inhibitory antibody" is an antibody that inhibits  
25 the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An "activating antibody" is an antibody that increases the activity of a polypeptide.

The term "epitope" includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of  
30 chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the

DEX-0360

32

PATENT

dissociation constant is less than 1  $\mu$ M, preferably less than 100 nM and most preferably less than 10 nM.

The term "patient" includes human and veterinary subjects.

Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

The term "breast specific" refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the breast as compared to other tissues in the body. In a preferred embodiment, a "breast specific" nucleic acid molecule or polypeptide is detected at a level that is 1.5-fold higher than any other tissue in the body. In a more preferred embodiment, the "breast specific" nucleic acid molecule or polypeptide is detected at a level that is 2-fold higher than any other tissue in the body, more preferably 5-fold higher, still more preferably at least 10-fold, 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid hybridization, such as Northern blot hybridization, or quantitative PCR. Polypeptide levels may be measured by any method known to accurately quantitate protein levels, such as Western blot analysis.

Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

*Nucleic Acid Molecules*

One aspect of the invention provides isolated nucleic acid molecules that are specific to the breast or to breast cells or tissue or that are derived from such nucleic acid molecules. These isolated breast specific nucleic acids (BSNAs) may comprise cDNA genomic DNA, RNA, or a combination thereof, a fragment of one of these nucleic acids, or may be a non-naturally occurring nucleic acid molecule. A BSNA may be derived from an animal. In a preferred embodiment, the BSNA is derived from a human or other mammal. In a more preferred embodiment, the BSNA is derived from a human or other primate. In an even more preferred embodiment, the BSNA is derived from a human.

In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to breast, a breast-specific polypeptide (BSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 104-190. In another highly preferred embodiment, the nucleic acid molecule

DEX-0360

33

PATENT

comprises a nucleic acid sequence of SEQ ID NO: 1-103. Nucleotide sequences of the instantly-described nucleic acid molecules were determined by assembling several DNA molecules from either public or proprietary databases. Some of the underlying DNA sequences are the result, directly or indirectly, of at least one enzymatic polymerization reaction (*e.g.*, reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Amersham Biosciences, Sunnyvale, CA, USA).

Nucleic acid molecules of the present invention may also comprise sequences that selectively hybridizes to a nucleic acid molecule encoding a BSNA or a complement or antisense thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may or may not encode a BSP. However, in a preferred embodiment, the hybridizing nucleic acid molecule encodes a BSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 104-190. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1-103 or the antisense sequence thereof. Preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a BSP under low stringency conditions. More preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a BSP under moderate stringency conditions. Most preferably, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a BSP under high stringency conditions. In a preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 104-190. In a more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule or the antisense sequence of a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1-103.

Nucleic acid molecules of the present invention may also comprise nucleic acid sequences that exhibit substantial sequence similarity to a nucleic acid encoding a BSP or

DEX-0360

34

PATENT

- a complement of the encoding nucleic acid molecule. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule encoding human BSP. More preferred is a nucleic acid molecule exhibiting substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 104-190. By substantial sequence similarity it is meant a nucleic acid molecule having at least 60% sequence identity with a nucleic acid molecule encoding a BSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 104-190, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90% sequence identity with a nucleic acid molecule encoding a BSP, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. Most preferred in this embodiment is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding a BSP.
- 15        The nucleic acid molecules of the present invention are also inclusive of those exhibiting substantial sequence similarity to a BSNA or its complement. In this embodiment, it is preferred that the nucleic acid molecule exhibit substantial sequence similarity to a nucleic acid molecule having a nucleic acid sequence of SEQ ID NO: 1-103. By substantial sequence similarity it is meant a nucleic acid molecule that has at least 60% sequence identity with a BSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1-103, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. More preferred is a nucleic acid molecule that has at least 90% sequence identity with a BSNA, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. Most preferred is a nucleic acid molecule that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a BSNA.

- 30        Nucleic acid molecules that exhibit substantial sequence similarity are inclusive of sequences that exhibit sequence identity over their entire length to a BSNA or to a nucleic acid molecule encoding a BSP, as well as sequences that are similar over only a part of its length. In this case, the part is at least 50 nucleotides of the BSNA or the nucleic acid molecule encoding a BSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at least 400 or 500 nucleotides.

DEX-0360

35

PATENT

The substantially similar nucleic acid molecule may be a naturally occurring one that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 104-190 or demonstrates significant sequence identity to the nucleotide sequence of SEQ ID NO: 1-103. The similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule from a human, when the BSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar nucleic acid molecule may also be a naturally occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally occurring substantially similar nucleic acid molecule may be isolated directly from humans or other species. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by directed mutation of a BSNA. In a preferred embodiment, the substantially similar nucleic acid molecule is an BSNA.

The nucleic acid molecules of the present invention are also inclusive of allelic variants of a BSNA or a nucleic acid encoding a BSP. For example, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes and the sequence determined from one individual of a species may differ from other allelic forms present within the population. More than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001) – Variants with small deletions and insertions of more than a single nucleotide are also found in the general population, and often do not alter the function of the protein. In addition, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that encodes a BSP. In a more preferred embodiment, the gene is transcribed into an mRNA that encodes a BSP comprising an amino acid sequence of SEQ ID NO: 104-190. In another preferred embodiment, the allelic variant is

DEX-0360

36

PATENT

a variant of a gene, wherein the gene is transcribed into an mRNA that is a BSNA. In a more preferred embodiment, the gene is transcribed into an mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1-103. Also preferred is that the allelic variant is a naturally occurring allelic variant in the species of interest, particularly human.

5 Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences comprising a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is a BSP. In a preferred embodiment, the part encodes a BSP. In one embodiment, the nucleic acid molecule comprises a part of a BSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that hybridizes or exhibits  
10 substantial sequence similarity to a BSNA. In another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that is an allelic variant of a BSNA. In yet another embodiment, the nucleic acid molecule comprises a part of a nucleic acid molecule that encodes a BSP. A part comprises at least 10 nucleotides, more preferably at  
15 least 15, 17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences that encode fusion proteins, homologous proteins, polypeptide fragments,  
20 muteins and polypeptide analogs, as described *infra*.

Nucleic acid molecules of the present invention are also inclusive of nucleic acid sequences containing modifications of the native nucleic acid molecule. Examples of such modifications include, but are not limited to, nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the  
25 art would recognize that the type of modification that may be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe, the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications  
30 will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the modifications will be limited to those that do not confer toxicity upon the isolated nucleic acid.

DEX-0360

37

PATENT

Accordingly, in one embodiment, a nucleic acid molecule may include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. The labeled nucleic acid molecules are particularly useful as hybridization probes.

Common radiolabeled analogues include those labeled with  $^{33}\text{P}$ ,  $^{32}\text{P}$ , and  $^{35}\text{S}$ , such as  $\alpha$ - $^{32}\text{P}$ -dATP,  $\alpha$ - $^{32}\text{P}$ -dCTP,  $\alpha$ - $^{32}\text{P}$ -dGTP,  $\alpha$ - $^{32}\text{P}$ -dTTP,  $\alpha$ - $^{32}\text{P}$ -3'-dATP,  $\alpha$ - $^{32}\text{P}$ -ATP,  $\alpha$ - $^{32}\text{P}$ -CTP,  $\alpha$ - $^{32}\text{P}$ -GTP,  $\alpha$ - $^{32}\text{P}$ -UTP,  $\alpha$ - $^{35}\text{S}$ -dATP,  $\gamma$ - $^{35}\text{S}$ -GTP,  $\gamma$ - $^{33}\text{P}$ -dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Biosciences, Piscataway, New Jersey, USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having other fluorophores. See Henegariu *et al.*, *Nature Biotechnol.* 18: 345-348 (2000).

Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

Nucleic acid molecules of the present invention can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3,

DEX-0360

38

PATENT

and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3' hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and Peptide Nucleic Acids (PNA) to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); *see Alers et al., Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al., J. NIH Res.* 5: 82 (1994); Van Belkum *et al., BioTechniques* 16: 148-153 (1994). Alternatively, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching or to report exonucleotidic excision. *See, e.g., Tyagi et al., Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al., Nature Biotechnol.* 16: 49-53 (1998); Sokol *et al., Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al., Science* 279: 1228-1229 (1998); Marras *et al., Genet. Anal.* 14: 151-156 (1999); Holland *et al., Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid *et al., Genome Res.* 6(10): 986-94 (1996); Kuimelis *et al., Nucleic Acids Symp. Ser.* (37): 255-6 (1997); and U.S. Patent Nos. 5,846,726, 5,925,517, 5,925,517, 5,723,591 and 5,538,848, the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules of the present invention may also be modified by altering one or more native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. *See Hartmann et al. (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science*, Kluwer Law International (1999); Stein *et al. (eds.),*

DEX-0360

39

PATENT

Applied Antisense Oligonucleotide Technology, Wiley-Liss (1998); Chadwick *et al.* (eds.), Oligonucleotides as Therapeutic Agents – Symposium No. 209, John Wiley & Son Ltd (1997). Such altered internucleoside bonds are often desired for techniques or for targeted gene correction, Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000). For double stranded RNA inhibition which may utilize either natural ds RNA or ds RNA modified in its, sugar, phosphate or base, see Hannon, *Nature* 418(11): 244-251 (2002); Fire *et al.* in WO 99/32619; Tuschl *et al.* in US2002/0086356; Kruetzer *et al.* in WO 00/44895, the disclosures of which are incorporated herein by reference in their entirety;. For circular antisense, see Kool in U.S. Patent No. 5,426,180, the disclosure of which is incorporated herein by reference in its entirety.

Modified oligonucleotide backbones include, without limitation, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative U.S. Patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Patent Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of which are incorporated herein by reference in their entireties. In a preferred embodiment, the modified internucleoside linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino

DEX-0360

40

PATENT

backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S. Patent Nos.

5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564;  
5 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086;  
5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312;  
5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred nucleic acid molecules, both the sugar and the internucleoside  
10 linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be  
15 synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent Nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference in its entirety. Automated PNA synthesis is readily achievable on commercial synthesizers  
20 (see, e.g., "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA). PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The T<sub>m</sub> of a PNA/DNA or PNA/RNA duplex is generally 1°C  
25 higher per base pair than the T<sub>m</sub> of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A  
30 single mismatch in mixed a PNA/DNA 15-mer lowers the T<sub>m</sub> by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the T<sub>m</sub> by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by

DEX-0360

41

PATENT

enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. See, e.g., Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5 (1999).

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and modified PCR reactions, as further described in, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), and U.S. Patent Nos. 5,760,012 and 5,731,181, the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acid molecules of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001); Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); and Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994). Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997); Rowley *et al.*, *Mol Med* 5(10): 693-700 (1999); Kool, *Annu Rev Biophys Biomol Struct.* 25: 1-28 (1996).

#### *Methods for Using Nucleic Acid Molecules as Probes and Primers*

The isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably

DEX-0360

42

PATENT

labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

In one embodiment, the isolated nucleic acid molecules of the present invention can be used as probes to detect and characterize gross alterations in the gene of a BSNA, such as deletions, insertions, translocations, and duplications of the BSNA genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g.,* Andreeff *et al.* (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999). The isolated nucleic acid molecules of the present invention can be used as probes to assess smaller genomic alterations using, *e.g.,* Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acid molecules of the present invention can be used as probes to isolate genomic clones that include a nucleic acid molecule of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

Alternatively, detection techniques such as molecular beacons may be used, see Kostrikis *et al. Science* 279:1228-1229 (1998).

The isolated nucleic acid molecules of the present invention can be also be used as probes to detect, characterize, and quantify BSNA in, and isolate BSNA from, transcript-derived nucleic acid samples. In one embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length, and quantify mRNA by Northern blot of total or poly-A<sup>+</sup>- selected RNA samples. In another embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g.,* Schwarczacher *et al., In Situ Hybridization, Springer-Verlag New York (2000). In another preferred embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to BSNAs, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.*

DEX-0360

43

PATENT

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000).

5 In another embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify and/or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In this embodiment, it is preferred that the probe or primer be derived from a nucleic acid molecule encoding a BSP. More preferably, the probe or primer is derived from a nucleic acid molecule  
10 encoding a polypeptide having an amino acid sequence of SEQ ID NO: 104-190. Also preferred are probes or primers derived from a BSNA. More preferred are probes or primers derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-103.

In general, a probe or primer is at least 10 nucleotides in length, more preferably at  
15 least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40  
20 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well known in the art. *See, e.g.*, Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

25 Methods of performing primer-directed amplification are also well known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR,  
30 Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); and McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995). Methods for performing RT-

DEX-0360

44

PATENT

PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; and Siebert (ed.), PCR Technique:RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995).

5 PCR and hybridization methods may be used to identify and/or isolate nucleic acid molecules of the present invention including allelic variants, homologous nucleic acid molecules and fragments. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules of the present invention that encode homologous proteins, analogs, fusion protein or muteins of the invention. Nucleic acid primers as described herein can be used to prime amplification of nucleic acid molecules  
10 of the invention, using transcript-derived or genomic DNA as template.

These nucleic acid primers can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.*, U.S. Pat. No. 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also  
15 now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7 (2001); international patent publications WO 97/19193 and WO 00/15779, and U.S. Patent Nos. 5,854,033 and 5,714,320, the disclosures of which are incorporated herein by reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. *See, e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3):  
20 225-32 (1998).

Nucleic acid molecules of the present invention may be bound to a substrate either covalently or noncovalently. The substrate can be porous or solid, planar or non-planar, unitary or distributed. The bound nucleic acid molecules may be used as hybridization probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic  
25 acid molecules are unlabeled.

In one embodiment, the nucleic acid molecule of the present invention is bound to a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or positively charged derivatized nylon. The nucleic acid molecule of the present invention can be used to detect a hybridizing nucleic acid molecule that is present within a labeled  
30 nucleic acid sample, *e.g.*, a sample of transcript-derived nucleic acids. In another embodiment, the nucleic acid molecule is bound to a solid substrate, including, without limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate,

DEX-0360

45

PATENT

polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof. The solid substrate may be any shape, including rectangular, disk-like and spherical. In a preferred embodiment, the solid substrate is a microscope slide or  
5 slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some combination thereof. The nucleic acid molecule of the present invention can be bound to a  
10 substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, e.g. on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used  
15 herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that comprise one or more of the nucleic acid molecules of the present invention.

In yet another embodiment, the invention is directed to single exon probes based on the BSNAs disclosed herein.

20

*Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides*

Another aspect of the present invention provides vectors that comprise one or more of the isolated nucleic acid molecules of the present invention, and host cells in which  
25 such vectors have been introduced.

The vectors can be used, *inter alia*, for propagating the nucleic acid molecules of the present invention in host cells (cloning vectors), for shuttling the nucleic acid molecules of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acid molecules of the present invention into host  
30 cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acid molecules of the present invention *in vitro* or within a host cell, and for expressing polypeptides encoded by the nucleic acid molecules of the present invention, alone or as fusion proteins with heterologous polypeptides (expression vectors). Vectors

DEX-0360

46

PATENT

- are by now well known in the art, and are described, *inter alia*, in Jones *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*,  
 5 Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000); Sambrook (2001), *supra*; Ausubel (1999), *supra*. Furthermore, a variety of vectors are available commercially. Use of existing vectors and modifications thereof are well within the skill in the art. Thus, only basic features need be described here.
- 10 Nucleic acid sequences may be expressed by operatively linking them to an expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences that control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic sequence of this  
 15 invention to an expression control sequence, of course, includes, if not already part of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.
- A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for  
 20 example, may consist of segments of chromosomal, non-chromosomal and synthetic nucleic acid sequences.
- In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred  
 25 embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their  
 30 derivatives, wider host range plasmids, such as RP4, phage DNAs, *e.g.*, the numerous derivatives of phage lambda, *e.g.*, NM989,  $\lambda$ GT10 and  $\lambda$ GT11, and other phages, *e.g.*, M13 and filamentous single stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*, typical markers confer resistance to antibiotics, such as ampicillin, tetracycline,

DEX-0360

47

PATENT

chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic genetic studies, due to the ease of targeting genetic changes by homologous recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, *e.g.* through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will typically, but not invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp and YEp series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are based on yeast linear plasmids, denoted YLp, pGPD-2, 2 $\mu$  plasmids and derivatives thereof, and improved shuttle vectors such as those described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as *ura3-52*, *his3-D1*, *leu2-D1*, *trp1-D1* and *lys2-201*.

Insect cells may be chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, *e.g.*, Sf9 and Sf21 cell lines, and expresSFT<sup>TM</sup> cells (Protein Sciences Corp., Meriden, CT, USA), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

The host cells may also be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway. Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral

origin, such as the SV40 origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, *e.g.*, in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include, include but are not limited to, resistance to neomycin (G418), blasticidin, hygromycin and zeocin, and selection based upon the purine salvage pathway using HAT medium.

Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (*e.g.*, vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (*e.g.*, bovine papillomavirus), and retroviral vectors (*e.g.*, murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these vectors to express the nucleic acid molecules of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include splice donor and acceptor sites and sequences that modify the half-life of the

DEX-0360

49

PATENT

transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that  
5 modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the trc promoter, a hybrid derived from the trp and lac promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC  
10 system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, and the araBAD operon. Prokaryotic expression vectors may further include transcription terminators, such as the aspA terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

15 Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the CYC1 promoter, the GAL1 promoter, the GAL10 promoter, ADH1 promoter, the promoters of the yeast  $\alpha$ -mating system, or the GPD promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the CYC1 or ADH1 gene.

20 Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include, but are not limited to, those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-  
25 promoter from SV40 and the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the BSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the  
30 polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron II of rabbit  $\beta$ -globin gene and the SV40 splice elements.

DEX-0360

50

PATENT

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well known in the art. Nucleic acid vectors may also comprise stabilizing sequences (*e.g.*, ori- or ARS-like sequences and telomere-like sequences), or may alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows a high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well known to those of skill in the art and are described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000), *supra*; and Ausubel (1992), *supra*, Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors include either naturally inducible promoters, such as the *trc* promoter, which is regulated by the *lac* operon, and the *pL* promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid *Plac/ara-1* promoter and the *PLtetO-1* promoter. The *PLtetO-1* promoter takes advantage of the high expression levels from the *PL* promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the *Tn10* tetracycline resistance operon, causing this promoter to be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

In one embodiment of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization. Such tags include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc.,

DEX-0360

51

PATENT

Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverly, MA, USA).

- 5 Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the polypeptides of the present
- 10 invention can be expressed as a fusion to glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a
- 15 myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope, detectable by anti-HA antibody.

- For secretion of expressed polypeptides, vectors can include appropriate sequences
- 20 that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

- Expression vectors can also be designed to fuse proteins encoded by the
- 25 heterologous nucleic acid insert to polypeptides that are larger than purification and/or identification tags. Useful protein fusions include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusions for use in two hybrid systems.

- 30 Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. See Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins;

A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996). Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the  $\alpha$ -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S.*

- 5 *cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet derived growth factor receptor.

- 10 A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711),  
15 FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. *See* Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be  
20 selected from GFP-like chromophores modified from those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well known in the art. *See* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Palm *et al.*, *Methods Enzymol.* 302: 378-394 (1999). A variety of such modified chromophores are now commercially available and can readily  
25 be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see, e.g.* Cormack *et al.*, *Gene* 173: 33-38 (1996); U.S. Patent Nos. 6,090,919 and 5,804,387, the disclosures of which are incorporated herein by reference in their entireties) is found  
30 on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g.* Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Cormack *et al.*, *Gene*

DEX-0360

53

PATENT

173: 33-38 (1996)). Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g., Heim et al., Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al., Nature* 388: 882-887 (1997)) and Citrine (*see, e.g., Heikal et al., Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Patent Nos. 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. *See also* Conn (ed.), Green Fluorescent Protein (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999); Yang, *et al., J Biol Chem*, 273: 8212-6 (1998); Bevis *et al., Nature Biotechnology*, 20:83-7 (2002). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

Fusions to the IgG Fc region increase serum half-life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412, the disclosures of which are incorporated herein by reference in their entireties.

For long-term, high-yield recombinant production of the polypeptides of the present invention, stable expression is preferred. Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The *bsd* gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.

Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-293, AmphoPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo

DEX-0360

54

PATENT

Alto, CA, USA) allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally well to express the nucleic acid molecules of this invention. Neither will all hosts function  
5 equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control  
10 integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be  
15 chosen for its ability to process the expressed polypeptide in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide BSPs with such post-translational modifications.

20 In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleic acid molecules of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the  
25 product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the nucleic acid molecules of this invention.

The recombinant nucleic acid molecules and more particularly, the expression  
30 vectors of this invention may be used to express the polypeptides of this invention as recombinant polypeptides in a heterologous host cell. The polypeptides of this invention may be full-length or less than full-length polypeptide fragments recombinantly expressed

DEX-0360

55

PATENT

from the nucleic acid molecules according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have biological activity.

Vectors of the present invention will also often include elements that permit *in vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

Transformation and other methods of introducing nucleic acids into a host cell (e.g., conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are well known in the art (*See*, for instance, Ausubel, *supra*, and Sambrook *et al.*, *supra*). Bacterial, yeast, plant or mammalian cells are transformed or transfected with an expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda* — e.g., Sf9 and Sf21 cell lines, and expresSFTM cells (Protein Sciences Corp., Meriden, CT, USA) — *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3 cells, 293 cells, HEPG2

cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and BW5147 cells. Other mammalian cell lines are well known and readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National  
5 Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from breast are particularly preferred because they may provide a more native post-translational processing. Particularly preferred are human breast cells.

Particular details of the transfection, expression and purification of recombinant  
10 proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in bacterial cell expression systems can be found in a number of texts and laboratory manuals in the art. See, e.g., Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*.

15 Methods for introducing the vectors and nucleic acid molecules of the present invention into the host cells are well known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged  
20 using a packaging extract (e.g., Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, e.g., with CaCl<sub>2</sub>, or a solution of Mg<sup>2+</sup>, Mn<sup>2+</sup>, Ca<sup>2+</sup>, Rb<sup>+</sup> or K<sup>+</sup>, dimethyl  
25 sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent strains are also available commercially (e.g., Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5α competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit  
30 (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent to take up exogenous DNA by electroporation by various pre-pulse treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided by BioRad (Richmond, CA, USA).

DEX-0360

57

PATENT

Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the action of hydrolytic enzymes such as a snail-gut extract, usually denoted Glusulase or Zymolyase, or an enzyme from *Arthrobacter luteus* to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and  $\text{Ca}^{2+}$ . Subsequently, the cells are resuspended in a solution of sorbitol, mixed with molten agar and then layered on the surface of a selective plate containing sorbitol.

For lithium-mediated transformation, yeast cells are treated with lithium acetate to permeabilize the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and subsequently spread on plates containing ordinary selective medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be coprecipitated with  $\text{CaPO}_4$  or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for  $\text{CaPO}_4$  transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent, FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA). Protocols for electroporating mammalian cells can be found in, for example, ; Norton *et*

DEX-0360

58

PATENT

*al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000). Other transfection techniques include transfection by particle bombardment and microinjection. *See, e.g.,* Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA* 5 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

Purification of recombinantly expressed proteins is now well within the skill in the art and thus need not be detailed here. *See, e.g.,* Thorner *et al.* (eds.), Applications of 10 Chimeric Genes and Hybrid Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press 15 (1996); and Roe (ed.), Protein Purification Applications, Oxford University Press (2001).

Briefly, however, if purification tags have been fused through use of an expression vector that appends such tag, purification can be effected, at least in part, by means appropriate to the tag, such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate 20 fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

Polypeptides, including Fragments Muteins, Homologous Proteins, Allelic Variants, Analogs and Derivatives

Another aspect of the invention relates to polypeptides encoded by the nucleic acid 25 molecules described herein. In a preferred embodiment, the polypeptide is a breast specific polypeptide (BSP). In an even more preferred embodiment, the polypeptide comprises an amino acid sequence of SEQ ID NO:104-190 or is derived from a polypeptide having the amino acid sequence of SEQ ID NO: 104-190. A polypeptide as defined herein may be produced recombinantly, as discussed *supra*, may be isolated from 30 a cell that naturally expresses the protein, or may be chemically synthesized following the teachings of the specification and using methods well known to those having ordinary skill in the art.

DEX-0360

59

PATENT

Polypeptides of the present invention may also comprise a part or fragment of a BSP. In a preferred embodiment, the fragment is derived from a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 104-190.

Polypeptides of the present invention comprising a part or fragment of an entire BSP may or may not be BSPs. For example, a full-length polypeptide may be breast-specific, while a fragment thereof may be found in other tissues as well as in breast. A polypeptide that is not a BSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing animals to prepare anti-BSP antibodies. In a preferred embodiment, the part or fragment is a BSP. Methods of determining whether a polypeptide of the present invention is a BSP are described *infra*.

Polypeptides of the present invention comprising fragments of at least 6 contiguous amino acids are also useful in mapping B cell and T cell epitopes of the reference protein. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and U.S. Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of a polypeptide of the present invention have utility in such a study.

Polypeptides of the present invention comprising fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize polypeptides of the present invention. *See, e.g., Lerner, Nature* 299: 592-596 (1982); Shinnick *et al., Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al., Science* 219: 660-6 (1983). As further described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic and are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the polypeptides of the present invention have utility as immunogens.

Polypeptides comprising fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire polypeptide, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition permits identification and separation of molecules that bind

DEX-0360

60

PATENT

specifically to the polypeptide of interest. See U.S. Patent Nos. 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

5 The polypeptide of the present invention thus preferably is at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the polypeptide of the present invention is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger polypeptides having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

10 One having ordinary skill in the art can produce fragments by truncating the nucleic acid molecule, *e.g.*, a BSNA, encoding the polypeptide and then expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally occurring polypeptide. Methods of producing polypeptide fragments are well known in the art. *See, e.g.*,  
15 Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment, preferably a fragment of a BSP, may be produced by chemical or enzymatic cleavage of a BSP polypeptide. In a preferred embodiment, a polypeptide fragment is produced by expressing a nucleic acid molecule of the present invention encoding a fragment,  
20 preferably of a BSP, in a host cell.

Polypeptides of the present invention are also inclusive of mutants, fusion proteins, homologous proteins and allelic variants.

A mutant protein, or mutein, may have the same or different properties compared to a naturally occurring polypeptide and comprises at least one amino acid insertion,  
25 duplication, deletion, rearrangement or substitution compared to the amino acid sequence of a native polypeptide. Small deletions and insertions can often be found that do not alter the function of a protein. Muteins may or may not be breast-specific. Preferably, the mutein is breast-specific. More preferably the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution  
30 compared to the amino acid sequence of SEQ ID NO: 104-190. Accordingly, in a preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to a BSP comprising an amino acid sequence of

DEX-0360

61

PATENT

SEQ ID NO: 104-190. In a yet more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 104-190.

- 5 A mutein may be produced by isolation from a naturally occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical techniques. In a
- 10 preferred embodiment, a mutein is produced from a host cell comprising a mutated nucleic acid molecule compared to the naturally occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid molecule of the invention and then expressing it recombinantly. These mutations may be targeted, in which particular encoded amino acids are altered, or may be
- 15 untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is breast-specific, as described below. Multiple random mutations can be introduced into the gene by methods well known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed
- 20 mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), as well as U.S. Patent No.
- 25 5,223,408, which is herein incorporated by reference in its entirety.

- The invention also contemplates polypeptides that are homologous to a polypeptide of the invention. In a preferred embodiment, the polypeptide is homologous to a BSP. In an even more preferred embodiment, the polypeptide is homologous to a BSP selected from the group having an amino acid sequence of SEQ ID NO: 104-190. By
- 30 homologous polypeptide it is means one that exhibits significant sequence identity to a BSP, preferably a BSP having an amino acid sequence of SEQ ID NO: 104-190. By significant sequence identity it is meant that the homologous polypeptide exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more

DEX-0360

62

PATENT

preferably at least 70%, yet more preferably at least 80% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 104-190. More preferred are homologous polypeptides exhibiting at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to  
5 a BSP comprising an amino acid sequence of SEQ ID NO: 104-190. Most preferably, the homologous polypeptide exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%, 99.7%, 99.8% or 99.9% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 104-190. In a preferred embodiment, the amino acid substitutions of the homologous polypeptide are conservative amino acid substitutions as  
10 discussed above.

Homologous polypeptides of the present invention also comprise polypeptide encoded by a nucleic acid molecule that selectively hybridizes to a BSNA or an antisense sequence thereof. In this embodiment, it is preferred that the homologous polypeptide be encoded by a nucleic acid molecule that hybridizes to a BSNA under low stringency,  
15 moderate stringency or high stringency conditions, as defined herein. More preferred is a homologous polypeptide encoded by a nucleic acid sequence which hybridizes to a BSNA selected from the group consisting of SEQ ID NO: 1-103 or a homologous polypeptide encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes a BSP, preferably an BSP of SEQ ID NO: 104-190 under low stringency, moderate  
20 stringency or high stringency conditions, as defined herein.

Homologous polypeptides of the present invention may be naturally occurring and derived from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, or baboon, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of  
25 SEQ ID NO: 104-190. The homologous polypeptide may also be a naturally occurring polypeptide from a human, when the BSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous  
30 polypeptide may also be a naturally occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule encoding the naturally occurring homologous polypeptide may be isolated and used to

DEX-0360

63

PATENT

express the homologous polypeptide recombinantly. The homologous polypeptide may also be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. Alternatively, the homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of a BSP. In a preferred embodiment, the homologous polypeptide encodes a polypeptide that is a BSP.

Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an antibody. It is, therefore, another aspect of the present invention to provide isolated polypeptide not only identical in sequence to those described with particularity herein, but also to provide isolated polypeptide ("cross-reactive proteins") that competitively inhibit the binding of antibodies to all or to a portion of various of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using immunoassays well known in the art.

As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, polypeptides of the present invention are also inclusive of those encoded by an allelic variant of a nucleic acid molecule encoding a BSP. In this embodiment, it is preferred that the polypeptide be encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 104-190. More preferred is that the polypeptide be encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1-103.

Polypeptides of the present invention are also inclusive of derivative polypeptides encoded by a nucleic acid molecule according to the instant invention. In this embodiment, it is preferred that the polypeptide be a BSP. Also preferred are derivative polypeptides having an amino acid sequence selected from the group consisting of SEQ ID NO: 104-190 and which has been acetylated, carboxylated, phosphorylated, glycosylated, ubiquitinated or other PTMs. In another preferred embodiment, the derivative has been labeled with, *e.g.*, radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , and  $^3\text{H}$ . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand.

DEX-0360

64

PATENT

Polypeptide modifications are well known to those of skill and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational modifications. See, e.g., [www.expasy.org](http://www.expasy.org) (accessed November 11, 2002), which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

General examples of types of post-translational modifications include, but are not limited to: (Z)-dehydrobutyrine; 1-chondroitin sulfate-L-aspartic acid ester; 1'-glycosyl-L-tryptophan; 1'-phospho-L-histidine; 1-thioglycine; 2'-(S-L-cysteinyl)-L-histidine; 2'-[3-carboxamido (trimethylammonio)propyl]-L-histidine; 2'-alpha-mannosyl-L-tryptophan; 2-methyl-L-glutamine; 2-oxobutanoic acid; 2-pyrrolidone carboxylic acid; 3'-(1'-L-histidyl)-L-tyrosine; 3'-(8alpha-FAD)-L-histidine; 3'-(S-L-cysteinyl)-L-tyrosine; 3', 3'', 5'-triiodo-L-thyronine; 3'-4'-phospho-L-tyrosine; 3-hydroxy-L-proline; 3'-methyl-L-histidine; 3-methyl-L-lanthionine; 3'-phospho-L-histidine; 4'-(L-tryptophan)-L-tryptophyl quinone; 42 N-cysteinyl-glycosylphosphatidylinositoethanolamine; 43 -(T-L-histidyl)-L-tyrosine; 4-hydroxy-L-arginine; 4-hydroxy-L-lysine; 4-hydroxy-L-proline; 5'-(N6-L-lysine)-L-topaquinone; 5-hydroxy-L-lysine; 5-methyl-L-arginine; alpha-l-microglobulin-Ig alpha

DEX-0360

65

PATENT

- complex chromophore; bis-L-cysteinyl bis-L-histidino diiron disulfide; bis-L-cysteinyl-L-N3'-histidino-L-serinyl tetrairon' tetrasulfide; chondroitin sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-alanine; D-allo-isoleucine; D-asparagine; dehydroalanine; dehydrotyrosine; dermatan 4-sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; D-glucuronyl-N-glycine; dipyrrolylmethanemethyl-L-cysteine; D-leucine; D-methionine; D-phenylalanine; D-serine; D-tryptophan; glycine amide; glycine oxazolecarboxylic acid; glycine thiazolecarboxylic acid; heme P450-bis-L-cysteine-L-tyrosine; heme-bis-L-cysteine; hemediol-L-aspartyl ester-L-glutamyl ester; hemediol-L-aspartyl ester-L-glutamyl ester-L-methionine sulfonium; heme-L-cysteine;
- 10 heme-L-histidine; heparan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-serine; heme P450-bis-L-cysteine-L-lysine; hexakis-L-cysteinyl hexairon hexasulfide; keratan sulfate D-glucuronyl-D-galactosyl-D-galactosyl-D-xylosyl-L-threonine; L-oxoalanine- lactic acid; L phenyllactic acid; l'-(8alpha-FAD)-L-histidine; L-2'.4'.5'-topaquinone; L-3'.4'-dihydroxyphenylalanine; L-3'.4'.5'-trihydroxyphenylalanine; L-4'-
- 15 bromophenylalanine; L-6'-bromotryptophan; L-alanine amide; L-alanyl imidazolinone glycine; L-allysine; L-arginine amide; L-asparagine amide; L-aspartic 4-phosphoric anhydride; L-aspartic acid 1-amide; L-beta-methylthioaspartic acid; L-bromohistidine; L-citrulline; L-cysteine amide; L-cysteine glutathione disulfide; L-cysteine methyl disulfide; L-cysteine methyl ester; L-cysteine oxazolecarboxylic acid; L-cysteine
- 20 oxazolinecarboxylic acid; L-cysteine persulfide; L-cysteine sulfenic acid; L-cysteine sulfinic acid; L-cysteine thiazolecarboxylic acid; L-cysteinyl homocitryl molybdenum-heptairon-nonasulfide; L-cysteinyl imidazolinone glycine; L-cysteinyl molybdopterin; L-cysteinyl molybdopterin guanine dinucleotide; L-cystine; L-erythro-beta-hydroxyasparagine; L-erythro-beta-hydroxyaspartic acid; L-gamma-carboxyglutamic acid;
- 25 L-glutamic acid 1-amide; L-glutamic acid 5-methyl ester; L-glutamine amide; L-glutamyl 5-glycerylphosphorylethanolamine; L-histidine amide; L-isoglutamyl-polyglutamic acid; L-isoglutamyl-polyglycine; L-isoleucine amide; L-lanthionine; L-leucine amide; L-lysine amide; L-lysine thiazolecarboxylic acid; L-lysinoalanine; L-methionine amide; L-methionine sulfone; L-phenylalanine thiazolecarboxylic acid; L-phenylalanine amide; L-proline amide; L-selenocysteine; L-selenocysteinyl molybdopterin guanine dinucleotide;
- 30 L-serine amide; L-serine thiazolecarboxylic acid; L-seryl imidazolinone glycine; L-T-bromophenylalanine; L-T-bromophenylalanine; L-threonine amide; L-thyroxine; L-tryptophan amide; L-tryptophyl quinone; L-tyrosine amide; L-valine amide; meso-

## DEX-0360

## 66

## PATENT

- lanthionine; N-(L-glutamyl)-L-tyrosine; N-(L-isoaspartyl)-glycine; N-(L-isoaspartyl)-L-cysteine; N,N,N-trimethyl-L-alanine; N,N-dimethyl-L-proline; N2-acetyl-L-lysine; N2-succinyl-L-tryptophan; N4-(ADP-ribosyl)-L-asparagine; N4-glycosyl-L-asparagine; N4-hydroxymethyl-L-asparagine; N4-methyl-L-asparagine; N5-methyl-L-glutamine; N6-1-
- 5 carboxyethyl-L-lysine; N6-(4-amino hydroxybutyl)-L-lysine; N6-(L-isoglutamyl)-L-lysine; N6-(phospho-5'-adenosine)-L-lysine; N6-(phospho-5'-guanosine)-L-lysine; N6,N6,N6-trimethyl-L-lysine; N6,N6-dimethyl-L-lysine; N6-acetyl-L-lysine; N6-biotinyl-L-lysine; N6-carboxy-L-lysine; N6-formyl-L-lysine; N6-glycyl-L-lysine; N6-lipoyl-L-lysine; N6-methyl-L-lysine; N6-methyl-N6-poly(N-methyl-propylamine)-L-lysine; N6-
- 10 mureinyl-L-lysine; N6-myristoyl-L-lysine; N6-palmitoyl-L-lysine; N6-pyridoxal phosphate-L-lysine; N6-pyruvic acid 2-iminyl-L-lysine; N6-retinal-L-lysine; N-acetyl-glycine; N-acetyl-L-glutamine; N-acetyl-L-alanine; N-acetyl-L-aspartic acid; N-acetyl-L-cysteine; N-acetyl-L-glutamic acid; N-acetyl-L-isoleucine; N-acetyl-L-methionine; N-acetyl-L-proline; N-acetyl-L-serine; N-acetyl-L-threonine; N-acetyl-L-
- 15 tyrosine; N-acetyl-L-valine; N-alanyl-glycosylphosphatidylinositoethanolamine; N-asparaginyl-glycosylphosphatidylinositoethanolamine; N-aspartyl-glycosylphosphatidylinositoethanolamine; N-formylglycine; N-formyl-L-methionine; N-glycyl-glycosylphosphatidylinositoethanolamine; N-L-glutamyl-poly-L-glutamic acid; N-methylglycine; N-methyl-L-alanine; N-methyl-L-methionine; N-methyl-L-phenylalanine;
- 20 N-myristoyl-glycine; N-palmitoyl-L-cysteine; N-pyruvic acid 2-iminyl-L-cysteine; N-pyruvic acid 2-iminyl-L-valine; N-seryl-glycosylphosphatidylinositoethanolamine; N-seryl-glycosylphosphatidylinositolphosphatidylcholine; O-(ADP-ribosyl)-L-serine; O-(phospho-5'-adenosine)-L-threonine; O-(phospho-5'-DNA)-L-serine; O-(phospho-5'-DNA)-L-threonine; O-(phospho-5'rRNA)-L-serine; O-(phosphoribosyl dephospho-coenzyme A)-L-
- 25 serine; O-(sn-1-glycerophosphoryl)-L-serine; O4'-(8alpha-FAD)-L-tyrosine; O4'-(phospho-5'-adenosine)-L-tyrosine; O4'-(phospho-5'-DNA)-L-tyrosine; O4'-(phospho-5'-RNA)-L-tyrosine; O4'-(phospho-5'-uridine)-L-tyrosine; O4-glycosyl-L-hydroxyproline; O4'-glycosyl-L-tyrosine; O4'-sulfo-L-tyrosine; O5-glycosyl-L-hydroxylysine; O-glycosyl-L-serine; O-glycosyl-L-threonine; omega-N-(ADP-ribosyl)-L-arginine; omega-N-omega-N'-
- 30 dimethyl-L-arginine; omega-N-methyl-L-arginine; omega-N-omega-N-dimethyl-L-arginine; omega-N-phospho-L-arginine; O-octanoyl-L-serine; O-palmitoyl-L-serine; O-palmitoyl-L-threonine; O-phospho-L-serine; O-phospho-L-threonine; O-phosphopantetheine-L-serine; phycoerythrobilin-bis-L-cysteine; phycourobilin-bis-L-

DEX-0360

67

PATENT

- cysteine; pyrroloquinoline quinone; pyruvic acid; S hydroxycinnamyl-L-cysteine; S-(2-aminovinyl) methyl-D-cysteine; S-(2-aminovinyl)-D-cysteine; S-(6-FW-L-cysteine; S-(8alpha-FAD)-L-cysteine; S-(ADP-ribosyl)-L-cysteine; S-(L-isoglutamyl)-L-cysteine; S-12-hydroxyfarnesyl-L-cysteine; S-acetyl-L-cysteine; S-diacylglycerol-L-cysteine; S-
- 5 diphytanylglycerol diether-L-cysteine; S-farnesyl-L-cysteine; S-geranylgeranyl-L-cysteine; S-glycosyl-L-cysteine; S-glycyl-L-cysteine; S-methyl-L-cysteine; S-nitrosyl-L-cysteine; S-palmitoyl-L-cysteine; S-phospho-L-cysteine; S-phytycobiliviolin-L-cysteine; S-phytycyanobilin-L-cysteine; S-phytycoerythrobilin-L-cysteine; S-phytychromobilin-L-cysteine; S-selenyl-L-cysteine; S-sulfo-L-cysteine; tetrakis-L-cysteiny l diiron disulfide;
- 10 tetrakis-L-cysteiny l iron; tetrakis-L-cysteiny l tetrairon tetrasulfide; trans-2,3-cis 4-dihydroxy-L-proline; tris-L-cysteiny l triiron tetrasulfide; tris-L-cysteiny l triiron trisulfide; tris-L-cysteiny l-L-aspartato tetrairon tetrasulfide; tris-L-cysteiny l-L-cysteine persulfido-bis-L-glutamato-L-histidino tetrairon disulfide trioxide; tris-L-cysteiny l-L-N3'-histidino tetrairon tetrasulfide; tris-L-cysteiny l-L-N1'-histidino tetrairon tetrasulfide; and tris-L-
- 15 cysteiny l-L-seriny l tetrairon tetrasulfide.

- Additional examples of PTMs may be found in web sites such as the Delta Mass database based on Krishna, R. G. and F. Wold (1998). Posttranslational Modifications. Proteins - Analysis and Design. R. H. Angeletti. San Diego, Academic Press. 1: 121-206. ;
- Methods in Enzymology, 193, J.A. McClosky (ed) (1990), pages 647-660; Methods in
- 20 Protein Sequence Analysis edited by Kazutomo Imahori and Fumio Sakiyama, Plenum Press, (1993) "Post-translational modifications of proteins" R.G. Krishna and F. Wold pages 167-172; "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. Nucleic Acids Res. 29; 332-335 (2001) "O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins" Gupta
- 25 et al. Nucleic Acids Research, 27: 370-372 (1999); and "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. Nucleic Acids Res 27(1):237-239 (1999) see also, WO 02/21139A2, the disclosure of which is incorporated herein by reference in its entirety.

- Tumorigenesis is often accompanied by alterations in the post-translational
- 30 modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from normal cells or tissues. A number of altered post-translational modifications are known.

One common alteration is a change in phosphorylation state, wherein the polypeptide from the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on different residues than the polypeptide from a normal cell. Another common alteration is

5 a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue. Changes in glycosylation may be critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are

10 important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr. Pharm. Des.* 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

Another post-translational modification that may be altered in cancer cells is prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either

15 farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signalling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).

20 Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to the corresponding polypeptides from noncancerous cells.

25 Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent

30 cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell

DEX-0360

69

PATENT

compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).

Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.

In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP kinase (e.g., p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally

modified are known in the art. See, e.g., the programs described above on the website  
www.expasy.org. The nucleic acid molecule may also be introduced into a host cell that is  
capable of post-translationally modifying the encoded polypeptide. Similarly, one may  
delete sites that are post-translationally modified by either mutating the nucleic acid  
5 sequence so that the encoded polypeptide does not contain the post-translational  
modification motif, or by introducing the native nucleic acid molecule into a host cell that  
is not capable of post-translationally modifying the encoded polypeptide.

It will be appreciated, as is well known and as noted above, that polypeptides are  
not always entirely linear. For instance, polypeptides may be branched as a result of  
10 ubiquitination, and they may be circular, with or without branching, generally as a result  
of posttranslation events, including natural processing event and events brought about by  
human manipulation which do not occur naturally. Circular, branched and branched  
circular polypeptides may be synthesized by non-translation natural process and by  
entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide,  
15 including the peptide backbone, the amino acid side-chains and the amino or carboxyl  
termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a  
covalent modification, is common in naturally occurring and synthetic polypeptides and  
such modifications may be present in polypeptides of the present invention, as well. For  
instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic  
20 processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to  
detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-  
reactive fluorophore derivatives have been synthesized that react under nondenaturing  
conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on  
25 the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of  
amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA),  
e.g., offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430,  
Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546,  
30 Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are  
available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa  
Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568,

DEX-0360

71

PATENT

Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY  
 5 TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

The polypeptides of the present invention can also be conjugated to fluorophores,  
 10 other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, *e.g.*, APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA);  
 15 common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS,  
 20 Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available Pierce, Rockford, IL, USA).

Polypeptides of the present invention, including full length polypeptides, fragments and fusion proteins, can be conjugated, using such cross-linking reagents, to  
 25 fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to polypeptides of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

Polypeptides of the present invention, including full length polypeptide, fragments and fusion proteins, can also usefully be conjugated using cross-linking agents to carrier  
 30 proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-BSP antibodies.

Polypeptides of the present invention, including full length polypeptide, fragments and fusion proteins, can also usefully be conjugated to polyethylene glycol (PEG);

PEGylation increases the serum half life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999). PEG monomers can be attached to the protein directly  
5 or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

Polypeptides of the present invention are also inclusive of analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred  
10 embodiment, this polypeptide is a BSP. In a more preferred embodiment, this polypeptide is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 104-190. Also preferred is an analog polypeptide comprising one or more substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally occurring polypeptide. In one embodiment, the analog is structurally similar to a  
15 BSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--, --CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>-- and --CH<sub>2</sub>SO--. In another embodiment, the analog comprises substitution of one or more amino acids of a BSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can  
20 readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific three-dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine,  
25 phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see, e.g., Krole et al., Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid  
30 phase chemical synthesis of peptides is well established in the art. Procedures are described, *inter alia*, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones,

Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993).

Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added using biotinoyl--(9-fluorenylmethoxycarbonyl)-L-lysine (Fmoc biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation into a fusion protein of a *E. coli* BirA substrate peptide. The Fmoc and tBOC derivatives of dabcyL-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyL chromophore at selected sites in the peptide sequence during synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyL quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS--Fmoc-L-glutamic acid or the corresponding tBOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated Fmoc synthesis of peptides using (Fmoc)--TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

A large number of other Fmoc-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, e.g., Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-

2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)- $\beta$ -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methylpapa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

#### *Fusion Proteins*

Another aspect of the present invention relates to the fusion of a polypeptide of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide of the present invention is a BSP. In a more preferred embodiment, the polypeptide of the present invention that is fused to a heterologous polypeptide comprises part or all of the amino acid sequence of SEQ ID NO: 104-190, or is a mutein,

DEX-0360

75

PATENT

homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the fusion protein is encoded by a nucleic acid molecule comprising all or part of the nucleic acid sequence of SEQ ID NO: 1-103, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103.

The fusion proteins of the present invention will include at least one fragment of a polypeptide of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the polypeptide of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of a polypeptide of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and preferably at least 15, 20, or 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP chromophore-containing proteins) are particularly useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of recombinantly-expressed proteins. *See, e.g.*, Ausubel, Chapter 16, (1992), *supra*. Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins into the periplasmic space or extracellular milieu for prokaryotic hosts or into the culture medium for eukaryotic cells through incorporation of secretion signals and/or leader sequences. For example, a His<sup>6</sup> tagged protein can be

DEX-0360

76

PATENT

purified on a Ni affinity column and a GST fusion protein can be purified on a glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

Other useful fusion proteins of the present invention include those that permit use of the polypeptide of the present invention as bait in a yeast two-hybrid system. See Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.* 10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); Colas *et al.*, *Nature* 380, 548-550 (1996); Norman, T. *et al.*, *Science* 285, 591-595 (1999); Fabbri *et al.*, *Oncogene* 18, 4357-4363 (1999); Xu *et al.*, *Proc Natl Acad Sci U S A* 94, 12473-12478 (1997); Yang, *et al.*, *Nuc. Acids Res.* 23, 1152-1156 (1995); Kolonin *et al.*, *Proc Natl Acad Sci U S A* 95, 14266-14271 (1998); Cohen *et al.*, *Proc Natl Acad Sci U S A* 95, 14272-14277 (1998); Uetz, *et al.* *Nature* 403, 623-627(2000); Ito, *et al.*, *Proc Natl Acad Sci U S A* 98, 4569-4574 (2001). Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded polypeptide on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above.

The polypeptides of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

Fusion partners include, *inter alia*, *myc*, hemagglutinin (HA), GST, immunoglobulins,  $\beta$ -galactosidase, biotin trpE, protein A,  $\beta$ -lactamase,  $\alpha$ -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), lacZ, green fluorescent protein (GFP), yeast  $\alpha$  mating factor, GAL4 transcription activation or DNA binding domain, luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. See, e.g., Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art.

5 Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well known in the art (e.g., a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding

15 proteins or other molecules that bind to the BSP.

As further described below, the polypeptides of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize polypeptides of the present invention including BSPs and their allelic variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the polypeptides of the present invention, particularly BSPs, e.g. by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of BSPs, as for example by immunoprecipitation, and for use as specific

20 agonists or antagonists of BSPs.

One may determine whether polypeptides of the present invention including BSPs, muteins, homologous proteins or allelic variants or fusion proteins of the present invention are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the polypeptide at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992);

30

DEX-0360

78

PATENT

combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, (Epicentre Technologies Corporation, Madison, WI, USA).

Purification of the polypeptides or fusion proteins of the present invention is well known and within the skill of one having ordinary skill in the art. *See, e.g.*, Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides is described above. Purification of chemically-synthesized peptides can readily be effected, *e.g.*, by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated polypeptides or fusion proteins of the present invention in pure or substantially pure form in the presence of absence of a stabilizing agent. Stabilizing agents include both proteinaceous and non-proteinaceous material and are well known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

Although high levels of purity are preferred when the isolated polypeptide or fusion protein of the present invention are used as therapeutic agents, such as in vaccines and replacement therapy, the isolated polypeptides of the present invention are also useful at lower purity. For example, partially purified polypeptides of the present invention can be used as immunogens to raise antibodies in laboratory animals.

In a preferred embodiment, the purified and substantially purified polypeptides of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides or fusion proteins of the present invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the bond can be covalent or noncovalent. For example, the peptides of the invention may be stabilized by covalent linkage to albumin. *See*, U.S. Patent No. 5,876,969, the contents of which are hereby incorporated in its entirety.

For example, the polypeptides or fusion proteins of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the polypeptides or fusion proteins of the present invention can be used

DEX-0360

79

PATENT

to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized polypeptide or fusion protein of the present invention.

As another example, the polypeptides or fusion proteins of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.

The polypeptides and fusion proteins of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biologic interaction there between. The polypeptides or fusion proteins of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the polypeptide or fusion protein of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound polypeptide or fusion protein to indicate biological interaction there between.

#### Antibodies

In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid molecules of the invention. In a preferred embodiment, the antibodies are specific for a polypeptide that is a BSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that comprises SEQ ID NO: 104-190, or a fragment, mutein, derivative, analog or fusion protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may be also

DEX-0360

80

PATENT

due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on a BSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or vis versa. In addition, alternative splice forms of a BSP may be indicative of cancer. Differential degradation of the C or N-terminus of a BSP may also be a marker or target for anticancer therapy. For example, an BSP may be N-terminal degraded in cancer cells exposing new epitopes to which antibodies may selectively bind for diagnostic or therapeutic uses.

As is well known in the art, the degree to which an antibody can discriminate among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-BSP polypeptides by at least two-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the polypeptide of the present invention in samples derived from human breast.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the present invention will be at least about  $1 \times 10^{-6}$  molar (M), typically at least about  $5 \times 10^{-7}$  M,  $1 \times 10^{-7}$  M, with affinities and avidities of at least  $1 \times 10^{-8}$  M,  $5 \times 10^{-9}$  M,  $1 \times 10^{-10}$  M and up to  $1 \times 10^{-13}$  M proving especially useful.

The antibodies of the present invention can be naturally occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In such case, antibodies to the polypeptides of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization, with the polypeptide of the present invention. Such antibodies will typically, but will not invariably, be polyclonal. In addition, individual polyclonal antibodies may be isolated and cloned to generate monoclonals.

Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic

DEX-0360

81

PATENT

mice capable of producing human antibodies and methods of producing human antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patent Nos. 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention are also usefully obtained from other species, including mammals such as rodents (typically mouse, but also rat, guinea pig, and hamster), lagomorphs (typically rabbits), and also larger mammals, such as sheep, goats, cows, and horses; or egg laying birds or reptiles such as chickens or alligators. In such cases, as with the transgenic human-antibody-producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the polypeptide of the present invention. One form of avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000.

As discussed above, virtually all fragments of 8 or more contiguous amino acids of a polypeptide of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptide of the present invention to other moieties. For example, polypeptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996). Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant, and may include naked DNA immunization (Moss, *Semin. Immunol.* 2: 317-327 (1990)).

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the polypeptides of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the polypeptides of the present invention. Antibodies from avian species may have particular advantage in detection of the polypeptides of the present invention, in human serum or tissues (Vikingo *et al.*, *Biosens. Bioelectron.* 13: 1257-1262 (1998)). Following immunization, the antibodies of the present invention can be obtained using any art-accepted technique. Such techniques are well known in the art and are described in detail in references such as Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); and Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997).

Briefly, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes encoding antibodies specific for the polypeptides of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: *e.g.*, genes encoding antibodies specific for the polypeptides of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further

DEX-0360

83

PATENT

described in U.S. Patent No. 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

5 Host cells for recombinant antibody production of whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region  
10 fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. See, e.g., Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*, 4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997); Aujame *et al.*, *Human*  
15 *Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994). Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. See, e.g., Barbas (2001), *supra*; Kay, *supra*; and Abelson, *supra*.

20 Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length antibody in a further prokaryotic or a eukaryotic host cell. Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the  
25 present invention. For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. See, e.g., Takahashi *et al.*, *Biosci. Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3): 1 57-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20 (1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1): 67-75 (1997);, Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); and  
30 Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998).

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells. See, e.g., Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8

DEX-0360

84

PATENT

(2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997); and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992).

Antibodies and fragments and derivatives thereof of the present invention can also  
 5 be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1): 128-38 (2000); Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et al.*, *Plant Physiol.* 109(2): 341-6 (1995).  
 10

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. *See, e.g.* Pollock *et al.*, *J. Immunol. Methods.* 231: 147-57 (1999); Young *et al.*, *Res. Immunol.* 149: 609-10 (1998); and Limonta *et al.*, *Immunotechnology* 1: 107-13 (1995).

15 Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells. Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81 (1998) review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies. Antibodies of the present invention can also be prepared by cell  
 20 free translation, as further described in Merk *et al.*, *J. Biochem. (Tokyo)* 125(2): 328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2): 147-57 (1999).

The invention further provides antibody fragments that bind specifically to one or  
 25 more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention. Among such useful fragments are Fab, Fab', Fv,  
 30 F(ab)'<sub>2</sub>, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).

The present invention also relates to antibody derivatives that bind specifically to one or more of the polypeptides of the present invention, to one or more of the

DEX-0360

85

PATENT

polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention.

5           Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus are more suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful method is PEGylation to increase the serum half life of the antibodies.

10           Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g., Morrison et al., Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al., Nature* 309(5966): 364-7 (1984); Takeda *et al., Nature* 314(6010): 452-4 (1985); and U.S. Patent  
15 No. 5,807,715 the disclosure of which is incorporated herein by reference in its entirety. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al., Nature* 332(6162): 323-7 (1988); Co *et al., Nature* 351(6326): 501-2 (1991); and U.S. Patent Nos.  
20 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties. Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

25           It is contemplated that the nucleic acids encoding the antibodies of the present invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. Accordingly, the present invention includes any recombinant vector containing the coding sequences, or part thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors  
30 may be prepared using conventional molecular biology techniques, known to those with skill in the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either with or without a signal sequence for intracellular transport. Such vectors may be

transduced or transfected into eukaryotic cells or used for gene therapy (Marasco et al., *Proc. Natl. Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

- 5       The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited
- 10   by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention. The choice of label depends, in part, upon the desired use.

- For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label can usefully be an enzyme that
- 15   catalyzes production and local deposition of a detectable product. Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well known, and include alkaline phosphatase,  $\beta$ -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG);
- 20   o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN);
- 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BluoGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS);
- 25   phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

- Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide ( $H_2O_2$ ), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol.
- 30   Immediately following the oxidation, the luminol is in an excited state (intermediate reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and

DEX-0360

87

PATENT

requiring only small amounts of antibody. *See, e.g., Thorpe et al., Methods Enzymol.* 133: 331-53 (1986); Kricka *et al., J. Immunoassay* 17(1): 67-83 (1996); and Lundqvist *et al., J. Biolumin. Chemilumin.* 10(6): 353-9 (1995). Kits for such enhanced chemiluminescent detection (ECL) are available commercially. The antibodies can also be labeled using colloidal gold.

As another example, when the antibodies of the present invention are used, *e.g.,* for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores. There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.

For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention.

For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.,* for western blotting applications, they can usefully be labeled with radioisotopes, such as  $^{33}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ , and  $^{125}\text{I}$ .

As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be  $^{228}\text{Th}$ ,  $^{227}\text{Ac}$ ,  $^{225}\text{Ac}$ ,  $^{223}\text{Ra}$ ,  $^{213}\text{Bi}$ ,  $^{212}\text{Pb}$ ,  $^{212}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{203}\text{Pb}$ ,  $^{194}\text{Os}$ ,  $^{188}\text{Re}$ ,  $^{186}\text{Re}$ ,  $^{153}\text{Sm}$ ,  $^{149}\text{Tb}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{111}\text{In}$ ,  $^{105}\text{Rh}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{97}\text{Ru}$ ,  $^{90}\text{Y}$ ,  $^{90}\text{Sr}$ ,  $^{88}\text{Y}$ ,  $^{72}\text{Se}$ ,  $^{67}\text{Cu}$ , or  $^{47}\text{Sc}$ .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

5 As would be understood, use of the labels described above is not restricted to the application as for which they were mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the polypeptides of the present invention. Commonly, the  
10 antibody in such immunotoxins is conjugated to *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. See Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998).

The antibodies of the present invention can usefully be attached to a substrate, and  
15 it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the polypeptides of the present invention, to one or more of the polypeptides encoded by the isolated nucleic acid molecules of the present invention, or the binding of which can be competitively inhibited by one or more of the polypeptides of the present invention or one or more of the polypeptides encoded by the isolated nucleic  
20 acid molecules of the present invention, attached to a substrate. Substrates can be porous or nonporous, planar or nonplanar. For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography. For example, the antibodies of the present invention can usefully be attached to paramagnetic microspheres,  
25 typically by biotin-streptavidin interaction, which microsphere can then be used for isolation of cells that express or display the polypeptides of the present invention. As another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in  
30 prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the BSPs of the present invention or to polypeptides encoded by the BSNA of the invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody molecule, or to alter it in any other way that may render it more suitable for a particular application.

#### 10 Transgenic Animals and Cells

In another aspect, the invention provides transgenic cells and non-human organisms comprising nucleic acid molecules of the invention. In a preferred embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding a BSP. In a preferred embodiment, the BSP comprises an amino acid sequence selected from SEQ ID NO: 104-190, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise a BSNA of the invention, preferably a BSNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-103, or a part, substantially similar nucleic acid molecule, allelic variant or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human BSG. The transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes. Methods of producing transgenic animals are well known in the art. *See, e.g., Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual*, 2d ed., Cold Spring Harbor Press (1999); Jackson *et al.*, *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press (2000); and Pinkert, *Transgenic Animal Technology: A Laboratory Handbook*, Academic Press (1999).

Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g., Paterson*

*et al.*, *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver *et al.*, *Biotechnology* 11: 1263-1270 (1993); Wright *et al.*, *Biotechnology* 9: 830-834 (1991); and U.S. Patent No. 4,873,191, herein incorporated by reference in its entirety); retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g.*, Van der Putten *et al.*, *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (*see, e.g.*, Thompson *et al.*, *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (*see, e.g.*, Lo, 1983, *Mol. Cell. Biol.* 3: 1803-1814 (1983)); introduction using a gene gun (*see, e.g.*, Ulmer *et al.*, *Science* 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g.*, Lavitrano *et al.*, *Cell* 57: 717-723 (1989)).

Other techniques include, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g.*, Campbell *et al.*, *Nature* 380: 64-66 (1996); Wilmut *et al.*, *Nature* 385: 810-813 (1997)). The present invention provides for transgenic animals that carry the transgene (*i.e.*, a nucleic acid molecule of the invention) in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i.e.* *e.*, mosaic animals or chimeric animals.

The transgene may be integrated as a single transgene or as multiple copies, such as in concatamers, *e. g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, *e.g.*, the teaching of Lasko *et al. et al.*, *Proc. Natl. Acad. Sci. USA* 89: 6232- 6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

DEX-0360

91

PATENT

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well known in the art. In general, a vector is designed to comprise some nucleotide sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science* 265: 103-106 (1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g., Smithies et al., Nature* 317: 230-234 (1985); Thomas *et al., Cell* 51: 503-512 (1987); Thompson *et al., Cell* 5: 313-321 (1989).

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that

contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g.,* Thomas, *supra* and Thompson, *supra*. However this approach can be  
5 routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to  
10 express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient in vivo. Such cells may be obtained from an animal or patient or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells  
15 are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures,  
20 including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered  
25 cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or  
30 vascular graft. *See, e.g.,* U.S. Patent Nos. 5,399,349 and 5,460,959, each of which is incorporated by reference herein in its entirety.

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the

DEX-0360

93

PATENT

development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

- 5 Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

10 Computer Readable Means

- A further aspect of the invention is a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred embodiment, the invention provides a computer readable means for storing SEQ ID NO: 15 104-190 and SEQ ID NO: 1-103 as described herein, as the complete set of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria, the comparison of sequences, the alignment or ordering of sequences meeting a set of 20 criteria, and the like.

- The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and "amino acid sequences of the invention" mean any detectable chemical or physical 25 characteristic of a polynucleotide or polypeptide of the invention that is or may be reduced to or stored in a computer readable form. These include, without limitation, chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

- This invention provides computer readable media having stored thereon sequences 30 of the invention. A computer readable medium may comprise one or more of the following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises

the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence comprising the sequence of an amino acid of the invention in a computer readable medium; and comparing said amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid

DEX-0360

95

PATENT

of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence. In addition, the invention includes a method of using patterns of expression associated with either the nucleic acids or proteins in a computer-based method to  
5 diagnose disease.

Diagnostic Methods for breast Cancer

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by  
10 comparing expression of a BSNA or a BSP in a human patient that has or may have breast cancer, or who is at risk of developing breast cancer, with the expression of a BSNA or a BSP in a normal human control. For purposes of the present invention, "expression of a BSNA" or "BSNA expression" means the quantity of BSNA mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any  
15 method known in the art in a cell, tissue, organ or whole patient. Similarly, the term "expression of a BSP" or "BSP expression" means the amount of BSP that can be measured by any method known in the art or the level of translation of a BSNA that can be measured by any method known in the art.

The present invention provides methods for diagnosing breast cancer in a patient,  
20 by analyzing for changes in levels of BSNA or BSP in cells, tissues, organs or bodily fluids compared with levels of BSNA or BSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of a BSNA or BSP in the patient versus the normal human control is associated with the presence of breast cancer or with a predilection to the disease. In  
25 another preferred embodiment, the present invention provides methods for diagnosing breast cancer in a patient by analyzing changes in the structure of the mRNA of a BSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for  
30 diagnosing breast cancer in a patient by analyzing changes in a BSP compared to a BSP from a normal patient. These changes include, *e.g.*, alterations, including post translational modifications such as glycosylation and/or phosphorylation of the BSP or changes in the subcellular BSP localization.

DEX-0360

96

PATENT

For purposes of the present invention, diagnosing means that BSNA or BSP levels are used to determine the presence or absence of disease in a patient. As will be understood by those of skill in the art, measurement of other diagnostic parameters may be required for definitive diagnosis or determination of the appropriate treatment for the disease. The determination may be made by a clinician, a doctor, a testing laboratory, or a patient using an over the counter test. The patient may have symptoms of disease or may be asymptomatic. In addition, the BSNA or BSP levels of the present invention may be used as screening marker to determine whether further tests or biopsies are warranted. In addition, the BSNA or BSP levels may be used to determine the vulnerability or susceptibility to disease.

In a preferred embodiment, the expression of a BSNA is measured by determining the amount of a mRNA that encodes an amino acid sequence selected from SEQ ID NO: 104-190, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the BSNA expression that is measured is the level of expression of a BSNA mRNA selected from SEQ ID NO: 1-103, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acid molecules. BSNA expression may be measured by any method known in the art, such as those described *supra*, including measuring mRNA expression by Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. See, e.g., Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. BSNA transcription may be measured by any method known in the art including using a reporter gene hooked up to the promoter of a BSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, e.g., aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary, BSNA expression may be compared to a known control, such as normal breast nucleic acid, to detect a change in expression.

In another preferred embodiment, the expression of a BSP is measured by determining the level of a BSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 104-190, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression

DEX-0360

97

PATENT

of a BSNA or BSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of breast cancer. The expression level of a BSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the BSP expression level may be determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g.*, Harlow (1999), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Alterations in the BSP structure may be determined by any method known in the art, including, *e.g.*, using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*

In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An antibody specific to a BSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-BSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a protein such as bovine serum albumin. A sample of interest is incubated with the antibody on the solid support under conditions in which the BSP will bind to the anti-BSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-BSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the BSP to the labeled antibody will occur. After binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of an BSP in the sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

Other methods to measure BSP levels are known in the art. For instance, a competition assay may be employed wherein an anti-BSP antibody is attached to a solid support and an allocated amount of a labeled BSP and a sample of interest are incubated with the solid support. The amount of labeled BSP attached to the solid support can be correlated to the quantity of a BSP in the sample.

DEX-0360

98

PATENT

Of the proteomic approaches, 2D PAGE is a well known technique. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size  
5 using an electric current (the second dimension). In general, the second dimension is perpendicular to the first dimension. Because no two proteins with different sequences are identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance  
10 of a given protein and the identity of the proteins in the sample.

Expression levels of a BSNA can be determined by any method known in the art, including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase  
15 PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

20 Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of expression of one or more BSNAs of interest. In this approach, all or a portion of one or more BSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the RNA  
25 is incubated with the solid support under conditions in which hybridization will occur between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid molecule or a  
30 secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy

DEX-0360

99

PATENT

material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. As used herein "blood" includes whole blood, plasma, serum, circulating epithelial cells, constituents, or any derivative of blood.

In addition to detection in bodily fluids, the proteins and nucleic acids of the invention are suitable to detection by cell capture technology. Whole cells may be captured by a variety methods for example magnetic separation, U.S. Patent Nos. 5,200,084; 5,186,827; 5,108,933; 4,925,788, the disclosures of which are incorporated herein by reference in their entirety. Epithelial cells may be captured using such products as Dynabeads® or CELLection™ (Dynal Biotech, Oslo, Norway). Alternatively, fractions of blood may be captured, e.g., the buffy coat fraction (50mm cells isolated from 5ml of blood) containing epithelial cells. In addition, cancer cells may be captured using the techniques described in WO 00/47998, the disclosure of which is incorporated herein by reference in its entirety. Once the cells are captured or concentrated, the proteins or nucleic acids are detected by the means described in the subject application. Alternatively, nucleic acids may be captured directly from blood samples, see U.S. Patent Nos. 6,156,504, 5,501,963; or WO 01/42504, the disclosures of which are incorporated herein by reference in their entirety.

In a preferred embodiment, the specimen tested for expression of BSNA or BSP includes without limitation breast tissue, breast cells grown in cell culture, blood, serum, lymph node tissue, and lymphatic fluid. In another preferred embodiment, especially when metastasis of a primary breast cancer is known or suspected, specimens include, without limitation, tissues from brain, bone, bone marrow, liver, lungs, colon, and adrenal glands. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, e.g., transthoracic needle aspiration, cervical mediastinoscopy, endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy, bone marrow biopsy and bone marrow aspiration.

All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of a BSNA or BSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other BSNA or BSPs as disclosed herein. Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer

DEX-0360

100

PATENT

marker in addition to a particular BSNA or BSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more preferably at least ten additional cancer markers are used.

5           *Diagnosing*

In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more BSNA and/or BSP in a sample from a patient suspected of having breast cancer. In general, the method comprises the steps of obtaining the sample from the patient, determining the expression level or structural  
10 alterations of a BSNA and/or BSP and then ascertaining whether the patient has breast cancer from the expression level of the BSNA or BSP. In general, if high expression relative to a control of a BSNA or BSP is indicative of breast cancer, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least one and a half times higher, and more preferably are at least two times higher, still more preferably five  
15 times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of breast cancer, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least one and a half times lower, and more preferably are at least two times lower, still more preferably five  
20 times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

The present invention also provides a method of determining whether breast cancer has metastasized in a patient. One may identify whether the breast cancer has  
25 metastasized by measuring the expression levels and/or structural alterations of one or more BSNAs and/or BSPs in a variety of tissues. The presence of a BSNA or BSP in a certain tissue at levels higher than that of corresponding noncancerous tissue (*e.g.*, the same tissue from another individual) is indicative of metastasis if high level expression of a BSNA or BSP is associated with breast cancer. Similarly, the presence of a BSNA or  
30 BSP in a tissue at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of a BSNA or BSP is associated with breast cancer. Further, the presence of a structurally altered BSNA or BSP that is associated with breast cancer is also indicative of metastasis.

DEX-0360

101

PATENT

In general, if high expression relative to a control of a BSNA or BSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the BSNA or BSP is at least one and a half times higher, and more preferably are at least two times higher, still more preferably five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the BSNA or BSP is at least one and a half times lower, and more preferably are at least two times lower, still more preferably five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

#### *Staging*

The invention also provides a method of staging breast cancer in a human patient. The method comprises identifying a human patient having breast cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more BSNAs or BSPs. First, one or more tumors from a variety of patients are staged according to procedures well known in the art, and the expression levels of one or more BSNAs or BSPs is determined for each stage to obtain a standard expression level for each BSNA and BSP. Then, the BSNA or BSP expression levels of the BSNA or BSP are determined in a biological sample from a patient whose stage of cancer is not known. The BSNA or BSP expression levels from the patient are then compared to the standard expression level. By comparing the expression level of the BSNAs and BSPs from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations of a BSNA or BSP to determine the stage of a breast cancer.

#### *Monitoring*

Further provided is a method of monitoring breast cancer in a human patient. One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor a human patient to determine whether a therapy, e.g., chemotherapy, radiotherapy or surgery, has decreased or eliminated the breast cancer. The monitoring may determine if

DEX-0360

102

PATENT

there has been a reoccurrence and, if so, determine its nature. The method comprises identifying a human patient that one wants to monitor for breast cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for expression levels of one or more BSNA or BSPs, and comparing the BSNA or BSP levels over time to those  
5 BSNA or BSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in a BSNA or BSP that are associated with breast cancer.

If increased expression of a BSNA or BSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an  
10 increase in the expression level of a BSNA or BSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. One having ordinary skill in the art would recognize that if this were the case, then a decreased expression level would be indicative of no metastasis, effective therapy or failure to progress to a neoplastic lesion. If decreased expression of a BSNA or BSP is associated  
15 with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting a decrease in the expression level of a BSNA or BSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. In a preferred embodiment, the levels of BSNA or BSPs are determined from the same cell type, tissue or bodily fluid as prior patient samples. Monitoring a  
20 patient for onset of breast cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of a BSNA and/or BSP. The present invention  
25 provides a method in which a test sample is obtained from a human patient and one or more BSNA or BSPs are detected. The presence of higher (or lower) BSNA or BSP levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly breast cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more BSNA or BSPs  
30 of the invention can also be monitored by analyzing levels of expression of the BSNA or BSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of

DEX-0360

103

PATENT

the physiological response of the human patient or cells, as the case may be, to the agent being tested.

*Detection of Genetic Lesions or Mutations*

5 The methods of the present invention can also be used to detect genetic lesions or mutations in a BSG, thereby determining if a human with the genetic lesion is susceptible to developing breast cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing breast cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of one or more nucleotides from the BSGs of this invention, a chromosomal rearrangement  
10 of a BSG, an aberrant modification of a BSG (such as of the methylation pattern of the genomic DNA), or allelic loss of a BSG. Methods to detect such lesions in the BSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

Methods of Detecting Noncancerous breast Diseases

15 The present invention also provides methods for determining the expression levels and/or structural alterations of one or more BSNA and/or BSPs in a sample from a patient suspected of having or known to have a noncancerous breast disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of a BSNA and/or BSP, comparing the expression  
20 level or structural alteration of the BSNA or BSP to a normal breast control, and then ascertaining whether the patient has a noncancerous breast disease. In general, if high expression relative to a control of a BSNA or BSP is indicative of a particular noncancerous breast disease, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least two times higher, and more preferably are at  
25 least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of a noncancerous breast disease, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least two times lower, more preferably are at least five times lower, even more  
30 preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid

DEX-0360

104

PATENT

of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether a BSNA and/or BSP is associated with a particular noncancerous breast disease by obtaining breast tissue from a patient having a noncancerous breast disease of interest and determining which BSNAs and/or BSPs are expressed in the tissue at either a higher or a lower level than in normal breast tissue. In another embodiment, one may determine whether a BSNA or BSP exhibits structural alterations in a particular noncancerous breast disease state by obtaining breast tissue from a patient having a noncancerous breast disease of interest and determining the structural alterations in one or more BSNAs and/or BSPs relative to normal breast tissue.

#### Methods for Identifying breast Tissue

In another aspect, the invention provides methods for identifying breast tissue. These methods are particularly useful in, *e.g.*, forensic science, breast cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a sample is breast tissue or has breast tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising breast tissue or having breast tissue-like characteristics, determining whether the sample expresses one or more BSNAs and/or BSPs, and, if the sample expresses one or more BSNAs and/or BSPs, concluding that the sample comprises breast tissue. In a preferred embodiment, the BSNA encodes a polypeptide having an amino acid sequence selected from SEQ ID NO: 104-190, or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the BSNA has a nucleotide sequence selected from SEQ ID NO: 1-103, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses a BSNA can be accomplished by any method known in the art. Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining whether a BSP is expressed. Determining whether a sample expresses a BSP can be accomplished by any method known in the art. Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the BSP has an amino acid sequence selected from SEQ ID NO: 104-190, or a homolog, allelic variant or fragment thereof. In

DEX-0360

105

PATENT

another preferred embodiment, the expression of at least two BSNA's and/or BSP's is determined. In a more preferred embodiment, the expression of at least three, more preferably four and even more preferably five BSNA's and/or BSP's are determined.

5 In one embodiment, the method can be used to determine whether an unknown tissue is breast tissue. This is particularly useful in forensic science, in which small, damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be used to determine whether a tissue is differentiating or developing into breast tissue. This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new breast tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation include gene transfer into the cells or tissues, alterations in pH, aqueous:air interface and various other culture conditions.

15 Methods for Producing and Modifying breast Tissue

In another aspect, the invention provides methods for producing engineered breast tissue or cells. In one embodiment, the method comprises the steps of providing cells, introducing a BSNA or a BSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of breast tissue cells. In a preferred embodiment, the cells are pluripotent. As is well known in the art, normal breast tissue comprises a large number of different cell types. Thus, in one embodiment, the engineered breast tissue or cells comprises one of these cell types. In another embodiment, the engineered breast tissue or cells comprises more than one breast cell type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the breast cell tissue. Methods for manipulating culture conditions are well known in the art.

25 Nucleic acid molecules encoding one or more BSP's are introduced into cells, preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode BSP's having amino acid sequences selected from SEQ ID NO: 104-190, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected from SEQ ID NO: 1-103, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly

DEX-0360

106

PATENT

preferred embodiment, a BSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well known in the art and are described in detail, *supra*.

5 Artificial breast tissue may be used to treat patients who have lost some or all of their breast function.

#### Pharmaceutical Compositions

10 In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, fusion proteins, antibodies, antibody derivatives, antibody fragments, agonists, antagonists, or inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises a BSNA or part thereof. In a more preferred embodiment, the BSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1-103, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity thereto. In another 15 preferred embodiment, the pharmaceutical composition comprises a BSP or fragment thereof. In a more preferred embodiment, the pharmaceutical composition comprises a BSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 104-190, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred 20 embodiment, the pharmaceutical composition comprises an anti-BSP antibody, preferably an antibody that specifically binds to a BSP having an amino acid that is selected from the group consisting of SEQ ID NO: 104-190, or an antibody that binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

25 Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

30 Pharmaceutical formulation is a well-established art that is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20<sup>th</sup> ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7<sup>th</sup> ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3<sup>rd</sup> ed. (2000) and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, 5 topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain suitable 10 carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium 15 carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, cornstarch, sodium starch glycolate, and alginic acid.

20 Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone™), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

25 Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, 30 polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or

DEX-0360

108

PATENT

sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

DEX-0360

109

PATENT

Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

The pharmaceutical compositions of the present invention can be administered topically. For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops, tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base.

For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such

DEX-0360

110

PATENT

as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for treating respiratory disorders.

Alternatively, the compounds of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of  
5 delivery.

The pharmaceutically active compound in the pharmaceutical compositions of the present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base  
10 forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.  
15

A "therapeutically effective dose" refers to that amount of active ingredient, for example BSP polypeptide, fusion protein, or fragments thereof, antibodies specific for BSP, agonists, antagonists or inhibitors of BSP, which ameliorates the signs or symptoms of the disease or prevent progression thereof; as would be understood in the medical arts, cure, although desired, is not required.  
20

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of  
25 administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical  
30 compositions that exhibit large therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of circulating concentrations that includes the ED50 with little or no toxicity. After

DEX-0360

111

PATENT

administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

- 5           The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age, weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting  
10   pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

- Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody  
15   agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1mg/kg to 5 mg/kg). The pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose.

- Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will  
20   employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

- Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the  
25   patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

#### Therapeutic Methods

- The present invention further provides methods of treating subjects having defects  
30   in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of breast function. As used herein, "treating" includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term "treating" encompasses any

DEX-0360

112

PATENT

improvement of a disease, including minor improvements. These methods are discussed below.

*Gene Therapy and Vaccines*

The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be driven from a vector, typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for the purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of "naked" nucleic acid vaccination, as further described in U.S. Patent Nos. 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. See, e.g., Doronin *et al.*, *J. Virol.* 75: 3314-24 (2001).

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid molecule of the present invention is administered. The nucleic acid molecule can be delivered in a vector that drives expression of a BSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of a BSP are administered, for example, to complement a deficiency in the native BSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. See, e.g., Cid-Arregui, *supra*. In a preferred embodiment, the nucleic acid molecule encodes a BSP having the amino acid sequence of SEQ ID NO: 104-190, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express a BSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in BSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode a BSP having the amino acid sequence of SEQ ID NO: 104-190, or a fragment, fusion protein, allelic variant or homolog thereof.

DEX-0360

113

PATENT

*Antisense Administration*

Antisense nucleic acid compositions, or vectors that drive expression of a BSG antisense nucleic acid, are administered to downregulate transcription and/or translation of a BSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of a BSG. For example, oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to BSG transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995).

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the BSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); and McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9 (2000). Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

In a preferred embodiment, the antisense molecule is derived from a nucleic acid molecule encoding a BSP, preferably a BSP comprising an amino acid sequence of SEQ ID NO: 104-190, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-103, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

*Polypeptide Administration*

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a BSP, a fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant BSP defect.

DEX-0360

114

PATENT

Protein compositions are administered, for example, to complement a deficiency in native BSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to BSP. The immune response can be used to modulate activity of BSP or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate BSP.

In a preferred embodiment, the polypeptide administered is a BSP comprising an amino acid sequence of SEQ ID NO: 104-190, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-103, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

*Antibody, Agonist and Antagonist Administration*

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is well known, antibody compositions are administered, for example, to antagonize activity of BSP, or to target therapeutic agents to sites of BSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to a BSP comprising an amino acid sequence of SEQ ID NO: 104-190, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antibody specifically binds to a BSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-103, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which bind to a BSP or have a modulatory effect on the expression or activity of a BSP. Modulators which decrease the expression or activity of BSP (antagonists) are believed to be useful in treating breast cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of a BSP can also be designed, synthesized and tested for use in the imaging and treatment of breast cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the BSPs identified herein. Molecules

DEX-0360

115

PATENT

identified in the library as being capable of binding to a BSP are key candidates for further evaluation for use in the treatment of breast cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of a BSP in cells.

5 In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of BSP is administered. Antagonists of BSP can be produced using methods generally known in the art. In particular, purified BSP can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of a BSP.

10 In other embodiments a pharmaceutical composition comprising an agonist of a BSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a BSP comprising an amino acid sequence of SEQ  
15 ID NO: 104-190, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a BSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1-103, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

20

#### *Targeting breast Tissue*

The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the breast or to specific cells in the breast. In a preferred embodiment, an anti-BSP antibody  
25 is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if breast tissue needs to be selectively destroyed. This would be useful for targeting and killing breast cancer cells. In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting breast cell function.

30 In another embodiment, an anti-BSP antibody may be linked to an imaging agent that can be detected using, *e.g.*, magnetic resonance imaging, CT or PET. This would be useful for determining and monitoring breast function, identifying breast cancer tumors, and identifying noncancerous breast diseases.

## EXAMPLES

**Example 1: Gene Expression analysis***Custom Microarray Experiment—Breast Cancer*

Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc. (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for the *in-situ* synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent, from gene sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever possible two different 60mers were designed for each gene of interest.

All microarray experiments were two-color experiments and were preformed using Agilent-recommended protocols and reagents. Briefly, each microarray was hybridized with cRNAs synthesized from polyA+ RNA, isolated from cancer and normal tissues, labeled with fluorescent dyes Cyanine3 and Cyanine5 (NEN Life Science Products, Inc., Boston, MA) using a linear amplification method (Agilent). In each experiment the experimental sample was polyA+ RNA isolated from cancer tissue from a single individual and the reference sample was a pool of polyA+ RNA isolated from normal tissues of the same organ as the cancerous tissue (*i.e.* normal breast tissue in experiments with breast cancer samples). Hybridizations were carried out at 60°C, overnight using Agilent *in-situ* hybridization buffer. Following washing, arrays were scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition and Analysis Software (Axon). Two different chip designs were evaluated with overlapping sets of a total of 36 samples, comparing the expression patterns of breast cancer derived polyA+ RNA to polyA+ RNA isolated from a pool of 10 normal breast tissues. For Chip 1, all 36 samples (9 stage I cancers, 23 stage II cancers, 4 stage III cancers) were analyzed. These samples also represented 10 Grade 1/2 and 26 Grade 3 cancers. The histopathologic grades for cancer are classified as follows: GX, cannot be assessed; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; and G4, undifferentiated. AJCC Cancer Staging Handbook, pp. 9, (5th Ed, 1998). Samples were further grouped based on the expression patterns of the known breast cancer associated genes Her2 and ERα (10 HER2 up, 26 HER2 not up, 20 ER up

DEX-0360

117

PATENT

and 16 ER not up) and For Chip 2, a subset of 20 of these samples (9 stage I cancers, 8 stage II cancers, 3 stage III cancers) were assessed.

Data normalization and expression profiling were done with Expressionist software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression analysis was performed using only experiments that meet certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed by the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a replicated negative control + 2 Standard Deviations (SD)) for each channel were calculated. The detection limit is a measure of non-specific hybridization. Acceptable detection limits were defined for each dye (80 for Cy5 and 150 for Cy3). Arrays with poor detection limits in one or both channels were not analyzed and the experiments were repeated. To evaluate normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression). If these features have a mean ratio of greater than 1.5-fold up or down, the experiments were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has minimum thresholding criteria that employ user defined parameters to identify quality data. These thresholds include two distinct quality measurements: 1) minimum area percentage, which is a measure of the integrity of each spot and 2) signal to noise ratio, which ensures that the signal being measured is significantly above any background (nonspecific) signal present. Only those features that meet the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60%  $[(\% \text{ pixels} > \text{background} + 2\text{SD}) - (\% \text{ pixels saturated})]$ , and a minimum signal to noise ratio of 2.0 in both channels. By these criteria, very low expressors, saturated features and spots with abnormally high local background were not included in analysis.

Relative expression data was collected from Expressionist based on filtering and clustering analyses. Up-regulated genes were identified using criteria for the percentage of experiments in which the gene is up-regulated. In general, up-regulation in ~30% of samples tested was used as a cutoff for filtering. The results for the statistically significant up-regulated genes on Chip 1 are shown in Tables 1, 2 and 3. The results for the statistically significant up-regulated genes on Chip 2 are shown in Table 4. The first

two columns of each table contain information about the sequence itself (Seq ID, Oligo ID), the next columns show the results obtained for all ("ALL") breast cancer samples, cancers corresponding to stage I ("ST1"), stages II and III ("ST2,3"), grades 1 and 2 ("GR1,2"), grade 3 ("GR3"), cancers exhibiting up-regulation of Her2 ("HER2up") or ER $\alpha$  ("ERup") or those not exhibiting up-regulation of Her2 ("NOT HER2up") or ER $\alpha$  ("NOT ERup"). '%up' indicates the percentage of all experiments in which up-regulation of at least 2-fold was observed (n=36 for Chip 1, n=20 for Chip 2), '%valid up' indicates the percentage of experiments with valid expression values in which up-regulation of at least 2-fold was observed.

10 Table 1. Expression data from Chip1 analysis with Breast cancer samples up-regulated genes.

DEX ID	oligoID	%up ALL n=36	%valid up ALL n=36	%up ST1 n=9	%valid up ST1 n=9	%up ST2,3 n=27	%valid up ST2,3 n=27
DEX0360_001.nt.1	34133	30.6	35.5	44.4	57.1	25.9	29.2
DEX0360_001.nt.1	34132	33.3	35.3	44.4	44.4	29.6	32
DEX0360_002.nt.1	13284	11.1	21.1	11.1	33.3	11.1	18.8
DEX0360_002.nt.1	13283	11.1	28.6	11.1	33.3	11.1	27.3
DEX0360_003.nt.1	14381	38.9	42.4	55.6	55.6	33.3	37.5
DEX0360_003.nt.1	14380	44.4	44.4	55.6	55.6	40.7	40.7
DEX0360_003.nt.2	14381	38.9	42.4	55.6	55.6	33.3	37.5
DEX0360_003.nt.2	14380	44.4	44.4	55.6	55.6	40.7	40.7
DEX0360_005.nt.1	29727	16.7	27.3	44.4	66.7	7.4	12.5
DEX0360_006.nt.1	20370*	8.3	8.6	33.3	33.3	0	0
DEX0360_007.nt.1	12615	13.9	13.9	33.3	33.3	7.4	7.4
DEX0360_008.nt.1	27530	30.6	30.6	22.2	22.2	33.3	33.3
DEX0360_009.nt.2	20208	25	25	11.1	11.1	29.6	29.6
DEX0360_010.nt.1	20592	33.3	34.3	44.4	50	29.6	29.6
DEX0360_010.nt.1	20591	41.7	41.7	44.4	44.4	40.7	40.7
DEX0360_010.nt.1	14008	30.6	31.4	33.3	33.3	29.6	30.8
DEX0360_010.nt.1	14007	33.3	33.3	44.4	44.4	29.6	29.6
DEX0360_011.nt.1	31615	30.6	30.6	44.4	44.4	25.9	25.9
DEX0360_011.nt.1	31614	36.1	37.1	44.4	44.4	33.3	34.6
DEX0360_011.nt.1	15033	33.3	33.3	44.4	44.4	29.6	29.6
DEX0360_011.nt.1	15032	27.8	27.8	33.3	33.3	25.9	25.9
DEX0360_012.nt.1	31927*	38.9	38.9	22.2	22.2	44.4	44.4
DEX0360_012.nt.1	31926*	30.6	30.6	11.1	11.1	37	37
DEX0360_015.nt.1	38922	19.4	28	0	0	25.9	36.8
DEX0360_015.nt.1	38921	19.4	23.3	0	0	25.9	30.4
DEX0360_016.nt.1	18250	30.6	30.6	44.4	44.4	25.9	25.9
DEX0360_016.nt.2	18250	30.6	30.6	44.4	44.4	25.9	25.9
DEX0360_016.nt.3	18250	30.6	30.6	44.4	44.4	25.9	25.9
DEX0360_016.nt.4	18250	30.6	30.6	44.4	44.4	25.9	25.9
DEX0360_016.nt.5	18250	30.6	30.6	44.4	44.4	25.9	25.9
DEX0360_018.nt.1	25674	22.2	25.8	11.1	14.3	25.9	29.2
DEX0360_019.nt.1	21562	22.2	28.6	22.2	33.3	22.2	27.3
DEX0360_019.nt.1	21561	22.2	32	22.2	40	22.2	30
DEX0360_021.nt.1	17942	36.1	36.1	33.3	33.3	37	37
DEX0360_021.nt.1	17938	36.1	38.2	33.3	33.3	37	40

DEX-0360

119

PATENT

DEX0360_021.nt.1	17934	30.6	31.4	33.3	33.3	29.6	30.8
DEX0360_021.nt.1	17933	38.9	38.9	33.3	33.3	40.7	40.7
DEX0360_021.nt.1	17932	36.1	37.1	44.4	44.4	33.3	34.6
DEX0360_022.nt.1	25824	30.6	33.3	44.4	44.4	25.9	29.2
DEX0360_022.nt.1	22397	13.9	18.5	22.2	40	11.1	13.6
DEX0360_023.nt.1	29794	47.2	68	44.4	80	48.1	65
DEX0360_023.nt.1	29793	50	72	55.6	83.3	48.1	68.4
DEX0360_026.nt.1	18383	25	27.3	33.3	37.5	22.2	24
DEX0360_026.nt.1	18382	25	26.5	33.3	33.3	22.2	24
DEX0360_027.nt.1	35954	19.4	21.9	33.3	37.5	14.8	16.7
DEX0360_027.nt.1	35953	27.8	41.7	55.6	71.4	18.5	29.4
DEX0360_028.nt.1	33040*	25	25	0	0	33.3	33.3
DEX0360_028.nt.2	33040*	25	25	0	0	33.3	33.3
DEX0360_029.nt.1	17496	33.3	36.4	22.2	25	37	40
DEX0360_030.nt.1	33276	27.8	29.4	33.3	37.5	25.9	26.9
DEX0360_030.nt.2	33276	27.8	29.4	33.3	37.5	25.9	26.9
DEX0360_032.nt.1	32497	8.3	8.3	33.3	33.3	0	0
DEX0360_032.nt.1	32496	8.3	9.1	33.3	33.3	0	0
DEX0360_032.nt.2	32497	8.3	8.3	33.3	33.3	0	0
DEX0360_032.nt.2	32496	8.3	9.1	33.3	33.3	0	0
DEX0360_032.nt.3	32497	8.3	8.3	33.3	33.3	0	0
DEX0360_032.nt.3	32496	8.3	9.1	33.3	33.3	0	0
DEX0360_033.nt.1	40414*	16.7	16.7	33.3	33.3	11.1	11.1
DEX0360_033.nt.1	40410*	13.9	14.3	33.3	33.3	7.4	7.7
DEX0360_033.nt.2	40414*	16.7	16.7	33.3	33.3	11.1	11.1
DEX0360_033.nt.2	40410*	13.9	14.3	33.3	33.3	7.4	7.7
DEX0360_033.nt.2	40364	11.1	11.1	33.3	33.3	3.7	3.7
DEX0360_033.nt.2	40363	11.1	11.1	33.3	33.3	3.7	3.7
DEX0360_033.nt.2	40320	11.1	11.1	33.3	33.3	3.7	3.7
DEX0360_033.nt.3	40364	11.1	11.1	33.3	33.3	3.7	3.7
DEX0360_033.nt.3	40363	11.1	11.1	33.3	33.3	3.7	3.7
DEX0360_033.nt.3	40320	11.1	11.1	33.3	33.3	3.7	3.7
DEX0360_034.nt.1	25931	33.3	33.3	11.1	11.1	40.7	40.7
DEX0360_034.nt.1	25930	36.1	36.1	11.1	11.1	44.4	44.4
DEX0360_034.nt.2	25931	33.3	33.3	11.1	11.1	40.7	40.7
DEX0360_034.nt.2	25930	36.1	36.1	11.1	11.1	44.4	44.4
DEX0360_034.nt.3	25931	33.3	33.3	11.1	11.1	40.7	40.7
DEX0360_034.nt.3	25930	36.1	36.1	11.1	11.1	44.4	44.4
DEX0360_039.nt.1	40103	33.3	33.3	0	0	44.4	44.4
DEX0360_039.nt.1	33301	36.1	38.2	33.3	33.3	37	40
DEX0360_039.nt.1	33300	33.3	36.4	33.3	33.3	33.3	37.5
DEX0360_039.nt.2	40103	33.3	33.3	0	0	44.4	44.4
DEX0360_039.nt.3	40103	33.3	33.3	0	0	44.4	44.4
DEX0360_040.nt.1	27218	61.1	62.9	55.6	55.6	63	65.4
DEX0360_040.nt.1	27217	61.1	62.9	55.6	55.6	63	65.4
DEX0360_040.nt.1	12631	55.6	58.8	55.6	55.6	55.6	60
DEX0360_041.nt.1	24443	16.7	26.1	11.1	16.7	18.5	29.4
DEX0360_041.nt.1	24442	25	25	11.1	11.1	29.6	29.6
DEX0360_041.nt.2	24443	16.7	26.1	11.1	16.7	18.5	29.4
DEX0360_041.nt.2	24442	25	25	11.1	11.1	29.6	29.6
DEX0360_041.nt.3	24443	16.7	26.1	11.1	16.7	18.5	29.4
DEX0360_041.nt.3	24442	25	25	11.1	11.1	29.6	29.6
DEX0360_043.nt.1	20612	25	25	11.1	11.1	29.6	29.6
DEX0360_046.nt.1	27064	11.1	28.6	33.3	100	3.7	9.1

DEX-0360

120

PATENT

DEX0360_046.nt.1	27063	22.2	38.1	33.3	75	18.5	29.4
DEX0360_046.nt.2	27064	11.1	28.6	33.3	100	3.7	9.1
DEX0360_046.nt.2	27063	22.2	38.1	33.3	75	18.5	29.4
DEX0360_046.nt.3	27064	11.1	28.6	33.3	100	3.7	9.1
DEX0360_046.nt.3	27063	22.2	38.1	33.3	75	18.5	29.4
DEX0360_047.nt.1	30176	50	66.7	33.3	50	55.6	71.4
DEX0360_048.nt.1	20370*	8.3	8.6	33.3	33.3	0	0
DEX0360_048.nt.2	20370*	8.3	8.6	33.3	33.3	0	0
DEX0360_051.nt.1	17127	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_052.nt.1	40306	33.3	33.3	33.3	33.3	33.3	33.3
DEX0360_052.nt.2	40306	33.3	33.3	33.3	33.3	33.3	33.3
DEX0360_053.nt.1	19465	41.7	41.7	33.3	33.3	44.4	44.4
DEX0360_053.nt.2	19465	41.7	41.7	33.3	33.3	44.4	44.4
DEX0360_056.nt.1	27617	16.7	16.7	33.3	33.3	11.1	11.1
DEX0360_057.nt.1	22448	25	25	33.3	33.3	22.2	22.2
DEX0360_057.nt.2	22448	25	25	33.3	33.3	22.2	22.2
DEX0360_058.nt.1	14317	27.8	27.8	22.2	22.2	29.6	29.6
DEX0360_059.nt.1	24447	22.2	22.2	33.3	33.3	18.5	18.5
DEX0360_060.nt.1	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.1	30041	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_060.nt.2	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.2	30041	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_060.nt.3	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.3	30041	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_060.nt.4	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.4	30041	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_060.nt.5	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.5	30041	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_060.nt.6	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.6	30041	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_060.nt.7	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.7	30041	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_060.nt.8	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.8	30041	38.9	38.9	55.6	55.6	33.3	33.3
DEX0360_060.nt.9	30042	25	25	44.4	44.4	18.5	18.5
DEX0360_060.nt.9	30041	38.9	38.9	55.6	55.6	33.3	33.3

\*data from lower PMT voltage scan

Table 2. Expression data from Chip1 analysis with Breast cancer samples up-regulated genes.

DEX ID	oligoID	%up GR1,2 n=10	%valid up GR1,2 n=10	%up GR3 n=26	%valid up GR3 n=26
DEX0360_001.nt.1	34133	80	80	11.5	14.3
DEX0360_001.nt.1	34132	80	80	15.4	16.7
DEX0360_002.nt.1	13284	30	37.5	3.8	9.1
DEX0360_002.nt.1	13283	30	33.3	3.8	20
DEX0360_003.nt.1	14381	40	44.4	38.5	41.7
DEX0360_003.nt.1	14380	40	40	46.2	46.2
DEX0360_003.nt.2	14381	40	44.4	38.5	41.7
DEX0360_003.nt.2	14380	40	40	46.2	46.2
DEX0360_004.nt.1	28910	30	30	0	0
DEX0360_005.nt.1	29727	30	33.3	11.5	23.1
DEX0360_008.nt.1	27530	40	40	26.9	26.9
DEX0360_009.nt.2	20208	30	30	23.1	23.1

## DEX-0360

121

## PATENT

DEX0360_010.nt.1	20592	70	70	19.2	20
DEX0360_010.nt.1	20591	70	70	30.8	30.8
DEX0360_010.nt.1	14008	70	70	15.4	16
DEX0360_010.nt.1	14007	70	70	19.2	19.2
DEX0360_011.nt.1	31615	30	30	30.8	30.8
DEX0360_011.nt.1	31614	30	30	38.5	40
DEX0360_011.nt.1	15033	40	40	30.8	30.8
DEX0360_011.nt.1	15032	20	20	30.8	30.8
DEX0360_014.nt.1	11156	80	80	3.8	4.2
DEX0360_014.nt.2	11156	80	80	3.8	4.2
DEX0360_015.nt.1	38922	10	10	23.1	40
DEX0360_015.nt.1	38921	10	10	23.1	30
DEX0360_016.nt.1	18250	20	20	34.6	34.6
DEX0360_016.nt.2	18250	20	20	34.6	34.6
DEX0360_016.nt.3	18250	20	20	34.6	34.6
DEX0360_016.nt.4	18250	20	20	34.6	34.6
DEX0360_016.nt.5	18250	20	20	34.6	34.6
DEX0360_018.nt.1	25674	30	30	19.2	23.8
DEX0360_019.nt.1	21562	50	50	11.5	16.7
DEX0360_019.nt.1	21561	50	50	11.5	20
DEX0360_020.nt.1	12954	40	40	15.4	15.4
DEX0360_020.nt.1	12953	40	40	15.4	15.4
DEX0360_021.nt.1	17942	50	50	30.8	30.8
DEX0360_021.nt.1	17938	50	50	30.8	33.3
DEX0360_021.nt.1	17934	40	40	26.9	28
DEX0360_021.nt.1	17933	50	50	34.6	34.6
DEX0360_021.nt.1	17932	50	50	30.8	32
DEX0360_022.nt.1	25824	60	60	19.2	21.7
DEX0360_022.nt.1	22397	40	44.4	3.8	5.6
DEX0360_023.nt.1	29794	90	90	30.8	53.3
DEX0360_023.nt.1	29793	90	90	34.6	60
DEX0360_024.nt.1	19174	30	30	3.8	4.8
DEX0360_025.nt.1	13892	0	0	30.8	30.8
DEX0360_026.nt.1	18383	40	40	19.2	21.7
DEX0360_026.nt.1	18382	40	40	19.2	20.8
DEX0360_027.nt.1	35954	50	55.6	7.7	8.7
DEX0360_027.nt.1	35953	70	77.8	11.5	20
DEX0360_029.nt.1	17496	60	60	23.1	26.1
DEX0360_030.nt.1	33276	10	10	34.6	37.5
DEX0360_030.nt.2	33276	10	10	34.6	37.5
DEX0360_031.nt.1	27825	30	30	7.7	8
DEX0360_031.nt.2	27825	30	30	7.7	8
DEX0360_034.nt.1	25931	30	30	34.6	34.6
DEX0360_034.nt.1	25930	30	30	38.5	38.5
DEX0360_034.nt.2	25931	30	30	34.6	34.6
DEX0360_034.nt.2	25930	30	30	38.5	38.5
DEX0360_034.nt.3	25931	30	30	34.6	34.6
DEX0360_034.nt.3	25930	30	30	38.5	38.5
DEX0360_035.nt.1	26914	40	44.4	11.5	11.5
DEX0360_035.nt.1	26913	30	30	3.8	4
DEX0360_036.nt.1	27220	30	30	11.5	11.5
DEX0360_037.nt.1	27220	30	30	11.5	11.5
DEX0360_037.nt.2	27220	30	30	11.5	11.5
DEX0360_039.nt.1	40103	40	40	30.8	30.8

DEX-0360

122

PATENT

DEX0360_039.nt.1	33301	80	88.9	19.2	20
DEX0360_039.nt.1	33300	70	87.5	19.2	20
DEX0360_039.nt.2	40103	40	40	30.8	30.8
DEX0360_039.nt.3	40103	40	40	30.8	30.8
DEX0360_040.nt.1	27218	60	60	61.5	64
DEX0360_040.nt.1	27217	60	60	61.5	64
DEX0360_040.nt.1	12631	50	55.6	57.7	60
DEX0360_041.nt.1	24443	0	0	23.1	33.3
DEX0360_041.nt.1	24442	10	10	30.8	30.8
DEX0360_041.nt.2	24443	0	0	23.1	33.3
DEX0360_041.nt.2	24442	10	10	30.8	30.8
DEX0360_041.nt.3	24443	0	0	23.1	33.3
DEX0360_041.nt.3	24442	10	10	30.8	30.8
DEX0360_042.nt.1	28910	30	30	0	0
DEX0360_043.nt.1	20612	40	40	19.2	19.2
DEX0360_046.nt.1	27064	40	44.4	0	0
DEX0360_046.nt.1	27063	60	60	7.7	18.2
DEX0360_046.nt.2	27064	40	44.4	0	0
DEX0360_046.nt.2	27063	60	60	7.7	18.2
DEX0360_046.nt.3	27064	40	44.4	0	0
DEX0360_046.nt.3	27063	60	60	7.7	18.2
DEX0360_047.nt.1	30176	60	75	46.2	63.2
DEX0360_051.nt.1	17127	80	80	23.1	23.1
DEX0360_052.nt.1	40306	50	50	26.9	26.9
DEX0360_052.nt.1	40305	30	30	3.8	4.3
DEX0360_052.nt.2	40306	50	50	26.9	26.9
DEX0360_052.nt.2	40305	30	30	3.8	4.3
DEX0360_053.nt.1	19465	80	80	26.9	26.9
DEX0360_053.nt.2	19465	80	80	26.9	26.9
DEX0360_054.nt.1	29054	30	30	7.7	8.3
DEX0360_055.nt.1	41778	30	30	0	0
DEX0360_056.nt.1	27617	30	30	11.5	11.5
DEX0360_057.nt.1	22448	30	30	23.1	23.1
DEX0360_057.nt.2	22448	30	30	23.1	23.1
DEX0360_058.nt.1	26101	30	30	19.2	19.2
DEX0360_058.nt.1	14317	40	40	23.1	23.1
DEX0360_059.nt.1	24447	50	50	11.5	11.5
DEX0360_060.nt.1	30041	40	40	38.5	38.5
DEX0360_060.nt.2	30041	40	40	38.5	38.5
DEX0360_060.nt.3	30041	40	40	38.5	38.5
DEX0360_060.nt.4	30041	40	40	38.5	38.5
DEX0360_060.nt.5	30041	40	40	38.5	38.5
DEX0360_060.nt.6	30041	40	40	38.5	38.5
DEX0360_060.nt.7	30041	40	40	38.5	38.5
DEX0360_060.nt.8	30041	40	40	38.5	38.5
DEX0360_060.nt.9	30041	40	40	38.5	38.5

Table 3. Expression data from Chip1 analysis with Breast cancer samples up-regulated genes.

DEX ID	oligoID	%up HER2up n=10	%valid up HER2up n=10	%up NOT HER2up n=26	%valid up NOT HER2up n=26	%up ERup n=20	%valid up ERup n=20	%up NOT ERup n=16	%valid up NOT ERup n=16
DEX0360_001.nt.1	34133	50	55.6	23.1	27.3	45	47.4	12.5	16.7

## DEX-0360

123

## PATENT

DEX0360_001.nt.1	34132	60	60	23.1	25	50	50	12.5	14.3
DEX0360_002.nt.1	13284	10	20	11.5	21.4	20	30.8	0	0
DEX0360_002.nt.1	13283	10	20	11.5	33.3	20	36.4	0	0
DEX0360_003.nt.1	14381	30	33.3	42.3	45.8	30	33.3	50	53.3
DEX0360_003.nt.1	14380	30	30	50	50	30	30	62.5	62.5
DEX0360_003.nt.2	14381	30	33.3	42.3	45.8	30	33.3	50	53.3
DEX0360_003.nt.2	14380	30	30	50	50	30	30	62.5	62.5
DEX0360_005.nt.1	29727	0	0	23.1	37.5	30	33.3	0	0
DEX0360_008.nt.1	27530	40	40	26.9	26.9	20	20	43.8	43.8
DEX0360_009.nt.1	20207	70	70	0	0	15	15.8	25	25
DEX0360_009.nt.2	20208	90	90	0	0	25	25	25	25
DEX0360_009.nt.2	20207	70	70	0	0	15	15.8	25	25
DEX0360_010.nt.1	20592	40	40	30.8	32	45	47.4	18.8	18.8
DEX0360_010.nt.1	20591	60	60	34.6	34.6	55	55	25	25
DEX0360_010.nt.1	14008	40	44.4	26.9	26.9	50	52.6	6.2	6.2
DEX0360_010.nt.1	14007	40	40	30.8	30.8	45	45	18.8	18.8
DEX0360_011.nt.1	31615	40	40	26.9	26.9	15	15	50	50
DEX0360_011.nt.1	31614	40	44.4	34.6	34.6	20	21.1	56.2	56.2
DEX0360_011.nt.1	15033	30	30	34.6	34.6	20	20	50	50
DEX0360_011.nt.1	15032	30	30	26.9	26.9	10	10	50	50
DEX0360_014.nt.1	11156	40	44.4	19.2	20	40	42.1	6.2	6.7
DEX0360_014.nt.2	11156	40	44.4	19.2	20	40	42.1	6.2	6.7
DEX0360_015.nt.1	38922	30	33.3	15.4	25	20	23.5	18.8	37.5
DEX0360_015.nt.1	38921	30	33.3	15.4	19	20	22.2	18.8	25
DEX0360_016.nt.1	18250	30	30	30.8	30.8	30	30	31.2	31.2
DEX0360_016.nt.2	18250	30	30	30.8	30.8	30	30	31.2	31.2
DEX0360_016.nt.3	18250	30	30	30.8	30.8	30	30	31.2	31.2
DEX0360_016.nt.4	18250	30	30	30.8	30.8	30	30	31.2	31.2
DEX0360_016.nt.5	18250	30	30	30.8	30.8	30	30	31.2	31.2
DEX0360_017.nt.1	40273	30	42.9	3.8	4.5	5	5.6	18.8	27.3
DEX0360_017.nt.1	19496	30	42.9	3.8	4.3	5	5.9	18.8	23.1
DEX0360_017.nt.2	40273	30	42.9	3.8	4.5	5	5.6	18.8	27.3
DEX0360_017.nt.2	19496	30	42.9	3.8	4.3	5	5.9	18.8	23.1
DEX0360_017.nt.3	40273	30	42.9	3.8	4.5	5	5.6	18.8	27.3
DEX0360_017.nt.3	19496	30	42.9	3.8	4.3	5	5.9	18.8	23.1
DEX0360_017.nt.4	40273	30	42.9	3.8	4.5	5	5.6	18.8	27.3
DEX0360_017.nt.4	19496	30	42.9	3.8	4.3	5	5.9	18.8	23.1
DEX0360_017.nt.5	40273	30	42.9	3.8	4.5	5	5.6	18.8	27.3
DEX0360_017.nt.5	19496	30	42.9	3.8	4.3	5	5.9	18.8	23.1
DEX0360_017.nt.6	40273	30	42.9	3.8	4.5	5	5.6	18.8	27.3
DEX0360_017.nt.6	19496	30	42.9	3.8	4.3	5	5.9	18.8	23.1
DEX0360_018.nt.1	25674	10	12.5	26.9	30.4	25	29.4	18.8	21.4
DEX0360_019.nt.1	21562	10	14.3	26.9	33.3	35	35	6.2	12.5
DEX0360_019.nt.1	21561	10	14.3	26.9	38.9	35	35	6.2	20
DEX0360_021.nt.1	17942	30	30	38.5	38.5	35	35	37.5	37.5
DEX0360_021.nt.1	17938	30	33.3	38.5	40	35	38.9	37.5	37.5
DEX0360_021.nt.1	17934	20	22.2	34.6	34.6	30	30	31.2	33.3
DEX0360_021.nt.1	17933	40	40	38.5	38.5	40	40	37.5	37.5
DEX0360_021.nt.1	17932	30	30	38.5	40	40	40	31.2	33.3
DEX0360_022.nt.1	25824	0	0	42.3	45.8	45	45	12.5	15.4
DEX0360_022.nt.1	22397	0	0	19.2	25	25	29.4	0	0
DEX0360_023.nt.1	29794	80	88.9	34.6	56.2	75	83.3	12.5	28.6
DEX0360_023.nt.1	29793	70	77.8	42.3	68.8	80	80	12.5	40
DEX0360_025.nt.1	13892	20	20	23.1	23.1	5	5	43.8	43.8

DEX-0360

124

PATENT

DEX0360_026.nt.1	18383	40	50	19.2	20	30	30	18.8	23.1
DEX0360_026.nt.1	18382	40	50	19.2	19.2	30	30	18.8	21.4
DEX0360_027.nt.1	35953	20	33.3	30.8	44.4	35	50	18.8	30
DEX0360_029.nt.1	17496	30	37.5	34.6	36	50	55.6	12.5	13.3
DEX0360_030.nt.1	33276	30	30	26.9	29.2	20	21.1	37.5	40
DEX0360_030.nt.2	33276	30	30	26.9	29.2	20	21.1	37.5	40
DEX0360_031.nt.1	27825	40	40	3.8	4	20	20	6.2	6.7
DEX0360_031.nt.2	27825	40	40	3.8	4	20	20	6.2	6.7
DEX0360_034.nt.1	25931	100	100	7.7	7.7	40	40	25	25
DEX0360_034.nt.1	25930	100	100	11.5	11.5	45	45	25	25
DEX0360_034.nt.2	25931	100	100	7.7	7.7	40	40	25	25
DEX0360_034.nt.2	25930	100	100	11.5	11.5	45	45	25	25
DEX0360_034.nt.3	25931	100	100	7.7	7.7	40	40	25	25
DEX0360_034.nt.3	25930	100	100	11.5	11.5	45	45	25	25
DEX0360_038.nt.1	27234	20	20	15.4	15.4	5	5	31.2	31.2
DEX0360_038.nt.2	27234	20	20	15.4	15.4	5	5	31.2	31.2
DEX0360_039.nt.1	40103	40	40	30.8	30.8	35	35	31.2	31.2
DEX0360_039.nt.1	33301	50	50	30.8	33.3	45	47.4	25	26.7
DEX0360_039.nt.1	33300	40	44.4	30.8	33.3	40	44.4	25	26.7
DEX0360_039.nt.2	40103	40	40	30.8	30.8	35	35	31.2	31.2
DEX0360_039.nt.3	40103	40	40	30.8	30.8	35	35	31.2	31.2
DEX0360_040.nt.1	27218	60	66.7	61.5	61.5	55	55	68.8	73.3
DEX0360_040.nt.1	27217	50	55.6	65.4	65.4	55	55	68.8	73.3
DEX0360_040.nt.1	12631	50	62.5	57.7	57.7	50	52.6	62.5	66.7
DEX0360_041.nt.1	24443	0	0	23.1	33.3	0	0	37.5	60
DEX0360_041.nt.1	24442	20	20	26.9	26.9	5	5	50	50
DEX0360_041.nt.2	24443	0	0	23.1	33.3	0	0	37.5	60
DEX0360_041.nt.2	24442	20	20	26.9	26.9	5	5	50	50
DEX0360_041.nt.3	24443	0	0	23.1	33.3	0	0	37.5	60
DEX0360_041.nt.3	24442	20	20	26.9	26.9	5	5	50	50
DEX0360_046.nt.1	27064	0	0	15.4	40	20	33.3	0	0
DEX0360_046.nt.1	27063	10	16.7	26.9	46.7	30	42.9	12.5	28.6
DEX0360_046.nt.2	27064	0	0	15.4	40	20	33.3	0	0
DEX0360_046.nt.2	27063	10	16.7	26.9	46.7	30	42.9	12.5	28.6
DEX0360_046.nt.3	27064	0	0	15.4	40	20	33.3	0	0
DEX0360_046.nt.3	27063	10	16.7	26.9	46.7	30	42.9	12.5	28.6
DEX0360_047.nt.1	30176	60	66.7	46.2	66.7	60	75	37.5	54.5
DEX0360_049.nt.1	34092	30	33.3	23.1	23.1	10	10.5	43.8	43.8
DEX0360_050.nt.1	26236	30	30	15.4	16	15	15.8	25	25
DEX0360_051.nt.1	17127	50	50	34.6	34.6	50	50	25	25
DEX0360_052.nt.1	40306	30	30	34.6	34.6	50	50	12.5	12.5
DEX0360_052.nt.2	40306	30	30	34.6	34.6	50	50	12.5	12.5
DEX0360_053.nt.1	19465	30	30	46.2	46.2	70	70	6.2	6.2
DEX0360_053.nt.2	19465	30	30	46.2	46.2	70	70	6.2	6.2
DEX0360_057.nt.1	22448	10	10	30.8	30.8	25	25	25	25
DEX0360_057.nt.2	22448	10	10	30.8	30.8	25	25	25	25
DEX0360_058.nt.1	26101	10	10	26.9	26.9	15	15	31.2	31.2
DEX0360_058.nt.1	14317	10	10	34.6	34.6	20	20	37.5	37.5
DEX0360_059.nt.1	24447	10	10	26.9	26.9	30	30	12.5	12.5
DEX0360_060.nt.1	30042	0	0	34.6	34.6	40	40	6.2	6.2
DEX0360_060.nt.1	30041	10	10	50	50	50	50	25	25
DEX0360_060.nt.2	30042	0	0	34.6	34.6	40	40	6.2	6.2
DEX0360_060.nt.2	30041	10	10	50	50	50	50	25	25
DEX0360_060.nt.3	30042	0	0	34.6	34.6	40	40	6.2	6.2

DEX-0360

125

PATENT

DEX0360_060.nt.3	30041	10	10	50	50	50	50	25	25
DEX0360_060.nt.4	30042	0	0	34.6	34.6	40	40	6.2	6.2
DEX0360_060.nt.4	30041	10	10	50	50	50	50	25	25
DEX0360_060.nt.5	30042	0	0	34.6	34.6	40	40	6.2	6.2
DEX0360_060.nt.5	30041	10	10	50	50	50	50	25	25
DEX0360_060.nt.6	30042	0	0	34.6	34.6	40	40	6.2	6.2
DEX0360_060.nt.6	30041	10	10	50	50	50	50	25	25
DEX0360_060.nt.7	30042	0	0	34.6	34.6	40	40	6.2	6.2
DEX0360_060.nt.7	30041	10	10	50	50	50	50	25	25
DEX0360_060.nt.8	30042	0	0	34.6	34.6	40	40	6.2	6.2
DEX0360_060.nt.8	30041	10	10	50	50	50	50	25	25
DEX0360_060.nt.9	30042	0	0	34.6	34.6	40	40	6.2	6.2
DEX0360_060.nt.9	30041	10	10	50	50	50	50	25	25

Table 4. Expression data from Chip2 analysis with Breast cancer samples up-regulated genes.

DEX ID	oligoID	%up ALL n=20	%valid up ALL n=20	%up ST1 n=9	%valid up ST1 n=9	%up ST2,3 n=11	%valid up ST2,3 n=11
DEX0360_044.nt.2	1689	35	35	44.4	44.4	27.3	27.3
DEX0360_044.nt.1	1689	35	35	44.4	44.4	27.3	27.3
DEX0360_013.nt.1	96144*	20	20	0	0	36.4	36.4
DEX0360_013.nt.1	96144.1*	15	15	0	0	27.3	27.3

\*data from lower PMT voltage scan

- 5 The location/mapping of the oligos on the breast Cancer genes were as follows:

SeqID	MasterOligoID	oligoID	ChipName	Location
DEX0360_001.nt.1	34132	34132	Chip 1	3024-3083
DEX0360_001.nt.1	34133	34133	Chip 1	2774-2833
DEX0360_002.nt.1	13283	13283	Chip 1	1216-1275
DEX0360_002.nt.1	13284	13284	Chip 1	1176-1235
DEX0360_003.nt.1	14380	14380	Chip 1	1388-1447
DEX0360_003.nt.1	14381	14381	Chip 1	1338-1397
DEX0360_003.nt.2	14380	14380	Chip 1	775-834
DEX0360_003.nt.2	14381	14381	Chip 1	725-784
DEX0360_004.nt.1	28910	28910	Chip 1	256-315
DEX0360_005.nt.1	29727	29727	Chip 1	1585-1644
DEX0360_006.nt.1	20370	20370	Chip 1	2786-2845
DEX0360_007.nt.1	12615	12615	Chip 1	535-594
DEX0360_007.nt.1	12616	12616	Chip 1	515-574
DEX0360_008.nt.1	27530	27530	Chip 1	1115-1174
DEX0360_009.nt.1	20207	20207	Chip 1	151-210
DEX0360_009.nt.2	20207	20207	Chip 1	1229-1288
DEX0360_009.nt.2	20208	20208	Chip 1	1158-1217
DEX0360_010.nt.1	14007	14007	Chip 1	5114-5173
DEX0360_010.nt.1	14008	14008	Chip 1	4960-5019
DEX0360_010.nt.1	20591	20591	Chip 1	5154-5213
DEX0360_010.nt.1	20592	20592	Chip 1	5114-5173
DEX0360_011.nt.1	15032	15032	Chip 1	1164-1223
DEX0360_011.nt.1	15033	15033	Chip 1	1065-1124
DEX0360_011.nt.1	31614	31614	Chip 1	2198-2257
DEX0360_011.nt.1	31615	31615	Chip 1	2114-2173
DEX0360_012.nt.1	31926	31926	Chip 1	602-655
DEX0360_012.nt.1	31927	31927	Chip 1	513-572
DEX0360_013.nt.1	96144	96144	Chip 2	5222-5281
DEX0360_013.nt.1	96144	96144.1	Chip 2	5222-5281

DEX-0360

126

PATENT

DEX0360_014.nt.1	11156	11156	Chip 1	2780-2839
DEX0360_014.nt.2	11156	11156	Chip 1	1892-1951
DEX0360_015.nt.1	38921	38921	Chip 1	598-657
DEX0360_015.nt.1	38922	38922	Chip 1	467-526
DEX0360_016.nt.1	17982	17982	Chip 1	1437-1495
DEX0360_016.nt.1	18250	18250	Chip 1	1991-2050
DEX0360_016.nt.1	18256	18256	Chip 1	1797-1856
DEX0360_016.nt.2	17982	17982	Chip 1	802-860
DEX0360_016.nt.2	18250	18250	Chip 1	1356-1415
DEX0360_016.nt.2	18256	18256	Chip 1	1162-1221
DEX0360_016.nt.3	17982	17982	Chip 1	639-697
DEX0360_016.nt.3	18250	18250	Chip 1	1193-1252
DEX0360_016.nt.3	18256	18256	Chip 1	999-1058
DEX0360_016.nt.4	18250	18250	Chip 1	726-785
DEX0360_016.nt.4	18256	18256	Chip 1	532-591
DEX0360_016.nt.5	18250	18250	Chip 1	531-590
DEX0360_016.nt.5	18256	18256	Chip 1	337-396
DEX0360_017.nt.1	19496	19496	Chip 1	3168-3227
DEX0360_017.nt.1	40273	40273	Chip 1	3227-3286
DEX0360_017.nt.2	19496	19496	Chip 1	3809-3868
DEX0360_017.nt.2	40273	40273	Chip 1	3868-3927
DEX0360_017.nt.3	19496	19496	Chip 1	3849-3908
DEX0360_017.nt.3	40273	40273	Chip 1	3908-3967
DEX0360_017.nt.4	19496	19496	Chip 1	3366-3425
DEX0360_017.nt.4	40273	40273	Chip 1	3425-3484
DEX0360_017.nt.5	19496	19496	Chip 1	4825-4884
DEX0360_017.nt.5	40273	40273	Chip 1	4884-4943
DEX0360_017.nt.6	19496	19496	Chip 1	4433-4492
DEX0360_017.nt.6	40273	40273	Chip 1	4492-4551
DEX0360_018.nt.1	25674	25674	Chip 1	1101-1160
DEX0360_019.nt.1	21561	21561	Chip 1	6216-6275
DEX0360_019.nt.1	21562	21562	Chip 1	5986-6045
DEX0360_020.nt.1	12953	12953	Chip 1	1204-1263
DEX0360_020.nt.1	12954	12954	Chip 1	1142-1201
DEX0360_021.nt.1	17932	17932	Chip 1	1059-1118
DEX0360_021.nt.1	17933	17933	Chip 1	958-1017
DEX0360_021.nt.1	17934	17934	Chip 1	571-626
DEX0360_021.nt.1	17938	17938	Chip 1	752-810
DEX0360_021.nt.1	17942	17942	Chip 1	753-812
DEX0360_022.nt.1	22397	22397	Chip 1	718-771
DEX0360_022.nt.1	25824	25824	Chip 1	2318-2377
DEX0360_023.nt.1	29793	29793	Chip 1	388-447
DEX0360_023.nt.1	29794	29794	Chip 1	154-213
DEX0360_024.nt.1	19174	19174	Chip 1	1281-1340
DEX0360_025.nt.1	13892	13892	Chip 1	277-336
DEX0360_026.nt.1	18382	18382	Chip 1	533-593
DEX0360_026.nt.1	18383	18383	Chip 1	500-558
DEX0360_027.nt.1	35953	35953	Chip 1	902-961
DEX0360_027.nt.1	35954	35954	Chip 1	812-871
DEX0360_028.nt.1	33040	33040	Chip 1	1983-2042
DEX0360_028.nt.2	33040	33040	Chip 1	1228-1287
DEX0360_029.nt.1	17496	17496	Chip 1	457-398
DEX0360_030.nt.1	33276	33276	Chip 1	2849-2908
DEX0360_030.nt.2	33276	33276	Chip 1	922-981
DEX0360_031.nt.1	27825	27825	Chip 1	1807-1865
DEX0360_031.nt.2	27825	27825	Chip 1	499-557
DEX0360_032.nt.1	32496	32496	Chip 1	552-611

DEX-0360

127

PATENT

DEX0360_032.nt.1	32497	32497	Chip 1	511-570
DEX0360_032.nt.2	32496	32496	Chip 1	552-611
DEX0360_032.nt.2	32497	32497	Chip 1	511-570
DEX0360_032.nt.3	32496	32496	Chip 1	552-611
DEX0360_032.nt.3	32497	32497	Chip 1	511-570
DEX0360_033.nt.1	40410	40410	Chip 1	2155-2208
DEX0360_033.nt.1	40414	40414	Chip 1	2162-2221
DEX0360_033.nt.2	31577	31577	Chip 1	1063-1122
DEX0360_033.nt.2	40320	40320	Chip 1	670-729
DEX0360_033.nt.2	40363	40363	Chip 1	608-667
DEX0360_033.nt.2	40364	40364	Chip 1	568-627
DEX0360_033.nt.2	40410	40410	Chip 1	156-209
DEX0360_033.nt.2	40414	40414	Chip 1	163-222
DEX0360_033.nt.3	31577	31577	Chip 1	899-958
DEX0360_033.nt.3	40320	40320	Chip 1	506-565
DEX0360_033.nt.3	40363	40363	Chip 1	444-503
DEX0360_033.nt.3	40364	40364	Chip 1	404-463
DEX0360_034.nt.1	25930	25930	Chip 1	807-866
DEX0360_034.nt.1	25931	25931	Chip 1	787-846
DEX0360_034.nt.2	25930	25930	Chip 1	999-1058
DEX0360_034.nt.2	25931	25931	Chip 1	979-1038
DEX0360_034.nt.3	25930	25930	Chip 1	886-945
DEX0360_034.nt.3	25931	25931	Chip 1	866-925
DEX0360_035.nt.1	26913	26913	Chip 1	3958-4017
DEX0360_035.nt.1	26914	26914	Chip 1	3793-3852
DEX0360_036.nt.1	27220	27220	Chip 1	1532-1591
DEX0360_037.nt.1	27220	27220	Chip 1	2197-2256
DEX0360_037.nt.2	27220	27220	Chip 1	2424-2483
DEX0360_038.nt.1	27234	27234	Chip 1	2317-2376
DEX0360_038.nt.2	27234	27234	Chip 1	1030-1089
DEX0360_039.nt.1	33300	33300	Chip 1	3417-3358
DEX0360_039.nt.1	33301	33301	Chip 1	3457-3398
DEX0360_039.nt.1	40103	40103	Chip 1	1363-1422
DEX0360_039.nt.2	40103	40103	Chip 1	1363-1422
DEX0360_039.nt.3	40103	40103	Chip 1	1363-1422
DEX0360_040.nt.1	12631	12631	Chip 1	523-582
DEX0360_040.nt.1	27217	27217	Chip 1	886-945
DEX0360_040.nt.1	27218	27218	Chip 1	523-582
DEX0360_041.nt.1	24442	24442	Chip 1	441-500
DEX0360_041.nt.1	24443	24443	Chip 1	348-407
DEX0360_041.nt.2	24442	24442	Chip 1	2751-2810
DEX0360_041.nt.2	24443	24443	Chip 1	2658-2717
DEX0360_041.nt.3	24442	24442	Chip 1	2648-2707
DEX0360_041.nt.3	24443	24443	Chip 1	2555-2614
DEX0360_042.nt.1	28910	28910	Chip 1	754-813
DEX0360_043.nt.1	20612	20612	Chip 1	487-546
DEX0360_044.nt.1	1689	1689	Chip 2	3045-3104
DEX0360_044.nt.2	1689	1689	Chip 2	4181-4240
DEX0360_045.nt.1	28899	28899	Chip 1	56-115
DEX0360_045.nt.2	28899	28899	Chip 1	985-1037
DEX0360_046.nt.1	27063	27063	Chip 1	1707-1766
DEX0360_046.nt.1	27064	27064	Chip 1	1488-1547
DEX0360_046.nt.2	27063	27063	Chip 1	1705-1764
DEX0360_046.nt.2	27064	27064	Chip 1	1486-1545
DEX0360_046.nt.3	27063	27063	Chip 1	1415-1474
DEX0360_046.nt.3	27064	27064	Chip 1	1196-1255
DEX0360_047.nt.1	30176	30176	Chip 1	596-655

DEX-0360

128

PATENT

DEX0360_048.nt.1	20370	20370	Chip 1	6933-6992
DEX0360_048.nt.2	20370	20370	Chip 1	6577-6636
DEX0360_049.nt.1	34092	34092	Chip 1	2471-2530
DEX0360_050.nt.1	26236	26236	Chip 1	3164-3223
DEX0360_051.nt.1	17127	17127	Chip 1	2169-2228
DEX0360_052.nt.1	40305	40305	Chip 1	467-526
DEX0360_052.nt.1	40306	40306	Chip 1	368-427
DEX0360_052.nt.2	40305	40305	Chip 1	382-441
DEX0360_052.nt.2	40306	40306	Chip 1	283-342
DEX0360_053.nt.1	19465	19465	Chip 1	25-83
DEX0360_053.nt.2	19465	19465	Chip 1	534-593
DEX0360_054.nt.1	29054	29054	Chip 1	1375-1434
DEX0360_055.nt.1	41778	41778	Chip 1	337-396
DEX0360_056.nt.1	27617	27617	Chip 1	2909-2968
DEX0360_056.nt.1	27618	27618	Chip 1	2791-2850
DEX0360_057.nt.1	22448	22448	Chip 1	4760-4819
DEX0360_057.nt.2	22448	22448	Chip 1	4977-5036
DEX0360_058.nt.1	14317	14317	Chip 1	2136-2195
DEX0360_058.nt.1	26101	26101	Chip 1	2878-2937
DEX0360_059.nt.1	24447	24447	Chip 1	2768-2827
DEX0360_060.nt.1	30041	30041	Chip 1	1143-1202
DEX0360_060.nt.1	30042	30042	Chip 1	1103-1162
DEX0360_060.nt.2	30041	30041	Chip 1	1393-1452
DEX0360_060.nt.2	30042	30042	Chip 1	1353-1412
DEX0360_060.nt.3	30041	30041	Chip 1	875-934
DEX0360_060.nt.3	30042	30042	Chip 1	835-894
DEX0360_060.nt.4	30041	30041	Chip 1	748-807
DEX0360_060.nt.4	30042	30042	Chip 1	708-767
DEX0360_060.nt.5	30041	30041	Chip 1	583-642
DEX0360_060.nt.5	30042	30042	Chip 1	543-602
DEX0360_060.nt.6	30041	30041	Chip 1	724-783
DEX0360_060.nt.6	30042	30042	Chip 1	684-743
DEX0360_060.nt.7	30041	30041	Chip 1	759-818
DEX0360_060.nt.7	30042	30042	Chip 1	719-778
DEX0360_060.nt.8	30041	30041	Chip 1	380-439
DEX0360_060.nt.8	30042	30042	Chip 1	340-399
DEX0360_060.nt.9	30041	30041	Chip 1	255-314
DEX0360_060.nt.9	30042	30042	Chip 1	215-274

The mapping of the nucleic acid ("NT") SEQ ID NO; DEX ID; chromosomal location (if known); open reading frame (ORF) location; amino acid ("AA") SEQ ID NO and AA DEX ID are shown in the table below:

NT_SEQ No	NT_SEQID	Chromo Map	ORF_Loc	AA_SEQ NO	AA_SEQID
1	DEX0360_001.nt.1	18q21.2	372-726	104	DEX0360_001.aa.1
2	DEX0360_002.nt.1	3q12.1	350-2305	105	DEX0360_002.aa.1
3	DEX0360_003.nt.1	1q42.2	917-1295	106	DEX0360_003.aa.1
4	DEX0360_003.nt.2	1q42.2	1-495	107	DEX0360_003.aa.2
5	DEX0360_004.nt.1	12q14.3	1-421	108	DEX0360_004.aa.1
6	DEX0360_005.nt.1	3p21.31	151-1729	109	DEX0360_005.aa.1
7	DEX0360_006.nt.1	*1q21.2	235-1553	110	DEX0360_006.aa.1
8	DEX0360_007.nt.1	11p15.5	357-780	111	DEX0360_007.aa.1
9	DEX0360_008.nt.1	3q26.1	263-812	112	DEX0360_008.aa.1
10	DEX0360_009.nt.1	17q12	1-399	113	DEX0360_009.aa.1
11	DEX0360_009.nt.2	17q12	643-1477	114	DEX0360_009.aa.2

DEX-0360

129

PATENT

12	DEX0360_010.nt.1	2q22.1	246-1425	115	DEX0360_010.aa.1
13	DEX0360_011.nt.1	8q22.1	252-720	116	DEX0360_011.aa.1
14	DEX0360_012.nt.1	5q35.2	206-518	117	DEX0360_012.aa.1
15	DEX0360_013.nt.1	12q23.1	2350-3715	118	DEX0360_013.aa.1
16	DEX0360_014.nt.1	4q21.1	462-1605	119	DEX0360_014.aa.1
17	DEX0360_014.nt.2	4q21.1	33-717	120	DEX0360_014.aa.2
18	DEX0360_015.nt.1	2q35	360-663	121	DEX0360_015.aa.1
19	DEX0360_016.nt.1	15q26.1	636-1953	122	DEX0360_016.aa.1
20	DEX0360_016.nt.2	15q26.1	64-1317	123	DEX0360_016.aa.2
21	DEX0360_016.nt.3	15q26.1	283-1153	124	DEX0360_016.aa.3
22	DEX0360_016.nt.4	15q26.1	120-687	125	DEX0360_016.aa.4
23	DEX0360_016.nt.5	15q26.1	118-456	126	DEX0360_016.aa.5
24	DEX0360_017.nt.1	6p21.1	718-2245	127	DEX0360_017.aa.1
25	DEX0360_017.nt.2	6p21.1	466-1756	128	DEX0360_017.aa.2
26	DEX0360_017.nt.3	6p21.1	718-2245	127	DEX0360_017.aa.1
27	DEX0360_017.nt.4	6p21.1	718-2245	127	DEX0360_017.aa.1
28	DEX0360_017.nt.5	6p21.1	718-2245	127	DEX0360_017.aa.1
29	DEX0360_017.nt.6	6p21.1	718-2245	127	DEX0360_017.aa.1
30	DEX0360_018.nt.1	1q21.2	308-674	129	DEX0360_018.aa.1
31	DEX0360_019.nt.1	11q22.1	2980-5275	130	DEX0360_019.aa.1
32	DEX0360_020.nt.1	16p13.3	1-806	131	DEX0360_020.aa.1
33	DEX0360_021.nt.1	18q21.32	471-771	132	DEX0360_021.aa.1
34	DEX0360_022.nt.1	*19q13.2	227-647	133	DEX0360_022.aa.1
35	DEX0360_023.nt.1	7p21.1	1-411	134	DEX0360_023.aa.1
36	DEX0360_024.nt.1	8q24.13	81-672	135	DEX0360_024.aa.1
37	DEX0360_025.nt.1	3q22.1	1-212	136	DEX0360_025.aa.1
38	DEX0360_026.nt.1	*12p11.22	22-548	137	DEX0360_026.aa.1
39	DEX0360_027.nt.1	*	94-472	138	DEX0360_027.aa.1
40	DEX0360_028.nt.1	5p15.33	579-900	139	DEX0360_028.aa.1
41	DEX0360_028.nt.2	5p15.33	7-721	140	DEX0360_028.aa.2
42	DEX0360_029.nt.1	5q14.3	1-206	141	DEX0360_029.aa.1
43	DEX0360_030.nt.1	12q13.12	303-2793	142	DEX0360_030.aa.1
44	DEX0360_030.nt.2	12q13.12	449-866	143	DEX0360_030.aa.2
45	DEX0360_031.nt.1	17q21.1	118-1504	144	DEX0360_031.aa.1
46	DEX0360_031.nt.2	17q21.1	13-196	145	DEX0360_031.aa.2
47	DEX0360_032.nt.1	*	168-1050	146	DEX0360_032.aa.1
48	DEX0360_032.nt.2	*	168-921	147	DEX0360_032.aa.2
49	DEX0360_032.nt.3	*	168-864	148	DEX0360_032.aa.3
50	DEX0360_033.nt.1	13q34	452-2567	149	DEX0360_033.aa.1
51	DEX0360_033.nt.2	13q34	1-487	150	DEX0360_033.aa.2
52	DEX0360_033.nt.3	13q34	16-102	151	DEX0360_033.aa.3
53	DEX0360_034.nt.1	17q12	1-309	152	DEX0360_034.aa.1
54	DEX0360_034.nt.2	17q12	10-635	153	DEX0360_034.aa.2
55	DEX0360_034.nt.3	17q12	1-309	152	DEX0360_034.aa.1
56	DEX0360_035.nt.1	2q32.3	220-1367	154	DEX0360_035.aa.1
57	DEX0360_036.nt.1	16p13.3	570-1374	155	DEX0360_036.aa.1
58	DEX0360_037.nt.1	16p13.3	578-1253	156	DEX0360_037.aa.1
59	DEX0360_037.nt.2	16p13.3	578-1481	157	DEX0360_037.aa.2
60	DEX0360_038.nt.1	10q22.3	142-575	158	DEX0360_038.aa.1
61	DEX0360_038.nt.2	10q22.3	1-352	159	DEX0360_038.aa.2
62	DEX0360_039.nt.1	11q13.1	1-235	160	DEX0360_039.aa.1
63	DEX0360_039.nt.2	11q13.1	1-235	160	DEX0360_039.aa.1
64	DEX0360_039.nt.3	11q13.1	1-235	160	DEX0360_039.aa.1
65	DEX0360_040.nt.1	15q22.31	199-514	161	DEX0360_040.aa.1
66	DEX0360_041.nt.1	6p22.3	1-118	162	DEX0360_041.aa.1
67	DEX0360_041.nt.2	6p22.3	253-1380	163	DEX0360_041.aa.2
68	DEX0360_041.nt.3	6p22.3	149-1277	164	DEX0360_041.aa.3

## DEX-0360

130

## PATENT

69	DEX0360_042.nt.1	12q14.3	295-919	165	DEX0360_042.aa.1
70	DEX0360_043.nt.1	*	1-216	166	DEX0360_043.aa.1
71	DEX0360_044.nt.1	9q22.31	292-2470	167	DEX0360_044.aa.1
72	DEX0360_044.nt.2	9q22.31	1272-1689	168	DEX0360_044.aa.2
73	DEX0360_045.nt.1	*	1-205	169	DEX0360_045.aa.1
74	DEX0360_045.nt.2	*	620-1208	170	DEX0360_045.aa.2
75	DEX0360_046.nt.1	8p11.21	88-410	171	DEX0360_046.aa.1
76	DEX0360_046.nt.2	8p11.21	85-405	172	DEX0360_046.aa.2
77	DEX0360_046.nt.3	8p11.21	2-395	173	DEX0360_046.aa.3
78	DEX0360_047.nt.1	6q22.1	1-208	174	DEX0360_047.aa.1
79	DEX0360_048.nt.1	*1p12	2985-5616	175	DEX0360_048.aa.1
80	DEX0360_048.nt.2	*1p12	2913-5262	176	DEX0360_048.aa.2
81	DEX0360_049.nt.1	2p25.2	17-1367	177	DEX0360_049.aa.1
82	DEX0360_050.nt.1	18q11.2	352-2339	178	DEX0360_050.aa.1
83	DEX0360_051.nt.1	6q14.1	684-1392	179	DEX0360_051.aa.1
84	DEX0360_052.nt.1	11p15.5	989-1463	180	DEX0360_052.aa.1
85	DEX0360_052.nt.2	11p15.5	904-1378	180	DEX0360_052.aa.1
86	DEX0360_053.nt.1	11p15.1	2-812	181	DEX0360_053.aa.1
87	DEX0360_053.nt.2	11p15.1	59-1151	182	DEX0360_053.aa.2
88	DEX0360_054.nt.1	5q13.3	322-811	183	DEX0360_054.aa.1
89	DEX0360_055.nt.1	10q26.12	1-130	184	DEX0360_055.aa.1
90	DEX0360_056.nt.1	Xq24	115-520	185	DEX0360_056.aa.1
91	DEX0360_057.nt.1	1q22	217-1407	186	DEX0360_057.aa.1
92	DEX0360_057.nt.2	1q22	856-1624	187	DEX0360_057.aa.2
93	DEX0360_058.nt.1	8q24.23	1-171	188	DEX0360_058.aa.1
94	DEX0360_059.nt.1	10q26.13	471-1629	189	DEX0360_059.aa.1
95	DEX0360_060.nt.1	1q23.1	1291-1825	190	DEX0360_060.aa.1
96	DEX0360_060.nt.2	1q23.1	1541-2075	190	DEX0360_060.aa.1
97	DEX0360_060.nt.3	1q23.1	1023-1557	190	DEX0360_060.aa.1
98	DEX0360_060.nt.4	1q23.1	895-1430	190	DEX0360_060.aa.1
99	DEX0360_060.nt.5	1q23.1	731-1265	190	DEX0360_060.aa.1
100	DEX0360_060.nt.6	1q23.1	872-1406	190	DEX0360_060.aa.1
101	DEX0360_060.nt.7	1q23.1	907-1441	190	DEX0360_060.aa.1
102	DEX0360_060.nt.8	1q23.1	528-1062	190	DEX0360_060.aa.1
103	DEX0360_060.nt.9	1q23.1	402-937	190	DEX0360_060.aa.1

- For the polypeptides of the invention, the following attributes were found, epitopes, post translational modifications, signal peptides and transmembrane domains.
- Antigenicity (Epitope) prediction was performed through the antigenic module in the
- 5 EMBOSS package. Rice, P., EMBOSS: The European Molecular Biology Open Software Suite, *Trends in Genetics* 16(6): 276-277 (2000). The antigenic module predicts potentially antigenic regions of a protein sequence, using the method of Kolaskar and Tongaonkar. Kolaskar, AS and Tongaonkar, PC., A semi-empirical method for prediction of antigenic determinants on protein antigens, *FEBS Letters* 276: 172-174 (1990).
- 10 Examples of post-translational modifications (PTMs) and other motifs of the BSPs of this invention are listed below. In addition, antibodies that specifically bind such post-translational modifications may be useful as a diagnostic or as therapeutic. The PTMs and other motifs were predicted by using the ProSite Dictionary of Proteins Sites and Patterns

DEX-0360

131

PATENT

- (Bairoch *et al.*, *Nucleic Acids Res.* 25(1):217-221 (1997)), the following motifs, including PTMs, were predicted for the BSPs of the invention. The signal peptides were detected by using the SignalP 2.0, *see* Nielsen *et al.*, *Protein Engineering* 12, 3-9 (1999). Prediction of transmembrane helices in proteins was performed by the application TMHMM 2.0,
- 5 "currently the best performing transmembrane prediction program", according to authors (Krogh *et al.*, *Journal of Molecular Biology*, 305(3):567-580, (2001); Moller *et al.*, *Bioinformatics*, 17(7):646-653, (2001); Sonnhammer, *et al.*, *A hidden Markov model for predicting transmembrane helices in protein sequences* in Glasgow, *et al.* Ed. Proceedings of the Sixth International Conference on Intelligent Systems for Molecular Biology, pages
- 10 175-182, Menlo Park, CA, 1998. AAAI Press. The PSORT II program may also be used to predict cellular localizations. Horton *et al.*, *Intelligent Systems for Molecular Biology* 5: 147-152 (1997). The table below includes the following sequence annotations: Signal peptide presence; TM (number of membrane domain, topology in orientation and position); Amino acid location and antigenic index (location, AI score, length); PTM and
- 15 other motifs (type, amino acid residue locations).

SeqID	Signal P	TMHMM	Antigenicity	PTM
DEX0360_001.aa.1	N	0 -o	104-114,1.158; 7-16,1.157; 53-67,1.106; 89-97,1.091; 29-35,1.089; 37-45,1.077	Myristyl 96-101;
DEX0360_002.aa.1	N	0 -o	191-209,1.254; 504-523,1.201; 134-146,1.198; 41-48,1.175; 17-28,1.172; 396-402,1.133; 90-109,1.13; 258-266,1.129; 279-288,1.111; 469-476,1.11; 623-634,1.104; 67-73,1.096; 553-561,1.091; 216-223,1.088; 113-122,1.087; 439-448,1.082; 151-158,1.082; 525-532,1.072; 230-236,1.071; 77-85,1.071; 364-370,1.067	Ww_Domain_1 360-385, 392-417, 467-492; Amidation 503-506; Asn_Glycosylation 18-21, 153-156, 156-159, 259-262, 277-280, 612-615, 645-648, 652-655; Camp_Phospho_Site 540-543; Ck2_Phospho_Site 81-84, 281-284, 282-285, 293-296, 304-307, 314-317, 327-330, 358-361, 380-383, 487-490, 590-593, 602-605, 623-626; Myristyl 133-138, 349-354, 548-553, 580-585, 587-592; Pkc_Phospho_Site 9-11, 20-22, 31-33, 58-60, 89-91, 92-94,

DEX-0360

132

PATENT

				179-181, 183-185, 421-423, 430-432, 474-476, 514-516, 555-557, 623-625, 649-651;
DEX0360_ 003.aa.1	N	0 -o	27-48,1.145; 5- 20,1.109; 76- 85,1.088; 87- 98,1.08	Ck2_Phospho_Site 56-59, 89-92; Pkc_Phospho_Site 28-30, 56-58, 127- 129;
DEX0360_ 003.aa.2	N	0 -o	42-144,1.183; 29- 37,1.176; 4- 17,1.167	Amidation 95-98; Myristyl 27-32, 29- 34, 102-107;
DEX0360_ 004.aa.1	N	3 - o52- 74i81 - 98o11 1- 133i	39-76,1.208; 4- 20,1.197; 78- 136,1.168; 26- 36,1.167	Ck2_Phospho_Site 112-115; Leucine_Zipper 111- 132; Pkc_Phospho_Site 26-28;
DEX0360_ 005.aa.1	N	0 -o	212-226,1.235; 496-508,1.194; 83-95,1.193; 132- 157,1.17; 181- 209,1.169; 103- 129,1.159; 512- 520,1.157; 465- 485,1.151; 286- 337,1.143; 252- 274,1.143; 58- 79,1.138; 411- 419,1.138; 436- 448,1.138; 382- 405,1.131; 276- 284,1.128; 4- 23,1.127; 346- 380,1.113; 47- 55,1.098; 487- 493,1.075; 244- 250,1.061	Camp_Phospho_Site 148-151, 493-496; Ck2_Phospho_Site 58-61, 75-78, 134- 137, 138-141, 234- 237, 261-264, 389- 392, 408-411, 452- 455, 454-457; Glycosaminoglycan 157-160; Myristyl 167-172; Pkc_Phospho_Site 234-236, 468-470, 492-494;
DEX0360_ 006.aa.1	N	0 -o	90-152,1.166; 420-435,1.158; 275-321,1.134; 31-77,1.134; 353- 366,1.124; 200- 245,1.12; 386- 418,1.117; 184- 193,1.106; 259- 268,1.098; 15- 24,1.098; 368- 384,1.092	Amidation 164-167, 169-172, 179-182, 333-336, 338-341; Camp_Phospho_Site 347-350; Ck2_Phospho_Site 69-72, 127-130, 173- 176, 313-316, 342- 345, 407-410; Myristyl 60-65, 304-309, 349-354; Pkc_Phospho_Site 173-175, 342-344;
DEX0360_ 007.aa.1	N	1 - i52- 74o	41-81,1.21; 91- 137,1.189; 17- 29,1.128	Asn_Glycosylation 90-93; Camp_Phospho_Site 3-6; Myristyl 65- 70, 96-101; Pkc_Phospho_Site 12-14, 32-34, 53-55,

DEX-0360

133

PATENT

				92-94;
DEX0360_008.aa.1	N	0 -o	14-29,1.149; 157-179,1.123; 105-114,1.096; 120-132,1.096; 31-46,1.081; 135-143,1.074; 64-71,1.073	Asn_Glycosylation 38-41, 76-79; Ck2_Phospho_Site 148-151; Pkc_Phospho_Site 44-46, 131-133, 152-154, 182-184;
DEX0360_009.aa.1	N	0 -o	71-111,1.241; 4-19,1.181; 122-129,1.155; 43-66,1.143; 22-34,1.14; 113-120,1.118	Ck2_Phospho_Site 20-23, 66-69, 75-78; Pkc_Phospho_Site 42-44;
DEX0360_009.aa.2	N	0 -o	216-256,1.241; 100-110,1.201; 143-156,1.179; 124-139,1.173; 161-173,1.163; 267-274,1.155; 187-211,1.143; 113-121,1.14; 62-87,1.118; 258-265,1.118; 41-49,1.115; 4-22,1.108; 90-97,1.055	Amidation 55-58; Camp_Phospho_Site 64-67; Ck2_Phospho_Site 17-20, 18-21, 168-171, 211-214, 220-223; Leucine_Zipper 136-157; Myristyl 27-32, 90-95, 116-121, 149-154; Pkc_Phospho_Site 32-34, 55-57, 94-96, 128-130;
DEX0360_010.aa.1	N	0 -o	82-101,1.245; 151-171,1.216; 325-337,1.171; 20-33,1.17; 282-323,1.167; 360-383,1.14; 179-188,1.128; 214-227,1.115; 200-209,1.109; 66-74,1.098; 272-280,1.07; 122-128,1.066	Asn_Glycosylation 45-48, 174-177, 301-304; Myristyl 340-345; Pkc_Phospho_Site 67-69, 124-126, 183-185, 241-243, 265-267; Prokar_Lipoprotein 88-98;
DEX0360_011.aa.1	y	0 -o	4-70,1.215; 98-113,1.099; 76-83,1.084; 121-133,1.062; 88-96,1.059	Asn_Glycosylation 79-82, 102-105; Myristyl 89-94, 118-123, 142-147;
DEX0360_012.aa.1	N	1 -o70-92i	62-100,1.293; 23-49,1.153	Ck2_Phospho_Site 22-25, 34-37, 53-56; Pkc_Phospho_Site 14-16; Prokar_Lipoprotein 80-90;
DEX0360_013.aa.1	N	1 -o411-430i	410-433,1.277; 34-45,1.229; 387-401,1.176; 291-297,1.151; 121-138,1.142; 304-312,1.108; 17-29,1.106; 439-450,1.101; 7-14,1.097; 143-150,1.089; 74-	Amidation 96-99; Asn_Glycosylation 29-32, 180-183, 183-186, 225-228, 295-298; Camp_Phospho_Site 98-101; Ck2_Phospho_Site 71-74, 72-75, 121-124, 172-175, 189-

DEX-0360

134

PATENT

			82,1.079; 207- 216,1.073; 270- 279,1.072; 159- 167,1.066; 359- 366,1.064; 240- 246,1.061; 372- 378,1.055	192, 195-198, 234- 237, 293-296, 332- 335; Myristyl 83- 88, 85-90, 181-186, 232-237, 241-246, 363-368; Pkc_Phospho_Site 51-53, 101-103, 104- 106, 142-144, 143- 145, 185-187, 216- 218, 242-244, 255- 257, 259-261, 262- 264, 367-369, 392- 394, 407-409, 410- 412; Prokar_Lipoprotein 358-368;
DEX0360_ 014.aa.1	N	0 -o	5-38,1.277; 215- 269,1.266; 96- 152,1.214; 280- 311,1.186; 42- 62,1.182; 194- 210,1.163; 369- 377,1.161; 158- 172,1.143; 317- 329,1.126; 182- 189,1.076; 73- 79,1.07; 361- 367,1.066	Asn_Glycosylation 278-281; Camp_Phospho_Site 272-275; Ck2_Phospho_Site 80-83, 113-116, 162- 165, 175-178, 297- 300, 327-330, 333- 336, 343-346, 348- 351, 353-356, 365- 368; Leucine_Zipper 13-34; Myristyl 95- 100; Pkc_Phospho_Site 187-189, 215-217, 258-260, 314-316; Tyr_Phospho_Site 184-192;
DEX0360_ 014.aa.2	N	0 -o	62-116,1.266; 127-158,1.186; 41-57,1.163; 216- 224,1.161; 164- 176,1.126; 29- 36,1.076; 208- 214,1.066	Asn_Glycosylation 125-128; Camp_Phospho_Site 119-122; Ck2_Phospho_Site 22-25, 144-147, 174- 177, 180-183, 190- 193, 195-198, 200- 203, 212-215; Myristyl 15-20; Pkc_Phospho_Site 34-36, 62-64, 105- 107, 161-163; Tyr_Phospho_Site 31-39;
DEX0360_ 015.aa.1	Y	1 - i62- 84o	48-95,1.27; 36- 46,1.134; 8- 25,1.122	Ck2_Phospho_Site 26-29; Myristyl 72- 77, 92-97; Pkc_Phospho_Site 98-100;
DEX0360_ 016.aa.1	Y	0 -o	4-15,1.225; 17- 45,1.22; 289- 299,1.202; 55- 76,1.192; 357- 366,1.179; 251-	Asn_Glycosylation 101-104, 398-401; Ck2_Phospho_Site 82-85, 162-165, 241- 244, 408-411;

DEX-0360

135

PATENT

			270,1.148; 189-208,1.13; 276-284,1.106; 375-385,1.104; 108-124,1.094; 141-148,1.058; 308-314,1.044; 152-158,1.042	Myristyl 102-107, 181-186, 185-190, 293-298, 382-387, 415-420, 419-424, 421-426, 425-430, 428-433; Pkc_Phospho_Site 69-71, 103-105, 156-158, 162-164, 214-216, 405-407; Idh_Imdh 275-294;
DEX0360_016.aa.2	y	0 -o	7-19,1.287; 268-278,1.202; 336-345,1.179; 107-127,1.175; 230-249,1.148; 168-187,1.13; 27-37,1.11; 255-263,1.106; 354-364,1.104; 59-75,1.094; 287-293,1.044; 131-137,1.042	Asn_Glycosylation 52-55, 377-380; Ck2_Phospho_Site 141-144, 220-223, 387-390; Myristyl 28-33, 29-34, 53-58, 160-165, 164-169, 272-277, 361-366, 394-399, 398-403, 400-405, 404-409, 407-412; Pkc_Phospho_Site 54-56, 135-137, 141-143, 193-195, 384-386; Idh_Imdh 254-273;
DEX0360_016.aa.3	N	0 -o	140-150,1.202; 29-60,1.194; 208-217,1.179; 65-79,1.163; 102-121,1.148; 127-135,1.106; 226-236,1.104; 159-165,1.044	Asn_Glycosylation 72-75, 249-252; Ck2_Phospho_Site 55-58, 92-95, 259-262; Myristyl 68-73, 144-149, 233-238, 266-271, 270-275, 272-277, 276-281, 279-284; Pkc_Phospho_Site 3-5, 86-88, 256-258; Idh_Imdh 126-145;
DEX0360_016.aa.4	N	0 -o	39-49,1.202; 107-116,1.179; 125-135,1.104; 27-37,1.058; 58-64,1.044	Asn_Glycosylation 148-151; Ck2_Phospho_Site 158-161; Myristyl 15-20, 43-48, 132-137, 165-170, 169-174, 171-176, 175-180, 178-183; Pkc_Phospho_Site 155-157;
DEX0360_016.aa.5	N	0 -o	4-15,1.169; 43-53,1.162; 72-88,1.071; 20-29,1.068	Amidation 104-107; Ck2_Phospho_Site 35-38; Myristyl 21-26;
DEX0360_017.aa.1	N	0 -o	223-244,1.245; 431-469,1.232; 51-79,1.227; 343-361,1.222; 289-309,1.22; 277-286,1.204; 311-338,1.193; 147-	Atp_Gtp_A 194-201; Amidation 139-142; Asn_Glycosylation 120-123; Ck2_Phospho_Site 26-29, 94-97, 165-168, 227-230, 255-

DEX-0360

136

PATENT

			160,1.185; 81-106,1.165; 484-501,1.158; 395-425,1.135; 212-221,1.128; 173-180,1.105; 42-48,1.104; 365-379,1.099; 182-188,1.097; 195-205,1.085; 128-134,1.078; 13-20,1.068; 476-482,1.052	258, 287-290, 309-312, 315-318, 380-383, 393-396, 485-488, 505-508; Myristyl 31-36, 62-67, 91-96, 397-402, 456-461, 490-495; Pkc_Phospho_Site 43-45, 287-289, 365-367, 473-475, 480-482, 485-487, 498-500; Cytochrome_C 455-460; Prokar_Lipoprotein 85-95;
DEX0360_017.aa.2	N	0 -o	144-165,1.245; 352-390,1.232; 264-282,1.222; 210-230,1.22; 198-207,1.204; 232-259,1.193; 68-81,1.185; 4-27,1.165; 405-422,1.158; 316-346,1.135; 133-142,1.128; 94-101,1.105; 286-300,1.099; 103-109,1.097; 116-126,1.085; 49-55,1.078; 397-403,1.052	Atp_Gtp_A 115-122; Amidation 60-63; Asn_Glycosylation 41-44; Ck2_Phospho_Site 15-18, 86-89, 148-151, 176-179, 208-211, 230-233, 236-239, 301-304, 314-317, 406-409, 426-429; Myristyl 12-17, 318-323, 377-382, 411-416; Pkc_Phospho_Site 208-210, 286-288, 394-396, 401-403, 406-408, 419-421; Cytochrome_C 376-381;
DEX0360_018.aa.1	N	0 -i	28-49,1.157; 105-114,1.146; 73-83,1.115; 61-68,1.076	Asn_Glycosylation 62-65; Ck2_Phospho_Site 5-8; Myristyl 30-35, 38-43; Pkc_Phospho_Site 5-7, 22-24, 117-119; Rgd 99-101;
DEX0360_019.aa.1	N	0 -o	84-96,1.25; 22-73,1.243; 326-358,1.218; 743-757,1.218; 654-665,1.206; 705-739,1.174; 589-650,1.171; 195-214,1.168; 554-587,1.151; 516-550,1.148; 503-509,1.136; 389-397,1.136; 446-454,1.124; 685-699,1.121; 380-386,1.115; 484-499,1.112; 473-481,1.111; 436-444,1.104; 295-	Amidation 570-573; Asn_Glycosylation 323-326, 609-612, 702-705; Ck2_Phospho_Site 62-65, 158-161, 295-298, 379-382, 387-390, 460-463, 513-516; Myristyl 25-30, 82-87, 119-124, 139-144, 289-294, 293-298, 309-314, 504-509, 508-513, 622-627, 695-700, 714-719; Pkc_Phospho_Site 85-87, 338-340, 362-364, 370-372, 441-

DEX-0360

137

PATENT

			303,1.102; 410-417,1.099; 247-253,1.094; 110-134,1.091; 11-20,1.082; 309-317,1.082; 423-430,1.079; 263-276,1.078; 99-108,1.065; 460-467,1.061; 673-679,1.051	443, 519-521, 545-547, 685-687; Prokar_Lipoprotein 620-630;
DEX0360_020.aa.1	N	0 -o	211-231,1.229; 137-156,1.186; 87-114,1.168; 68-83,1.156; 57-63,1.129; 159-166,1.088; 18-28,1.075; 240-246,1.066; 31-38,1.043	Ck2_Phospho_Site 239-242; Glycosaminoglycan 57-60, 118-121; Myristyl 52-57, 60-65, 132-137, 136-141, 151-156; Pkc_Phospho_Site 128-130, 194-196, 256-258;
DEX0360_021.aa.1	N	1 - 134- 56o	59-67,1.232; 29-46,1.176; 48-56,1.119; 4-17,1.115; 75-82,1.088	Spase_I_1 71-78; Ck2_Phospho_Site 19-22, 60-63; Myristyl 9-14; Rgd 80-82;
DEX0360_022.aa.1	N	0 -o	121-136,1.144; 70-103,1.137; 24-35,1.136; 47-60,1.095; 111-118,1.083	Ck2_Phospho_Site 16-19; Myristyl 66-71; Pkc_Phospho_Site 7-9, 73-75;
DEX0360_023.aa.1	N	0 -o	31-53,1.153; 82-101,1.124; 116-123,1.101; 21-27,1.075; 9-18,1.06	Ck2_Phospho_Site 12-15, 22-25; Myristyl 18-23, 26-31; Pkc_Phospho_Site 33-35, 80-82, 102-104, 112-114;
DEX0360_024.aa.1	N	0 -o	74-89,1.266; 6-30,1.222; 95-115,1.216; 185-193,1.186; 44-56,1.182; 160-168,1.14; 33-39,1.098; 129-141,1.073	Ck2_Phospho_Site 115-118, 123-126; Myristyl 5-10; Pkc_Phospho_Site 149-151, 184-186;
DEX0360_025.aa.1	N	0 -i	14-30,1.142; 55-66,1.125; 33-41,1.09	
DEX0360_026.aa.1	Y	0 -o	58-69,1.244; 148-168,1.153; 5-17,1.131; 30-37,1.122; 118-132,1.119; 81-95,1.115; 98-104,1.055	Amidation 138-141; Ck2_Phospho_Site 56-59; Myristyl 26-31, 145-150, 148-153; Pkc_Phospho_Site 29-31, 138-140;
DEX0360_027.aa.1	N	0 -i	21-32,1.156; 102-115,1.134; 6-13,1.098; 71-77,1.074; 94-	Asn_Glycosylation 48-51; Ck2_Phospho_Site 38-41, 52-55, 53-56;

DEX-0360

138

PATENT

			100,1.057	Myristyl 124-129; Pkc_Phospho_Site 26-28, 84-86, 125-127;
DEX0360_028.aa.1	N	0 -o	28-44,1.18; 90-103,1.176; 60-84,1.129	Amidation 19-22; Ck2_Phospho_Site 45-48, 69-72; Myristyl 91-96; Pkc_Phospho_Site 7-9;
DEX0360_028.aa.2	N	0 -o	184-196,1.196; 92-102,1.123; 206-221,1.11; 12-39,1.095; 148-169,1.09; 49-58,1.078; 60-67,1.077; 223-234,1.075; 72-78,1.06	Asn_Glycosylation 91-94, 118-121; Ck2_Phospho_Site 81-84, 107-110; Glycosaminoglycan 16-19, 157-160; Myristyl 15-20, 116-121, 207-212, 208-213; Pkc_Phospho_Site 42-44, 101-103, 201-203, 225-227, 228-230; Ef_Hand 73-85, 140-152;
DEX0360_029.aa.1	N	0 -o	47-56,1.114; 27-45,1.107	Camp_Phospho_Site 22-25; Ck2_Phospho_Site 7-10, 25-28, 49-52; Pkc_Phospho_Site 25-27, 31-33, 65-67;
DEX0360_030.aa.1	N	0 -o	427-447,1.229; 301-326,1.203; 797-823,1.202; 757-779,1.186; 705-717,1.176; 465-509,1.17; 720-750,1.169; 136-155,1.162; 32-41,1.153; 514-525,1.152; 372-396,1.151; 540-559,1.148; 329-354,1.14; 239-261,1.137; 658-676,1.129; 625-638,1.129; 276-288,1.128; 684-693,1.128; 201-224,1.126; 607-614,1.125; 164-176,1.115; 117-131,1.108; 80-86,1.107; 562-571,1.107; 181-193,1.102; 640-648,1.102; 8-26,1.101; 585-605,1.093; 363-370,1.091; 50-66,1.086; 398-	Asn_Glycosylation 536-539; Camp_Phospho_Site 236-239, 352-355; Ck2_Phospho_Site 196-199, 231-234, 274-277, 384-387, 431-434, 517-520, 585-588, 593-596, 618-621, 626-629, 659-662, 812-815; Glycosaminoglycan 137-140; Myristyl 140-145, 160-165, 171-176, 241-246, 279-284, 443-448, 504-509; Pkc_Phospho_Site 3-5, 31-33, 84-86, 103-105, 166-168, 184-186, 227-229, 242-244, 368-370, 413-415, 426-428, 625-627, 658-660, 747-749, 794-796; Tyr_Phospho_Site 785-793;

DEX-0360

139

PATENT

			405,1.08; 695-703,1.08; 410-418,1.08; 782-791,1.075; 265-271,1.074; 574-581,1.06	
DEX0360_030.aa.2	y	0 -o	106-132,1.202; 66-88,1.186; 22-34,1.175; 48-64,1.13; 4-14,1.103; 91-100,1.075	Ck2_Phospho_Site 121-124; Myristyl 35-40, 39-44, 42-47; Pkc_Phospho_Site 103-105; Tyr_Phospho_Site 94-102;
DEX0360_031.aa.1	N	0 -o	98-109,1.186; 216-242,1.18; 120-146,1.156; 369-380,1.118; 169-186,1.117; 80-88,1.117; 431-448,1.11; 301-307,1.099; 343-357,1.098; 5-14,1.094; 313-323,1.091; 421-427,1.085; 68-74,1.079; 41-50,1.079; 55-62,1.069; 391-403,1.058; 160-167,1.034	Camp_Phospho_Site 335-338; Ck2_Phospho_Site 170-173, 257-260, 376-379, 397-400, 423-426, 432-435; Glycosaminoglycan 330-333; Myristyl 44-49, 91-96, 120-125, 145-150, 195-200, 213-218, 214-219, 215-220, 216-221, 217-222; Pkc_Phospho_Site 3-5, 131-133, 206-208, 257-259, 302-304, 330-332, 343-345, 363-365, 455-457;
DEX0360_031.aa.2	N	0 -o	30-47,1.11; 20-26,1.085	Ck2_Phospho_Site 22-25, 31-34; Pkc_Phospho_Site 54-56;
DEX0360_032.aa.1	y	0 -o	242-253,1.236; 76-86,1.208; 101-119,1.19; 276-291,1.19; 256-269,1.186; 166-187,1.178; 127-143,1.165; 36-43,1.092; 63-70,1.076; 148-159,1.071; 4-15,1.064; 222-228,1.056; 230-236,1.035	Ck2_Phospho_Site 56-59, 152-155, 168-171, 175-178, 202-205, 238-241; Complex1_24k 171-189; Myristyl 38-43, 162-167, 183-188, 234-239, 274-279; Pkc_Phospho_Site 202-204, 225-227;
DEX0360_032.aa.2	y	0 -o	76-86,1.208; 236-247,1.198; 101-119,1.19; 166-187,1.178; 127-143,1.165; 36-43,1.092; 63-70,1.076; 148-159,1.071; 4-15,1.064; 222-228,1.056	Ck2_Phospho_Site 56-59, 152-155, 168-171, 175-178, 202-205, 238-241; Complex1_24k 171-189; Myristyl 38-43, 162-167, 183-188, 234-239; Pkc_Phospho_Site 202-204, 225-227, 240-242;
DEX0360_	y	0 -o	161-229,1.255;	Ck2_Phospho_Site

DEX-0360

140

PATENT

032.aa.3			76-86,1.208; 101-119,1.19; 127-143,1.165; 36-43,1.092; 63-70,1.076; 148-155,1.071; 4-15,1.064	56-59, 152-155; Myristyl 38-43; Pkc_Phospho_Site 224-226;
DEX0360_033.aa.1	Y	8 - o285- 307i3 14- 336o3 51- 373i4 28- 450o4 55- 477i4 98- 520o5 54- 573i5 80- 602o	413-488,1.288; 551-629,1.224; 4-36,1.212; 296-309,1.21; 686-701,1.174; 378-398,1.173; 265-294,1.165; 109-120,1.158; 325-338,1.152; 311-323,1.147; 499-543,1.144; 214-220,1.128; 344-376,1.125; 90-98,1.121; 51-61,1.086; 154-167,1.085; 63-85,1.083; 655-663,1.083; 675-682,1.081; 125-131,1.066; 139-145,1.045; 177-190,1.044	Asn_Glycosylation 109-112, 179-182, 211-214, 235-238; Camp_Phospho_Site 60-63; Ck2_Phospho_Site 90-93, 183-186, 237-240, 327-330, 518-521, 551-554; Myristyl 121-126, 332-337, 371-376, 406-411, 424-429, 434-439, 447-452, 530-535, 535-540, 657-662, 658-663, 660-665; Pkc_Phospho_Site 58-60, 139-141, 213-215, 237-239, 318-320, 407-409, 689-691; Rgd 409-411; Tyr_Phospho_Site 412-418;
DEX0360_033.aa.2	N	2 - o64- 86i12 6- 148o	48-113,1.224; 117-146,1.216; 4-11,1.132; 148-154,1.122; 16-23,1.081	Camp_Phospho_Site 162-165; Myristyl 26-31, 35-40, 37-42; Pkc_Phospho_Site 38-40;
DEX0360_033.aa.3	N	0 -o	5-23,1.13	
DEX0360_034.aa.1	N	0 -o	44-51,1.12; 4-16,1.118; 73-90,1.093; 57-63,1.06	Amidation 68-71; Camp_Phospho_Site 98-101; Ck2_Phospho_Site 21-24; Glycosaminoglycan 55-58; Myristyl 39-44, 51-56; Pkc_Phospho_Site 21-23, 97-99;
DEX0360_034.aa.2	N	0 -o	113-141,1.174; 177-186,1.14; 161-168,1.133; 194-204,1.117; 62-82,1.114; 98-107,1.08; 44-51,1.08	Asn_Glycosylation 63-66; Ck2_Phospho_Site 21-24, 31-34, 84-87, 134-137, 172-175; Myristyl 40-45, 49-54, 156-161; Pkc_Phospho_Site 57-59; Prokar_Lipoprotein 195-205;
DEX0360_035.aa.1	N	5 - o48-	311-330,1.226; 4-14,1.182; 252-	Amidation 96-99; Asn_Glycosylation

DEX-0360

141

PATENT

		65i23 5- 257o2 80- 302i3 09- 331o3 51- 370i	275,1.174; 40- 68,1.173; 344- 378,1.159; 277- 291,1.155; 108- 114,1.118; 144- 151,1.106; 194- 209,1.097; 119- 125,1.088; 235- 245,1.08; 160- 177,1.074; 19- 28,1.073; 299- 305,1.072	133-136, 187-190, 236-239, 313-316; Camp_Phospho_Site 98-101; Ck2_Phospho_Site 138-141, 163-166, 170-173, 212-215; Myristyl 121-126, 240-245, 244-249, 250-255, 253-258, 254-259, 300-305, 304-309, 308-313, 362-367; Pkc_Phospho_Site 40-42, 282-284;
DEX0360_ 036.aa.1	N	0 -o	187-212,1.258; 82-100,1.189; 143-173,1.178; 11-27,1.136; 42- 72,1.128; 177- 184,1.121; 258- 264,1.107; 219- 235,1.103	Ck2_Phospho_Site 165-168, 202-205, 240-243; Myristyl 80-85, 81-86, 84-89, 95-100, 100-105, 120-125, 178-183; Pkc_Phospho_Site 182-184;
DEX0360_ 037.aa.1	N	0 -o	187-212,1.258; 143-173,1.178; 11-27,1.136; 75- 96,1.128; 42- 69,1.128; 177- 184,1.121	Camp_Phospho_Site 74-77; Ck2_Phospho_Site 165-168, 202-205; Myristyl 120-125, 178-183; Pkc_Phospho_Site 182-184;
DEX0360_ 037.aa.2	N	1 - o247- 269i	231-288,1.292; 208-218,1.205; 143-173,1.178; 11-27,1.136; 75- 96,1.128; 42- 69,1.128; 177- 184,1.121; 188- 196,1.112	Camp_Phospho_Site 74-77; Ck2_Phospho_Site 165-168, 209-212, 278-281; Myristyl 120-125, 178-183, 230-235, 232-237; Pkc_Phospho_Site 182-184;
DEX0360_ 038.aa.1	N	0 -o	120-134,1.162; 37-63,1.15; 16- 25,1.138; 92- 100,1.089; 72- 90,1.076	Ck2_Phospho_Site 15-18, 36-39, 81-84, 137-140; Myristyl 108-113, 125-130; Pkc_Phospho_Site 15-17, 68-70;
DEX0360_ 038.aa.2	N	0 -o	13-24,1.192; 95- 113,1.139; 57- 69,1.097; 86- 92,1.093; 29- 39,1.075	Ck2_Phospho_Site 45-48; Glycosaminoglycan 15-18, 87-90; Myristyl 13-18, 16- 21, 73-78, 86-91, 96-101; Pkc_Phospho_Site 37-39, 45-47, 80-82, 87-89; Rgd 50-52; Prokar_Lipoprotein 104-114;
DEX0360_ 039.aa.1	N	0 -o	11-54,1.18; 60- 74,1.178	Camp_Phospho_Site 11-14;

DEX-0360

142

PATENT

				Ck2_Phospho_Site 78-81; Myristyl 64-69, 72-77; Pkc_Phospho_Site 7-9, 14-16, 50-52;
DEX0360_040.aa.1	N	0 -o	51-59,1.155; 4-30,1.153; 36-42,1.041	Asn_Glycosylation 40-43; Ck2_Phospho_Site 78-81; 82-85; Glycosaminoglycan 95-98; Myristyl 17-22, 33-38, 56-61, 96-101; Pkc_Phospho_Site 45-47, 46-48, 64-66, 78-80, 82-84; Tyr_Phospho_Site 47-53;
DEX0360_041.aa.1	N	0 -o	4-34,1.151	Myristyl 30-35;
DEX0360_041.aa.2	N	0 -o	157-169,1.166; 343-354,1.14; 107-115,1.103; 172-186,1.098; 219-229,1.096; 328-336,1.095; 86-100,1.09; 274-285,1.08; 63-81,1.08; 309-319,1.072; 119-133,1.072; 137-143,1.052; 188-203,1.037	Amidation 60-63; Asn_Glycosylation 214-217, 300-303; Camp_Phospho_Site 105-108, 303-306; Ck2_Phospho_Site 24-27, 37-40, 164-167, 209-212, 235-238, 236-239, 237-240, 248-251, 249-252, 256-259, 302-305, 306-309, 311-314, 312-315, 326-329, 374-377; Myristyl 90-95, 123-128, 133-138; Pkc_Phospho_Site 24-26, 104-106, 127-129, 194-196, 201-203, 209-211, 264-266, 275-277, 278-280, 281-283, 294-296, 295-297, 301-303, 302-304, 333-335, 347-349, 365-367, 374-376;
DEX0360_041.aa.3	N	0 -o	157-169,1.166; 343-354,1.14; 107-115,1.103; 172-186,1.098; 219-229,1.096; 328-336,1.095; 86-100,1.09; 274-285,1.08; 63-81,1.08; 309-319,1.072; 119-133,1.072; 137-143,1.052; 188-203,1.037	Amidation 60-63; Asn_Glycosylation 214-217, 300-303; Camp_Phospho_Site 105-108, 303-306; Ck2_Phospho_Site 24-27, 37-40, 164-167, 209-212, 235-238, 236-239, 237-240, 248-251, 249-252, 256-259, 302-305, 306-309, 311-314, 312-315, 326-329, 374-377;

DEX-0360

143

PATENT

				Myristyl 90-95, 123-128, 133-138; Pkc_Phospho_Site 24-26, 104-106, 127- 129, 194-196, 201- 203, 209-211, 264- 266, 275-277, 278- 280, 281-283, 294- 296, 295-297, 301- 303, 302-304, 333- 335, 347-349, 365- 367, 374-376;
DEX0360_ 042.aa.1	Y	7 - o10- 28i41 - 58o63 - 85i90 - 112o1 22- 144i1 49- 166o1 79- 201i	4-113,1.251; 122- 144,1.208; 146- 204,1.168	Ck2_Phospho_Site 79-82, 91-94, 119- 122, 180-183; Leucine_Zipper 179- 200; Myristyl 56- 61; Pkc_Phospho_Site 35-37, 119-121;
DEX0360_ 043.aa.1	N	0 -o	22-46,1.114	Camp_Phospho_Site 38-41; Ck2_Phospho_Site 49-52, 53-56; Myristyl 58-63; Pkc_Phospho_Site 37-39, 41-43;
DEX0360_ 044.aa.1	N	0 -o	552-569,1.221; 389-409,1.207; 577-592,1.184; 173-187,1.181; 501-511,1.163; 603-614,1.159; 631-639,1.155; 423-433,1.152; 648-661,1.152; 711-722,1.149; 267-317,1.144; 29-52,1.137; 348- 357,1.133; 257- 263,1.125; 202- 220,1.11; 148- 170,1.109; 114- 123,1.107; 234- 245,1.104; 535- 542,1.103; 101- 108,1.093; 680- 693,1.082; 193- 199,1.077; 11- 18,1.076; 327- 334,1.07; 622- 629,1.067; 668- 674,1.067; 461-	Amidation 446-449; Asn_Glycosylation 208-211, 291-294, 341-344; Camp_Phospho_Site 448-451, 528-531; Ck2_Phospho_Site 81-84, 126-129, 391- 394, 419-422, 456- 459, 458-461, 491- 494, 508-511, 534- 537, 545-548, 624- 627, 663-666, 691- 694, 711-714; Glycosaminoglycan 5-8; Myristyl 23- 28, 204-209, 264- 269, 415-420, 487- 492, 518-523, 564- 569, 645-650; Pkc_Phospho_Site 5- 7, 73-75, 270-272, 386-388, 419-421, 446-448, 482-484, 531-533, 534-536, 542-544, 554-556,

DEX-0360

144

PATENT

			468,1.066; 695-701,1.045; 247-253,1.027	599-601, 659-661;
DEX0360_044.aa.2	N	0 -o	56-73,1.221; 81-97,1.184; 5-15,1.163; 116-135,1.156; 100-110,1.117; 39-46,1.103	Camp_Phospho_Site 32-35; Ck2_Phospho_Site 12-15, 38-41, 49-52; Myristyl 22-27, 68-73, 106-111; Pkc_Phospho_Site 35-37, 38-40, 46-48, 58-60;
DEX0360_045.aa.1	N	0 -o	4-23,1.122; 49-55,1.095	Amidation 30-33; Ck2_Phospho_Site 36-39; Myristyl 30-35; Pkc_Phospho_Site 36-38, 44-46, 63-65;
DEX0360_045.aa.2	N	0 -o	29-81,1.173; 84-103,1.156; 132-141,1.155; 4-14,1.107; 105-121,1.099; 19-27,1.069	Ck2_Phospho_Site 12-15, 134-137; Myristyl 182-187, 188-193; Pkc_Phospho_Site 88-90, 107-109, 175-177;
DEX0360_046.aa.1	N	0 -i	92-103,1.125; 6-28,1.107; 65-72,1.086	Camp_Phospho_Site 90-93, 104-107; Ck2_Phospho_Site 48-51; Pkc_Phospho_Site 20-22, 36-38, 107-109;
DEX0360_046.aa.2	N	0 -i	92-103,1.125; 6-28,1.107; 65-72,1.086	Camp_Phospho_Site 90-93, 104-107; Ck2_Phospho_Site 48-51; Pkc_Phospho_Site 20-22, 36-38, 107-109;
DEX0360_046.aa.3	N	0 -o	31-53,1.107; 90-97,1.086; 10-17,1.075; 112-118,1.061	Asn_Glycosylation 127-130; Camp_Phospho_Site 115-118; Ck2_Phospho_Site 12-15, 73-76; Pkc_Phospho_Site 30-32, 45-47, 61-63;
DEX0360_047.aa.1	N	0 -i	45-52,1.117; 9-18,1.094; 20-27,1.075	Leucine_Zipper 30-51;
DEX0360_048.aa.1	N	0 -o	130-141,1.208; 196-218,1.184; 71-87,1.183; 175-193,1.182; 323-331,1.175; 268-279,1.161; 524-558,1.157; 378-391,1.155; 228-235,1.152; 348-362,1.136; 402-	Amidation 796-799, 801-804, 812-815; Asn_Glycosylation 232-235, 493-496; Camp_Phospho_Site 9-12, 803-806; Ck2_Phospho_Site 185-188, 366-369, 437-440, 464-467, 479-482, 495-498,

DEX-0360

145

PATENT

			414,1.135; 663-709,1.134; 41-59,1.13; 722-784,1.123; 433-444,1.116; 478-485,1.112; 817-826,1.106; 833-873,1.1; 647-656,1.098; 588-625,1.092; 289-298,1.09; 18-30,1.085; 466-476,1.079; 575-581,1.072; 158-168,1.066; 95-101,1.051	514-517, 523-526, 550-553, 701-704, 759-762; Myristyl 44-49, 81-86, 150-155, 153-158, 225-230, 385-390, 546-551; Pkc_Phospho_Site 7-9, 15-17, 39-41, 73-75, 244-246, 507-509, 805-807, 806-808; Tyr_Phospho_Site 321-329;
DEX0360_048.aa.2	N	0 -o	36-47,1.208; 102-124,1.184; 81-99,1.182; 229-237,1.175; 174-185,1.161; 430-464,1.157; 284-297,1.155; 134-141,1.152; 254-268,1.136; 308-320,1.135; 569-615,1.134; 628-690,1.123; 339-350,1.116; 384-391,1.112; 723-732,1.106; 739-779,1.1; 553-562,1.098; 494-531,1.092; 195-204,1.09; 372-382,1.079; 481-487,1.072; 64-74,1.066	Amidation 702-705, 707-710, 718-721; Asn_Glycosylation 138-141, 399-402; Camp_Phospho_Site 709-712; Ck2_Phospho_Site 91-94, 272-275, 343-346, 370-373, 385-388, 401-404, 420-423, 429-432, 456-459, 607-610, 665-668; Myristyl 56-61, 59-64, 131-136, 291-296, 452-457; Pkc_Phospho_Site 150-152, 413-415, 711-713, 712-714; Tyr_Phospho_Site 227-235;
DEX0360_049.aa.1	N	0 -o	184-215,1.243; 71-105,1.238; 107-122,1.23; 346-378,1.206; 421-428,1.175; 431-444,1.172; 268-290,1.163; 31-50,1.154; 219-246,1.153; 249-259,1.145; 324-332,1.141; 143-163,1.136; 59-68,1.117; 302-317,1.111; 4-27,1.109; 402-408,1.098; 129-136,1.092; 334-344,1.083; 173-179,1.04	Atp_Gtp_A 264-271; Amidation 22-25, 186-189; Ck2_Phospho_Site 276-279, 383-386, 399-402, 450-453; Myristyl 26-31, 126-131, 127-132, 131-136, 264-269, 395-400; Pkc_Phospho_Site 268-270, 280-282, 327-329; Tyr_Phospho_Site 412-419;
DEX0360_050.aa.1	N	0 -o	416-440,1.249; 536-547,1.217; 394-406,1.206;	Asn_Glycosylation 58-61, 167-170, 175-178, 232-235, 258-

DEX-0360

146

PATENT

			151-159,1.16; 18-25,1.141; 81-90,1.138; 575-596,1.136; 639-654,1.129; 516-534,1.113; 188-218,1.109; 447-454,1.108; 32-38,1.106; 292-298,1.103; 617-625,1.1; 488-503,1.1; 305-318,1.096; 549-563,1.095; 139-145,1.092; 127-133,1.09; 57-66,1.088; 329-340,1.088; 261-268,1.087; 608-615,1.081; 355-367,1.08; 462-470,1.076; 174-182,1.065; 369-375,1.063; 245-251,1.024	261, 296-299, 312-315, 345-348, 359-362; Camp_Phospho_Site 84-87, 107-110, 171-174; Ck2_Phospho_Site 17-20, 68-71, 73-76, 111-114, 115-118, 129-132, 141-144, 303-306, 308-311, 367-370, 414-417, 447-450, 569-572, 586-589, 628-631; Myristyl 165-170, 201-206, 400-405, 408-413, 546-551, 624-629; Pkc_Phospho_Site 7-9, 16-18, 17-19, 83-85, 115-117, 153-155, 169-171, 197-199, 261-263, 293-295, 347-349, 356-358, 465-467;
DEX0360_051.aa.1	N	0 -o	160-170,1.175; 53-63,1.149; 67-74,1.112; 207-215,1.105; 19-26,1.096; 120-129,1.073; 99-107,1.07; 90-96,1.059	Asn_Glycosylation 54-57; Camp_Phospho_Site 85-88; Ck2_Phospho_Site 55-58, 88-91, 97-100; Pkc_Phospho_Site 36-38, 142-144, 192-194;
DEX0360_052.aa.1	N	0 -o	40-49,1.152; 14-34,1.143; 137-154,1.127; 51-59,1.122; 65-83,1.119; 125-131,1.094; 96-113,1.058	Ck2_Phospho_Site 3-6, 55-58, 95-98, 119-122; Myristyl 12-17, 14-19, 27-32, 31-36, 39-44, 43-48, 44-49, 87-92, 126-131, 142-147; Pkc_Phospho_Site 95-97;
DEX0360_053.aa.1	N	0 -o	225-244,1.131; 98-104,1.102; 159-170,1.084; 123-129,1.072; 260-266,1.063; 249-258,1.062; 201-208,1.058; 5-18,1.056; 115-121,1.053	Ck2_Phospho_Site 18-21, 26-29, 48-51, 59-62, 161-164, 168-171, 197-200; Leucine_Zipper 215-236; Myristyl 11-16, 92-97, 258-263; Pkc_Phospho_Site 161-163, 176-178; Tyr_Phospho_Site 27-34, 38-45, 126-132; Ef_Hand 108-120, 160-172;
DEX0360_053.aa.2	Y	1 - i5- 27o	5-28,1.211; 89-102,1.159; 50-68,1.14; 34-	Ck2_Phospho_Site 25-28, 106-109, 129-132, 158-161, 169-

DEX-0360

147

PATENT

			43,1.125; 249-255,1.102; 132-145,1.09; 312-318,1.084; 274-280,1.072; 114-126,1.063; 343-352,1.062; 163-169,1.022	172, 177-180, 199-202, 210-213, 312-315, 319-322; Myristyl 243-248, 352-357; Pkc_Phospho_Site 47-49, 72-74, 90-92, 312-314, 327-329; Tyr_Phospho_Site 178-185, 189-196, 277-283; Ef_Hand 259-271, 311-323;
DEX0360_054.aa.1	N	0 -o	12-21,1.188; 143-158,1.175; 26-40,1.13; 132-138,1.104; 63-83,1.101; 100-115,1.089; 92-98,1.088; 117-130,1.08	Asn_Glycosylation 97-100; Myristyl 64-69; Pkc_Phospho_Site 50-52, 53-55;
DEX0360_055.aa.1	N	0 -o	22-28,1.06	Ck2_Phospho_Site 3-6, 34-37;
DEX0360_056.aa.1	N	1 - i51- 73o	50-89,1.252; 26-43,1.241; 121-128,1.149; 5-20,1.069; 106-112,1.025	Amidation 48-51; Asn_Glycosylation 29-32, 42-45, 53-56; Camp_Phospho_Site 51-54, 135-138; Ck2_Phospho_Site 121-124; Myristyl 28-33, 33-38; Pkc_Phospho_Site 13-15;
DEX0360_057.aa.1	N	0 -o	89-97,1.175; 276-333,1.174; 32-39,1.169; 168-180,1.158; 115-138,1.154; 216-272,1.139; 141-161,1.131; 343-372,1.126; 206-214,1.115; 41-51,1.108; 100-106,1.096; 61-70,1.094; 182-188,1.072	Asn_Glycosylation 18-21, 33-36; Camp_Phospho_Site 381-384; Ck2_Phospho_Site 35-38, 62-65, 82-85, 204-207; Myristyl 29-34, 71-76, 157-162, 223-228, 312-317; Pkc_Phospho_Site 20-22, 32-34, 52-54, 75-77, 138-140, 204-206; Tyr_Phospho_Site 206-213;
DEX0360_057.aa.2	N	0 -o	135-192,1.174; 27-39,1.158; 75-131,1.139; 4-20,1.131; 202-231,1.126; 65-73,1.115; 41-47,1.072	Camp_Phospho_Site 240-243; Ck2_Phospho_Site 63-66; Myristyl 16-21, 82-87, 171-176; Pkc_Phospho_Site 63-65; Tyr_Phospho_Site 65-72;
DEX0360_058.aa.1	N	0 -o	8-32,1.169; 34-43,1.131; 45-53,1.094	Myristyl 43-48, 48-53; Pkc_Phospho_Site 20-22, 56-58;

DEX-0360

148

PATENT

DEX0360_059.aa.1	N	0 -o	5-28,1.227; 146-170,1.178; 108-125,1.175; 194-211,1.159; 84-93,1.145; 95-102,1.14; 249-283,1.138; 51-58,1.131; 324-341,1.13; 214-220,1.128; 290-297,1.111; 347-354,1.102; 35-43,1.094; 74-80,1.085; 234-244,1.079; 133-139,1.041	Amidation 217-220; Asn_Glycosylation 87-90; Camp_Phospho_Site 235-238; Ck2_Phospho_Site 49-52, 95-98, 148-151, 197-200, 259-262, 379-382; Myristyl 36-41, 37-42, 314-319, 350-355; Pkc_Phospho_Site 40-42, 44-46, 49-51, 81-83, 100-102, 110-112, 181-183, 239-241;
DEX0360_060.aa.1	N	0 -o	73-90,1.171; 11-26,1.068; 28-34,1.043; 58-71,1.043; 164-174,1.033; 95-101,1.006	Camp_Phospho_Site 107-110, 152-155; Myristyl 17-22, 65-70, 80-85, 118-123, 119-124, 171-176; Pkc_Phospho_Site 51-53, 54-56, 126-128, 155-157, 165-167;

### Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman<sup>®</sup> probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman<sup>®</sup>) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

The tissue distribution and the level of the target gene are evaluated for every sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently,

DEX-0360

149

PATENT

first strand cDNA is prepared with reverse transcriptase and the polymerase chain reaction is done using primers and Taqman<sup>®</sup> probes specific to each target gene. The results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the  
5 calibrator tissue.

One of ordinary skill can design appropriate primers. The relative levels of expression of the BSNA versus normal tissues and other cancer tissues can then be determined. All the values are compared to the calibrator. Normal RNA samples are commercially available pools, originated by pooling samples of a particular tissue from  
10 different individuals.

The relative levels of expression of the BSNA in pairs of matched samples may also be determined. A matched pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. All the values are compared to the calibrator.

15 In the analysis of matching samples, the BSNA that show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples. Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer state (*e.g.* higher  
20 levels of mRNA expression in the cancer sample compared to the normal adjacent).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in matched samples tested are indicative of SEQ ID NO: 1-103 being a diagnostic marker for cancer.

### Example 3: Protein Expression

25 The BSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the BSNA is subcloned in pET-21d for expression in *E. coli*. In addition to the BSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH<sub>2</sub>-terminus of the coding sequence of BSNA, and six histidines, flanking the COOH-terminus of the coding sequence of BSNA, are incorporated to serve as initiating  
30 Met/restriction site and purification tag, respectively.

DEX-0360

150

PATENT

An over-expressed protein band of the appropriate molecular weight may be observed on a Coomassie blue stained polyacrylamide gel. This protein band is confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

Large-scale purification of BSP is achieved using cell paste generated from 6-liter bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that are separated from total cell lysate were incubated with a nickel chelating resin. The column is packed and washed with five column volumes of wash buffer. BSP is eluted stepwise with various concentration imidazole buffers.

#### Example 4: Fusion Proteins

The human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 2, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. *See, e.g.*, WO 96/34891.

#### Example 5: Production of an Antibody from a Polypeptide

In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from

DEX-0360

151

PATENT

the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

5 The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide. Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific  
10 antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein specific antibody and can be used to immunize an animal to  
15 induce formation of further protein-specific antibodies.

**Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA is isolated from individual patients or from a family of individuals that have  
20 a phenotype of interest. cDNA is then generated from these RNA samples using protocols known in the art. *See*, Sambrook (2001), *supra*. The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1-103. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*,  
25 *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*, *Science* 278(5340): 1054-9 (1997).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons are also determined and genomic PCR products  
30 analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing. PCR products is cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156

DEX-0360

152

PATENT

(1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements may also be determined. Genomic clones are nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and  
5 FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C-and R-bands. Aligned images for precise mapping  
10 are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. Johnson (1991). Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the  
15 genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably  
20 a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced. The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial  
25 dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 :l of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate. 75 :l of  
30 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

DEX-0360

153

PATENT

The reaction is measured by a microtiter plate reader. A standard curve is prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

#### Example 8: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1,  $\mu\text{g/kg/day}$  to 10  $\text{mg/kg/day}$  of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01  $\text{mg/kg/day}$ , and most preferably for humans between about 0.01 and 1  $\text{mg/kg/day}$  for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1  $\mu\text{g/kg/hour}$  to about 50  $\text{mg/kg/hour}$ , either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

DEX-0360

154

PATENT

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No. 3,773,919, EP 58,481, the contents of which are hereby incorporated by reference herein in their entirety), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., *Biopolymers* 22: 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., *J. Biomed. Mater. Res.* 15: 167-277 (1981), and R. Langer, *Chem. Tech.* 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein et al., *Proc. Natl. Acad. Sci. USA* 82: 3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. USA* 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324, the contents of which are hereby incorporated by reference herein in their entirety. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably, the carrier is a parenteral carrier, more preferably, a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

**Example 9: Method of Treating Decreased Levels of the Polypeptide**

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by  
5 administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

10 For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

**15 Example 10: Method of Treating Increased Levels of the Polypeptide**

Antisense or RNAi technology are used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

For example, a patient diagnosed with abnormally increased levels of a  
20 polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided above.

**25 Example 11: Method of Treatment Using Gene Therapy**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a  
30 tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of

the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

At this time, fresh media is added and subsequently changed every several days.

After an additional two weeks in culture, a monolayer of fibroblasts emerge. The  
5 monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al.,  
DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine  
sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf  
intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using  
glass beads.

10 The cDNA encoding a polypeptide of the present invention can be amplified using  
PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in  
Example 3. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a  
HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and  
the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA  
15 ligase. The resulting mixture is maintained under conditions appropriate for ligation of the  
two fragments. The ligation mixture is then used to transform bacteria HB 101, which are  
then plated onto agar containing kanamycin for the purpose of confirming that the vector  
has the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to  
20 confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum  
(CS), penicillin and streptomycin. The MSV vector containing the gene is then added to  
the media and the packaging cells transduced with the vector. The packaging cells now  
produce infectious viral particles containing the gene (the packaging cells are now referred  
to as producer cells).

25 Fresh media is added to the transduced producer cells, and subsequently, the media  
is harvested from a 10 cm plate of confluent producer cells. The spent media, containing  
the infectious viral particles, is filtered through a millipore filter to remove detached  
producer cells and this media is then used to infect fibroblast cells. Media is removed  
from a sub-confluent plate of fibroblasts and quickly replaced with the media from the  
30 producer cells. This media is removed and replaced with fresh media.

If the titer of virus is high, then virtually all fibroblasts will be infected and no  
selection is required. If the titer is very low, then it is necessary to use a retroviral vector

that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

5

#### Example 12: Method of Treatment Using Gene Therapy-In Vivo

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences  
10 into an animal to increase or decrease the expression of the polypeptide.

The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, Tabata H. *et al. Cardiovasc. Res.* 35 (3): 470-479 (1997); Chao J  
15 *et al. Pharmacol. Res.* 35 (6): 517-522 (1997); Wolff J. A. *Neuromuscul. Disord.* 7 (5): 314-318 (1997), Schwartz B. *et al. Gene Ther.* 3 (5): 405-411 (1996); and Tsurumi Y. *et al. Circulation* 94 (12): 3281-3290 (1996); WO 90/11092, WO 98/11779; U. S. Patent No. 5,693,622; 5,705,151; 5,580,859, the contents of which are hereby incorporated by reference herein in their entirety.

20 The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, breast, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free  
25 from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. *et al. Ann. NY Acad. Sci.* 772: 126-139 (1995) and Abdallah B. *et al. Biol. Cell* 85 (1): 1-7 (1995)) which  
30 can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art

DEX-0360

159

PATENT

can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the  
5 desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, breast, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue.  
10 Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to  
15 the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin  
20 fibroblasts. In vivo muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05  $\mu\text{g/kg}$  body weight to about 50  $\text{mg/kg}$  body weight. Preferably the dosage will be from about 0.005  $\text{mg/kg}$  to about 20  $\text{mg/kg}$  and  
25 more preferably from about 0.05  $\text{mg/kg}$  to about 5  $\text{mg/kg}$ . Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of  
30 injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to breasts or bronchial tissues, throat or mucous membranes of the nose. In addition, naked

DEX-0360

160

PATENT

polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle in vivo is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

### Example 13: Transgenic Animals

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (I. e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., *Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver et al., *Biotechnology* 11: 1263-1270 (1993); Wright et al., *Biotechnology* 9: 830-834 (1991); and U. S. Pat. No. 4,873,191, the contents of which is hereby incorporated by reference herein in its entirety); retrovirus mediated gene transfer into germ lines (Van der Putten et al., *Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., *Cell* 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, *Mol Cell. Biol.* 3: 1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., *Science* 259: 1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer (Lavitrano et al., *Cell* 57: 717-723 (1989). For a review of such techniques, see Gordon, "Transgenic Animals," *Intl. Rev. Cytol.* 115: 171-229 (1989).

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., *Nature* 380: 64-66 (1996); Wilmut et al., *Nature* 385: 810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, I. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., *Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene

DEX-0360

162

PATENT

may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., *Science* 265: 103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

**Example 14: Knock-Out Animals**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see Smithies et al., Nature 317: 230-234 (1985); Thomas & Capecchi, Cell 51: 503512 (1987); Thompson et al., Cell 5: 313-321 (1989)) Alternatively, RNAi technology may be used. For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention in vivo. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, supra). However, this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site in vivo using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a patient in vivo. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered in vitro using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be  
5 introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U. S. Patent No. 5,399,349; and  
10 Mulligan & Wilson, U. S. Patent No. 5,460,959, the contents of which are hereby incorporated by reference herein in their entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the  
15 cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of  
20 polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other  
25 than the described embodiments, which are presented for purposes of illustration only and not by way of limitation. The present invention is limited only by the claims that follow.

DEX-0360

165

PATENT

## SEQUENCES

&gt;DEX0360\_001.nt.1

5 TCCAGTAAGGTGTGCCAGCTTTCTTCTGGGCACAGACAAGAAAGATGGAAAGTATAGGTTAAAGTCCCC  
ACTCTAAAGTGCTTTACATTTTAAATGTGGACCACAAAAGTGCCACGAGCCAAAAAGATTCCAAGAAGC  
TGTGTAAGCAAATCCATGATTGAATGTTACAAACGTGTGTATAAAGTGCTGTGAGATCAGAAAGCCAGGA  
AGTGGTCTTAAAAAATAAATACTACAACCAATCTTCTCTCTGGGTCTTTCAGGCAATTTCTCTGCCAC  
ATTCCCATTTCCTTAAGATATTCCATAAGGGCCAGTCACGGAGAATTCATACCTGAAAGGGAACTGTTA  
TTTGTGTTGTTGTCAAAGATATGTGGACTAAGTTTCAGAACTACCCACTGTGTTTCCCTGGCAGGTTCCG  
10 GAGTCTCACCACCTGCATTTTTCAGAGACGCCATGGGCTTCTTATTAATGTTTGACCTCACCAGTCAACAG  
AGCTTCTTAAATGTCAGAACTGGATGAGCCAAGTCAAGCAAAATGCTTATTGTGAAATCCAGATATAG  
TATTAATTGGCAACAAGGCAGACCTACCAGATCAGAGGGAAGTCAATGAACGGCAAGCTCGGGAAGTGGC  
TGACAAATATGGCTGCAAATTGAGTACACTGGGAATCAACAAATTTGATGAAGCCTGTCTGTCTCTCAC  
CAGTGGAGTGAGTGCAGCAGTTAGAAAGAGAAGCAATATTGTGCAAACTGGTGCAGTGGTGAGTTAATCAT  
15 AGTGATAACCTTGTGTTTCATGAACAGGTTGTTTTCATTGTTCTGCATCTCTCTCATTTAAAGGATAC  
ACAATTTCTTCTCATTGCATATTACACCAACGTTTGAGGGAAAAATCCTCATTCTGTAAGGATTTTGG  
ATTTATAATCTAAACTCAACAATAAAGAAATAATATTCCAAGTCTCTGGTTTCTTAAGATACATAATAA  
CTGTTTATAAAGAGGTCTAAGAGCTGATATTGCCAAAGTGATAGAAGAGTTGTTTTTCTCTCTACT  
ACCAAGCTTTAAGACATTAAAGAGTCTAGTTGTTGAATATTTAGAGAAAGCTTTATCATTTTCTG  
20 AGATGCCAAGATGCTGCCTACGTTTGCAAAAGTTGTCTAAGAATTCACCATGAGCTATATTTCTCTG  
ATCTTTGACCAAGGTGATGTGAGCTTATTTCTGGGGAAGGTGTTGAGCTCTTATACATGAAATGGATAT  
AGGCTATTTCTCTGGGATGAGTGTCAATTTCAATGCTTTATAAATCCATGAAGCTGCTTGTCTCATAAAGTA  
GAACTGATACAAATTTTGGTTGGATATATAGAGAATTTATAAATGTATTGCCCTTAGAATTTCTGGGTGG  
AGACCAACTACAATGACATTGTCTGCAAGAACTATAAAGATAATTAGAGTTAAAGTTGTTTAAATTTG  
25 TGCCCTTAAATACAGCAGAACCTGGAGAAGGTCATACTTCAAAGGTCGATTTTGAGTCCGAATTAAGAAA  
GACCTAGTAACAGATAGTTTTTTTTTGTTCATTTTCTTCTACCAAGTAGAGGTTTATGCCCTCAGAACTA  
AAGTAGTAAAAATATCTGAACAAAAACCTTTCTGTTGTTGGCATAAAAAATGTGATACACTTAGAGACATT  
TTGTTTATTTGTCATATAAATCTAATTTTCCATAAATAGATTTATGATATTTTCATAAAGCACTTGATTA  
GTTTTTCAAGGCGTACCATCACAAAGATGCTTTCTCTGCAGAGTTCTTTGTATCAACAGCCTATGGTTGAG  
30 ATGTTTTCTCATTTTCTGTAGAGAGAGAATACCCTAACAAACAAGCAAAACCTTTAGTCCAAAAATAGT  
GGAACATTTTTGTGATCTTTTGTAGAAAAAATATACAAAGAAGTCATCTTTTCATTAAGTGGATTCCCTG  
GTTCTTTCCAGCTGGTTGTGGAAGTAATGGCTAACATCCTTCAGCTGACTTTGTCTACAAGGATTATTA  
GCAAAATCTGTAGAGCAAGCATGTCTGACCTTAACCTTAATGGATCCCTTATTCAATCAGTGGCTTCTGT  
CTTTATGTCTGTTGGCATATCAAAATGGTTTCTGTTCTAGAAAAGTAATAACATATGCTTATCTTTATT  
35 CTTTTTCCAGGTGATTTTGTTTTCAAATGCTCCTTGTGAAAACACCTAGTGTGTAGAAAAGGAAAGTGGC  
CAGAAAGAACAACCTGGGACCATGAGTAGGTCAATTAATAGCTTAGTGATTTATCCTCATATAGGGCTTA  
TAAACCTGTATGTGTTTATATGTGCTTCACAGAGTTTCGTGTGAGCTCAAAGGAGATATGTATAAGAAA  
GTGGTTTGTAAATTATGTTCCATTTTCAATAATAGACACTATTCACAACTAAATCTAATAAAAAACCAC  
AGTTGTAATTTAAACTGCTTGATATAAAAAAGAGGTATCATAGCAGGGAACACACATAATTTTCATACAG  
TAGAGGTATTGAAAAGTGAATGGGAAGGCAACTTGAAGTCATTGTATTTGATTGAAAATGTTTAAATAC  
40 ATCTCATTATTGACAAAATATGTCATCTTGATTTTATTTCAAGGAAACCAATGAATTCAGGTAGTATAT  
TACAAGTTGGTCAAAATATTCATGTACAAATAGGGCTTCTGTGTCCATAGCCTTGTAGAGATACTGAT  
TGTATCTGAAATTATTTTTTAAAAAATAAATTTATCTGCTTTAGTGTGTTAAAGTAGACGATGTTCTA  
ATATAACACTGAAGTGCTTCATTGTATCCCAACAGTTTACCTTCAAGTAATATTATCTTTATTTTAGGC  
45 TAAGCAGTTTGTATTTTGTCTGTCTCTATATAGATCTGTTTGTCTAGTGTATGAATGTAACCTTA  
AAACTATAAAGTTGAAGTTTATTTCTATATGCCCCCTTAATAGACTGTGGTTCTGACGCACACTGTTAG  
GTCATTATTTTGTGTACCAAAGTTCTAGTGGCTTCAGAAATCATAGCATCCAATGATTTTTTGGTGTCT  
GGCTATGAATACCTATGGTTGAGAATTGTATTTCAGTGATTGTTTCTGCACACTTTTCAAATAAAAAATGAA  
TTTTTATCAATTA

50 &gt;DEX0360\_002.nt.1

TAAGCTCGGAAGCGACTCTAGGGCRGGGGAGGGTCTGGGTGTCGGCGAGCTCCGCGTGCGGGTTCGAGT  
GGCTGCTGGCGGCTGGGCTGCCGGGCGGACGCTGGGTGGCTGCTGCCGCGCGCCTGCTGCGAGATG  
GCGATCTTGGGCGCGGAAGGTTGAGGGCGCCCGCAGGAGGAGTGCCGCTGCCGTGGCCGCGCGGCT  
55 GCCGGGAGCCGACAGCTTCGCGCCGGGGTGTCTCTCTCACAGACTATGAGCTCCTTGAAAGAGGGAATCG  
TGCTTTACTCATCTTTGTATCCCCAGTGTCTAGCAGTTTCTGATACATAGTTTGTAGCTGAATTTTGGGAC  
ATGGCCACTGCTTCACCAAGGTCTGATACTAGTAATAACCAAGTGGAAAGGTTGCAGTTACAGGTAAGT  
TTTCTAGTGCACAACTTAAAGAAAAAAGAACTGGTTCGGAACAGCAATATATACAGAAGTAGTTGTAGA  
TGGAGAAATTACGAAAACAGCAAAATCCAGTAGTTCTTCTAATCCAAATGGGATGAACAGCTAACTGTA  
AATGTTACGCCACAGACTACATTGGAATTTCAAGTTTGGAGCCATCGCACTTTAAAGCAGATGCTTTAT

DEX-0360

166

PATENT

TAGGAAAAGCAACGATAGATTTGAAACAAGCTCTGTTGATACACAATAGAAAATTGGAAAGAGTGAAAGA  
ACAATTAAAACTTTCTTGGAAAACAAGAAATGGCATAGCACAACTGGTGAATTGACAGTTGTGCTTGAT  
GGATTGGTGAATTGAGCAAGAAAATATAACAACTGCAGCTCATCTCCAACCATAGAAATACAGGAAAATG  
5 GTGATGCCTTACATGAAAATGGAGAGCCTTCAGCAAGGACAACCTGCCAGGTTGGCTGTTGAAGGCACGAA  
TGGAAATAGATAATCATGTACCTACAAGCACTCTAGTCCAAAACCTCATGCTGCTCGTATGTAGTTAATGGA  
GACAACACACCTTCATCTCCGTCTCAGGTTGCTGCCAGACCCAAAATAACACCAGTCCAAAACCACTCG  
CATCTGAGCCTGCCGATGACACTGTTAATGGAGAATCATCCTCATTTGCACCAACTGATTAATGCGTCTGT  
CACGGGTACTCCAGTAGTGTCTGAAGAAAATGCCTTGCTCCAAATTGCACCTAGTACTACTGTTGAAGAT  
CCTCCAGTTCAAGAAATACTGACTTCCTCAGAAAACAATGAATGTATTCTTTCTACCAGTGCAGAATTGG  
10 AATCTGAAGCTAGAAGTATATTAGAGCCTGACACCTCTAATTCTAGAAGTAGTTCTGCTTTTGAAGCAGC  
CAAATCAAGACAGCCAGATGGGTGTATGGATCCTGTACGGCAGCAGTCTGGGAATGCCAACACAGAAACC  
TTGCCATCAGGGTGGGAACAAAGAAAAGATCCTCATGGTAGAACCTATTATGTGGATCATATACTCGAA  
CTACCACATGGGAGAGACCACAACCTTTACTCCAGGTTGGGAAAGAAGAGTTGATGATCGTAGAAGAGT  
TTATTATGTGGATCATAACACCAGAACAACAACGTGGCAGCGGCTTACCATGGAATCTGTCCGAAATTTT  
15 CGGCTTCAATGTTAGCTGCAGAAAATGACCTTATGGACCTTGCCACCAGGCTGGGAAAAGAGAGTGGAA  
TTCAACAGACAGGGTTTACTTTGTGAATCATAACACAAAAACAACCCAGTGGGAAGATCCAAGAAGTCAA  
GGCTTACAGAAATGAAGAAACCTTGGCAGAAGGCTGCGACAATTTAGAATATTCTCCGTGAAGGTGCTAA  
GGTCACCTTGCTGCACTCATTCAACCCAGCAACCCACCCCTTTCCAAGACTCCTCCGCATGCGGAAACC  
20 CACTGACACTTCAAACGGTGGTCCAGCAAACTGCCCTACCGAACGCGGAGTACAGGTGAAGCCAGCCAAA  
TACCCAAAGATGGGGCCAGCCTAATGGCCTACCCACGACGGAACGAACACAGCGTCCCCCGGCCAAC  
AATCTGCGACGGAACCCCCCAACAAGATGGGGCAACACCCCAAGACAGAGAAGGCCGCCACAGAAA  
CCTTACCGCGGAGCCAGCACCAATCAGGCGACGAGAAAAGAGCCGACCCACAACGTACCACCCACAGT  
GCAGACGCACAACCAACTTAGCAACGACAACAACACGAACACTATACGCAACAACACAAGCAACA  
25 >DEX0360\_003.nt.1  
TTTTTTTTTATATTTCTAAAATTTTTATTTCTTGTTCATTTTGTCTTAAGATATTCACCTCACATATTAA  
AAATAACAACGCTCTCAAAACATTTGAAGCAACTCTCTTCATCCCTTTTAAAAATACCTTGCTGTTTCGGG  
GGTTAAAAAAGCCACAAGGGAGATTAAAAACAATACAAATATTTATTTTCCCAACTCCCCTGCCATGGGT  
30 TCTGGGACGTCACCGCCTCTTTCTGGGGCCGTTTCATCCTTTTCTTTTAAATCCAAGAAGCGATGGTGTT  
GTGCGCCTGTAGTCCCAGCTACCTGGGAGCGAGGATCTTTTGGGTCCAGGATTTTGA  
GGCTGCAGTAAGCCGTGTCTCACCCTGCACTCGAGACTGGGCGGAAGAGCGAGACACTGTATCAAAAA  
CAAAACAAAACAAAACGAGAAGGCATCGCGGCTCTGTAACTCCGTCCAGCTCTCGCACTCTCAGATGC  
AACTTCCACACAACTCCTCGGCTCGCCTTGTCGCCGCGGAGTACATATCAAGCCTTCCGGGACACAC  
35 CGTGCGATGATATATACGTATATACCCCTCTTGCCCTTGAAGGCCGAAGTCCGGTCTTACAGATAAAAGC  
GAAACAGGAAGTCCCGCCCTCTATGAAAGTAAATGGTAGCTCGGAAGGGTCAAAAGAGTCCGCGGTTT  
CGCCGCGTGAGTTGCTTTTTTGCGGCTGGGGAGGTCTACGCTTCTAGAGCTTGAGCCAGCGGGGCGACCC  
GCAGTGGCAGGACTCGGCACCGCGCCTCCACCGCCGCTGGTGGCCTGCGTGACAGTTTCTCCCGTGC  
40 ACATCGAAAGGAAGCCGGACGTGGGCGGGCAGAGGTCGGCTTGCTGATGGGTCCGGGTGGGGCGCGCG  
TGGACTATGGGCGCGGAGGTCCCTTACTGTCCCGAGCCGCGGTTCTCTTGTCGAAAACGGGGTGGC  
ACTCCAATCGCCTGCTTGGTGATTGTGGGCCCCACACACCTGTTTCTACAGCGCTTAGCTTCATCGCAGT  
AGGAATGGCAGCCCCATCTATGAAGGAAAGACAGGTCTGCTGGGGGGCCCGGGATGAGTACTGGAAGTGT  
TTAGATGAGAACTTAGAGGATGCTTCTCAATGCAAGAGTTAAGAAGCTCTTTCGAATCAAGTTGTCCCC  
AACAGTGGATAAAATATTTTGATAAAAGAAGAGACTACTTAAATTCAAAGAAAAATTTGAAGCAGGACA  
45 ATTTGAGCCTTCAGAAACAAC TGCAAAATCTAGGCTGTTTATAAAGATTGAAAGTATTCTTTCTGGACA  
TTGAAAAAGCTCCACTGACTATGGAACAGTAATAGTTTGAATCATAGTGAACATCAATACTTGTTCCTTA  
TATACGACACTTGATAATTAAGATGATCAAGAACCAGAAGATCTGTGAAGAAATGAAATAAAATGGTATT  
TAGTAAGAAATCTCTATTTTAAGAAAAAAGTAAACCTGTTATAAACACAAAAAAGAAAAAAGAAAAA  
50 AAAACAAAAAAGAAAAAAGAAAAAGAACGGAACAAAGACAAAAAAGAAAAAAGAAAAAAGAAAAAAG  
AGGAAGGG  
TTAGAGAGGTCCATCACATCATCCATCGCTAAGAACACCAACCAACATGGAACATGGAATTAATAC  
ACATCACACCATGTTATGTGCTCTAAGAACAACCAACGATCCGTAGCTAACAGTTAGCAAACTACG  
ACATCTATATGTTCAATATTGATTAAATATTTGTTTAAAGTCAGTTGACAATCTCTGTGATATCTGTACA  
55 ATTTTAACA  
>DEX0360\_003.nt.2  
TTTTTTTTTGAACCATGTGCGCCTTTATTAGCTGAGCCACTACTTGAGAGGGATGAAGCAGAAGGAGTGG  
GTGGCGCCGATGCCGACCGGCATTGCTTTACGGGCTTGTTAGGTGATGGAGAACTCGCCAGGTAGTGGC  
CAATCATCTCGGGCTTGACCTCCACCTGGTTGAGGTCTTGCCGTTGTGGACGCCCCACCATGCTGCCAC  
60 CACCTCGGGCAGGATGATCACGTCCCTCAGGTGCGCTTCACCACTTCCGGCTTCTCCATGGGCGGGCC

DEX-0360

167

PATENT

TCCTTCTTGGCCTTGGCGAGGCGCTTCAGCAGGGAGTGCTGCTTCCGCCGAGGCCCGGTTTCAGCCGCC  
GCCCTGGCGCGCACTGTACAGCTGCATCAGCTGCTCGTAGGACATGTCCAGCAGCTGGTCGAGGTCCACG  
CCGCGCTTCATCGCAGTAGGAATGGCAGCCCCATCTATGAAGGAAAGACAGGTCTGCTGGGGGGCCCCGGG  
ATGAGTACTGGAAGTGTTTAGATGAGAACTTAGAGGATGCTTCTCAATGCAAGAAGTTAAGAAGCTCTTT  
5 CGAATCAAGTTGTCCCCAACAGTGGATAAAATATTTTGATAAAAGAAGAGACTACTTAAATTCAAAGAA  
AAATTTGAAGCAGGACAATTTGAGCCTTCAGAAACAACCTGCAAAATCCTAGGCTGTTTCATAAAGATTGAA  
AGTATTCTTTCTGGACATTGAAAAAGCTCCACTGACTATGGAACAGTAATAGTTTGAATCATAGTGAACA  
TCAATACTTGTTCCTATATACGACACTTGATAATTAAGATGATCAAGAACCAGAAGATCTGTGAAGAAA  
TGAAATAAAATGGTATTTAGTAAGAAATCTCTATTTTAAGAAAAAAGTAAAACCTGTTATAAACACATG  
10 CACTTTTGTTTTGTTTTGTTTTGTTTTGTATTAAGAGGATGGGTAGTAGGCAGATGATAAAATTTATAAT  
ATACATAGAAGTGAAATAAATGGGAGTTAGCATTTTAATACAGGCAAGAGCTATTACAACAACCCAAAGTG  
AGAAATGATGAGGTTTGTGGAAGGTTTATAAGGAAGAAGGGTGAACCTTAAATATACAAGTAAAATAAT  
AAAAGCCATCTATAAAAAAGCCCATAGCTAATATCAACACTTAATGTTGGGACAGGAACTGGATGTCTAG  
CTAGTCCAGTGAGACAAAAAGCAATACACACTGGGAAGGAAGAAAGAAAAGTAACTAGCTCTACTCAC  
15 ATATAATAAATACTATCTTATAGAAATGTACCAATGGATGCACAAAAGAGCTCCTAGAACTATAAGTCAA  
TCATAGAAAGGTTGCAGGAACAAGGTCAATATACACAAGGAAAATATATTCCTATATATCAGCAATAA  
ACAACCTGGAATTTAAACTTAAAAATACCATTTGTGAATAGCACCAAAAAAATTAAGGAATACTTAGG  
TATAAATCTAATATATGGAGGCTCTATGCTGAGAACTAGAAAACACTTGAAGCAGACTACATCAGATT  
AAATGGAGAGGTATACAGTTGGCCCTCTGTGGGTTCTGCATCCATGGATTCAACCCCGAAGAGAAAATTT  
20 TTGGGAAAAGGAAAAACGAGTAAAAATAATAAAAAATTTAAAAATCCAGTATAACACCTATTTACATTGTA  
TTAGGTATTGTAAGTCATTGAGATGATTTAAAGTATAGGCATACCTCAAAGATACCTGCAGGTTTGGTTAC  
AGACCACTGCATTAAGTGAATATCACAATAGAGTGGGTTACACAAATGTTTTGGTTTTCCAGTACACAT  
AGAAGTTATGTTTATACTGTTGTCTAGTAAGTGTGCAATAGCATTATGTCTGCTCAGTATATATGC

25 >DEX0360\_004.nt.1  
AGATCCAAGATGGGCATTATATTCATTGTATGTTTACAAATCTTACATTTTAGTTATTCTTCAGCAAAA  
AATCCAGATGGATGTTTTTTTCAGAAAGTGTTGAATGGGTTTACAAAGTTTTTTTGTAAAGAACAAATATT  
GCAAATTACTAAAATTGTATTTTATAGGCTGTTTGCTCTTTTGTGGATATTGTGCTGTCAGGATTCTTT  
30 GAAGTTTTTTTTTATAGTGAGATAATGGAGTTGGTCTTAGCCGCTGCAGGAGCCCTTCTTTCTGTGGA  
TTCATCATCTATGACACACACTCACTGATGCATAAAGTGTACCTGAAGAGTACGTATTAGCTGCCATCA  
GCCTCTACTTGGATATCATCAATCTATTCTGCACCTGTTACGGTTTCTGGAAGCAGTTAATAAAAAAGTA  
ATTAAGATCTCAGCTCAACTGAAGAACAACAAAAAATTTAACGAGAAAAAAGGATTAAAGTAATT  
GGAAGCAGTATATAGAACTGTTTCATTAAGTAATAAAGTTTGAACAATGATTAATACTGTTTACAATC  
TTTATTTGTATCATATGTAATTTTGAGAGCTTTAAATCTTACTATTCTTTATGATACCTCATTTCTAAA  
35 TCCTTGATTTAGGATCTCAGTTAAGAGCTATCAAAATCTTATTAATAATGCTTTTCTGGCTGGGCACAGT  
GGCTCACGCTGTAATCCACCCTTTGGGAGACCGAGGCAGGTGGATCACGAGGTCAAGAGGTTGGAGAC  
CATCTGGCCAACATGGTGAAACCCGCTCTCTACTAAATAACAAAAATTAGCTGGATGTGGTGGCACAC  
ACCTGTAGTCCCAGCTAGTCAAGAGGCTGAGGCCAGAGAATCGCTTGAACCTGGGAGGTGGAGGTTGCAT  
TGAGCCAAAGATCACGCCACTGCATTCCAGCCTGGTGACAGAGCGAGACTCAGTCTCAAAAAA  
40 AATTTTCTTCTTAAATTAGCCACGCATAGCGGTTCTGTTGCAATTCAAAAATAATTTATGATAGATA  
AGAATATCAGTTTACCGTTGTCTAGTGATTTTATCTAAATTTTCCCTGAATTATTAAGTAATATTGATTT  
GGCTTTGATCTGAAGTAGTAGAGTCTTTACCATTATAAAGTAAATCTCTTTTGTCTTAAAGGAAAA  
AAATGTAAAGATAAATTCACAGAGAATTATTCAGTATTACATTAAAAATGTTAATGACTTTTATTTTA  
AATTGTACTAACATTAAAAAGTTGGCCTGAAAGTCAGATATTATGACAAAATTTGACATTAAATTTGTTT  
45 AAGTATAGATTTTCAATTTGAAATTATAGAATGCTAATGTGGTTAGAGGACACCAAGATACTGGGTCA  
GCCATTAAAGTATATCTATTTCAAAATTAATAATTTTGGGAAGTATTGTCTTATGGTTTCATTTGTGTTGG  
TCCACACAGCATGTTAGGTCAGTGATACCAGTAACCAATGAAATTTTGTCAAATTTCCCTCACTGTACTAGT  
TTGTTAGGCTGCCATAACAAAGTTCTACAGCTTGGGTGGCTTCAACAAGAAATTTGTTTTCCACAGTTT  
TGGAGGCTAAAAAGTCAAGATCAAGGTGTTAGCAGGTTGGTTTCTTTGAGGCCTTTCTCTTTGATTTG  
50 TAGATGGCCATCTTCTCCCTGTGCTTTTAAATGGCTTCCCTCTGTACTTGTCTGTGCCCAAATTTCTTC  
TTCTTATGAGGACACCAGTCATACTGGATTAGGGCCACACTGAGGACCTCATTTTCTTAAATATCTC  
TTTCAAACCTATCTCCAAATACAGTCACATTCTGAAGTGCTGGGATTAGGATTTCTTCATGTGAATTT  
GGGGGACTACAACCTAGCCCATACACCCCTAAGTATTTCCCA

55 >DEX0360\_005.nt.1  
CCCGTTTCCATGGCTGCGAGAACTGACGCTCCCCAACCGTCCCGCAACTGTCCTGTCCCAGACTTTGGCA  
CCGTCGGGGTCCGTCGTCCCCGAATGTGACAGCATCCCCACCCCGCTGCTGCCAGGATCCGCCGGACC  
CCGGCCTCGATATGGGAGACCTGGAAGTGTGCTGCCCCGGGAAGCTGAAGTGCTGGTGGGGGTCTGCG  
CAGCTTCCCGCTACGCGAGATGGGCTCCGAAGGTTGGAACCAGCAGCATGAGAACCCTGGAGAAGCTGAAC  
60 ATGCAAGCATCTCGATGCCACAGTCAGCCAGGCGAGCCCATTCAGGAGCTGCTGGTCACCCATGGGA

DEX-0360

168

PATENT

AGGTCCCAACACTGGTGGAGGAGCTGATCGCAGTGGAGATGTGGAAGCAGAAGGTGTTCCCTGTGTTCTG  
CAGGGTGGAGGACTTCAAGCCCCAGAACACCTTCCCCATCTACATGGTGGTGCACCACGAGGCCTCCATC  
ATCAACCTCTTGGAGACAGTGTCTTCCACAAGGAGGTGTGTGAGTCAGCAGAAGACACTGTCTTGGACT  
TGGTAGACTATTGCCACCGCAAACCTGACCCTGCTGGTGGCCAGAGTGGCTGTGGTGGCCCCCTGAGGG  
5 GGAGGGATCCCAGGACAGCAACCCCATGCAAGGAGCTGCAGAAGCAGGCAGAGCTGATGGAATTTGAGATT  
GCACTGAAGGCCCTCTCAGTACTACGCTACATCACAGACTGTGTGGACAGCCTCTCTCTCAGCACCTTGA  
GCCGTATGCTTAGCACACACAACCTGCCCTGCCCTCCTGGTGGAACTGCTGGAGCATAGTCCCTGGAGCCG  
GCGGGAAGGAGGCAAGCTGCAGCAGTTCGAGGGCAGCCGTTGGCATACTGTGGCCCCCTCAGAGCAGCAA  
AAGCTGAGCAAGTTGGACGGGCAAGTGTGGATCGCCCTGTACAACCTGCTGCTAAGCCCTGAGGCTCAGG  
10 CGCGCTACTGCCCTCACAAGTTTGGCCAAGGGACGGCTACTCAAGGTCAAGCTCCCTCCGCACCAAGCCCC  
ACAGCCCCAGTACCGCCCTCCCCATCCTACCCGACTGCGCTCCCTGCTGTTTATCTTGGCCACCCACCT  
CAACCCAGTGTCTTTTCAGTCTTGGGCCCTCAGGTGACACACCAGCTAGTGGGACATGGGCCCCCACA  
GGCATTCTCAGCCCAACCCAGCCCCCTTCCCTTTTCCCTTGGCCCCCTGGCCAGCACCTGCATCACACTGGCC  
TCCACTGGACACCCCTTGCAGCTTCGGGCCCTTCTCAGAGACACACTGCTGGACCAGCTGCCCAACCTGGC  
15 CCCTTGCAGAGTTTCTTGGCCCATCTGACCCTAACTGAAACCCAGCCTCCTAAGAAGGACCTGGTGTG  
GAACAGATCCCAGAAATCTGGGAGCGGCTGGAGCGAGAAAACAGAGGCAAGTGGCAGGCAATTGCCAAGC  
ACCAGCTCCAGCATGTGTTTCCAGCCCTCAGAGCAGGACCTGCGGCTGCAGGCGCAAGGTGGGCTGAGAC  
CTACAGGCTGGATGTGCTAGAGGCAAGTGGCTCCAGAGCGCCCCGCTGTGCTTACTGCAGTGCAGAGGCT  
TCTAAGCGCTGCTCAGCATGCCAGAATGAGTGGTATGCTGCAGGGAGTGCCAAGTCAAGCACTGGGAAA  
20 AGCATGGAAAGACTGTGTCTTGGCAGCCGAGGAGTACAGAGCCAAATGAGGGCTGCAGTTGCTGAGGGC  
CGACCACCCATGCCAAGGGAATCCACCCAGAATGCACCCCTGAACCTCAAGATCACGGTCCAGCCTTGC  
CGGAGCCCCAGTCTCCGCACTGGAGAGCAGAGCGGGCGGTAAAGCTGCTGACCGATCTCCCTCCTCTCA  
CCCCAAGTGAAGCTCGAGACTTCTGCCCCACCCAGTGGGTAGGCCAAGTGTGTGCTTACAGCAACCCG  
GACCAGGAGGGCCAGGGCCGGATGTGGGGACCTCTTCCCTCTAGCACAGTAAAGCTGGCCTCCAGAAA  
25  
>DEX0360\_006.nt.1  
AGATCAAAGAAGGAAAGAAGAGAAGGGGAAGAAAAGAAGGGGAAGAAGATCAAAACCCACCATGCCCCAG  
GCTCAGCAGGGAGCTGCTGGATGAGAAAGAGCCTGAAGTCTTGCAGGACTCACTGGATAGATGTTATTCA  
ACTCCTTCAGGTTGTGTTGAACGTGTGTGACTCATGCCAGCCCTACAGAAGTGCCCTTTTATGTATTGGAGC  
30 AACAGCATGTTGGCTTGGCTGTGACATGGATGAAATGAAAAGTACCAAGAAGTGAAGAAGACCAAGA  
CCCATCATGCCCCAGGCTCAGCAGGGAGCTGCTGGATGAGAAAGAGCCTGAAGTCTTGCAGGACTCACTG  
GATAGATGTTATTCGACTCCTTCAGGTTATCTTGAACGTGCTGACTTAGGCCAGCCCTACAGCAGTGCTG  
TTTACTCATTGGAGGAACAGTACCTTGGCTTGGCTCTTGCAGTGGACAGAAATAAAAAGGACCAAGAAGA  
GGAAGAAGACCAAGGGCCACCATGCCCCAGGCTCAGCAGGGAGCTGCTGGAGGTAGTAGAGCCTGAAGTC  
35 TTGCAGGACTCACTGGATAGATGTTATTCAACTCCTTCCAGTTGTCTTGAACAGCCTGACTCCTGCCAGC  
CCTATGGAAGTTCCTTTTATGCATTGGAGGAAAACATGTTGGCTTTTCTCTTGGAGGAGAAATTGA  
AAAGAAGGGGAAGGGGAAGAAAAGAAGGGGAAGAAGATCAAAGAAGGAAAGAAAGAAGGGGAAGAAAAGA  
AGGGGAAGAAGATCAAAACCCACCATGCCCCAGGCTCAGCAGGGAGCTGCTGGATGAGAAAGGGCCTGAA  
GTCTTGCAGGACTCACTGGATAGATGTTATTCAACTCCTTCCAGTTGTCTTGAACAGCTGACTCATGCC  
40 AGCCCTCAGCAAGTGCCCTTTTATGTATTGGAGCAACAGCGTGTGTTGGCTGTTGACATGGATGAAAT  
TGAAAAGTACCAAGAAGTGAAGAAGACCAAGACCCATCATGCCCCAGGCTCAGCAGGGAGCTGCTGGAT  
GAGAAAGAGCCTGAAGTCTTGCAGGACTCACTGGATAGATGTTATTTCGACTCCTTCCAGTTTATCTTGAAC  
TGCCCTGACTTAGGCCAGCCCTACAGCAGTGCTGTTTACTCATTGGAGGAACAGTACCTTGGCTTGGCTCT  
TGACGTGGACAAAATTGAAAAGAAGGGGAAGGGGAAAAAGAAGGGGAAGAAGATCAAAGAAGGAAAGA  
45 AGAAGGGGAAGTAAAGAAGGGGAAGAAGATCAAACCCACCATGCCCCAGGCTCAGCGGTGTGCTGATGG  
AAGTGAAGAGCCTGAAGTCTTACAGGACTCACTGGATAGATGTTATTTCGACTCCGTCATGTACTTTGA  
ACTACCTGACTCATTCCAGCACTACAGAAGTGTGTTTTACTCATTGTGAGGAACAGCACATCAGCTTCGCC  
CTTGACGTGGACAATAGGTTTCTTACTTTGATGGGAACAAGTCTCCACCTGGTCTTCCAGATGGGAGTCA  
TATTTCCACAGTAAGCAGCCCTTACTAAGCCGAGAGATGTCATTCTGCAGGCAGGACCTATAGGCACGT  
50 GAAGATTTGAATGAACTATAGTTCCATTTGGAAGCCGACACATAGGATGGGTCACTGGGTCATGGCTCTA  
TTCCATTCTCAGACCATGCCAGTGGCAACCTGTGCTCAGTCTGAAGACAATGGACCCAAGTTAGGTGTG  
ACACGTTACATAACTGTGCAGCACATGCCGGGAGTGATCAGTCAGACATTTTAATTTGAACCACGTATC  
TCTGGGTAGCTACAAAGTTCTCAGGGATTTCAATTTGCAGGCATGTCTCTGAGCTTCTATACCTGCTCA  
AGGTCAGTGTCTCTTTGTGTTTAGCTCATCCAAAGGTGTTACCTGGTTTCAATGAACCTAACCTCATT  
55 CTTTGTATCTTCACTGTTGAATTTAGCTGATCCATCTTTAACACAGGAGGGATCCTTGGCTGAGGA  
TTGTATTTCAAGAACCAACTGCTCTTGACAATTTGTTAACCCGCTAGGCTCCTTTGGTTAGAGAAGCCA  
CAGTCTTTCAGCCTCCAATTTGGTGTAGTACTTAGGAAGACCACAGCTAGATGGACAAACAGCATTGGGA  
GGCCTTAGCCCTGCTCCTTCGATTCCATCTGTAGAGAACAGGAGTCAGGAGCCGCTGGCAGGAGACAG  
CATGTCACCCAGGACTCTGCCGCTGCAGAAATGAACAACGCCATGTCTTGCAGAAAACGCTTAGCCTG  
60 AGTTTCATAGGAGGTAATCACCAGACAACCTGCAGAATGTGGAACACTGAGCAGGACAACCTGGCCTGTCTC

CTTCACATAGTCCATATCACCACAAAATCACACAACAAAAAGGAGAAGAGATATTTTGGGTTCAAAAAAG  
TAAAAAGATAATATAGCTGCATTCTTTAGTTATTTTGAACCCCAAATATTTCTCATCTTTTGTGTGTT  
GTCATTGATGGTGGTGACATGGACTTGTATATAGAGGACAGGTGAGTGTCTGGCTCAGTGATCTACATT  
CTGAAGTTGTCTGAAAATGTCTTCATGATTAATTCAGCCTAAACGTTTTGCGGGGAACACTGCAGAGAC  
5 AATGCTGTGAGTTTCCAACCTTAGCCCATCTGCGGGCAGAGAAGGTCTAGTTTGTCCATCAGCATTTATCA  
TGATATCAGGACTGGTTACTTGGTTAAGGAGGGTCTAGGAGATCTGTCCCTTTTAGAGACACCTTACTT  
ATAATGAAGTATTTGGGAGGGTGGTTTTCAAAAGTAGAAATGTCCGTATTCGGATGATCATCTGTAAA  
CATTTTATCATTTTATTAATCATCCCTGCCTGTGTCTATTATTATATTCATATCTCTACGCTGGAACTTT  
10 CTGCCCTCTATGTTTACTGTGCCTTTGTTTTTGTCTAGTGTGTGTTGTTGAAAAAAAACATTCTCTGCCT  
GAGTTTTAATTTTTTGTCCAAAGTTATTTTAACTATACAATTAAAAGCTTTTGCCTATCAAAAAAAAAG  
GGGGGGGTAAAATACCGAGGGGCCAATTGGTCCCTTTTGTAAAGGGCTCAGGAGGGTAAAAGCAGAGGG  
GGGTAAACGGAGGGAAGCGCAGGATGAGAACTGGGGA

>DEX0360\_007.nt.1

15 GCTTTGTCTGTGTGATCTGTGTGTGTATGTTGCTTTGGGAATCCTGCCCAGTGCAGTTTAGGAGGAGCTC  
CAGGAGKCTGCTGKCTGCGCTCAGAGTCTGTCCCGGCTATCCACTAGCCCAGAGCAGTTCTCCCTATAGC  
CCAGTAAGAAATTACACCTTCACCTTCCAGACTGGCACCCACGCTCTCCAGAAAGTGAGAAGGGAAGT  
ACAGGTGACTTCACCCCATGGTGGGGAGAACAGCCTGTGCTGGGGTCAAGGCAGAAGGAGGATGAGCCCC  
GAGGCTCCTGGAGAGTCTGAGCCTGGGTGAGGAAGGGGAGGAGGTGGTCCCTGATCTCAGGGCGGGGAGA  
20 GCCAATGAGGAGACGGAGCCATAGCACGCGCTCTCAGCTGGGGGATCCTGGTCCCTCACCATCTCCTC  
TCCCCAGCTACTCCGTGAAGTCTAGGGACAGGAAGATGGTTGGCGACGTGACCGGGGGCCAGGCCTATG  
CCTCCACCGCCAAGTGCCTGAACATCTGGGCCCTGATTCTGGGCATCCTCATGACCATTTGGATTCTATG  
GTTACTGGTATTTCGCTCTGTGACAGTCTMCCATATTATGTTWCAGATAATACAGGAAAAACGGGGTTAC  
TAGTAGCCGCCCCATAGCCTGCAACCTTTGCACTCCACTGTGCAATGCTGGCCCTGCACGCSKGGCTGTTG  
25 CCCCTGCCCCCTTGGTCCCTGCCCCCTARATACAGCAGTTTATACCCACACACCTGTYTACAGTGTCAATCA  
ATAAAGCGCACGTGCTTGTG

>DEX0360\_008.nt.1

30 TGCACGACTCCGGCTGGGCAGGATTCCGGACAACGCCCTGGTTCCCTCTTGGGTCCCTCCGGCGTCCGGGA  
TGGAATTGATCCGGGAGTTGAAGAGGGCTGCAAGGTGGGAAGTGAAGTCAGTGCCTCAGTTGCTGATCAG  
TGTGTTTTTTGTGTCCAATTCTTTTATCACCAGAGAGAGAAATATTGCAAGTGAATGAAGATTCCCTC  
TGCATTTTAGCACTGCTTTTTTCAACTGTAGTTGGCTTTTGAATGAGGATGACAATGGAAGAGATGAAGAA  
TGAAGCTGAGACCACATCCATGGTTTCTATGCCCTCTATGCAGTCATGTATCCTGTGTTTAAATGAGCTA  
GAACGAGTAAATCTGTCTGCAGCCAGACACTGAGAGCCGCTTTTCATCAAGGCTGAAAAAGAAAATCCAG  
35 GTCTCACACAAGACATCATTATGAAAATTTTAGAGAAAAAAGCGTGGAAGTTAACTTCACGGAGTCCCT  
TCTTCGTATGGCAGCTGATGATGTAGAAGAGTATATGATTGAACGACCAGAGCCAGAATTCGAAGACCTA  
AACGAAAAGGCACGAGCACTTAAACAAATTCTCAGTAAGATCCAGATGAGATCAATGACAGATGAGGT  
TTCTGCAGACAATCAAGCACTTGAACACCAAAAGAAAGAAATTTGTAAAGTACTCCAAAAGTTTCAGTGAT  
ACTCTGAAAACGTATTTTAAAGATGGCAAGGCAATAAATGTGTTTCGTAAGTGCCAACCGACTAATTCATC  
40 AAACCAACTTAACTTACAGACCTTCAAAACTGTGGCCCTGAAAGTTGTATATGTTAAGAGATGTACTTCT  
CAGTGGCAGTATTGAACTGCCCTTTATCTGTAAATTTTAAAGTTTGAAGTGTATAAATATCAGTCCCTCCT  
GAAGGGATCTAATCCAGGATGTTGAATGGGATTATTGCCATCTTACACCATATTTTGTAAATGTAGCT  
TAATCATAATCTCACACTGAAGATTTTGCATCACTTTTGTCTATTATCATCTTTTAAAGATTTATAAGCCA  
AAAGAAATTTACGCCCTTAATGTGTCATTATATAACATTCCTTAAAGAAATTTGTAATATTGGTGTGTTT  
45 CTGACATTTTAACTTGAAGCGATATGCTGCAAGATAATGTATTAAACAATATTTGGTGGCAAAATATTCA  
ATAAATAGTTTACATCTGTAAACATTTCTTTACTTTGAAAAAA

>DEX0360\_009.nt.1

50 GGAAGAGTTCCCTTGCCTTAGGAGTGCAGACTCTGCCTCAAACCTTGTGATGAACCCAAAGCCACACCA  
GCTTCCAAATCTCCCTAAGTGTGAGTTACACAGGGTCCGAGCGGCCCGGGCAGGTACGAACTGTTCAA  
GAGCTCCCCACACTCCCTGTTCCAGAAAAAATGGTCTCCAGCTGTCTCGATGCACACACTGGTATATCC  
CATGAAGACCTCATCCAGGTGGGGGACCCCCCATTTCACTGCAGATTACAGACTCCCCAGCATTTGGCCA  
GTGCTTCTCCACCTTAAGTCCCTGTGCCTCCCTCTATGTTGTAGAAAGAGCCAAATCACAGTCCCTGTGT  
GACTGGGGACAGTCACTTTCCCTGCCTGAGCATCAGTTTCTTCTATTAAATGGGGGCGAGAAATGCATGT  
55 GGAGCATTTCTTGTGTAACCTGAGGGTGGGCTGGGCACGGTGGCTCATGCTATAATCCAGCACTTT  
GGGAGGCTGAGGCGGGAGGATTACTTAAGCCTAGAAGTTTGAAGTTTGAAGTTTGAAGTTTGAAGTTTGAAGTTT  
TGAGACCTCGTCTCTCCAAAAAAGAAAAAAGAAAAA

>DEX0360\_009.nt.2

60 CTGGCTGGCGTCCCTCTCGGCAGGGTGTCTTTTCCCCATGGGGTGGGATCCAGAGCTGCAGACAGGCC

DEX-0360

170

PATENT

CCAGGCTTGGCCCAATGAACAGACCAGGTTTCGGGGAGGGTGTTCGAAAAGAGTGGATGGGGTGGTTCCCTT  
TACCTTGCAGCCCCCAGGCCCTCCCCCTCCCTCCAGGTGGTCGGGACTCTTGATCTTCGCTCGTGGT  
ACTGTCTGTTTCGGCTGTCTTCCCCGCCTCTCCCCAGGCACCTGCATCCTCCCTTGGCACCTGCTGCCAGG  
5 CTAGGAAGGGCAAAAACAATCCCAGTTGGCGTAGTCAGGGAGTCTCCGCCCTCCTCCAGGTTTCCCTCCT  
CCCAGGCGCCTCCCTGGACCCGCCCCCATCTGCCCAAGATAATTTTAGTTTCCTTGGGCTGGAATCTG  
GACACACAGGGCTCCCCCGCCTCTGCATTCTCTGTCCGAAGTCGGGACACCTCCTACCACCTGTAGA  
GAAGCGGGAGTGGATCTGAAATAAAATCCAGGAATCTGGGGGTTCCTAGACGGAGCCAGACTTCGGAACG  
GGTGTCTCTGCTACTCTGCTGGGGCTCCTCCAGGACAAGGGCACACAACCTGGTTCCGTTAAGCCCCCTCTC  
10 TCGCTCAGACGCCATGGAGCTGGATCTGTCTCCACCTCATCTTAGCAGCTCTCCGGAAGACCTTTGCCCA  
GCCCTTGGGACCCCTCCTGGGACTCCCCGGCCCCCTGATACCCCTCTGCCTGAGGAGGTAAAGAGGTCCC  
AGCCTCTCCTCATCCCAACCACCGGCAGGAACTTCGAGAGGAGGAGAGGCGTGCCACCTCCCTCCCTC  
TATCCCCAACCCCTTCCCTGAGCTCTGCAGTCTCCCTCACAGAGCCCAATTTCTCGGGGCCCTCCAGT  
GCAAGGGGGCTGCTCCCCCGCATGCCAGCCGCCCCCATGTAGTAAAGGTGTACAGTGGAGATGGGGCT  
GCAGGTCTGTGGAGGTGGCAGCAGGTGCCACAGCTCGCCACGTGTGTGAAATGCTGGTGCAGCGAGCTCA  
15 GCCTTTGAGCGACGAGACCTGGGGCTGGTGGAGTGCACCCCCACCTAGCACTGGAGCGGGGTTTGAG  
GACCACGAGTCCGTGGTGAAGTGCAGGCTGCCTGGCCGTGGGCGGAGATAGCCGCTTCGTCTTCCGGA  
AAAACCTCGCCAAGTACGAACGTGTCAAGAGCTCCCCCACTCCCTGTTCCTCCAGAAAAAATGGTCTCCAG  
CTGTCTCGATGCACACACTGGTATATCCCATGAAGACCTCATCCAGGTGGGGGACCCCCCATTTCACTG  
CAGATTCACGACTCCCCAGCATTTGCCAGTGCTTCTCCACCTTAAGTCTGTGCTCCCTCTATGTTG  
20 TAGAAAGAGCAAAATCAGATCCTGTGTGACTGGGGACAGTCACTTTCCCTGCCTGAGCATCAGTTTCTT  
CTATTAAATGGGGGCGAGAAATGCATGTGGAGCATTTCTTGTAAAAACCTGAGGGTGGGCTGGGCACGG  
TGGCTCATGCCTATAATCCCAGCACTTTGGGAGGCTGAGGCGGGAGGATTACTTAAAGCTAGAAGTTTGA  
GAGTTTGAGACCAGCCTGGGCAACATAATGAGACCTCGTCTCTCAAAAAAAAAAAAAAAAAAAAAA

25 >DEX0360\_010.nt.1  
AGATAGGGAAGGAGGGCGGGTCGGGAGGAGGGATGCGGTTTCGGCGGAGGCGGCCCCACAGGGACTTGC  
CGCCATCACCCCTGCTGCCACCACCGCAGCCTCGGGCTCCAGGGCGGACACGGCCACCGCCTCAGCGGG  
AGAGGAGTCTCCACCAGGACTGACCGCTGCCGCCAGCACGTCCAGGTAAGGTACTCAACTGTGTGGGGT  
ACTACATAAATCCTGAAAGACTACAATAAAGTGGTGATGTCTCGGGAACCCACCCACCTCTACTTGGAG  
30 ATATGCTACTGGTCCCATAGCAGAAAGCTGGTGTTACACACAGGTAAAGTAGTAAATTTTCTATAT  
GTGGACCATTAAATACTTCAGTTTGTGTCGAGAGGAAATGGGTGAAGTGTAAAGTTCAACATTTTCA  
TCTGGCCCAAGTGACAAAATGAAATGGTGCCTGAGGGTAAACCCAAAGGGATTAGATGATGAAGTAAAG  
ACTACTTGTCTTATATTTGCTTTTAGTCAGCTGCCCAAAAGTGAAGTTCGAGCAAAATTCAAATTTTC  
CCTTCTGAATGCTAAAAGGGAAGAAACAAAGCAATGGAAGCCAAAGAGCATATCGATTTGTGCAAGGG  
35 AAGGACTTGGGGTTTAAAAAATTCATTAGAAGGGACTTTTGTCTGATGAAGCTAATGGTCTTTTACCAG  
ATGACAAGCTTACATTATTTGTGAGGTGAGTGTGTTCAAGATTCAAGTAAACATATCAGGACATACTAA  
TACAAATACTTTGAAGGTGCCTGAGTGTGCTTAGCAGAAGATTTAGGTAATCTCTGGGAAACACAAGA  
TTTACAGACTGCAGTTTTCGTGAGAGGACAGAATTTAAAGCTCATAAATCTGTGCTTGCAGCTCGAT  
CTCAGTTTAAACGCCATGTTTGAACATGAAATGGAAGAAAGCAAAAGAAATCGAGTGGAAATAAATGA  
40 TTTAGACCTTGAAGTTTAAAGAAATGAGACTTACATTACACAGGGAGAGCACCACCTTGACAAA  
ATGGCTGACAACCTTGTGGCAGCTGCAGACAAATATGCACCTGGAACGGCTGAAGGTGATGCGCAAG  
CTTGTGTAGTAACCTCTCAGTAGAGAATGTTGCAGATACCCCTTGTCTTGCAGATTGTCACAGTGCAGA  
ACAGTTGAAAGCACAGCCATAGACTTTATTAATAGGTGCAGTGTACTTCGACAACCTTGGGTGTAAAGAT  
GGGAAAAACTGGAACAGCAACCAAGCAACCGACATAATGGAACATCAGGGTGGAAAGTCCATGATTCAAGT  
45 CTCACCTCATTTAGTAGCAGAAGCCTTTCGAGCAGTATGATCTGCACAGTGTCCACAGTTTGGCATTTCC  
ACGCAACCGGCTAAACAGTCTGAAATCTTCCATGAACAGTTGAAAAATGGAATTGACTTTCACCTCTCC  
CAGGTCCAGAAGGATTCTAATACACAACCCATAAGCAAGAGTTGTTTCTGTTATTTTGTCCACAGAACAG  
AAGCTGAAAAAGCATATTGCTTGCATTTACAGTGGATAATTTATGGTTTATTCTTTCAGCTTTAAATTAGA  
CTGATTAATTCATTCAAGGCCTTAAATATCTTCAATGACTTCTCTTGTTCATATAACTTTAATTTT  
50 TTTTATTGTGCTTGTCAATTTGACCAAGGCTATGACAGGATGCACTAGCTCCATAATGCAGTAATATT  
GATAACTGAAGATACTAAGTTTCAAAGGATCTTCCATTATTTGCAAAAAGAAAAATGAATTTTATAGG  
GTTTGTCTATGCTATCTCAAAGTTTAAAGTCTCTTAAAGCACTTGTATTGGAGATTACCAGTAATAT  
CTCCAATCTAAGTTCTATAAATATGGGAGAACCCTCTTACCTTCAAGGTAAGTTATGGCAATACACTGCT  
TCAATTCTAATTTATTTTTCATTTACAGGGGCAAAATATGCAATGAGTTGGCCTAGATTTTATGACATT  
55 TATGATGTTTGTCTTGTATGTTAATCTGTTCAACAAACTGTGGGTTTATTCTAAGTTTACAATTATTGAGA  
ACTGATTGAGGTAAAGATTTTCATGAAGAAAGCATGTATTGTGTGGAAGTAATTTTAAATTTTAACT  
GACCTACATTTATACGAAGAATCTGTACATGTTAAAGTAAGGATGACCAATGCAAAATTAATGAGTG  
GGCAATTAAGAAAGATACATATGCATTTTACTGTGTAACCTTTGTATGCTGAATGGTACATATATTTT  
TTTGCTTTTGGAGGAATTAATAAGGTATAATTAATTTGTCTTAACTTTTCAAAGAAATTTTATAGTGA  
60 GGCAACTGGGATGTTTGTGATAATAGATGAGAAAGACATCCTTGATTGTAGTTAAATTTGGTTTGGATTAC

DEX-0360

171

PATENT

AGATATTCATTATTGAATTGACTCCTATTTTCTCACACTTTGGAAAAAGACACCTGAACAATAAATGAATC  
 CTGGATAGTCTACTCTCCTTCAAACAATTAACCTGATACCTTGCCCTTTGGGAGATGCATACAAAAGGAGAGA  
 ACCCTTAGACTATGTCAGGTCACACTAGGAACCTCCCCCTACTCCCCGTTTTTCTTCATTTGTGTTTCAGT  
 TACTGTACTAACATTTGTGGATGATACTGAAATTCTGCATAATGTGAACAGGATAAACTATTATATAAACTG  
 5 CTTTTTCATGGGCCAGTTCTTTATTATAAATGAATTTTAGCTTTAAATGCATATACACGTTTCAGTGTGTTGA  
 TAGTTGTGTTCTTAAGGGAGGTTTGTCTGCTGTCATTGTCTCGAGAGAAGCAGAAGCAGTCAGTGTGGGG  
 TACCACATCTGACTTACTGTGGTGGTGACCAGTGTGCTTCTTAAGGGCAAGATTTATATTTGACCACAAG  
 GGAAAAAGTGTGCTACTGGAAAAAACGCATATACCTATGTTTGCAAACATAACTATCTTCAGATTAAA  
 ATTTGTATAAATTTGTTTATTATTAATGTTTGAATTCAGGACAAAAGAAAAATGAAGCTTGAGGTGTTTTCA  
 10 AATAGACCTTTATTTTGTCTATCTCTTTGTAGGTGTTAACTGAAGCAATTCGAATATGTCAGATTTCATT  
 TGGATTTCATATTACATTGAAAAAACTCAACTAAGCATTTGTTATCCACAACAACCTAGAGTTTAAAAAG  
 ATCGTATTTTCACTGTCTTCATTACTTTCTATGTAGTTTCATTCTTTGTCTGTTGTAACCTTAAATTTGAA  
 ATTTGGAAGATCTCTTTGGGATAGAAAGAAAGATTCTTACCTGGTGATGGAACCTTCATCTTCATCTGTGT  
 AAGAGTATTATGGGAAGTAGAAATTCACTTCCCTAAATCCATCGTAAGATTGAGCCTCAAGTTTGCAATA  
 15 TACAATTTTAAAAATACACATACATACATATGATATGTTTCCAGTTTTAAGATTTTGCAGGGTCT  
 TTATAAGAAAAACAAAATTCCTCAGGCTATAGAATTATGTTGTCATATATCAGAAAAAGTACTGATGTAT  
 CCATTTATATCCAATGCGCACACACCGGCACATTGTGATTTAATTCACCGCTTGAATCTATATTTCTAA  
 CCACAGTGACTTCAGTAAAAATACCGTATAATGAACATTTTCAGCTTCTTCTTACTTACTCGAGAGTTTAT  
 TGCAAAATCTTAAGGATTTTATTATAAAGATTTTGTAGTTTGGTAGCACATTTTGTACCAAAAATGT  
 20 TCAAACTGTGCTGTAAGAATATCCATGTTGTAGAAATGTCCACTTTTCAGATAATATAATGCCTACCA  
 TTATACTAACAGAATCATATGGTAGTTGATTTATTTTTTTTAGTTTGGTAGCACATTTTGTACCAAAAATGT  
 TTCTTGAGGCAATGATAAAAACACTTAATGTATTCTGCATGAGTGCTCTAATAGCCTCCTTCTCCTCAT  
 TTTTAACTGCATACATTACTTTCAAATAGGTATAGATATCTGTGCCGCTTTTGAGCTATTAGCCTG  
 TTTCTGTTTCCCTTTGTACCTAAGCAAGGCTTTTCTGAGAAGGTAGTGAATGGTTTCAAATGTTGCAT  
 25 ACTATAAGAAATAATCATTGGGTAACTGTTTGTAGACCAACACTTAGAAATACATATTTGTGCCTTTTC  
 ATTTTTTAATTTAATGTGTGTTGATATTTGGAGCACAAATAATGAAGGTGCCATAATATGGCTTGCCAA  
 GTTACCTCCTTGAATAGTCATGTGTCTTGAATTTGGTAATTGGAGAACCTTGCATGAAATATGTG  
 ATCGTGTGTGTGTGTGTGTATGCCGTGTGTGTCTGTGTGTTGTGTACATACCTGTATTTGCTTGGGGC  
 TTGTGTGTGGTATGTTACAAAGAGTGAATTTCTGGAATAGAAATCAGTTAAATGTTGAAAGTTTCAGGTT  
 30 AGCAGAAATATTTTCAATTTAAATATGCTTTTACTTTGGAGGACAATTGATTACAGAGGAAATGATAATTT  
 CAAAAATGTGATCAATTTACTGCATGATGAAATGTGAAAAACAGTGCCCTTTTATAGACATCAATTATAATA  
 AAATTTGTTTTAAATATTTAACAAGATCTCAAAAAGTTGTCTATGAACATTTATTCATTTATTTTTAACTG  
 GATCTAAATAAGAGCTTAGATGGCCAAAATTAGAATTAATAATATACCCATTTAAATTTTGTTCATAAAT  
 TTAATAATCTTAATCAGAATCTTTATAAAATGTGGGTCATAGATATGACCCAGTGTACTAAATAGAAAC  
 35 AGGGAATTTGAAAAATCCAGCTCAACATACCTTAAGTAACTTGGCTTAGAGCCAAGTATACCTGAAGAGGT  
 GAATTTATCTGACTTGGACATGCATGCTCTTTGATGGATAAAAATAAAAATATTCATTTTATTCTTACAAA  
 AGAAGGTGGGTGGGTGAGTGGGTTCGTTTTAGTGTCTCAGATTATAAAGACAGCTATAAAGACAGCACT  
 TTCCGCACACAAAGTGTATTTTACAAACCTTTTTTATACAAATTAATGAGCTCTACTTTATTTAAGTGT  
 CATGGAAATGATGAAATTTTAGGTCCAGTTGAACAAATTTAGTGCCTATCATATGCAAGACTAATCTCC  
 40 TTACTAGGAATGAAATCACACAGTGTCTTCTGTTTGCAGTATGTGAACCTTTATGTTTGAAGAAGAAATAT  
 TATATTTAAATTTTGGTGGCAAGTATCATGTTCTGGCCAGAATTGCTCCGTTAAAAAAGAYWMCAGCYCT  
 TGAGAAAYCRSATTAAATGGGGGSAACGGKAAAAATACGGGGAAGAAAACGGCGTGTCAAAAAA  
  
 >DEX0360\_011.nt.1  
 45 AGAGTTGGTTTGTAGTAACTGGCACTCAGGAACATGAGGGAAAAAATTACATATTGTGAAATGGTTGAG  
 AAGACATGAAAATCCACTTGATTTTGGTGTTCGGAATTTAGGCAAGAACTGTTTTTTAGGTTGACAG  
 GGTGGAATTCAGATACTTCTATGCATTAACCTGTATAATCAAAAGGAAATTGCTTGGGATAGGATAAAGAA  
 CTGTGGTCTCTTTCTTTAAATGTGTAGATGGAACAGTGACTATGTTTTTAGTGCTAGCACGTGCATGTC  
 AGCTGTTACAAATATGTCTCAAAGAATCTCTCTTTGCATATCTAGGCCCTGTCTCCTCCCTCCTACACATT  
 50 TCCAGCTCCTGCTGCAATTATTCCTACAGAAGCTGCCATTTACCAGCCCTCTGTGATTTTGAATCCACGA  
 GCACTGCAGCCCTCCACAGCGTACTACCCAGCAGGCACTCAGCTCTTCATGAACATACACAGCGTACTATC  
 CCAGCCCCCAGGTTGCGCTAATAGTCTTGGCTACTTCCCTACAGCTGCTAATCTTAGCGGTGTCCCTCC  
 ACAGCCTGGCAGGTTGCTCAGAATGCAGGGCCTGGCCTACAATACCTGGAGTTAAGGAAATCTTAACTTC  
 TTCCAAGGTTACCAGTATGCAACCGAGGATGGACTTATACACACAAATGACCAGGCCAGGACTCTACCCA  
 55 AAGAATGGGTTTGTATTTAAGGGCCCCAGGATFAGAACATCCTCAGAAAAGAAGTGTGTTGAAAGATGTA  
 TGGTGTACTTTGAACCTCCAGACACAAGAAACTTCTAGCAAAATCAGGGGAAGTTGTCTACACTCAGG  
 CTGCAGTATTTTTCAGCAAACTTGATTGGACAAACGGGCTGTGCCTTATCTTTTGGTGGAGTGAAAAAAT  
 TTGAGCTAGTGAAGCCAAATCGTAACCTTACAGCAAGCAGCATGCAGCATACCTGGCTCTTTGCTGATTGC  
 AAATAGGCATTTAAATGTGAATTTGGAATCAGATGTCTCCATTACTTCCAGTTAAAGTGGCATCATAGG  
 60 TGTTCCTAAGTTTAAAGTCTTGGATAAAAACTCCACCAGTGTCTACCATCTCCACCATGAACCTGCTGTTA

AGGAAGCTTCATTCTTTGTATATATCCCGCTCTTTCTCTCATTTCCCTGTCTTCTGCATAATCATGCCTT  
CTTGCTAAGTAATCAAGCATAAGATCTTGGAAATAATAAAATCACAATCTTAGGAGAAAGAAATAAAATTT  
TTATTTTCCAGTCTCTTGGCCATGATGATATCTTATGATTAAAAACAAATTAATTTTAAAAACACCTGA  
AGATATATTAGAGAAATTTGTGCACCCCTCCACAAAACATACAAAGTTTAAAAGTTTGGATCTTTTCTCA  
5 GCAGGTATCAGTTGTAAATAATGAATTAGGGGGCCAAAATGCAAAACGAAAAATGAAGCAGCTACATGTAG  
TTAGTAATTTCTAGTTTGAAGCTGTAATTTGAATATTGTGGCTTCATATGTATTATTTATATTGTACTTTT  
TTCATTATTGATGGTTTGGACTTTAATAAGAGAAATTCATAGTTTAAATATCCGAGAGTGAGACAAAT  
TTGAACAGTGTATTCTAGAAAACAATACTAAGTGAACAGAGTGAATGCTTATATATATTATGATAGC  
10 CTTAAACCTTTTCTCTAATGCCTTAACTGTCAAATAATTATAACCTTTTAAAGCATAGGACTATAGTC  
AGCATCTAGACTGAGAGGTAACACTGATGCAATTAGAACAGGTACTGATGCTGCTCAGTGTTTAACACT  
ATGTTTAGCTGTGTTTATGCTATAAAAAGTGCAATATTAGACACTAGTACTGCTGCCTCATGTAAC  
CCAAAGAAAACAGGATTTTCATTAAAGTGCATTGAATGTGGCTATTTCTCTAAGTTACTCATATTGTCCTTT  
GCTTGAATGCAATGCCGTGCAGATTTATGTGGCTGCTATTTTATTTTCTGTGCATTACTTTAACACCTT  
15 AAAGGGAGAGCAACATTTCTCTCAGCTGACTGGCAATGGCCCTTTAACTGCAATAGGAAGAAAA  
AAAAAGGTTTGTGTGAAAATTTGTGATACTGGCATTAAAGATCGAAAGAAATTTCTGTATACTTGAT  
GCCTTAAGATGCCCAAAGCTGCCCAAAGCTCTGAAGACTTTAAGATAGGCAATGCTTACTACAATA  
CTACTGAGTTTGTAGAGTTAACATTTGATAATAAACTTGCCTGTTTAACTCTCAA

>DEX0360\_012.nt.1

20 CAGGCAGCTGCCAGGAGCTCTTCCTGCTCGCTCAGCCTGCTCTCAGAAGCTCCGATCCAGACACACGC  
GAGGCGCTGTCCTTTTCAGCACCACAAGCTCGGGCTGAGGAGGGAGGACTCCTGGCCGTCTCTCTCTCTT  
CAAATTGGCTTGAATCTGCTCTGACCCCCACGAGTGCAGCACAGTCTGGGAAGAAAGGCGTAAGGATGG  
TGAAGCTGAACAGTAACCCCCAGCGAGAAGGGAACCAAGCCGCTTCAGTTGAGGATGGCTTCCAGACCGT  
25 CCTCTCATCTCTCTTGGAGGTTAATCACTTACAGCTGCCTGCTCCAGAAAAGGTGATTGTGAAGACA  
AGAACGGAATATCAGCCGGAAGCAGAAGAACAAAGGGAAGTTCCGGGTGCCGAAATCGCTGAATTTACGG  
TCACCATCTTGTGAGCTGGCCCTAGCTTTCTTGCCTGTCATCGTGTCTTCTGGTGTTCAGGCTT  
CACCTATTTGAAGGASCTAAATTCGTAGCAMATTCTGTGGCAGTTTAAAAAGTTAAGCTGCTATAGTAA  
GTTACTGGGCATTCTCAATACTTGAATATGGAACATATGCACAGGGGAAGGAAATAACATTGCACCTTAT  
30 AACACTGTATTGTAAGTGGAAAT

>DEX0360\_013.nt.1

AACTGAGATTTCAACTGATGACAAGGTTTCAAGATCTGACTGATACCGAAGTGGTTAAGACGCAAGAGAG  
GAACAAATTTGTTGGAGATGAAGAGGTCAGAGGCTAAGAGGCCAAGTGTGGTGTGTCATGGGTACCTA  
CAAGCATCTGAATTCAGATAGAATGTAGACAAGAGGATGGTGAGGAAAACCTACGGCAAGCAGCTCTA  
35 TAATTTCTGAAAGTGACCAGGAGGCTCGTGGATGATGGCAGGAAGGAGATGAGAAGTGATTTAGCC  
AAGATATGAAGTTCAATATTTTGAAGCAGAAAAGAGCAGAAATGGTTTGAAGTAGCAATCAGGACCA  
AAGAGACCACCCAACTCAATAGCCCAACCTCTTAGCCTTAGGGTACGAGAATCTGAAAAGTGAATCT  
CAATTTGGAGCTCTACAGCAGTAATTCGAAGTAACCACTGTAGCTAATGTCCAGGGATTAAGAAAA  
40 AGATAATGAAAATGTTTGTGCCAGGAACATTAATTTACGGCTATCTAGAATGCAGTTCTTGCATTAT  
ACGTACTGGGTTACCAGTCATTGCAAAGTCATGGTCTTTGGCTCTCAGCTCAGTTCCCTTCTGTAAGAT  
AAAAACATTTGCCTATGTGTCCAGGGAAGCTGTGAGGACAAAAACCAAGCAACTTTTACAAGGGATCAT  
AAAAACCTACCTAACCACTTGCTAATTAACCTTGATTTTAAATTTGCAATTATTGAGCTTAATACCATTG  
CTTAAGTATGTGAATFACTGAGATTTTATAAAGGAATTAGTTACCTCTAGGAAAATAATTATCACTAA  
45 AAGAAATAATATCGCAATTTGAATAAAAGTAAAGTGCCTTAAATCAGGAAACATTTTAGTGAAGCGT  
TTGTTTAAATGTATTCTAACCTAGCAATGTAGAAAGCAGGCAACATTTAAAAAAATTTAACAGTTT  
CTAAACATAGTTTGGAGCTCAGATTCTGGGGAAATGATTAACACACCTACATCCAAGGTCTCTTTCC  
TTTCTAGAAAGAAAGCATCTTTAAACATACATATTTCATCAGAAATACAAATATTTGTCATCAGTGATACT  
AATTTCCAGGCAACATTTAATTCAGTCAATGTATTAGTCTTACCAGGTTTAAATTTGGATCGGTAA  
TACGGGTTTGATTAGGTTTCTAGGCTAATTTATAGGTCACTAGTCTTCTCTTTAGGATTATGCACCATCTG  
50 TTATTTTAAATTGACCATTGAGGGGTTCCCAAGGGTTCTCTCTCGTTTGTGTTTATAGGTTTAA  
GGATTCTTGGGGTGGTGGGATCCAAAGCCAGAGACGGTTTCAACAAAAATGCAAGCGCGAATTTGTCTT  
CGCTCTGAACGCATGTTCAAAATTAACAATTTAGACATGCCCAACTATGACACTAAGAAGTGAATGGT  
ATAGTACACTTTTGTCAAAATTCAGGGTAAATTTAAGTGCCCGATGGTAGAGGCTTGGCTTCCCTGGG  
TTTCTGGAACAAAAAGCGTTTCGCGAGGAGAGGGGTAATCTCCCGGCTCCCTCCCAAGGATAATCA  
55 AATCAAGGAATATGAGTGCCTGCAGACAAGCCTCGCTTCTTTCTTCCCTTCAAGGCTAGCGTTTGGG  
AAGGAAGGCTCGGCTACTCTTGGAGCTTCAGTGTCCGGGAGGAAGAAAGGCCAGCCAAGGTCCTC  
ACACTGGCGTGAATTCGGCGGCTTCGTAGGCGATCGACCCAGAGACGAAAGCTGCTTCTCAAGCTGGG  
GGAGGAGAGGAAACGGCGCACAAAGCAGTACGACCTGTCCCTTATCGGCGTCAAGGGGAAGGTTGGA  
GAAACGAAACAGAAGCGGGCCGGAGCCTCGGCTCCCGCCAGCGCTTTTAAAGTCGTTTCTTACC  
60 TCCTCTCGCTCAGCGCGGCGCTAATGGAACCGCGCGAGCGCTCTCGCAATCACCGCGCGCTTCTCTC

DEX-0360

173

PATENT

CCGTCGCCCGCQAATGGCGGCGCGCTTCTTGGGGCGTGGGCGAAGCAGGCTGCTCGCCTCCTGCCTGTA  
GTGTGTGGGCTGGGGTTGGTGCAGCTTCCAGCTTGGCCGAGTTGGTTCGTAGTTCGGCTCTGGGGTCT  
TTTGTGTCCGGGCTGGCTTGGCTTTGTGTCCGCGAGTTTGTTCGGCTCCGCGAGCGCTCTTCCGGGC  
AGGAGCCGTGAGGCTCGGAGGCGGAGCGCGGTCCCGGCCAGGAGCAAGCGCGCGCGGTGAGCGGGC  
5 CGGCAAAGGCTGTGGGGAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTTCTTGAAGACCCCTCGGTC  
CTGACAAAAGACAAGTTGAAGAGTGAGTTGGTCGCCAACAATGTGACGCTGCCGGCCGGGAGCAGCGCA  
AAGACGTGTACGTCCAGCTCTACCTGCAGCACCTCACGGCTCGCAACCGGCCGCGCTCCCCGCCGGCAC  
CAACAGCAAGGGGCCCCCGGACTTCTCCAGTGACGAAGAGCGCGAGCCACCCCGGTCTCGGCTCTGGG  
GCCGCCGCCGCGGGCCGAGCCGAGCAGCCGTCGGCAGGAAAGCCACAAAAAAACTGATAAACCCAGAC  
10 AAGAAAGATAAAGATGATCTAGATGTAACAGAGCTCACTAATGAAGATCTTTTGGATCAGCTTGTGAAATA  
CGGAGTGAATCCTGGTCTATTGTGGGAACAACCAGGAAGCTATATGAGAAAAAGCTTTTGAACTGAGG  
GAACAAGGAACAGAATCAAGATCTTCTACTCTCTGCCAACAATTTCTTCTCAGCAGAAAAACAAGGC  
AGAATGGAAGTAATGATTCTGACAGATACAGTGACAATGAAGAAGACTCTAAAAAGAGCTCAAGCTTGA  
GAGAGAGAACCCTAAAGGGCAGAGCAAGACTCCAGTAACACTCAAGCAAGAAAGAGTTGAGCACAAT  
15 CAGAGCTATTCTCAAGCTGGAATAACTGAGACTGAATGGACAAGTGGATCTTCAAAGGGCGGACCTCTGC  
AGGCATTAAGTGGGAATCTACAAGAGGGTCAAGAAGAACTCCAAGGAAAGGGTGGAACTTCAGAACAA  
TTTTCGTATAGATGGTCCAGTAATTTTCAGAGAGTACTCCCATAGCTGAAACTATAATGGCTTCAAGCAAC  
GAATCCTTAGTTGTCAATAGGGTGACTGGAATTTCAAGCATGCATCTCTATTCTGCCAATCACTGAAT  
TCTCAGACATACCAGAAGAGCACCAGAAAGAACTTCTCAGTAAGAGCTGAACTGGGAGAAAAACAGAGGA  
20 AAGAAGAGTAGAAAGGGATATTCTTAAGGAAATGTTCCCTATGAAGCATCTACACCAACAGGAATTAGT  
GCTAGTTGCCCGCAGACCAATCAAAGGGGCTGCAGGCCGGCCATTAGAACTCAGTGATTTCAGGATGGAGG  
AGTCTTTTTCATCTAAATATGTTCTTAAGTATGTTCCCTTGGCAGATGTCAAGTCAGAAAAGCAAAAAA  
GGGACGCTCCATTCCCGTATGGATAAAAAATTTGCTGTTTGTGTGTGGCAGTTTGTGTTTGGTCT  
TATCAAGCTATGGAACCAACCAAGTAAATCCCTTCTCTAATTTTCTCATGTGTGACCTTGAATAATCCA  
25 ACTGAATGGTATCTCTTTGGCACGTTCAACTTGGTCTCCTATTTTCAATACTGTTGAAAAACATTTGTG  
TACACTTGTGACTCCAAGAACTAAAAATAATGTGATTTTCGCCTCAATAAATGTAGTATTTCAATTGAAAA  
GCAACCAAAATATATATAAATGGACTTCATTAAATGTTTGTGAACTTTGGACTAGTAGGAGATCACTTT  
GTGCCATATGAATAATCTTTTGTAGCTCTGGAATTTTGTAGGCTTTATTTTAAATGTGGGCATCTT  
ATTTCAATTTTGAATAATGTATATGTTTGTGTTTGTGTTTGGGAAACGAAGGTGAAACATGGTAGTATA  
30 ATGTGAAGCTACACATTTAAATACTTAGAATCTTACAGAAAAGATTTTAAGAATTATCTCTGCTGAAT  
AAAACTGCAATATGTGAACATAATGAAATTCAGTAAGAGGAAAAGTAACTTGGTGTGACTTTTGTGTA  
ACTGCAACAAAGTTTGATGGTGTATGAGGAAAAGTACAGCAATAATCTCTTCTGTAACCTTTATTAAT  
AGTAATGTTGTGTAGCCCTATCATACTCACTTTTAAAGACACAGTATCATGAAAGTCTATTTTCAGTAA  
GACCCATTTACATACAGTAGATTTTACGAGAGATCTTTTAGTGTAACATACATATTTTAGAGAATTGTT  
35 GGCTAGCTGTACATGTTTGAAGAGCTGTTTAGCTAGCTATAAGGCTATAATTTGGAATTTGTATTTT  
ATTTACAGCAAAACATTTATTCAGTCATCCAGTTTGTACCAAAATATGTTTGTAGATAAGTGTGTGTATG  
TTTGTTTAGAAAGTTAGAAATTTGTAACACTGGTCTTATGTTTCATTTGGATTCAATTATGCAATGTCTTG  
TTACAGAAACAAATCCTCCCGGGTCAAGCAATTTTCTGCCTCGGCAGAGACGGGGTTCACCATGTT  
40 GGCCAGGCTGGTCTCGAACCCCTGACCTCAAGTATCAGCCACCTCAGCTTCCAAAGGTCTGGGATTA  
CAGGTGTGATCCACTGCACCCGGCCGGCATTATGATTTTGTGTAATCTTGAATGGTTATCTTTGTGGAT  
GATTTTGTGTTTAAAGCTGAACTTACCTCATGAATAACTTGATTAAAGTAGTAGGTGATTAATAATTTCA  
ATAGAATCAAATGAGACAAAAATTTTAAACTGACTCATTTGAGTTTCAACTTTACAGTCATTGACCATAA  
AGCACACTAAAAATGTAAGTTATTTTAAATACATCTGAAATAAAAAATACTTACTAAAAAGGAAGAAGCC  
GAAGATGTATATTTAGACCAGCACACAATTTTGATTTCAATTAGCCTTATTCTAATATTAGCTTTTAGA  
45 TCTTTCATACACATTTTCACGTACTTTGCAATTGAGACCAGAAAGACTTGTAGGTCTTTCTGCAGAAATGA  
GTGGGTCTTGAAGAGTGAGTGGGAACTTACTCCTAGATCAGAAATGTTTGCCTCTCTGAGTAAAAATGT  
TTCTTTTCAGATGAGCCATAGAGGGGACCTTTTACTCAACTTTTCTTTGTTTGAAGCTTTGTTTCCCA  
TACTGTTTTCAGCTTTTGTGTTTATAATTAGAAATTTGTGAGAAGCTTCATTTAGTGTGTTAAAAATGTGGG  
AGATAAATCAGACTTAACATGTATGTAAAGTCAATTCACCTTAAAGATATGGTCCAAATGAGCAAAATAGG  
50 ACCAGGTGAAACATGTAGTCATTTTAAAAACATGTACTTGGTCTTTTGTGTGTGTCTGTTTATTTCCA  
TTAGAATAAATGTGCTTGTATGTAATGCAAGCATTTCTTCTGATTAAATTTGTAGATGTAGACTTTA  
CAATATAATTCAATAATAAAAAAGTAATTAACCTCTA

&gt;DEX0360\_014.nt.1

55 GAGCCGGCTACTTTGGGCGGACTTTTCAAACAGCGAAAACAAAACAAATCGGGGACCTTTAAAGGCGT  
AATGAGACCAGAAACGATCTCCTTCCGCCCTCTGTCTTCCCCCGTTCCCAACGCAGATCAATCGCGGA  
ATAAGCCCGACGCCAGATTCGCTCTCCGCCCTAGCGCCAGGCGGGGAGGACTGGCTCGGCAAGCCAAAG  
GAGAGCTAGGGAGGCCGCGAGAGAGGCTCGAGACGGCAGCTTAGGGGCGGGACTCTTTTAAAGTCCGT  
GGAGGAAGTGCAGGATCCCTCCGCGGGAGTCAAGTGCCTCCGCCGCCCTTGGGGGCTCGAAACTCTTAAC  
60 AAAACAAGGGGCTCGGGGAGGTTTCCGCTGAGCGCGGGGGTGGCGGGTGGGCTGGTCTTCCGCGGC

CGGCGTTGCGCCGCGGCGGAGGGTGGGCGCGCGGGAGCGGGATGGAGCTGGGGCGACCCTTGCTGGAGG  
TACTGGCCTCAGCCCTTTCTCCCGCTTCCCCACCCCTCTTACCCCCAGATTACATTCTCTGTGTGGTGTC  
TTTACTGCAGATGAAGGATTTGGGGGCGAGAGCACTTGGCAGGTCATGAAGGGGTCCAACCTCTCGGGTTG  
5 TTGAACGTCTACCTGGAACAAGAAGAGAGATTTCCAACCTCGAGAAAAAGGGCTGAGTTTGATTGAGGCTA  
CCCCGAGAATGATAACACTTTGTGTCCAGGATTTGAGAAATGCCAAAGTTGAAGATTTAAGGAGTTTAGC  
CAACTTTTTTGGATCTTGCAGTGAACCTTTTGTCTGGCTGTCAATATTTTGGACAGGTTCTTGGCTCTT  
ATGAAGGTGAAACCTAAACATTTGTCTTGCATTTGGAGTCTGTCTTTTTTGTCTGGCTGTCTAGAATAGT  
AAGAAGACTGCAATATTTCCATCCACTCATGTGTATCCGGATTAGTCAGTGTAATGTACTGCTTCTGA  
10 CATAAACGGATGGAAAAATAATTTTCAGAAAAATTCAGTATGAATTTGGAAGCTACTACTGCCTTAAAC  
TTTTTGCACTTATACCATACTATTATACCTTTGTCTACTTTCAGAAAGGAAAGAAATACTGAGCCTTGATA  
AACTAGAAGCTCAGCTGAAAGCTTGAACCTGCCGACTCATCTTTTCAAAGCAAACCACTCTGTATTAGC  
CTTGTGCCTTCTCAATTTGGAAGTGGAACTTTGAAATCTGTTGAATTACTGGAATTTCTTGTCTAGTT  
AAAAACATTTCCAAGATTAATGACACTGAGTTCTTCTACTGGAGAGAGTTGGTTTCTAAATGCCTAGCCG  
AGTATTCTTCTCTGAATGTTGCAAACAGATCTTAAGAAGTTGGTTTGGATCGTTTCAAAGGCGCACAGC  
15 CCAGAACCTCCACAACAGCTACTATAGTGTCTCTGAGCTGCCAACGATACCTGAGGGGGGTGTTTGTAT  
GAAAGTGAAAGTGAGGACTCTTGTGAAGATGAGTTGTGGAGAGGAGAGTCTCAGCAGCTCTCTCCCA  
GTGATCAAGAGTGCACCTTCTTTTTCAACTTCAAAGTGGCACAAACACTGTGCTTTCCATCTTAGAAATC  
TGATTGTTCTGTGAGAATTTATATTTACAGGTTTCAAAGCAATAAATGGGGGAATAGGTAGTTTCTGGT  
TTAGCCCCCATCTAGTCAGGAATTAATATACCTGGAATACCTTCTATTGTTTATTCAGATCAGATCT  
20 GGCCTATTTTTCATATTTATCCTAAGCCATCAAATGGGGTAGTGCCTCTTAAACCATTAACAGTACTTTAG  
ACATTGGCACTTTATTTTTCTCGTAGATCTTTAGCTACTTTGGGGAGGAGGGAAGGTGCTGATACCTTCA  
ATTTGTTACTTTTCAAGATTTTTTAAAAATACTAGTGTAGCTTATCTTAAACATTTTATAAAACCTTCAG  
ATGCTTTTAAAGCAGATTGGAAGTATGCAAGTGCTTCTTAGCAGGGACAGTGGATAATCCTTAATGGTTT  
ATCATAGATTTTCAACCTCCCCCTTCTCAGAAGAGTGAGTATGCTCTTAAATGTCAAACACATTTTTGTT  
25 GTTTTGTTTTTTAAATGATCAGTGTCTATTTGATGTGATGCAGATCTTATAAATTTGGGAATTATAATAT  
TGACATTTCTGTGATTTTTATATATGTAATGTCTTAAATTTGAGATTCTGTGTTAAGGCAGAAATAATTAGGC  
TAGGGCTCTTAGTTTTCTATCTTATGCCCCAAGTATTTGTCAAACTATGGTATTATTTAATGTTACTTTA  
AAAATCCATAATCTGCTAGTTTTGTCATGTACTTATATGAAAACAGTGCAGTAAGTTGAAAACCTCAGTATC  
30 TATGGAAATGATAAATGTTGATCTGGTGTAGTATATTTATCGCATTTTCTTATATTAATAAATGTCTGC  
ATGATTACATTTTATTTTCTGATGTTTAAAGCAATCTGTGTGGTGATACAGCCATAAGA  
AATATGAAGAACCCGAGTGTGTTGTAGTATTATAGTTTAAAGCAATCTGTGTGGTGATACAGCCATAAGA  
ATGGGGCTTATATAAATCTGTACATGTAAGATTTTGTACAGAGAATTTTAACTTTATAAATGTATAT  
GAACATGTAAATCTTTTAAATGTACATAAATACCTGTATTTTTTACCTTGTGTGTGATAGTCTAGTCA  
TTGCATGTAAATATAATTTATATGATTCTGTAGTATAAATCATACATTGATGACTTACATTTTACTG  
35 GTAAGTCAACATCCGTTGGATGTTTTCTGAAGTGGCTCTTTTTGAAGTGATAATAGATTGTAATTCAAAA  
TAAATTTATTAATGAA

>DEX0360\_014.nt.2

TGATACATCACTATAGGGCAACTGGTCTCTAGATGCTGCTCGAGCGGCGSSCAGTGTGATGGATDGGCGC  
40 GCGGCCGAGGTACTGCTTCTGACATAAAACGGATGGAAAAATAATTTCAAAAAATGCACTATGAATT  
GGAAGCTACTACTGCCTTAAACTTTTTGCACTTATACCATACTATTATACCTTTGTCTACTTCAGAAAG  
AAAGAAATACTGAGCCTTGATAAACTAGAAGCTCAGCTGAAAGCTTGCAACTGCCGACTCATCTTTTCAA  
AAGCAAAACCATCTGTATTAGCCTTGTGCCCTTCAATTTGGAAGTGGAACCTTTGAAATCTGTTGAATT  
ACTGGAAATTTCTTTGCTAGTTAAAAAACATTCCAAGATTAATGACACTGAGTTCTTCTACTGGAGAGAG  
45 TTGGTTTCTAAATGCCCTAGCCGAGTATTTCTCTGATGTTGCAAAACAGATCTTAAGAAGTTGGTTT  
GGATCGTTTCAAAGGCGCACAGCCAGAACCCTCCACAACAGCTACTATAGTGTCTGAGCTGCCAACGAT  
ACCTGAGGGGGGTGTTTGTATGAAAGTGAAGTGAGGACTCTTGTGAAGATATGAGTTGTGGAGAGGAG  
AGTCTCAGCAGCTCTCTCCAGTGATCAAGAGTGCACCTTCTTTTTCAACTTCAAAGTGGCACAAACAC  
TGTGCTTTCCATCTTAGAAATCTGATTGTTCTGTGCAATTTATATTTACAGGTTTCAAAGCAATAAATG  
50 GGGGAATAGGTAGTTTCTGGTTTACCCCCATCTAGTCAGGAATTAATATACCTGGAATACCTACCTTCT  
ATTTGTTATTCAGATCAGATCTGGCCTATTTTTCATATTTATCCTAAGCCATCAAATGGGGTAGTGCCTCT  
TAAACCATTAACAGTACTTTAGACATTGGCACTTTATTTTTCTCGTAGATCTTTAGCTACTTTGGGGAGG  
AGGGAAGGTGCTGATACCTTCAATTTGTACTTTTCAAGATTTTTTAAAAATACTAGTGTAGCTTATCTT  
AAACATTTTATAAAACCTTCAGATGCTTTAAGCAGATTGGAAGTATGCAAGTGCTTCTTAGCAGGGAC  
55 AGTGGATAATCCTTAATGGTTTATCATAGATTTTCAACCTCCCCCTTCTCAGAAGAGTGAGTATGCTCTT  
AAATGTCAAACACATTTTGTGTTTGTGTTTTTAAATGATCAGTGTCTATTTGATGTGATGCAGATCTT  
ATAAATTTGGGAATTATAATATTGACATTTCTGTGATTTTTATATATGTAATGTCTTAAATGAGATTCTT  
GTTAAGGCAGAAATAATTAGGCTAGGGCTCTTAGTTTTCATTCCTATTGCCCCAAGTATTTGTCAAACATG  
GTATTATTTAATGTTACTTTAAAAATCCATAATCTGCTAGTTTTGTCATGTACTTATATGAAAACAGTGC  
60 AGTAAGTTGAAAACCTCAGTATCTATGGAATTGATAAATGTTGATCTGGTGTAGTATATTTATCGCATTT

DEX-0360

175

PATENT

TCTTATATTAAAAATGTCTGCATGATTACATTTTATTTCTTTGTAATTTACATTTTCAGAATAGTGTAT  
TGCTATATGGGTGCCAAGATTGAATATGAAGAACCCGAGTGTGTTGTAGTATTATAGTTTAAAGCAAATCT  
GTGTGGTGATACAGCCATAAGAATGGGGCTTATATAAACTCTGTACATGTAAGATTTTGTACAGAGAATT  
TTTAACTTTTATAAATGTATATGAACATGTAAATCTTTTAAATGTACATAAAATACGTATTTTTTTAC  
5 CTGTGTGTGATAGTCTAGTCATTGCATGTAAATATAATTTATTATGTATTCTGTAGTATAAATCATACA  
TTGATGACTTACATTTTTACTGGTAAGTCAACATCCGTTGGATGTTTCTGAAGTGGCTCTTTTTGAAGT  
GATAATAGATTGTAATTCAAAATAAAATTATTAATGAATTCCTTGTGTTGGGATCAGATCTTAATTTTT  
AATCTGTTAAAAGTTCTTGATGTATTTTAAAGAGAAGACTTTAGGTGAGGCTACAGTGATTCCAGAGTGA  
GCCTTCTAATCGGCTAGCAGAAGTTCTCTAGGTTTGGCATCTGTGCCTTGGAGATACTGAAAGAGAATCT  
10 GTCATTTGACAAATTGACCTCTTTGTGGGATGGACTCATTAAGTATGCTCTCAGAGACTGGTATATTACCA  
GAATGCCTATTAAATTTTCAGTGAGAGGCAACAGGTATTAAAGTAGAACAGAATGCTCAGGTTGGCAGATTA  
GAACGATCTTTTCAGGAGACAAAGCAAGTTTAAATCAGTTGTTTGGTTAATAAGTATGGGGTGTTCGCTGT  
GATAGGGCCCCGCCAGCTTCTGGCTCTTGTGGACCTCAAAAGTATCAGGTGGTTTTCGAAGTGGTGGTCC  
TTTCCCTTGGCCCCACCCCAATAGGTTCCCATCTGTCTAGTTTGATTTTTGTAGACCTTTGTTTTCTCTA  
15 GTTAGAAAATCAGGTACACTGAATATGGTTTTCATGTAACACCTCTTCTCTGGAGATAGGGGTATGTTTT  
CCTACCCTTCTAGTGGAGAATCCTACTTGGAGGATGACCTTTCTCTCTTACTAAATAATATTAGTAAATA  
GTGGGCAATATATCTGCTTTTCAGATTTTGATTTGTTGAGATGTAAAAGTTGTTTGGGGCTTACCAAATC  
TCAAGACTCTCTTAGCTCCTGCAGGATGTATTGCTTTTCTTACTGGATATTTTTCTGGGTAAGCATC  
TTTGTGGCTTTCATCTCTTCCCCCTGTGGTTTTTCAGTGTATTTAGTCGAGACCTCTCTGCTGAGCTTGCAA  
20 CCTGTTTTATTACATGGCCTGCCATGCCACTTGGAGGTTTCTGATTACTCCCAAACCTGCTGGTTCTTTA  
TGTCTTTCTCAGCGAATAATCCATCTGTTCATGTTGGAACTTAGGTGATATGCTCATCTCTCTGTCCCC  
TGTTTTATGGAGGTCACCAGCCTCTATCATTTGTATGATTTTCGTTTACACTGTTTATATCTCTGTCCCC  
CCTTTTTCTGCCATTGGCATGGTTTAGACCTGTACTCTTATCAGCAGAGGACTGTAAATATATTTGTGA  
25 TCCCTCAGCTTCCAGGCTTACTCCTGGTCTCTGCCCTCTCTATCTACATATCCTTTTAAATAAAATTTTA  
ACTATCTCCTGAAAAATTTGTTGAGTAGGTCACGCAACAATCAGGAGAAAAATCTATTATGACATACAAGT  
CTCTGTCTAATCTGAACACTGCACCTGTCTCTGGCCTTTTTTCTTGTCTATTCTTAGACCTTAAAAAT  
GTGTATTGAGAAAGAATCTGTGTAGCTATACAGAAGATGAACGAGGCAATATAGAGTAGCAGCATGGAGA  
CCAGTCTGACTGAACTAAGGCAGTGGAAGTGTGGATGAGGAAGAGAGGTGAAAATTGAGAAGCGCTATCC  
30 TTTCTCTTTGGGCATTATTAGGAGGCTCACAGACAAGTCCAGGAGCCTGGTTATACCCTCCTGTGCCATT  
CAACCAGGTGGCTTTTCCCATGACTGTGATGAATAAAATTGAGAAGCCCCGCTTTTTCAGAGCAGAGGG  
TGAGGAGAAAGCTACCATTGTTGCTCTCATCTTACCCCGTTGACTTGGCGAGAGATTTGACCTTTCAGG  
TTTTGATCCTGTCTATTTCTAGGATGTGGTGACGCACTTTGCTGTTGGCGATGGTGAAGTATTGTGCTT  
AGGTCTCGGGTCTTCATCTGTTTGGCTCTGCTACTGTTTCCCTCCTCCAGGAAGTGTGGTTAGACAAATA  
35 ATGTGTTTTAATTACCTGTCACACTCAGGATTAATACATACTCAGGTTAACTGTAGAGAGGCATTGGCTT  
CAGAACACTCCTCGTGACAATTTTAACCAATTTTCTTGTCTAGAGTCTGCCTTTTTCTTTTTTACAATTT  
CTTTTATTTCAACACTAGGTTTCAATATGGTGTCTTCTGCTACCTCCCACTCCCTCCTCATCACAC  
ATGCAAAATTGTGAGCTTATTTGAGACAACCCACTTAGATTATATATGGACAAGGACAAGGTATTTGCAAT  
TTGTTACTGGAATTCAGTTTTCCTAACTATTTACTACCAGAAATGGTCAATAAATTTACTTTGTGTTTAGC  
40 AAATCAAATTGTGTGATAGATAGTTTCCAGTATGATGGCCAGTCAGTCTTTCCATCCCTGTGCTTACAT  
GCTGCTCTTCCCGTCCACAAGTGGAGTCTGTTTCTTGTGAGTTTGGCTGGCCTTATGAATGGCTTTGCT  
TACTGAAGTGCAGCAGAAGAAATTTAGTATATGTCCAAGCCTAGGCTTTAAGAGACTGGCAGCTTTCCTT  
TTATCCTTTTTTGGAAAGCTAGCCACCATGCTGCAAGAAGCTCAGCTGGATTACTGAAAGATGAGAGGCCA  
TGTTGGAGAGAGACTCTTGGAGATGAGAGATTATCTTGGATGTTCCAGCCTTAAGCTCCCAGCTGAATGTG  
45 GGTGTATCCTCAGCTACACCACAGAAAACAGAGGAACTACTCAGTCGATCCCAATCAACCACAGACTCA  
CTAGAAAATAACAAATTTATTGTTTTAAGCCACGAGGTTTTTGGGGGAGGGTTGTTAAACAGTAATAGATAAG  
TGAGACAGATTGCTTGTATTATTTATGGTCAAATGGTGATTATCTCTGGTGAGATTACAGGTGATGTTTTT  
TTAAGTTATGCCTATCTGTAGTTTCTTTTTTCTTAAATTTGATTTGAATTATTAGTGTATTAAACAGAA  
TAAAGAATGAATTTTAAACACACACGCTGGTTATATGCTTCTCTAATTTAAATTTATGGCTCTCACCA  
50 CACCTTAGCATCAAGTTCCAACCTCGTACTGCGGCTTAGAAGACCCAGCTTGATTTGTTCCCGGCTCCCT  
TTTCAGCCTTGTTCATGGCATCCACATCCAGTATTTCCAGGCCACTACATCTGAGATGAGTCAGAG  
ACCCCTCTTAGGGGCTGTTCCCTACTCCCAACATGGAAATTTAAAAAATAATCGTGAGTTCTTCCAAG  
AGAAATTCCAGGCATCTGGCTAGCCCTGAGAAGTAAGAGAGAAATGTGATAAGCAACAAATAGCGGCTCA  
AAACAATAGCCAGTAAGTTAGAATCATGGGATGTTTGGTTCCCTATAGAACTACAGATAACATCTTA  
ATATATATCCCTGAGTTGTTTTCCAGAAACCTGAACCCCTAGCAAATGGATGCGCTAGCACATAGACCTC  
55 AGATAAGAGGGAGCTGAGGACTGAACTCTGACCACCGTTCTTTGTTCTAAATTT

>DEX0360\_015.nt.1  
CCAGAAAACACAGAATGAACATCATCATGAATACATGAATCGGCTGTGATGTGTGAAGTGTGTAAGGGCC  
AAATGAACGTTTGCAGAGCAGTGGGCACAATGTTTACAAATGTATGTGTATGTCACTTTCGGTACCTGTGA  
60 ATGCATGGGACGTGCTGAACCCGAAAAAAGTGCCTTTCCATAAGGACTGCAATAGAGAGGGCAATTTA

DEX-0360

176

PATENT

CCCTGGTGGTACACGGAACCTAGATTCACTCCTGCCATGCCTTGCCAATAGTAAGCTGCAGGGTGAACA  
AGAAATCACTTGCTCTGGGGGAAGGGAGGGGGGAATGGGTGTGTGCTGAGCTGGGTAGATACAAACCTGAA  
AAGAGAATCCATGTGCTGCTGGCAGGCAACATTTTAAAGCTCTTTCAGAAACCTCATATTTGGGGTT  
TCTTTTCAGGAAACATTCTGTGGAGGGAACGAATATGAAGATAATTTTCAGCTAATTATCTGGGTGA  
5 CCCAGAATCGTGTATATGGCTATAGGATAGACTTCTTAATAATGGCAAGTGACGTGGCCCTGGGGAAAGG  
TGCTTTATGTACCGTGTGTGCGTGTATGTGTGTATCTATACAAGTTTGTGACGTTTGGCATGACTGTT  
TGTTTGTCTCGAAACCAATAAACTCAAAGTTT

&gt;DEX0360\_016.nt.1

10 TCAGGCGGGGCTGTCCCCAGCAGTCCGTGTTGTGATGGTGCCAGATCCACACGTTCTGTCAACTTTG  
AGAAGCTTCAAGGTTAATCCTGTATCATTTCCATCTTGATCCCCACGTTTGGCTCACTTCTTGAAAG  
GAGTGAAAAGGGAACAGGGCTGGTGTGTAGGGCAGTGACCCAGCCTGCAGTTGTGACGAGCCACCATGGC  
AAAGGGGTCCCAGAGTGGCCGCTTGGCTTCTCCAAAGTTGCCGTGGTCTATGTATGTCCAGGAGAGCATG  
TAGTCCTTGTGAAGGCCCCACACTGTGTGTGCGTTTCATGGGACAAAAGTTGAGAACTGTCACTTCCAAC  
15 GTAAGATCTCAAAGCACTTGAGAAGAGGAAACCAAGTTGTATAGAGAAATCTAGATGTACTTGGGGTTGGG  
GTTTGGCTGAGTTGATGGGCCATGTGAGGGGGGCACACAGGCACAGTGGAGGAAGAACCTCCAAAGAG  
TGCGGCCTGGCCTGCCAACCTCTCTCCAAAGCCCCAGCCTCTGCCAGCTCTGGCCAGGCCCCACTGAGAA  
ATGGCTGACTCCAGCTTCTGTCTGCGCCCTCCACTGGCCTTCACTCATCCCTGTTTGGACTGACTGTCC  
CTGCCATGGCCTGCAGACTTCTTATCCTGCCCTTGTGTGTCATGTCCCTGAGTCACTGGGGTGACGCCCT  
20 TGCTCTGGCCCTCTGTCCCCAGCTCATCTGCCCCACGTGGACATCCAGCTAAAGTATTTTGACCTCGGG  
CTCCCCAAACCGTGACCAGACTGATGACCAGGTCACCATTGACTCTGCAGTGGCCACCCAGAGTACAGTG  
TGGCTGTCAAGTGTGCCACCATCACCCCTGATGAGGCCGTGTGGAAGAGTTCAAGCTGAAGAAGATGTG  
GAAAAGTCCCAATGGAATATCCGGAACATCCTGGGGGGGACTGTCTTCCGGGAGCCCATCATCTGCAAA  
AACATCCCAACGCTAGTCCCTGGCTGGACCAAGCCCATCACCATTTGGCAGGCACGCCCATGGCGACCACT  
25 ACAAGGCCACAGACTTTGTGGCAGACCGGCCCGGCACTTTCAAAATGGTCTTCACCCCAAAAGATGGCAG  
TGGTGTCAAGGAGTGGGAAGGTACAACCTTCCCCGAGCGCGGTGGGCATGGGCATGTACAACACCGAC  
GAGTCCATCTCAGGTTTTTGGCGCACAGCTGCTTCCAGTATGCCATCCAGAAGAAATGGCCGCTGTACATGA  
GCACCAAGAACACCATACTGAAAGCCTACGATGGGCGTTTCAAGGACATCTTCCAGGAGATCTTTGACAA  
GCATTATAAGACCGACTTCGACAAGAATAGATCTGGTATGAGCACCAGGCTCATTGATGACATGGTGGCT  
30 CAGGTCTCAAGTCTTCCGGTGGCTTTGTGTGGGCTTGCAGGCTTCAAGAACTATGACGGAGATGTGCAGTCAGACA  
TCCTGGCCACAGGCTTTGGCTCCCTTGGCCTGATGACGTCCGTCTGGTCTGCCCTGATGGGAAGACGAT  
TGAGGCTGAGGCCGCTCATGGGACCGTCAACCGCCACTATCGGGAGCACCAGAAGGGCCGGCCACCAGC  
ACCAACCCCATCGCCAGCATCTTTGCCTGGACACGTGGCCTGGAGCACCAGGGGAAGCTGGATGGGAACC  
AAGACCTCATCAGGTTTGGCCAGATGCTGGAGAAGGTGTGCGTGGAGACGGTGGAGAGTGGAGCCATGAC  
35 CAAGGACCTGGCGGGCTGCATTACGGCCCTCAGCAATGTGAAGCTGAACGAGCACTTCTGAACACCAG  
GACTTCTCTGACACCATCAAGAGCAACCTGGACAGAGCCCTGGGCAGGCAGTAGGGGGAGGCGCCACCCA  
TGGCTGCAGTGGAGGGGCCAGGGCTGAGCCGGCGGGTCTCTGAGCGCGGCAGAGGGTGGAGCTCACAG  
CCCTCTCTGGAGGGCTTTCTAGGGGATGTTTTTTTATAAGCCAGATGTTTTTAAAGCATATGTGTGTT  
TCCCCATATGGTGAAGTGGAGCAGGAGTGGCTTTTACCTCAGCCAGTCAAGTATGTTTGCATACACTGT  
40 AATTTATATTGCCCTTGGAAACACATGGTGCCATATTTAGCTACTAAAAAGCTCTTCACAAAA

&gt;DEX0360\_016.nt.2

GGCAGGAGAATTGGCAGACTCCAGAGCCCCACACATTTGCACTCTAGACTCTACTGCCTTCCTCATGAAGA  
ATTTTAGGACCCCCGTCTGGCTGTGTTGTTGCTTGGGGTTCAAATTTCTGGTTGAAAGATGGCGGCTGCAG  
45 TGGGACCACTATTATCTCTGTCTCACAGAGTTCAAGCTGAAGAAGATGTGGAAGATGCCAATGGAAT  
ATCCGGAAACATCCTGGGGGGGACTGTCTCCGGGAGCCCATCATCTGCAAAAACATCCACGCTTAGTCC  
CTGGCTGGACCAAGCCCATCACCATTTGGCAGGCACGCCCATGGCGACCAGGTAGGCCAGGGTGGAGAGGG  
GATCCACTGACCTGGGCACCCCCGACTGGAGCTCCTCGCCTAGCCATCCTCTTGTCTCTGCAGTACAAG  
GCCACAGACTTTTGTGGCAGACCGGGCCGGCACTTCAAATGGTCTTCAACCCAAAAGATGGCAGTGGTG  
50 TCAAGGAGTGGGAAGTGTACAACCTCCCGCAGGCGGCGTGGGCATGGGCATGTACAACACCGACGAGTC  
CATCTCAGGTTTTTGGCGCACAGCTGCTTCCAGTATGCCATCCAGAAGAAATGGCCGCTGTACATGAGACC  
AAGAACCACATACTGAAAGCCTACGATGGGCGTTTCAAGGACATCTTCCAGGAGATCTTTGACAAGCACT  
ATAAGACCGACTTCGACAAGAATAAGATCTGGTATGAGCACCAGGCTCATTGATGACATGGTGGCTCAGGT  
CCTCAAGTCTTCCGGTGGCTTTGTGTGGGCTTGCAGAACTATGACGGAGATGTGCAGTCAGACATCTTG  
55 GCCCAGGGCTTTGGCTCCCTTGGCCTGATGACGCTCCGTCCTGGTCTGCCCTGATGGGAAGACGATTGAGG  
CTGAGGCGGCTCATGGGACCGTCAACCGCCTACTATCGGGAGCACCAGAAGGGCCGGCCACAGCACCA  
CCCCATCGCCAGCATCTTTGCCCTGGACACGTGGCCTGGAGCACCAGGGGAAGCTGGATGGGAACCAAGAC  
CTCATCAGGTTTGGCCAGATGCTGGAGAAGGTGTGCGTGGAGACGGTGGAGAGTGGAGCCATGACCAAGG  
ACCTGGCGGGCTGCATTACGGGCTCAGCAATGTGAAGCTGAACGAGCACTTCTGAAACACCAGGACTT  
60 CCTCGACACCATCAAGAGCAACCTGGACAGAGCCCTGGGCAGGCAGTAGGGGGAGGCGCCACCCATGGCT

DEX-0360

177

PATENT

GCAGTGGAGGGGCCAGGGCTGAGCCGGCGGGTCCCTCTGAGCGCGGCAGAGGGTGAACCTCACAGCCCCCT  
CTCTGGAGGCCCTTTCTAGGGGATGTTTTTTTATAAGCCAGATGTTTTTAAAGCATATGTGTGTTTCCCC  
TCATGGTGACGTGAGGCAGGAGCAGTGCGTTTTTACCTCAGCCAGTCAGTATGTTTTGCATACTGTAATTT  
ATATTGCCCTTGGAACACATGGTGCCATATTTAGCTACTAAAAAGCTCTTCACAAAA

5

&gt;DEX0360\_016.nt.3

CCAAAAAAGGCGGTGTTTTACAAAGCAAAGTTGAGAGGGAGAGGCTGGGCCAGCAGAAACAT  
CGTGTGCACTGCACGGAGGCTGGTGTAAACAGTCGCGTGGGCGGCGGGTACCGTTCCCTGGAGAGCTGG  
GCCTTGCCCTGGGAGGTGGGAGGTGGCGGCAATCGCCAGGCTAGGGCACCACGCCAGGGCCCTGTCTCT  
CCCCCTGCAGTCCATCTCAGGTTTTGCGGCACAGCTGCTTCCAGTATGCCATCCAGAAGAAATGGCCGCTG  
TACATGAGCACCAGAACACCATACTGAAAGCCTACGATGGGCGTTTTCAAGGACATCTTCCAGGAGATCT  
TTGACAAGTAAAGCCTCATCCATGTACTCTGTGGCCTTTCTTCCCTTCCCCCATGCTGTTCCCATCCTA  
CCCTGGGAAGGTCGCTATTAGAGTGCAATTTGGCTCAGCTCCGAGGCTCAGGGAGGGATCCCCAACCTGTG  
AGCCTTCTGCCCTCTCCCCATAACAGACCTTTTTACTCCAGGCACTATAAGACCGACTTCGACAAGAAT  
AAGATCTGGTATGAGCACCAGGCTCATTGATGACATGGTGGCTCAGGTCCTCAAGTCTTCGGGTGGCTTTG  
TGTGGGCTGCAAGAACTATGACGGAGATGTGAGTCAGACATCTTGGCCAGGGCTTGGCTCCCTTGG  
CCTGATGACGTCCTGCTGGTCTGCCCTGATGGGAAGACGATTGAGGCTGAGGCGCTCATGGGACCGTC  
ACCCGCCACTATCGGGAGCACCAGAAGGGCGGGCCACCAGCACCACCCCATCGCCAGCATCTTTGCCCT  
GGACACGTGGCCTGGAGCACCAGGAGGCTGGATGGGAACCAAGACCTCATCAGGTTTGGCCAGATGCT  
GGAGAAGGTGTGCTGGAGACGGTGGAGAGTGGAGCATGACCAAGGACCTGGCGGGCTGCATTACGGC  
CTCAGCAATGTGAAGCTGAACGAGCACTTCTGAACACCACGGACTTCTCGACACCATCAAGAGCAACC  
TGGACAGAGCCCTGGGCAGGCAGTAGGGGAGGCGCCACCCATGGCTGCAGTGGAGGGGCCAGGGCTGAG  
CCGGCGGGTCTCTCTGAGCGCGGCAGAGGGTGAACCTCACAGCCCTCTCTGGAGGCTTTCTAGGGGAT  
GTTTTTTTATAAGCCAGATGTTTTTAAAGCATATGTGTGTTTCCCTCATGGTGACGTGAGGCAGGAGC  
AGTGCGTTTTTACCTCAGCCAGTCAGTATGTTTTGCATACTGTAATTTATATTGCCCTTGGAACACATGGT  
GCCATATTTAGCTACTAAAAAGCTCTTCACAAAA

10

15

20

25

&gt;DEX0360\_016.nt.4

ACCCTCCAGTGCCCTCCAGCCCTGTGCTGGGCGCTGGAGACCCACAGGAGGGTGAAGAGACCTGGAACAG  
TCCCTGTCTCCAGTTGACGCTGGGGAGGCTGAGTAGAGCCACGAACATATGGCAGCTACAATATTGGG  
TTGTAGAGGGCAGCAGGGCTCAGCTGGGTGGCCCCAGGAGAGGCGAGGCCCTGAGAGAAAGGCTTTCTAC  
CCTCCAGGCTTTGGCTCCCTTGGCTGATGACGTCCTGCTGGTCTGCCCTGATGGGAAGACGATTGAGG  
CTGAGGCGCTCATGGGACCGTCACCCGCCACTATCGGGAGCACCAGAAGGGCGGGCCACCAGCACCAG  
CCCCATCGCCAGCATCTTTGCCCTGGACACGTGGCCTGGAGCACCAGGGGGAAGCTGGATGGGAACCAAGAC  
CTCATCAGGTTTGGCCAGATGCTGGAGAAGGTGCGCTGGAGACGGTGGAGAGTGGAGCCATGACCAAGG  
ACCTGGCGGGCTGCATTACGGCCTCAGCAATGTGAAGCTGAACGAGCACTTCTGAAACACCAGGACTT  
CCTCGACACCATCAAGAGCAACCTGGACAGAGCCCTGGGCAGGCAGTAGGGGGAGGCGCCACCCATGGCT  
CAGTGGAGGGGCCAGGGCTGAGCCGGCGGGTCTCTGAGCGCGGCAGAGGGTGAACCTCACAGCCCTCT  
CTCTGGAGGCTTTCTAGGGGATGTTTTTTATAAGCCAGATGTTTTTAAAGCATATGTGTGTTTCCCC  
TCATGGTGACGTGAGGCAGGAGCAGTGCGTTTTTACCTCAGCCAGTCAGTATGTTTTGCATACTGTAATTT  
ATATTGCCCTTGGAACACATGGTGCCATATTTAGCTACTAAAAAGCTCTTCACAAAA

30

35

40

&gt;DEX0360\_016.nt.5

TGCCCCGCGGGCCAGCGCCCGAGGCCAGCGTTAGCGTTAGCCCGCGGCCAGGCAGCCGGGAGGAGCG  
GCGCGCGCTCGGACCTCTCCCGCCCTGCTCGTTTCGCTCTCCAGCTTGGGATGGCCGGCTACCTGCGGGT  
GTGCGCTCGCTCTGCAGAGCCTCAGGCTCGCGCCGGCCTGGGCGCCGGCGGCCCTGACAGCCCCACCT  
CGCAAGAGCAGCCGCGGCCCACTATGCCGACAAAAGGATCAAGGTGGCGAAGCCCGTGGTGGAGATGGA  
TGGTGTATGAGATGACCCGTATTATCTGGCAGTTTCATCAAGGAGAAGTGTGAAGCTGAACGAGCACTTCT  
GAACACCACGGACTTCTCGACACCATCAAGAGCAACCTGGACAGAGCCCTGGGCAGGCAGTAGGGGGAG  
GCGCCACCCATGGCTGCAGTGGAGGGGCCAGGCTGAGCCGGCGGGTCTCTGAGCGCGGCAGAGGGT  
AGCCTCACAGCCCCCTCTCTGGAGGCTTTCTAGGGGATGTTTTTTATAAGCCAGATGTTTTTAAAGCA  
TATGTGTGTTTTCCCCCTCATGGTGACGTGAGGCAGGAGCAGTGCGTTTTTACCTCAGCCAGTCAGTATGTTT  
TGCATACTGTAATTTATATTGCCCTTGGAACACATGGTGCCATATTTAGCTACTAAAAAGCTCTTCACAA  
AATTGTCTGCTGTGTTTGTCCCTGAGGGGAGGAGGTAGTGGGACCTGAGGCAGAGGCCCTGCTAGAGCT  
GGCAGGTTCCCTGGGGCAGACCAGAGCACTCAGGAAGGGGCTGCCACGGCAGGGAAGGGACAGGCAG  
CCCTGGGAGCCCGCATTCACAGGGGCCACTGCGGAGTTCTCGGACACTCAGGGCACAGGCCCTGTGGGT  
TCCCTGGAATTTCTAGCATGATCCAGTTTCTGTGTCCAGTTCTCCATTCTGAGAGTCAATCAGTTCCGT  
ATAGGTGTGATGATTTTTTTCTTCGTTGGTTTTAACCTTCTAAACATCTCCAGGCCACTTTCTTAGCC  
TTTTTCTAGGTACTAAAAAGAGGTCCTACCCACACCTGCCCTCACACTTCTCCTTTCAAGGCTGCCTGAG  
TTTGGAGGGGCTGGGTGTGTGTGAACAAGGGCCCTGCATTGTCTAGGCCTGCAGTTCCAGGCTTGGGT

45

50

55

60

DEX-0360

178

PATENT

TCACCTTTCACCATGCAATTGGCAAACTAGAAAAGTAAGCTTGTGACAAATTGTTCTCGGCCGGGCACAGT  
GGCGCACGCCCTATAATCCCTGTACTTTGGGAGGCTGAGGTGGGTGGATCACTTGAGGCCAGGAGTTCCGAG  
ACCAGCCTGGCCAACATGGTGAAACCCCATCTCTACTCAAAATACAAAATTAGCCAGGCGTGGTGATGC  
GCACCTGCAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAAAATGGCTTGAACCTGGGAGGCAGAGGTTGC  
5 AGTGAGCCGAGACTGCACCCTGCACCTCCAGCCTGGGTGACAGAGCAAGACTCTGTCTCAAAAAAAAAA  
AAAAAAA

&gt;DEX0360\_017.nt.1

10 ACACTGGGTTTCGAGTTCCTCAACCTCAGGTCATCTGCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAGG  
CGTGAGCCACCGTGCCCTGGCCGTAAAGGTATTATTTTAAAGGTTAGCTCACCTAAGACTTCCGCAGCTGA  
GGGCAGTAACAAGATAGGCATGATGCACAGAGCCATGTGGGGATTCCAGACCCCTCTGTTGCATAGTTT  
CCCAGTTGAATTTGACTCTTCTCCATTTATCTCATTTTTCTGGATAGGTCTACCTGCAAGTCGGATTT  
CCCAGGTTATTTGTTGGAGATGAGCGGCAGCAATACCCTTGGTGATTGGGCAGGTTGTAGTGATGTCCAG  
15 TTAGCTCAGCGTTTGGCTCAGGCGAATGAAATTGTCTATCTCTGGAACCTGCTGGATGCTTTGCAAGCAGT  
ATATGTTTGAAGTGGCAATCATGAGGGAGGATGAAGCTGTGAAGATTGATGAAGGCCAGCCTATAGAGTA  
TGTAATCTGAATTCCGTACGATGACTCTGGTTTTGGTCAGCCTAGAGTTCCACAGGACAGCGTGGATGTTG  
CATTTGTGTCATCTTATCCAGGAGGCTGCCTTATACATCTCCACAGTCATTGAGAAAGGGGGCGGCCAGC  
TGAGTCGGATCTTTATGTTTGAGAAAGGCTGCATGTTCTCTGTGTTTTCGGCCCTTCTGGTGATAAGAA  
GCCAGACGAGTGTGCACATGCCCTGGAGAGCTCCTTCAGCATCTTCAGCTTCTGCTGGGAGAATCTTGCT  
20 AAGACCAACTGAGGAGGAAGGTGGGGCAGAGAGGAGCTTCTCAGGCCCCAGGGGCTCTTCAGGCAGGATC  
CCTAGATTTGTTTCCATCAGTATCACTAATGGACCAGTATTCTGTGGCGTGGTTGGAGCAGTAGCAAGAC  
ACGAATATACAGTTATTGGCCCCAAAGTGAGTCTTGCGGCCAGAATGATAACTGCTTATCCAGGTTTGGT  
GTCCTGTGATGAGGTAACATATCTAAGATCCATGCTACCTGCTTACAACCTCAAGAACTCCCAGAGAAA  
25 ATGATGAAAAACATCTCCAACCCAGGGAAGATATATGAATATCTTGGCCACAGAAGATGTATAATGTTTG  
GAAAAGACATTTGGCAAGAAAGAGAAACAAAATCACCCCTTTGTTAGGAGTGTAGCTCCTCTGCTCT  
CTCTACAGACTGGGAGAAAGAATTGGAAGCCTTCCAATGGCACAGCAAGGGTGTGTCACCAGAAGAAG  
GGACAAGCAGTTCTGTATGAAGGTGGAAGGCTATGGAAAAGCCAGCTGTTGGCTGAAATAAATCTTC  
TGGCACAGAAAGAGGGCATAGCTACCCCTTCACAGGTGCTTTGGAACCCACTTTATTTGTGAGGTCTTAT  
GCCAGGACCTTCTCTCTAAGGACGTGTGCTCTTTCATGTCTTACAAAAGGAGGAAGAGGAAACAGCAA  
30 GTGGGAACCCCTCTCAGCCAATGCCATGAAATCCATATGTATAGTATTTCTCCTGCCAATCAGGAA  
GGCCAGGAACCTTTATGTCTGCACAGTCAAGGATGATGTGAACCTGGATACAGTACTTCTCCTACCCCTTTT  
TGAAAGAAATAGCAGTAAGCCAACCTGGATCAACTGAGCCACAGGAACAGTTGCTGGTCAAGTGTGCTGC  
AATCATTGGTCACTCTTCCATATAGATTTGCTGCAGCACCTCCTGCTGGCTGGGATAAAAAATAAGCTA  
CTTCAGGTCTTGAGAGCTCTTGTGGATATACATGTGCTCTGCTGGTCTGACAAGAGCCAAGAGCTTCTCTG  
35 CTGAGCCCATATTATGCTTCTCTATCCAGATCATTCATGATGGAACCAAGAGACAAAGTTAGTA  
TGGTGGGTGAGCCTCTCTCTCAGGCTACAAGAAGAATTATCCCTACCACAACTGAGGTGTTGGAATTT  
GGAGTGCCTCTGCTACGGGCAGCTGCTTGGGAGCTCTGGCCCAAGGAACAACAGATAGCTCTGCACCTTG  
AATGTGCCTGCTTTCTCCAAGTTTTGGCCTGCCGCTGTGGGAGCTGCCATGGAGGAGACTTTGTCCCTT  
TCATCATTTTGCAGTTTGTCTACTAAGAATTTCAAGGGGACCTCTCGATTCTGTACTTACAGAGATACT  
40 GCTCAGTGTCAACACAGTGATCAGACAGAAATTTGACAGTGCCTTCTCCCAAGAACAGGAAGAGTT  
CCTAGATCAAGTGAAGAGGAAGCTGGCTCAGACCAGCCCTGAGAAAAGACCTGTTGACCACAAAGCCTTGT  
CACTGTAAGGATATCTGAAGTTAGTGCTCTTACCCCTCACCAGCATTGCTTGGTCTGTTGGAGAAACCA  
CCTGTGCATTTTATACCTGCTGGAGGCTGCGGCTGCCTGCTTGGACCTGTGAGATAATATATGGTCTG  
TTTCAACATGGGACGTATCACTTTAGCCAAAAAATTGGCTAGGAAAGCCCTTCGACTGCTGAAAAGGAAT  
45 TTCCCTTGACCTGGTTTGGTGTCTTTTCCAGACATTCCTGGAAAAGTATTGGCATTCTGTACCTGA  
GCCAACCTCCAACGACCCTAGTGAGAAGTTGTCTTACCTATGTGGAGCTCTCTCAGTTCTCCCAGAGT  
GTGGGCATCAAGGACAAGTGGCTGCACGTGTGAGCAGATGGCCATTGAGAAAAGCAGTTTATGTTGGTTCT  
CCAGGGAGGGGTTGTTGGCCACAGCTCAGCTCATGCAGGCCCTGGCCTACACCAAGCTCTGCTTGGTCA  
TCTTGACTTCTCCATCAAGCTGGGATTGCTGTGTCGGCCCTTTAGTGAGTGTCTGCGTTTCGTTCAAGTC  
50 TACGAGCACAGCCGTGTCTAACCTCTCAGACCAATGTGATGCTGGGGGTCCACTCCTCCTGGCCATGT  
GTACTGTAAGGAGTTCTCTCTCAATGTGTGACCTGCCCTGTCTATCACCAGTGGGTATCTGAGCTTAAG  
GCCTCTGTAATGAGATGTGAAAAGAGAGAATTGATGTCCCTGACTAACAGCATCAGACCTTTTGACACCT  
GCTTGACCAGGATTTGGATAAAAGGAGAATTCTGTCAGGAAAATAACTCTTAGAAAAGAACTTAGGAAT  
55 ACAGAGATTTGACAGAGTGGCTGATGTCAAGGAGAACAAAGGATGCAGAAAGAACTCAAGATGTATGTATT  
AAAACAAAAGAACAAATAACCTGAAGGGACCATGATTCTGTTATGTATATAACAAAGGAATGCCCCAG  
ATTCTCCTTTAAAAGATATAATGTACATATTAGTATACTAGCCTTTATAGTTACTGCTATCTACATGTT  
TATCAAAATAAAAGACTATTTTTTCTAAACA

&gt;DEX0360\_017.nt.2

60 GGTAACCAATGTGCTTTTATAGATTGATGAAGGCCAGCCTATAGAGTATGTATCTGAATTCCGTACGAT

DEX-0360

179

PATENT

GACTCTGGTTTTTGGTCAGCCTAGAGTTCACAGGACAGCGTGGATGTTGCATTTGTGTCATCTTATCCAG  
 GAGGCTGCCTTATACATCTCCACAGTCATTGAGAAAGGGGGCGCCAGCTGAGTCGGATCTTTATGTTTG  
 AGAAAGGCTGCATGTTCTCTGTGTTTTTCGGCCTTCCTGGTGATAAGAAGCCAGACGAGTGTGCACATGC  
 CCTGGAGAGCTCCTTCAGCATCTTCAGCTTCTGCTGGGAGAACTCTGCTAAGACCAACTGAGGAGGAAGA  
 5 TCCCTAGATTTGTTTCCATCAGTATCACTAATGGACCAGTATTCTGTGGCGTGGTTGGAGCAGTAGCAAG  
 ACACGAATATACAGTTATTGGCCCAAAGTGAGTCTTGGCGCCAGAATGATAACTGCTTATCCAGGTTTG  
 GTGTCTGTGATGAGGTAACATATCTAAGATCCATGCTACCTGCTTACAACCTTCAAGAACTCCCAGAGA  
 AAATGATGAAAAACATCTCCAACCCAGGGAAGATATGAATATCTTGGCCACAGAAGATGTATAATGTT  
 TGGAAAAAGACATTGGCAAGAAAGAGAAACAAAATCACCCTTGTGTAGGAGTGTAGGTGCTCCCTGT  
 10 CTCTCTACAGACTGGGAGAAAGAATTGGAAGCCTTCCAATGGCACAGCAAGGGTGTTCACACCAGAAGA  
 AGGGACAAGCAGTCTGTATGAAGGTGGAAAAGGCTATGGAAAAAGCCAGCTGTTGGCTGAAATAAACTT  
 TCTGGCACAGAAAGAGGGCATAGCTACCTTTCACAGGTGCTTGGAAACCCACTTTATTGTGAGGTCTT  
 ATGCCAGGACCTTCTCTCTAAGGACGTGTGCTCTTTCATGTCTTACAAAAGGAGGAAGAGGAAAACAGC  
 AAGTGGGAAACCTCTCAGCCAATGCCATGAATCCATAATGTATAGTATTCTCTGCCAATCTGTGAGG  
 15 AAGGCCAGGAACCTTATGTCTGCACAGTCAAGGATGATGTGAACCTTGGATACAGTACTTCTCTACCTT  
 TTTGAAAGAAATAGCAGTAAGCCAACTGGATCAACTGAGCCCAGAGGAACAGTTGCTGGTCAAGTGTGCT  
 GCAATCATTGGTCACTCTCTCCATATAGATTTGCTGTCAGCACCTCTGCTGGCTGGGATAAAAATAAGC  
 TACTTCAGGTCTTGAGAGCTCTTGTGGATATACATGTGCTCTGCTGGTCTGACAAGAGCCAAGAGCTTCC  
 TGCTGAGCCCATATTAAATGCCCTTCTCTATGACATCATTTGATGGAACCAAGAGAAAGCAAGTTA  
 20 GATGGTGGGTGAGCCTCTCTCTCAGGCTACAAGAAGAATTATCCCTACCACAACTGAGGTGTTGGAAT  
 TTTGGAGTGCCTCTGCTACGGGCAGCTGCTTGGGAGCTCTGGCCCAAGGAACAACAGATAGCTCTGCACCT  
 TGAATGTGCCTGCTTTCTCCAAGTTTGGCCTGCCGCTGTGGGAGCTGCCATGGAGGAGACTTTGTCCCC  
 TTTTCATCATTTTGCAGTTTGTCTTACTAAGAATTCCAAGGGGACCTCTCGATTCTGTACTTACAGAGATA  
 CTGGCTCAGTGCTAACACAAGTGATCACAGAAAAATTCAGACTGCTTCTCCCCAAGAACAGAGGAAGAG  
 25 TTCCCTAGATCAAGTGAAGAGGAAGCTGGCTCAGACCAGCCCTGAGAAAGACCTGTTGACCACAAAGCCTT  
 GTCAGTGAAGGATATCCTGAAGTTAGTGCTCTTACCCCTCACCCAGCATGTGCTTGGTCGTTGGAGAAAC  
 CACCTGTGCATTTTATTACCTGCTGGAGGCTGCGGCTGCTGCTTGGACCTGTGAGATAATTATATGGTC  
 TGTTTCAACATGGGACGTATCACTTTAGCCAAAAAATTTGGCTAGGAAAGCCCTTCGACTGCTGAAAAGGA  
 30 ATTTCCCTTGGACCTGGTTTGGTGTCTCTTTCCAGACATTTCTGGAAGATTTGGCATCTCTTACCCT  
 GAGCCAACTCCAACGACCCCTAGTGAGAAGTTGTCTCTACCTATGTGGAGCTCTCTCAGTTCTCCCAGA  
 GTGTGGGCATCAAGGACAAGTGGCTGCACTGTGAGCAGATGGCCATTACAGAAAAGCAGTTTATGTTGGTT  
 CTCCAGGAGGGGTTGTTGGCCACAGCTCAGCTCATGCAGGCCCTGGCCTACACCAAGCTCTGCCCTGGT  
 CATCTTGACTTCTCCATCAAGCTGGGATGCTGTGTCGGCCCTTTAGTGAGTGTCTGCGTTTCGTTCAAG  
 35 TCTACGACACAGCCGTGTTCTAACCTCTCAGAGCAATGTCTGTCATGCTGGGGGTCCACTCTCCCTGGCCAT  
 GTGGTAATGTCTTACTCAAGGGCTGTGGAAAAGGATAGACATTTATGTCAATTAAGCTGTCTCTCCCCAC  
 CAGACAGGACTTTTGAACCTCTCTAACCAACTTTTAAAGACCATTACCTCCCATACCTCCCATCTTAT  
 TAGAAGGGCTCTTGTCTTTAACAGGTTTGGCCTATAGGTCAAGGGTTACGTTTAGGGTTACATTTAAC  
 TGCTAGAGTAACCCATAGCAAGGCTGAATATAATTGGTCTCCTTTTAAGTTTCCTTGTATGTGAGTTAGT  
 40 AGCCTTGGTCACTTTCTAGCATCACAATTCTGATTGTCCATGAGGTCTTAGAGCCTTAAAGAAGTGATGA  
 TTTTAAAGCAAAAGTCATGGTGGGTAAGCAGCGGATATTGCTGCAAGCTGTACTCTTTTCTCCAGGTTT  
 GCCCAGGAATCACAGTGGGACCTGTTTAAGCACTATTTCTCCAACGCTTGCAGTTGGTGAAAAGAACCAA  
 TGCCTCGCTATTGGTGCACATGGCTTTGTCCGATTCTTAGAATGCCATGTGTTAATGTTACAGAAAAATG  
 CCAGAGGGTATCTTCATGCATATTCCTCTAGAGCTTTCACAGCCAAACCTTGGGTACCTGTTTCTCAGC  
 45 TGTCTTTTGACTAACACCTGATTCACTTAGTTACTTACCTATGGTGTCTTTCTACCACCTGCATCTCTTC  
 CTTTTTTCCCTTTTACTGGCTCTGTTTCCCTTTACTCTTTGAATCCTTTGTTTCTCCACCTAGAAAGTTT  
 CTACCTACCTTATGTATCCTTCCCGATATTATTGCATCTAGTTCTGGACTGGGTTTCTTAACCTTCCACC  
 TTTGGCAGCTGCTACCCAGTATCATTAATAATTAACATTTAGCCTTGCTCAATGGACCTGTAGTCTATG  
 GTTCAGTCTATAATTTGATACAGCTCCCTCCAGCCCTTCTGAGTCTAAAACACATTTCCAATTCCTCTGTT  
 50 TTCCAGGCTTATTTTGGCATCAGTAACCTCTCTGTTTCCCCAGCCATGAGTGAATATGCTGAATGAGG  
 ACCTTTGTAAGTTCTGATGAAGTAGCATGTTAGGAGAATGAAGCACTAATCCCAGAGCTAATGGACCTTC  
 CTTTCTCTTCTCAGTACTGTAAGGAGTTCTTCTCTCAATGTGTGACCTGCCCTGTCTATCACCAGTGGGTAT  
 CTGAGCTTAAAGGCTCTGTAATGAGATGTGAAAAGAGAGAATTGATGTCCCTGACTAACAGCATCAGACC  
 TTTTGACACCTGCTTGACCAGGATTTGGATAAAAGGAGAAATTTCTGCAGGAAAAAATACTCTTAGAAAAGA  
 55 AACTTAGGAATACAGAGATTTGACAGAGTGGCTGATGTCAAGGAGAAACAAGGATGCAGAGAAACTCAAG  
 ATGTATGTATTAAAAACAAAGAACAATAACCTGAAGGGACCATGATTCTGTATTGTATATAACACAAGG  
 AAATGCCCCAGATTCTCTTTTAAAGATATAATGTACATATTAAGTATACTAGCCTTTATAGTTACTGCT  
 ATCTACATGTTTATCAAAATAAAAGACTATTTTTTTCTAAAAACA

&gt;DEX0360\_017.nt.3

60 ACACTGGGTTTCGAGTTCCTCAACCTCAGGTTCATCTGCCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAGG

60 >DEX0360\_017.nt.4

DEX-0360

181

PATENT

ACACTGGGTTTCGAGTTCCCAACCTCAGGTCATCTGCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAGG  
CGTGAGCCACCGTGCCGTGGCCGTAAGGTATTATTTTAAAGGTTAGCTCACCTAAGACTTCCGCAGCTGA  
GGGCAGTAACAAGATAGGCATGATGCACAGAGCCATGTGGGGATTCCAGACCCCTCCTGTTGCATAGTTT  
CCCAGTTGAATTTGACTCTTCTCCATTTATCTCATTTTCTTCTGGATAGGTCTACCTGCAAGTCGGATTT  
5 CCCAGTTTATTGTTGGAGATGAGCGGCAGCAATACCTCTTGGTGATTGGGCAGGTTGTAGTGATGTCCAG  
TTAGCTCAGCGTTTGGCTCAGGCGAATGAAATTGTCTTATCCTTGAAGTCTGATGCTTGTGAAGCAGT  
ATATGTTTGAAGTGGCAATCATGAGGGAGGATGAAGCTGTGAAGATTGATGAAGGCCAGCTATAGAGTA  
TGTATCTGAATTCCTACGATGACTCTGGTTTGGTTCAGCCTAGAGTTCCACAGGACAGCGTGGATGTTG  
CATTGTGTCTATCTTATCCAGGAGGCTGCCTTATACATCTCCACAGTCATTGAGAAAGGGGGCGGCCAGC  
10 TGAGTCGGATCTTTATGTTTGAAGAGGCTGCATGTTCTCTGTGTTTTCGGCCCTTCTGTTGGGAGAATCTTGCT  
GCCAGACGAGTGTGCACATGCCCTGGAGAGCTCCTTCAGCATCTTCAGCTTCTGCTGGGAGAATCTTGCT  
AAGACCAACTGAGGAGGAAGGTGGGGCAGAGAGGAGCTTCTCAGGCCCCAGGGGCTCTTCAGGCAGGATC  
CCTAGATTTGTTTCCATCAGTATCACTAATGGACCAGTATTTCTGTGGCGTGGTTGGAGCAGTAGCAAGAC  
ACGAATATACAGTTATTGGCCCCAAAGTGAGTCTTGGCGCCAGAATGATAACTGCTTATCCAGGTTTGGT  
15 GTCCTGTGATGAGGTAACATATCTAAGATCCATGCTACCTGCTTACAACCTTCAAGAACTCCCAGAGAAA  
ATGATGAAAAACATCTCCAACCCAGGGAAGATATATGAATATCTTGGCCACAGAAGATGTATAATGTTTG  
GAAAAAGACATTTGGCAAGAAAGAGAAACAAAATCACCCCTTGTAGGAGTGTAGTGCTCCTGCTCT  
CTCTACAGACTGGGAGAAAGAATTGGAAGCCTTCCAAATGGCACAGCAAGGGTGTTCACCAGAGAAG  
GGACAAGCAGTTCTGTATGAAGGTGGAAAAGGCTATGGAAAAGCCAGCTGTTGGCTGAAATAAATTTTC  
20 TGGCACAGAAAGAGGCGATAGCTACCCCTTCACAGGTGCTTTGGAACCCACTTTATTGTGAGGTCTTAT  
GCCAGGACCTTCTCTAAGGACGTGTGTCTCTTTCATGTCTTACAAAGGAGGAAGGAAAACAGCAA  
GTGGGAAACCTCTCAGCCAATGCCATGAAATCCATAATGTATAGTATTTCTCCTGCCAACTCTGAGGAA  
GGCCAGGAACCTTATGTCTGCACAGTCAAGGATGATGTGAACCTGGATACAGTACTTCTCTACCCCTTTT  
TGAAGAAAATAGCAGTAAGCCAACTGGATCAACTGAGCCCAGAGGAACAGTTGCTGGTCAAGTGTGCTGC  
25 AATCATTTGCTCACTCCTTCCATATAGATTGCTGCAGCACCTCCTGCCCTGGCTGGGATAAAAATAAGCTA  
CTTCAGGTCTTGAGAGCTCTTGTGGATATACATGTGCTCTGCTGGTCTGACAAGAGCCAAGAGCTTCTCTG  
CTGAGCCCATATTAATGCCTTCTCTATCGACATCATTTGATGGAACCAAAGAGAAGAAGACAAAGTTAGA  
TGGTGGGTTCAGCCTCTCTCTCAGGCTACAAGAAGAATTATCCCTACCACAACTGAGGTGTTGGAATTT  
30 GAGTGGCTCTGCTACGGGACGTGCTTGGGAGCTCTGGCCCAAGGAACACAGATAGCTCTGCACCTTG  
AATGTGCCCTGCTTTTCTCCAAGTTTGGCCTGCGCTGTGGGAGCTGCCATGGAGGAGACTTTGTCCCTT  
TCATCATTTTGCAGTTTGTCTACTAAGAATTCCAAGGGGACCTCTCGATTCTGTACTACAGAGATACT  
GGCTCAGTGCTAACACAAGTGATCACAGAAAAATGCAGCTGCCCTTCTCCCAAGAACAGAGGAAGGTT  
CCTAGATCAAGTGAAGAGGAAGCTGGCTCAGACCAGCCCTGAGAAAGACCTGTTGACCACAAAGCCTTGT  
35 CACTGTAAGGATATCCTGAAGTTAGTGCTCTTACCCCTCACCCAGCATTGCTTGGTGGTGGAGAAACCA  
CCTGTGCATTTTATTACCTGCTGGAGGCTGCGGCTGCCTGCTTGGACCTGTGAGATAATTATATGGTCTG  
TTTCAACATGGGACGTATCACTTTAGCCAAAAAATTGGCTAGGAAAGCCCTTCGACTGCTGAAAGGAAT  
TTCCCTTGGACCTGGTTTGGTGTCTTTTCCAGACATTCCTGGAAAAGTATTGGCATTCTGTACCCTGA  
GCCAACCTCCAAACGACCCTAGTGAGAAGTTGTCTCTACCTATGTGGAGCTCTCTCAGTTCTCCAGAGT  
40 GTGGGCATCAAGGACAAGTGGCTGCAGTGTGAGCAGATGGCCATTTCAGAAAAGCAGTTTATGTTGGTTCT  
CCAGGGAGGGGTGTTGGCCACAGCTCAGCTCAGCCAGGCTTGGCCCTACACCAAGCTCTGCCTTGGTCA  
TCTTGACTTCTCATCAAGCTGGGATTGCTGTGTGCGGCCCTTATGTAGTGTCTGCGTTTCGTTCAAGTC  
TACGAGCACAGCCGTGTTCTAACCTCTCAGAGCAATGTCTGCTGGGGTCCACTCCTCCCTGGCCATGT  
GGTTTGGCCAGGAATCACAGTGGGACCTGTTAAGCACTATTTCTCCAACGCTTGCAAGTTGGTGAAGA  
45 ACCAATGCCTCGCTATTTGGTGCATATTCCTCTAGAGCTTACAGCCAAACCTTGGAGTCTGTAATG  
AAATGCCAGAGGGTATCTTTCATGCATATTCCTCTAGAGCTTACAGCCAAACCTTGGAGTCTGTAAGGA  
GTTCTTCTCTCAATGTGTGACCTGCCCTGTCTATCACCAGTGGGTATCTGAGCTTAAAGGCTCTGTAATG  
AGATGTGAAAAGAGAGAATTGATGTCCCTGACTAACAGCATCAGACCTTTTGACACCTGCTTGACCAGGA  
TTTGGATAAAAGGAGAATTTCTGCAGGAAAATAACTTTAGAAAAGAACTTAGGAATACAGAGATTTGA  
50 CAGAGTGGCTGATGTCAAGGAGAACAAAGGATGCAGAAGAACTCAAGATGTATGTTTAAAAACAAAGAA  
CAATAACCTGAAGGGACCATGATTCTGTATTGTATATAACACAAGGAAATGCCCCAGATTCTCCTTTAA  
AAGATATAATGTACATATTAAGTATACTAGCCTTTATAGTTACTGCTATCTACATGTTTATCAAAATAAA  
AGACTATTTTTTCTAAACA

>DEX0360\_017.nt.5

55 ACACTGGGTTTCGAGTTCCCAACCTCAGGTCATCTGCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAGG  
CGTGAGCCACCGTGCCGTGGCCGTAAGGTATTATTTTAAAGGTTAGCTCACCTAAGACTTCCGCAGCTGA  
GGGCAGTAACAAGATAGGCATGATGCACAGAGCCATGTGGGGATTCCAGACCCCTCCTGTTGCATAGTTT  
CCCAGTTGAATTTGACTCTTCTCCATTTATCTCATTTTCTTCTGGATAGGTCTACCTGCAAGTCGGATTT  
60 CCCAGTTTATTGTTGGAGATGAGCGGCAGCAATACCTCTTGGTGATTGGGCAGGTTGTAGTGATGTCCAG  
TTAGCTCAGCGTTTGGCTCAGGCGAATGAAATTGTCTTATCCTGGAAGTCTGATGCTTGTGAAGCAGT

DEX-0360

182

PATENT

ATATGTTTGAAGTGGCAATCATGAGGGAGGATGAAGCTGTGAAGATTGATGAAGGCCAGCCTATAGAGTA  
TGTATCTGAATCCGTACGATGACTCTGGTTTTGGTCAGCCTAGAGTTCACAGGACAGCGTGGATGTTG  
CATTTGTGTCATCTTATCCAGGAGGCTGCCCTTATACATCTCCACAGTCATTGAGAAAGGGGGCGCCAGC  
TGAGTCGGATCTTTATGTTTGAGAAAGGCTGCATGTTCCCTCTGTGTTTTCGGCCCTTCTGGTGATAAGAA  
5 GCCAGACGAGTGTGCACATGCCCTGGAGAGCTCCTTCAGCATCTTCAGCTTCGTCTGGGAGAATCTTGCT  
AAGACCAACTGAGGAGGAAGGTGGGGCAGAGAGGAGCTTCTCAGGCCCCAGGGGCTCTTCAGGCAGGATC  
CCTAGATTTGTTTCCATCAGTATCACTAATGGACCAGTATTCTGTGGCGTGGTTGGAGCAGTAGCAAGAC  
ACGAATATACAGTTATTGGCCCCAAAAGTGAGTCTTGGCGCCAGAATGATAACTGCTTATCCAGGTTTGGT  
10 GTCCGTGATGAGGTAAACATATCTAAGATCCATGCTACCTGCTTACAACCTCAAGAACTCCAGAGAAA  
ATGATGAAAAACATCTCCAACCCAGGGAAGATATATGAATATCTTGGCCACAGAAGATGTATAATGTTTG  
GAAAAAGACATTTGGCAAGAAAGAGAAAACAAAATCACCCTTTGTTAGGAGTGTAGGTGCTCCCTGTCT  
CTCTACAGACTGGGAGAAAGAAATTGGAAGCCTTCCAATGGCACAGCAAGGGTGTTCGACCAGAAGAAG  
GGACAAGCAGTTCTGTATGAAGGTGGAAGGCTATGGAAAAAGCCAGCTGTTGGCTGAAATAAACTTTC  
15 TGGCACAGAAAGAAAGGCGATAGCTACCCTTCACAGGTGCTTTGGAACCCACTTTATGTGAGGTCTCTAT  
GCCAGGACCTTCTCTAAGGACGTGTGCTCTTTCATGTCTTACAAAAGGAGGAAGAGGAAAAACAGCAA  
GTGGGAAACCCCTCTCAGCCAATGCCATGAAATCCATAATGTATAGTATTTCTCTGCCAACTCTGAGGAA  
GGCCAGGAACTTTATGTCTGCACAGTCAAGGATGATGTGAACCTGGATACAGTACTTCTCTACCCTTTT  
TGAAAGAAATAGCAGTAAGCCAACCTGGATCAACTGAGCCCAGAGGAACAGTTGCTGGTCAAGTGTGCTGC  
AATCATTTGGTCACTCCTTCCATATAGATTTGCTGCAGCACCTCCTGCCTGGGTAAAGGATGAGGCTA  
20 TTTCAAGTCTTGAGAGCTCTTGTGGATATACATGTGCTCTGTCTGGTCTGACAAGAGCCAAGAGCTTCCTG  
CTGAGCCCATATTAATGCCTTCTCTATCGACATCATTGATGGAACCAAGAGAAGACAAAGTTAGA  
TGGTGGGTGAGCCTCTCTCTCAGGCTACAAGAAGAAATATCCCTACCACAACTGAGGTGTTGGAATTT  
GGAGTGCCCTCTGCTACGGGCAGCTGCTTGGGAGCTCTGGCCCAAGGAACAACAGATAGCTCTGCACCTTG  
AATGTGCTGCTTTCTCCAAGTTTGGCCTGCCGCTGTGGGAGCTGCCATGGAGGACTTTGTGCCCTT  
25 TCATCATTTTGCAGTTTGTCTACTAAGAATTCCAAGGGGACCTCTCGATTCTGTACTTACAGAGATACT  
GGCTCAGTGCTAACACAAGTGATCACAGAAAATTGCAGCTGCCCTTCTCCCAAGAACAGAGGAAGAGTT  
CCTAGATCAAGTGAAGAGGAAGCTGGCTCAGACCAGCCCTGAGAAAGACCTGTTGACCACAAAGCCTTGT  
CACTGTAAGGATATCCTGAAGTTAGTGCTCTTACCCTCACCAGCATTGCTTGGTCTTGGAGAAACCA  
CCTGTGCATTTTATTACCTGCTGGAGGCTGCGGCTGCCGCTGCTTGGACCTGTGATGATGATGTTGCTG  
30 TTTCAACATGGGACGTATCACTTTAGCCAAAAAATTGGCTAGGAAAGCCCTTCGACTGCTGAAAAGGAAT  
TTCCCTTGGACCTGGTTTGGTGTCTTTTCCAGACATTCTCTGAAAAGTATTGGCATTCTGTACCCTGA  
GCCAACCTCCAAACGACCCTAGTGAGAAGTTGTCTCTACCTATGTGGAGCTCTCTCAGTTCTCCCAGAGT  
GTGGGCATCAAGGACAAGTGGCTGCATGTGAGCAGATGGCCATTGAGAAAGCAGTTTATGTTGGTTCT  
CCAGGGAGGGGTGTTTGGCCACAGCTCAGCTCATGAGGCCCTGGCCTACACCAAGCTCTGCCCTGGTCA  
35 TCTTGACTTCTCCATCAAGCTGGGATTGTCTGTCTGGGCCCTTAGTGAGTGTCTGCGTTTCTGTTCAAGTC  
TAGGAGCACAGCCGTGTTCTAACCTCTCAGAGCAATGTATGCTGGGGGTCCACTCCTCCCTGGCCATGT  
GGTAATGTCTTACTCAAGGGCTGTGGAAGGATAGACATTTATGTCAATTAAGCTGTCTCTCCCCACCA  
GACAGGACTTTTGAACCTCTCTAACCAACTTTTAAAGACCATTACCTCCCCATCCTTATTA  
GAAGGCTCTTGTCTTTAACAGGTTTGGCTTATAGGTTCAAGGGTTACGTTTAGGGTTACATTTAACTG  
40 CTAGAGTAACCCATAGCAAGGCTGAATATAATTGGTCTCCTTTTAAAGTTTCTTGTATGTGAGTTAGTAG  
CCTTGGTCACTTTCTAGCATCACAATTCGATGTCTCATGAGGCTTAGAGCCTTAAAGAAAGTGATGATT  
TTAAGCAAAAGTCATGGTGGGTAAGCAGCGGATATTGCTGCAAGCTGTTACTCTTTTCTCCAGGTTTGC  
CCAGGAATCACAGTGGGACCTGTTTAAAGCACTATTCTTCCAACGCTTGCAAGTGGTGAAGAACCAATG  
CCTCGCTATTTGGTGACATGGCTTTGTCCGATTTCTAGAAATGCCATGTGTTAATGTTACAGAAAATGCC  
45 AGAGGGTATCTTCATGCATATTCCTCTAGAGCTTCACAGCCAAACCCTTGAGGTACCTGTTTCTCAGCTG  
TCCTTTGACTAACACCTGATTCACTTAGTTCTACCTATGGTGTCTTTCTACCACCTGCATCTCTTCTCT  
TTTTTCCCTTTTACTGCTCTGTTTCCCTTTACTCTTTGAATCCTTTGTTTCTCCACCTAGAAAGTTCT  
ACCTACCTTATGTATCCTTCCCAGATATTATGCATCTAGTTCTGGACTGGGTTTCTTAACCTTCCACCTT  
TGCCAGCTGCTACCCAGTATCATTAATAATTAACATTAGCCTTGCTCAATGGACCTGTAGTCTATGGT  
50 TCAGTCTATAATTTGATACAGCTCCCTCCAGCCCTTCTGAGTCTAAAACACATTCCAATTCCTCTGTTTT  
CCAGGCTTATTTTGGCATCAGTAACCTCCTTCTGTTCCCCCAGCCATGAGTGAATATGCTGAATGAGGAC  
CTTTGTAAGTTCTGATGAAGTAGCATGTTAGGAGAATGAAGCAC'AAATCCAGAGCTAATGGACCTTCTCT  
TTCCCTTTCAGTACTGTAAGGAGTTCTTCTCAATGTGTGACCTGCCCTGTCTATCACCAGTGGGTATCT  
GAGCTTAAGGCCTCTGTAAAGAGATGTGAAAAGAGAGCAATTTGATGTCTCCCTGACTAACAGCATCAGACTT  
55 TTGACACCTGCTTGACCAGGATTTGGATAAAAGGAGAATTTCTGCAGGAAAAAACTCTTAGAAAAGAAA  
CTTAGGAATACAGAGTAAGCATTTCTTCTGGAAGCCTTGTGTGAGAGACATAAAGACAGTCTCAGATTC  
TTACTCACAAGCAGTCAAAGCTGCACCTCTGAAATAAAAAGGGACACACAGATGTAAGGAGTTAGTCTCT  
TGCTCCAGAGGTAAGTATAATCCTCTTCTAGTGTAGGCCCTGCCCTGGACAGATAGGAATCCCTTCTAT  
TGTTAAACAGCAATTTCTCAGCTTCTCTCAGCTCTTTGTTTTCAGTATTGGTAACTCTTTGGCATAGAAA  
60 GTTCTTCCCTTGCTTTTAGCCAAAGCAGTTGGGTGTTTCTTGAAGTAACGGATGGTCACTAAGGAGAG

DEX-0360

183

PATENT

5 AAAAAGGTCTTAGAAGTCACAATGTAATGTCTATGAAGGTGAATGATAAGATTAGGCAAGAAAAGGAGAG  
 GAAAGAATATAGTTCCTTTCCCTCAGAGGCCGTGCAAATCTTCTTTCCCATGGCTGCTATTTTAACTTTGTAA  
 TTGCTGAGGACATCTTTGTATTTGTGACATCTTTGTGTTCCTTCTTTTCAGGATTTGACAGAGTGGCTG  
 ATGTCAAGGAGAACAAGGATGCAGAAGAACTCAAGATGTATGTATTAAAAACAAAAGAACATAACCTGA  
 AGGGACCATTGATCTGTATTGTATATAACACAAGGAAATGCCCCAGATTCTCCTTTAAAGATATAATG  
 TACATATTAAGTATACTAGCCTTTATAGTTACTGCTATCTACATGTTTATCAAAATAAAAGACTATTTTT  
 TTCTAAAACA

>DEX0360\_017.nt.6

10 ACACCTGGGTTCGAGTTCCCAACCTCAGGTCATCTGCCCCGTCTCAGCCTCCCAAAGTGCTGGGATTACAGG  
 CGTGAGCCACCGTGCCTGGCCGTAAGGTATTATTTTTTAAAGGTAGCTCACCTAAGACTTCCCGCAGCTGA  
 GGGCAGTAACAAGATAGGCATGATGCACAGAGCCATGTGGGGATTCCAGACCCCTCCTGTTCATAGTTT  
 CCCAGTTGAATTTGACTCTTCTCCATTTATCTCATTTTTTTCTGGATAGGTCTACCTGCAAGTCGGATTT  
 CCCAGGTTATTGTTGGAGATGAGCGGCAGCAATACCTCTTGGTGATTGGGCAGGTTGTAGTGATGTCCAG  
 15 TTAGCTCAGCGTTTGGCTCAGGCGAATGAAATTGTCTATCTCTGGAAGTGTGATGAAGCCAGCCTATAGAGTA  
 ATATGTTTGAAGTGGCAATCATGAGGGAGGATGAAGCTGTGAAGATTGATGAAGCCAGCCTATAGAGTA  
 TGTATCTGAATTCGATGACTCTGGTTTTGGTTCAGCCTAGAGTTCCACAGGACAGCGTGGATGTTG  
 CATTTGTGTATCTTATCCAGGAGGCTGCCTTATACATCTCCACAGTCATTGAGAAAGGGGGCGGCCAGC  
 TGAGTCGGATCTTTATGTTTGAAGAGGCTGCATGTTCTCTGTGTTTTCGGCCCTTCCTGGTGATAAGAA  
 20 GGCAGACGAGTGTGCACATGCCCTGGAGAGCTCCTTCAGCATCTTCAGCTTCTGCTGGGAGAATCTTGCT  
 AAGACCAACTGAGGAGGAAGGTGGGGCAGAGAGGAGCTTCTCAGGCCCCAGGGGCTCTTCAGGCAGGATC  
 CCTAGATTGTTTCCATCAGTATCACTAATGGACCAGTATTCTGTGGCGTGGTTGGAGCAGTAGCAAGAC  
 ACGAATATACAGTTATTGGCCCAAAAGTGAGTCTTGGCGCCAGAATGATAACTGCTTATCCAGGTTTGGT  
 TCTCTGTGATGAGGTAACATATCTAAGATCCATGCTACCTGCTTACAACCTCAAGAACTCCCAGAGAAA  
 25 ATGATGAAAAACATCTCCAACCCAGGGAAGATATGAATATCTTGGCCACAGAAGATGTATAATGTTTG  
 GAAAAAGACATTTGGCAAGAAAGAGAAACAAAAATCACCTTTGTTAGGAGTGTAGGTGCTCCCTGTCT  
 CTCTACAGACTGGGAGAAAGAATTGGAAGCCTTCCAAATGGCACAGCAAGGGTGTGTCACCAAGAAAG  
 GGACAAGCAGTTCTGTATGAAGGTGGAAAAGGCTATGGAAAAGCCAGCTGTTGGCTGAAATAAACTTTC  
 TGGCACAGAAAGAAGGGCATAGCTACCCCTTCACAGGTGCTTTGGAAACCCACTTTATTGTGAGGTCTTAT  
 30 GCCAGGACCTTCTCTTAAGGACGTGTTGCTCTTTCATGTCTTACAAAAGGAGGAAGAGGAAAACAGCAA  
 GTGGGAAACCCCTCTCAGCCAATGCCATGAAATCCATAATGTATAGTATTTCTCTGCAACTCTGAGGAA  
 GGCCAGGAACCTTATGTCTGCACAGTCAAGGATGATGTGAAGTTGGATACAGTACTTCTCTACCCCTTTT  
 TGAAAGAAATAGCAGTAAGCCAACCTGGATCAACTGAGCCCAGAGGAACAGTTGCTGGTCAAGTGTGCTGC  
 AATCATTTGGTCACTCCTTCCATATAGATTTGCTGCAGCACCTCCTGCTGGCTGGGATAAAAAATAAGCTA  
 35 CTTCAGGTCTTGAGAGCTCTTGTTGATATACATGTGCTCTGCTGGTCTGACAAGAGCCAAGAGCTTCTCTG  
 CTGAGCCCATATTAATGCCCTTCTCTATCGACATCATGTGATGGAACCAAGAGAAGAAGACAAGCTTAGA  
 TGGTGGGTGAGCCTCTCTCTCAGGCTACAAGAAGAATTATCCCTACCACAAACTGAGGTGTTGGAATTT  
 GGAGTGCCTCTGTACGGGCAGCTGCTTGGGAGCTCTGGCCCAAGGAACAACAGATAGCTCTGCACCTTG  
 AATGTGCTGCTTTCTCCAAGTTTGGCCCTGCCGCTGTGGGAGCTGCCATGGAGGAGACTTTGTCCCTTT  
 40 TCATCATTTTGGCAGTTTGTCTACTAAGAATTCCAAGGGGACCTCTCGATTCTGTACTTACAGAGATACT  
 GGCTCAGTGCTAACACAAGTGATCACAGAAAAATTCAGCTGCCTTCTCCCAAGAACAGAGGAAGAGTT  
 CCTAGATCAAGTGAAGAGGAAGCTGGCTCAGACCAGCCCTGAGAAAGACCTGTTGACCACAAAGCCTTGT  
 CACTGTAAGGATATCCTGAAGTTAGTGCTCTTACCCCTCACCCAGCATTGCTTGGTCTGTTGAGAAACCA  
 CCTGTGCATTTTATTACCTGCTGGAGGCTGCGGCTGCCTGCTTGGACCTGTGAGATAATTATATGGTCTG  
 45 TTTCAACATGGGACGTATCACTTTAGCCAAAAATTTGGCTAGGAAAGCCCTTCGACTGCTGAAAAGGAAT  
 TTCCCTTGGACCTGGTTTGGTGTCTTTTCCAGACATTTCCCTGGAAAAGTATTGGCATTCCTGTACCCCTGA  
 GCCAACCTCCAAACGACCCTAGTGAGAAGTTGTCTCTACCTATGTGGAGCTCTCTCAGTTCTCCAGAGT  
 GTGGGCATCAAGGACAAGTGGCTGCACTGTGAGCAGATGGCCATTGAGAAAAGCAGTTTATGTTGGTTCT  
 CCAGGGAGGGTTGTTGGCCACAGCTCAGCTCATGCAGGCCCTGGCCCTACACCAAGCTCTGCCTTGGTCA  
 50 TCTTGACTTCTCCATCAAGCTGGGATTTGCTGTGTGCGCCCTTTAGTGAGTGTCTGCGTTTCGTTCAAGTC  
 TACGAGCACAGCCGTGTTCTAACCTCTCAGAGCAATGTCTGCTGGGGTCCACTCCTCCCTGGCCATGT  
 GGTAAATGTCTTACTCAAGGGCTGTGGAAGAGGATAGACATTTATGTCAATTAAGCTGTCTCTCCCACT  
 GACAGGACTTTTGAACCTCTCTAACCAACTTTTAAAGACCATTACCTCCCATACCCCTCCCATCTTATTA  
 GAAGGGCTCTGTCTTTTAAACAGGTTTGGCCCTATAGGTCAAGGGTTACGTTTAGGGTTACATTTAACTG  
 55 CTAGAGTAACCCATAGCAAGGCTGAATATAATTGGTCTCCTTTTAAAGTTTCTTGTATGTGAGTTAGTAG  
 CCTTGGTCACTTTCTAGCATCACAATTTCTGATTGTTCCATGAGGTCTTAGAGCCTTAAAGAAGTGTATGAT  
 TTAAGCAAAAGTCATGGTGGGTAAGCAGCGGATATTGCTGCAAGCTGTTACTCTTTTCTCCAGGTTTGC  
 CCAGGAATCACAGTGGGACCTGTTTAAAGCACTATTCTCCAACGCTTGCAGTTGGTGAAGAAACCAATG  
 CCTCGCTATTTGGTGCACATGGCTTTGTCCGATTCTTAGAATGCCATGTGTTAATGTTACAGAAAATGCC  
 60 AGAGGTATCTTCATGCATATCTCTTAGAGCTTCACAGCCAAACCCCTTGAGGTACCTGTTTCTCAGCTG

DEX-0360

184

PATENT

TCCTTTGACTAACACCTGATTCACTTAGTTCTACCTATGGTGCTCTTTCTACCACCTGCATCTCTTCCT  
TTTTTCCCTTTTACTGGCTCTGTTTCCCTTTACTCTTTGAATCCTTTGTTTCTCCACCTAGAAAGTTTCT  
ACCTACCTTATGTATCCTTCCCGATATTATTGCATCTAGTTCTGGACTGGGTTTCTTAACCTTTCCACCTT  
TGCCAGCTGCTACCCAGTATCATTAAATATTAACATTTAGCCTTGCTCAATGGACCTGTAGTCTATGGT  
5 TCAGTCTATAAATTTGATACAGCTCCCTCCAGCCCTTCTGAGTCTAAACACATTTCCAATTCCTCTGTTTT  
CCAGGCTTATTTTGGCATCAGTAACCTCTTCCCTGTTCCCTCCAGCCATGAGTGAATATGCTGAATGAGGAC  
CTTTGTAAGTTCTGATGAAGTAGCATGTTAGGAGAATGAAGCACTAATCCAGAGCTAATGGACCTTCTCT  
TTCTTTTCAGTACTGTAAGGAGTTCTTCTCTCAATGTGTGACCTGCCCTGTCTATCACCAGTGGGTATCT  
10 GAGCTTAAGGCCTCTGTAATGAGATGTGAAAAGAGAGAATTGATGTCCCTGACTAACAGCATCAGACCTT  
TTGACACCTGCTTGACCAGGATTTGGATAAAAGGAGAATTTCTGCAGGAAAATAACTCTTAGAAAAGAAA  
CTTAGGAATACAGAGTAAGCATTCTTCCCTGGAAGCCTTGTTGTGAGAGACATAAAGACAGTCTCAGATTC  
TTACTCACAAGCAGTCAAAGGCTGCACCTCTGAAATAAAAGGGACACACAGATGTAAGGAGTTAGTCTCT  
TGCTCCAGAGGATTTGACAGAGTGGCTGATGTCAAGGAGAACAAGGATGCAGAAGAACTCAAGATGTAT  
GTATTAACAAAGAAACAATAACCTGAAGGGACCATGATTCTGTTATTGTATATAACACAAGGAAATGC  
15 CCCAGATTCTCTTTTAAAGATATAATGTACATATTAAGTATACTAGCCTTTATAGTTACTGCTATCTAC  
ATGTTTATCAAAATAAAGACTATTTTTTTCTAAACA

&gt;DEX0360\_018.nt.1

CTCCCTCCTCCTCCACTCTGCTCAGGTCCCTCTCACTCTTTTTTTTTTTTAAACCGCTACGCCACAGTCCC  
20 CGGGAGAATTCAGATCCCAACCGGGGCTTCCGGATTCTGTAGTGGCTTTGGCCTGTGTCTGGTCTGAGGA  
CGCCCGGAAGGCATTGCAGTGAAGCTAAGGGAAGGCTCTTGAGGGAGCCTCAGGAAGAGCAAAATGGAG  
GCCAGAGACTGGCAGGAGCGCGCCAGCGCAGGATTTAATCCCGACGAGCGGATTCCAGAGCCGTCTTATA  
TAAAGCTTCAGGAAGCGCCGTTCCGACGATGAGGTCGACACGCGAGAGGCGACCTCAAGAGCGGCGCGC  
CAGGGATCTGTGCGCAAGGGAGGACGGGAGGGAGCAGGTTCCGCATAATTCTGGCTCCAGGCTCTGTT  
25 TTGTTGGACCGAGCCACTGTATTTAGCTCACACAGGAGAATTCTGGCCCTGGGAAAATTGGTCTCAGCA  
TGCTGCCAAGCTTTCTCATGGACGTCAGCGAATCCCAACACTGTCTGGTCAAAGCCGTGCTGGAAGAAA  
CAAAACAGTTCTCCCTCGGTAGAACTGAGAGGGGATTGGTCCAGGGCCCCCGGATACCAAAATCCAGG  
TTGCTCAAGTCTCTCATAGAAAGTGGCGTAGTATTTGCACATAACTATGCACATCCTCCCGTGTACTTTA  
AATAGTCTCTAAATTAATCTGTAACACCTAATCCAGTGTAAATGCTATGTAAGTAATTGTTATACTGTTT  
30 TATATTTTACTATCTTTTGTGTACTTTTTTTTAAAGAAATTCATTGTTTAAATATTTTCCGCTTTG  
GGGAACCCCGGTATATGGAGGGCCTGCTACATAGAGAAGACTGAGGGATATTCTGTGCATCCGTTTCTAC  
GGATCCTCTAAATCGGCCCTTTGTTTTTTCAGCCAGGATTTAGTGCCAGCTGTGTCTTTGGAGGCCACCA  
TGGAGCTAGCAAAGTTTGTAAATCGGGTTTTTGCAAGAGGACTGTCTGCTCCATACTGGGAGTAGTTACC  
GCAAACGCCCCATGAAATTTGGTTGGGGTTTCTTACTGTTAGCATGTTTATTACTTTATCAGGGCTCTCTG  
35 TAGGAGAGTCTATGAGAAAATCTTCTGGTTTCTGCTGAAAGAATCGTGTGTTTGGTGGGGTTTTTTCCCG  
AAAAATATTATTTTTTAAAACTCTTCTGTGCCCTGTTTAAATCTCTCCCTTGGATCCACCTTCTGTGTGCT  
CATAAATCGTAAATCTGTATTCAGACTTCTGGACTCGAGACACGTAGATCCACCTGGTGGTTCTTCAGTC  
ATTTTAAAGCCCAAACTCAAATCTCCGAAATCAAATGTTTAACTTATAATCTCCAGGGTGTGACTC  
ACGGGGGATGAGGGGAGCAATCTCTCCCTCCCGCATAAAGCTGGTTCTCTGTCTGCTCATTGAACGG  
40 TTCCACTGCGCATCACAGCATCTACATGCCAAACCAACACCCAGCATTGGCAACAGATATCTTCCCTCT  
CCCTTGGCTGCTTCAGGACAGGGAAGAAACATGCTTGCCTTTTCTGACTCTTTAGTAACCTTGCCCGAA  
TCTATCACATTATTTTACATCTCTTACATCTTACTACTCCCCATCTTGGCTGTGTGTTCCCTACTGGC  
AGTGATTTTGTGTTATTCATTTTTGTAACTGACACTTAGTTCAAGTGTCATATAAGCTCAACAATAGT  
TTATAAAGGAAAAGTTCTGCCTTTGATTGCTTTTAAACACTATTAGAAAAGACATAACCAAAATGCAAC  
45 ATGATAAAACAACCGCAAACAAGGCTGAGAGAAGTGGTGATTCTGTTGTCTAGAGGGCACAGGACCTGG  
GCAGAATCAGAGATACGGTGTCTGTGCAGT

&gt;DEX0360\_019.nt.1

GCCTTTCCCAAGTGCTTTGTAATGAATAGAAATGGAACCAAAAAAACGTATACAGGCCTTCAGAAATA  
50 GTAATTGCTACTATTTTGTTCATTAAAGCCATAGTTCTGGCTATAATTTTATCAAATCACCAGCTATA  
TTCTACAGTGAAAGCAGGATTTCTAGAAAGTCTCACTGTTTATTTATGTACCATGTGCTATGATATATT  
TGGTTGAATTCATTGAAATTAGGGCTGGAAGTATTCAAGTAATTTCTTCTGCTGAAAAAATACAGATGTT  
TTGAGTTTAGGGCTGTTTTATCAAAGTCTAAAGAGCCTATCACTCTTCCATTGTAGACATTTTAAAT  
AATGACACTGATTTTAACTTTTAAAGTGTCTTTTTAGAACAGAGAGCCTGACTAGAACACAGCCCCCTCC  
55 AAAAAACCATGCTCAAATTTTACTATGGCAGCAATTCACAAAAGGGAACATGGGTTTAGAAAT  
ACAATGAAGTCATCAACCAAAAAACATCCCTATCCCTAAGAAGGTTATGATATAAAATGCCACAAGAA  
ATCTATGCTGCTTTAATCTGTCTTTTATTGCTTTGGAAAGGATGGCTATTACATTTTATGTTTGTGCT  
GAATACCTGAGCAGTTTCTCTCATCCATACTTATCCTTCACACATCAGAAGTCAGGATAGAATATGAATC  
ATTTTAAAACTTTTACAACCTCCAGAGCCATGTGCATAAGAAGCATTCAAAACCTGCCAAAACATACATT  
60 TTTTTTCAAATTTAAAGATACTCTATTTTTGTATTCAATAGCTCAACAACCTGTTGGTCCCCACTGATAAG

DEX-0360

185

PATENT

TGAAGTGGACAAGGAGACAAGTAATGGCATAAGTTGTTTTCCCAAAGTATGCCTGTTCAATAGCCATT  
GGATGTGGGAAATTTCTACATCTCTTAAATTTTACAGAAAATACATAGCCAGATAGTCTAGCAAAAAGTT  
CACCAAGTCCTAAATTGCTTATCCTTACTTCACTAAGTCATGAAATCATTTTAATGAAAAGAACATCACC  
TAGGTTTTGTGGTTTTCTTTTTTCTTATTTCATGGCTGAGTGAAAACAACATCTCTGTTTCTCCCTAGCA  
5 TCTGTGGACTATTTAATGTACCATTATTCCACACTCTATGGTCTTACTAAATACAAAATTGAACAAAA  
GCAGTAAAACAACCTGACTCTTACCCATATTATAAAATATAATCCAAGCCAGATTAGTCAACATCCATAA  
GATGAATCCAAGCTGAACCTGGGCTAGATTATTGAGTTTCAAGTTGGATTCACATCCCTATTTTATTAATAA  
CTTAGGAAAGAAGGCCCTTACAGACCATCAGTTAGCTGGAGCTAATAGAACCTACACTTCTAAAGTTCCGGC  
10 CTAGAATCAATGTGGCCTTAAAGCTGAAAAGAGCAGGAAAGAACAGTTTCTTCAATAATTTGTCCAC  
CCTGTCACTGGAGAAAATTTAAGAATTTGGGGGTGTTGGTAGTAAGTTAAACACAGCAGCTGTTTCATGGC  
AGAAATTATTCAATACATACCTTCTCTGAATATCTATAAACCAGCAAGGAAAGAAAACCAAGGGGTTTG  
TTCTCCTCCTTGGAGTTGACCTCATTCCAAGGCAGAGCTCAGGTCACAGGCACAGGGGCTGCGCCCAAGC  
TTGTCCGCAGCCTTATGCAGCTGTGGAGTCTGGAAGACTGTTGCAGGACTGCTGGCCTAGTCCAGAATG  
15 TCAGCCTCATTTCGATTTACTGGCTCTTGTGCTGTATGTCATGCTGACCTTATTGTTAAACACAGGTT  
TGTTTGCTTTTTTCCACTCATGGAGACATGGGAGAGGCATTATTTTAAGCTGGTTGAAAGCTTTAACC  
GATAAAGCATTTTTAGAGAAATGTGAATCAGGCAGCTAAGAAAGCATACTCTGTCCATTACGGTAAAGAA  
AATGCACAGATTATTAATCTGCACTGTGGCATTAGTGTCTGGTCAATATTCGGATAGATATGAATAAA  
ATATTTAAATGGTATTTGTAATAGTTTTCAGGACATATGCTATAGCTTATTTTTATTATCTTTTGAATTT  
20 GCTCTTAATACATCAAATCCTGATGTATTTCAATTTATCAGATATAAATTATTCTAAATGAAGCCCAGTTA  
AATGTTTTTGTCTTGTCACTTATATGTTAAGTTTCTGATCTCTTGTCTATGACGTTTACTAATCTGCAT  
TTTTACTGTTATGAATTTATTTAGACAGCAGTGTTTCAAGCTTTTTGCCACTAAAATACCTTTTATTT  
TCTCCTCCCCAGAAAAGTCTATACCTTGAAGTATCTATCCACCAAAGTGTACTTCTATTAAAGAAATAGT  
TATTGTGTTTTCTTAATGTTTTGTTATTTCAAAGACATATCAATGAAAGCTGCTGAGCAGCATGAATAACA  
25 ATTATATCCACAGATTTGATATATTTTGTGAGCCTTAACTTGATAGTATAAATGTCAATTGCTTTTTT  
AAATAATAGTTAGTCAATGGACTTCTATCAGTTTCTTCCCTAACTAGGTTAAGATCCAGAGCTTTGGGGT  
CATAATATATTACATACAATTAAGTTATCTTTTTCTAAGGGCTTTAAATTCATGAGAATAACCAAAAA  
GGTATGTGGAGAGTTAATACAAACATACCATATCTTGTGTTGAAACAGAGATGTGGCTCTGCTTGTCTCC  
ATAAGGTAGAAATACTTTCCAGAAATTTGCCTAACTAGTAAGCCCTGAATTTGCTATGATTAGGGATAGG  
30 AAGAGATTTTCACATGGCAGACTTTAGAATTTCTCACTTTAGCCAGTAAAGTATCTCCTTTTGATCTTAG  
TATTCTGTGTATTTTAACTTTTCTGAGTTGTGCATGTTTATAAGAAAATCAGCACAAGGGTTTAAAGTT  
AAAGCCTTTTACTGAAATTTGAAAAGAAACAGAGAAAATATCAAAGTTCTTTGTATTTTGAGAGGATTA  
AATATGATTTACAAAAGTTACATGGAGGGCTCTCTAAAACATTAAATTAATTATTTTTTGTGAAAAGTC  
TTACTTTAGGCATCATTTTATTCCTCAGCAACTAGCTGTGAAGCCTTTACTGTGCTGTATGCCAGTCACT  
35 CTGCTAGATTGTGGAGATTACCAGTGTTCCCGTCTTCTCCGAGCTTAGAGTTGGATGGGGAATAAAGACA  
GGTAAACAGATAGCTACAATATGTACTGTGAATGCTTATGCTGGAGGAAGTACAGGGAACCTATTGGAGC  
ACCTAAGAGGAGCACCTACCTTGAATTTAGGGGTTAGCAGAGGCATCCTGAAAAAAGTCAAAGCTAAGCC  
ACAACTATAAGCAGTTTAGGAATTAGCAGAACCTGCGTGGTGAGGAGATGCCAAAGGCAAGAGAGAAG  
AGTATTTCAAACAGGAGGGATTCCAAAGAGAGAGAGATATCCAAACACATTTGCACAAACCTGATGGG  
40 GAGAGAGAATGTGGGGTGGGGATGGATGATGAGACTGAAGAAGAAAGCCAGGTCTAGATAATCAGTGGCC  
TTGTACACCATGTTAAAGAGTGTAGACTTGAATTTCTGTTGTAACAGGAAAGCAGCACAATTCATAGAA  
ATTTTAGAAGACTCCCACTGGAATATGGAGAATAAAGTTGGAGATGACTAATCTGGAAGCAGGAGAAC  
ATTTTTGAGGAAGTTGCACTATTTTGGTGAAATGATGGTCATAAACATGAAGAATTGTAGGTGATCATG  
ACCTCCTCTCTAATTTTCCAGAAGGGTTTTGGAAGATATAACATAGGAACATTGACAGGACTGACGAAAG  
45 GAGATGAAATACACCATATAAATGTCAAACACAAGGCCAGATGTCTAATTTATTTTGTGTTTGA  
ATTACAAATTTTTTCATCAGGAAACCAAAACTACAAAACCTAGTTTCCCAAGTCCCAGAATTCTATCTG  
TCCAAACAATCTGTACCACTCCACCTATATCCCTACCTTTGCATGCTCTGTCCAACTCAAAGTCAAGGTC  
TATACACACGGGTAAAGACTAGAGCAGTTCAAGTTTCAGAAAATGAGAAAGAGGAACCTGAGTTGTGCTGAA  
CCCATACAAAATAAACACATTTCTTGTATAGATTCTTGGAACTTCGAGAGGAATTCACCTAACTCATAGG  
50 TATTTGATGGTATGAATCCATGGCTGGGCTCGGCTTTTAAAGCCTTATCTGGGATTCCTTCTATGGAA  
CCAAGTTCCATCAAAGCCCATTTAAAGCCTACATTAATAAACAATTTCTTGTGCTGATTTGATACAAATA  
ATGATGTATGATCAAATAATCAGATGCCATTATCAAGTGAATTAACAAATGGTATACCCACTCCAAAA  
AAAAAAGCTAAATTTCTCAGTAGAACATTGTGACTTCATGAGCCCTCCACAGCCTTGGAGCTGAGGAGG  
AGCACTGGTGAGCAGTAGGTTGAAGAGAAAACCTGGCGCTTAATAATCTATCCATGTTTTTTCATCTAAA  
55 AGAGCCTTCTTTTGGATTACCTTATTCAATTTCCATCAAGGAAATTTGTTAGTTCCACTAACCAGACAGC  
AGCTGGGAAGGCAGAAAGCTTACTGTATGTACATGCTGAGTGTGGGAAGGAGGTTCTTTCTCAGGTCCT  
CACTGGCCATACACAGTCCCTTGTGTTATGCTTATGCTCATAGACCCCGTGTCTATCATCTCATATTT  
AAGTCTTTGCTTGTGAATTTATCTATTTCTTTCAGCTTCAGCACTGCAGAGTGTGGGACTTTGCTAACT  
TCCATTTCTTGTGCTGGCTTAGCACATTTCTCATAGGCCAGCTCTTTTCTCATCTGGCCCTGCTGTGGAGT  
60 CACCTTGGCCCTTCAGGAGAGCCATGGCTTACCCTGCTGCTAAGCCTCCACTCAGCTGCCACCACACT  
AAATCCAAGCTTCTCTAAGATGTTGCAGACTTTACAGGCAAGCATAAAAGGCTTGATCTTCTCGGACTTC

DEX-0360

186

PATENT

CCTTTACTTGTCTGAATCTCACCTCCTTCAACTTTTCAGTCTCAGAATGTAGGCATTTGTCTCTTTGCCC  
 TACATCTTCCTTCTTCTGAATCATGAAAGCCTCTCACTTCTCTTGCTATGTGTGGAGGCCTCTGTCTAG-  
 GTTTTAGAATGAGTTCTCATCTAGTCCTAGTAGCTTTTGATGCTTAAGTCCACCTTTTAAGGATACCTTT  
 5 GAGATTTAGACCATGTTTTTCGCTTGAGAAAGCCCTAATCTCCAGACTTGCCCTTTCTGTGGATTTCAAAG  
 ACCAACTGAGGAAGTCAAAGCTGAATGTTGACTTTCTTTGAACATTTCCGCTATAACAATTTCAATTCT  
 CCTCAGAGCAATATGCCCTGCCCTCAACTGACCAGGAGAAAGGTCCAGTGCCAAAGAGAAAAACACAAAGA  
 TTAATTTATTTTCAAGTTGAGCACATACTTTCAAAGTGGTTTGGGTATTCATATGAGGTTTTCTGTCAAGAGG  
 GTGAGACTCTTCATCTATCCATGTGTGCCCTGACAGTTCTCTGGCACTGGCTGGTAACAGATGCAAACT  
 GTAAAAATTAAAGTGATCATGTATTTTAACGATATCATCACATACTTATTTTCTATGTAATGTTTTAAATT  
 10 TCCCTAACATACTTTGACTGTTTTGCACATGTAGATATTCACATTTTTTGTGTTGAAGTTGATGCAA  
 TCTTTCAAAGTTATCTACCCCGTTGCTTATTAGTAAACTAGTGTAAATACTTGGCAAGAGATGCAGGGAA  
 TCTTTCTCATGACTCACGCCCTATTTAGTTATTAATGCTACTACCCCTATTTTGAGTAAGTAGTAGGTCCT  
 TAAGTACATTTGTCCAGAGTTATACTTTTAAAGATATTTAGCCCCATATACTTCTTGAATCTAAAGTCATA  
 CACCTTGCTCCTCATTTCTGAGTGGGAAAGACATTTGAGAGTATGTTGACAATTGTTCTGAAGGTTTTTG  
 15 CCAAGAAGGTGAAACTGTCTTTTCATCTGTGTATGCTTACCTGGGCTGGGCTGGGTCCCTGGCAGTGATGGGGTGACA  
 ATGCAAAGCTGTAAAACTAGGTGCTAGTGGGCACCTAATATCATCATCATATATCTTATTTCAAGCTAA  
 TATGCAAATCCCATCTCTGTTTTTAACTAAGTGTAGATTTTCAGAGAAAATATTTTGTGGTTTCATATAA  
 GAAAAAGTCTACTCAGCTTGACAAGTGTATGTTAAATTGGCTGGTGGTTTGAATGAATCATCTTC  
 ACATAATGTTTTCTTTAAAAATATTGTGAATTTAACTCTAATTTCTTGTATTCTGTGTGATAATAAAGAA  
 20 TAAACTAATTTCTATATCTCTCTTTATT

&gt;DEX0360\_020.nt.1

AGGTGCGGGCGCCAGCCAGGGCAGGCGGGCAGGGCTGAGGGCGCGGATCCCCAACAGGCCCCGCGCA  
 CCTTCATGACGGTTTCAGAACTGCTCCGAGGCAAACCTCAGACAACTCTCTGAGGACAACGTCCGCCCCCGC  
 25 GCGCGCCGCCCTCTCTTCGGGGCCAGGACCGGGTCTCGGTCTATTTCGAAAGGGACGGAGAATACATTT  
 TCCCGGCATGCCATCGCGCACTCCGGGCTGCGACGGAAGAGCTCTTCGCGAGCCGAACCTATTCCCGC  
 TGCGCTACTGGGACCACGTTCTGTAGTCTGTAGCGGAGGCTGGTATGGCGCCCGGTTTCCGGTTTTCCGG  
 CGACGGAAGTGACGCTATCACGGCGCGCAAGGCGTCACTCGAGGAGTCAAGGCGCAATGAATCGTGTCT  
 30 TTGTGTGCCCCGCGCGGGCCGTCGCGGGCGCTGAGGCTCATAGGCTGGGCTTCCCGAAGCCTTCATC  
 CGTTGCCCCGTTTCCCGGATCGGGCCCACTTGCCTGCGCGGAGGAAGGACGACCCCTGACCGCCCCATTGA  
 GTTTTCTCCAGCAAAGCCAACCCCTCACCGCTGGTCCGTGGGCTATACCATGGGAAAGGACATCAGCGG  
 CCCTGGTGGAAGGTGCTGCCCTCAGCTGCTTCTCGTGGCGCTGATCATCTGGTGCTACCTGAGGGAGG  
 AGACGAGGCGGACAGTGGTTGAGACAGGTGTGGGAGAGGTGCCAGAGCCAGTGATCGTTCTGAGGA  
 GCCTGAGACTCCAGCTGCCCTACAGAGCGAGAATTTGACGGGGTGCCCGCTGGGGCTGGCAGGAAGGGAGC  
 35 CGACAGCCGCCCTTCGGATTGTGATGTACGTTTTGCCGTGACTGTCTTGGCTATGCGTGCGTCCCTCAGCA  
 CTGAAGGACTTGGCTGGTGGATGGGGCACTTGGCTATGCTGATTTCGCGTGAAGGCGGAGCAGAACTCAG  
 CAGATCGGAACTGCTCCTCGCTGGCTCTTGTATGTCCAAGGATTCCATCGGCAAGACTTCTCAGATCCT  
 TGGGGAAGGTTTCAGTTGCACTGTATGCTGTTGGATTGCAAGTCTTTGTATAACATAATCATGTTTCC  
 40 AAAGCACTTCTGGTGACACTTGTCTATCCAGTGTTAGTTTGCAGGTAATTTGCTTTCTGAGATAGAATATC  
 TGGCAGAAGTGTGAAACTGTATGTCATGCTGCGGCTGTGCAAGGAACACTTCCACATGTGAGTTTACA  
 CAACAACAAATGAAATAAATTTTAATTTTATAATATGGGATTAGATGATTCCC

&gt;DEX0360\_021.nt.1

TTTCTCGCTGCAGTCATCCAATAGCCAAGATACACGGCTAGGTGATTTGCGAGCGGGAGTTAGGTGTCC  
 45 TCTTGGCGCCTGACCAGAGTCGGGAAATTCAGCTCCTCTTGAGTAGTCCCTTCCCCGAGTTGCCCCCGA  
 GGTATGCGGGGTCACTCGCTGCTCGATGTTCCCTCCGAAGGGTCGGACAAGGCTCCGGAGCCCTGTAGCT  
 GCCCTCCCTAGGAGCCCCGGGTCTTCACTGGCCGAGGTGCCACCCCGCAGCATTCCTGGGAGTGGTAGTT  
 TTCTTCTTTCAGGTTTCATTCCTGGCTGGCCAGTGCCCAAGACTGGCGGAGACTACGATTCCAGACGCCCCA  
 50 AGCGAGTCGCGGTCACGTGGCCGCAAGGACGCTGGGCGGGTGGGCGGGGGCCGGCAGGTGCTCCGCAGC  
 CGTCTGTGCCACCCAGAGCCGGCGGGCCGTAGGTCCCGGAGACCCTGCTATGGTGCGTGCGGGCGCCG  
 TGGGGGCTCATCTCCCCGCGTCCGGCTTGGATATCTTCGGGGACCTGAAGAAGATGAACAAGCGCCAGCT  
 CTATTACCAGGTTTTAACTTCGCCATGATCGTGTCTTCTGCACTCATGATATGGAAAGGCTTGTAGCTG  
 CTCACAGGCAGTGAGAGCCCCATCGTGGTGGTGTGAGTGGCAGTATGGAGCCGGCCTTTACAGAGGAG  
 55 ACCTCCTGTTCTCACAATTTCCGGGAAGACCAATCAGAGCTGAGATAATGGAGACATCAAATTTCTG  
 ACTAAAGGAGATAATAATGAAGTTGATGATAGAGGCTGTACAAAGAAGGCCAGAACTGGCTGGAAAAGA  
 AGGACGTGGTGGGAAGAGCAAGAGGGTTTTTACCATATGTTGGTATGGTACCATTAATGAATGACTA  
 TCCAAAATTCAGTATGCTCTTTTGGCTGTAATGGGTGCATATGTGTTACTAAACGTGAATCCTAAAAT  
 GAGAAGCAGTTCTGGGACCAGATTGAAATGAATTTCTGTGAAAAAGAGAAAACTAATATATTTGAGAT  
 60 GTTCCATTTTCTGTATAAAAGGGAACAGTGTGGAGATGTTTTTGTCTTGTCCAAATAAAGATTCCACAG  
 TAAA

DEX-0360

187

PATENT

&gt;DEX0360\_022.nt.1

5 AGACTGGCTGAGGAAGGAATTTGGGGCAAGAGACAAAAATACAGCAACAGGAGAAAAGACTCACGGAGGT  
AGAAAGAGACTGGGAGACAAAAAGAGAGAAACACATCAAAAAGATGTGGAGAGAGATAGAAACAGAGCCA  
GGCAGAGTAAAAAGAGGCTGAGAGAGATGAGTTAGAGATGTGCAGCTGGACATGTAGAGGACAGAGAAAA  
GCAAAATTTGGGCCAGATAATGTCAAAGACCTTCAGGCCAAACGGAGGGCAGCCAGGGAGACAGGCGTGTGCA  
CAGCAAGGCTACAGCCTCTCCTGACCCCTGCCCTCCCCTCCCCTACTGTGGACGCAGGAGAAATCCAACCCA  
CACAGTGAATTCAGCCACCAGAACCTCATCATCAACACGCTCTCGCTCTTCTTTGCTGGCACTGAGACCA  
CCAGCACCACCTCTCCGCTACGGCTTCCTGCTCATGCTCAAATACCCTCATGTGCGAGAGAGAGTCTACAA  
GGAGATTGAACAGGTGGTTGGCCACATCGCCCTCCAGCGCTTGATGACCGAGCCAAAATGCCATACACA  
10 GAGGCAGTCATCCGTGAGATTTCAGAGATTTGCTGACCTTCTCCCCATGGGTGTGCCCCACATTGTACCCC  
AACACACCAGCTTCTGAGGGTACACCATCCCCAAGGACACGGAAGTATTTCTCATCCTGAGCACTGCTCT  
CCGTGACCCACACTACTTTGAAAAACAGACGCTTCAATCCTGACCACCTTCTGGATGCCAATGGGGCA  
CTGAAAAAGAATGAAGCTTTTATCCCCCTCTCCTTAGGGAAGCGGATTTGTCTTGGTGAAGGCATTGCCC  
15 GTGCGGAAATTTCTCTCTTCTCACCACCATCTCCAGAACTTCTCCGTGGCCAGCCCCGTGGCTCCTGA  
AGACATCGATCTGACACCCAGGAGTGTGGTGTGGCAAAAATACCCCAACATACCAGACTCTGCTTCTG  
CCCCGCTGAAGGGGCTGAGGGAAGGGGGTCAAAGGATTCCAGGGTCATTGAGTGTCCCTGCTGTAGA  
TAATGGCTCTGACTCCCTGCAACTTCTGCTCTGAGAGACCTGCTGCAAGCCAGCTTCTTCTCCCTTCCA  
TGCCACCACTGTCTGAGGTGCGAGTGCAATGAGTGGAGGAGTGAATTTGAAAATTATAATATACA  
20 AAATTATATATATATATATTTTGAGACAGAGTCTCACTCAGTTGCCAGGCTGGAGTGCAGTGGCGTGATCT  
CGGCTCACTGCAACCTCCACCCCGGGGTTCAAGAAATCTCCTGCTCAGCCTCCCTAGTAGCTGGGAT  
TACAGGTGTGTGCTACCATGCCTGGCTAATTTTGTATTTTGTAGTAGAGATGGGGTTTACCCTGTGTGGC  
CAGGCTGATCTCAAACCTCCGAACTCAAGTGATTCACCCACCTTAGCCTCCCAAAGTGTGGGATTACAG  
GTGTGAGTCAACATGCCCGGCCATGTATATATATATATTTTAAAAATTAGATGAAATTCACATAAAATAA  
25 AATTAGCCATTTTAAAGTGTAATTTTAGTGGTGTGTGGTTTCAATTCACAAAGCTGTACAACCACCAT  
CTAGTTCCAAACATTTTCTTTTCTGAGACGGAGTCTCACTCTGTCACCCAGGTTGAGTTTCACTGGT  
CTTGAACTCCTGATGTGAGGTGATTCTCCTAGTTCCAAATGTTTTTCAATATCTCTCCCCAACAAAACCC  
ATACCTATCAAGCTGTCACTCCCCATACCCCATCTCTTTTTTCACTCTCAGCCCCGTGCAATCTGGTTTTT  
GTCCTTATGGACTTACCAATTTCTGAATATTTCTTATAAACAGAAATCACAAATATTTGATTTTTTTTTTA  
30 AAACCTAAGCCTTGGCTCTGCTCCCCAGGCTGGAGTGTGTGGCGTGATTTTGGTTCACTGCAACCTCCGCC  
TTCCAAGTTCAAGAGATTCTCCTGCCTCAGCTTCCAAGTAGCTGGGATTACAGGCATGTGGTACCACGCC  
TGGCTAATTTTCTTGTATTTTGTAGGGACATGTTGGCCAGGCTGGTTGTGAGCTCCTGGCCTCAGGTG  
ATCCACACGCCTCAGTGTCCCAGAGTGTGATATTACAGGCGTAATATGTGATCTTTTGTGTCTGGTTCC  
TTTACAGTTGAACGCTATTTTTGAGGTTCTGTCCTGTTGTAGACCACAGTCACACACTGCTGTAGTCTTC  
35 CCCCCTCTCATTTCCAGCTGCCTCCTCTACTGTTTCCCTCTATCAAAAAGCCTCCTTGGCGCAGGTTT  
CCTGAGCTGTGGGATTCTGCACTGGTGTCTTGGATTCCCTGATATGTTTCTTCAAATCCACTGAGAATTA  
ATAAACATCGCTAAAGCCTGACCTCCCCACGTC

&gt;DEX0360\_023.nt.1

40 ATGCTGCTCGAGCGGCGCAGTGTGATGGATCCGCCCCGGGCAGGTACAACTTATGAAGAAGGTCTCTTTT  
ATGCTCAAAAAAGTAAGAAGCCATTAAATGGTTATTCATCACCTGGAGGATTGTCAATACTCTCAAGCACT  
AAAGAAAGTATTTGCCCCAAATGAAGAAATACAAGAAATGGCTCAGAATAAGTTTCATCATGCTAAACCTT  
ATGCATGAACCACTGATAAGAATTTATCACCTGATGGGCAATATGTGCCTAGAATCATGTTTGTAGACC  
45 TTTCTTTAACAGTTAGAGCTGACATAGCTGGAAGATACCTAACAGATTGTACACATATGAGCCTCGGGA  
TTTACCCCTATTGATAGAAAACATGAAGAAAGCATTAAAGACTTATTCAGTCAGAGCTATAAGAGATGATA  
GAAAAAAGCCTTCACTTCAAAGAAGTCAAATTTTCATGAAGAAACCTCTGGCACATTGACAAATACTAAA  
TGTGCAAGTATATAGATTTTGTAAATATTACTATTTAGTTTTTTTAATGTGTTTGAATAGTCTTATTA  
ATAAATGTTTTTAAATC

&gt;DEX0360\_024.nt.1

50 TGGCTGTACGGCGAGTTTTAGATCCTACGCTGTGTTCCAGTCCGCTCTTCTCCGGCCCCGGGCCCTGGCCCA  
GCTAGCCGCCCCATGGAAGGTAATGGCCCCGCTGCTGTCCACTACCAGCCGCGCCAGCCCCCGGGGACGC  
CTGCGTCTACAGCAGCTGCTACTGTGAAGAAAATATTTGGAAGCTCTGTGAATACATCAAAAACCATGAC  
CAGTATCCTTTAGAAGAATGTTATGCTGTCTTCAATCTAATGAGAGGAAGATGATACCTATCTGGAAC  
55 AACAGGCGAGACCTGGAGATGGACCTGTGATCTGGGATTACCATGTTGTTTTGCTTTCATGTTTCAAGTGG  
AGGACAGAATTCATTTATGATCTCGATACTGTCTTGCATTTCCTGCTCTTTGACACTTATGTAGAA  
GATGCTTTAAGTCTGATGATGACATTCACCCACAGTTTAGGAGGAAATTTAGAGTGATCCGTGACAGAT  
CATATTTGAAGAATTTGCTTCTGACCGATCTCATGAAAGACTCCAGTGGGAATTTGGAGAGAGCCTCC  
GCCGCCATATCCCTGCATTGAGACTGGAGGCATCAATCCAGTTGATAATTTCTGACATTTAAGAAGATA  
60 AAGGGTCCTTACCCTATTACTATTGTTTGGCATTTCATATGAGTTTGAAGTATTATTACGTTTATTCCA

DEX-0360

188

PATENT

AAATGAACCTGAACGATTTTCATCAGTATGGATCCCAAGGTAGGATGGGGCGCCGTCTACACACTATCCGA  
ATTTACACATCGGTTTGGCAGTAAAACTGCTGAACCTGGTCTCAAGATGTGGAACTGTGGAGAAATTC  
AGGACATGAACAAGCTATCCTTTTCATCGAGGACAGCAAAACATTATGGTACAGTTGGCTTGGAAATTATGTC  
TTTTCTCTTTTAATTTGATTGAGTGGAAATCTGAGTGAATACAAATATAAATGAACAACATAAAAACTTTT  
5 GTTTTGACATGTCAAATTGAACTTGATAAAGTGGTACTTGCTAAGATATTCCTGTGGCTCATGCGTTA  
CAACACGAGGACTTAAGCCAGTAATCGTTTTTGTTCAGATAGAGGTGTGGAGGTAGAGCCAGCCCCCTCAT  
GTCGTGTTTGGATGTTTTGTGTCTCTCCAGCTACATTGTAAGTTCCCTTGAGGGCAGGGCCATGGCCCCATT  
GCTCTGTGAATCTCAAATGCCCATAAAAGGTGCCCATAAAATGTTTTCTTGAACATTGAATGTGCTGTT  
10 GTCTGGAAAGGGGTAATATTGTGAGCTGAATCAGCAATAAGTATTAGTCTTTTTTGGACTATGGTATTGTT  
AAAAAGACTGCAGCCCTCTCAGACTTGAGCGTTAATTGGCTTATTTATTATGGCTTTAAATAAAATCGA  
TTTAACGTTA

&gt;DEX0360\_025.nt.1

AGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGGACATAAAAAATTGCTTAGTAAAGGTCAAAGATTTC  
15 TAAACTGCCTGCATATAAGGATCTCGGTAAAAATCTACCATTCCCTACATATTTTCTGATGGAGATGAA  
GAGGAACTGCCAGAGATTGTATGATGAAAACGTGTGTGTCAGCCCGGTGCGCCTTCTATTACATTTGCCCT  
AACATCTTTGGACGTGGCAGAACCTTACATATTCTGTGAGCTTCGATGAGCCAGAGTGATATCATAACCA  
CCAGAAATCATACTCTCCTTTCTTAGTCACAACAAAATCACACATGTCATCTTTGTCAAGGGCATAAAATA  
TATCATTATACCCCCATTAAATTTTGTAGAAAAATTACCACATTAAATATATGAGTTAAGTAGATTGG  
20 ATTTGCTGAAAATTGGTGTGGGCATATTAGCAAAATATTCTTAATTTGTGGACTCGATTCTTTTTTACTA  
CATATTTCCCAAGTTATCTTAAGATGTCTGTAAATTTAACTTTTATTAAAGTTTGTCAATCTTTGTGAA  
ATAGTGGTTGTGGAACAGTAGAAAACCATATGGGGACTATAGTGCAACCTATTTGGGTAAAGAAACCAT  
TGCTAAAATGGAGAAAGTAAATAGATTTTTATTTAAATTACAGAAACATGTTAAAGGCCGACAAAGGAA  
25 AGACAATAAAATCATAAATTATCGGTCTGTTTA

&gt;DEX0360\_026.nt.1

GGCCATCCAGCCCTGTGGACCGAATGGAGTCCCGCACGCTGTTGAGGTCAAGTTGTGGGTTCCTTGGCCT  
CGGGCTGGGCGCGGGGTGAGCGCACCTGCAGGCGGCGCTTGGCGGTACGGGCTGGTGAAAGTGGAGATGGA  
30 CGGCAGGATGGATTCACTTGGCCACATGGCGCGAASSTGGGAAGACGGACACCGACCTAAGTCAGTGTTA  
GTCTACCACTGTACATCTGGTAACCTCAATCCCTGCAACCGGGGCAAAATGGGTTTCAGGCTTTGGCAA  
CCTTTGAAAATTTCAATTCCATTGAGAGAGCTTTGACGAGGCCATATGCTGATTTACCACCAGCAACTT  
CAGAACCCAGTACTGGAATGCCATCAGCCAGCAGGCCCTGCCATCATCTATGACTTCTATCTGTGGCTC  
ACTGGAAGGAAACCCAGGCAAGGCCAAGATGGCTCAAAGAGCAACCAGCCACCTCTGCAGCCTGCCACCT  
35 CCTGCTGGCAAGATTTGTTTTTGCATCCTGTGAAGAGCCAAGGAGGCCAGGGGCATAAGTCTACTCACT  
TATATCTGTCTGGAACATAACGCTTGTGTTTTTACAACAAATAAAATTGATCTTGAATAAAAACAGAT  
GCGGCCGACATCCTCATCTATATTTTCGTTTCGACATAAAATATGGGTGTATTC

&gt;DEX0360\_027.nt.1

GCATGCTGCAACGACTCTCTTAATCCTCCACCGCTACAGACTAAATGAGGGATTCTTCTTGGTTTGGAT  
40 CCATTGCTGGCAAAGTTGTTATCTATGCAACAAGCCAGAGAACTGCAGTTCAACAGTACAAAAACTGG  
AAGAGGAAATCCAGACCCTTCGAGTTTACTACAGTTTACACAAATCTTTATCTCAAGAAGAAAATCTGAA  
GGATCAGTTTAACTATACCCTTAGTACATATGAAGAAGCTTTAAAAAACAGAGAGAACATTGTTTCCATC  
ACTCAACAACAAATGAGGAACTGGCTACTCAACTGCAACAAGCTCTGACAGAGCGAGCAAAATATGGAAT  
TACAACCTTCAACATGCCAGAGAGGCCTCCCAAGTGGCCAATGAAAAAGTTCAAAGTTGGAAGGCTGGT  
45 GGATGTAAGGGAAGAGGTTGGAACCGGACCATTGAGGACAGTGATCTGATTGAAAAAAACGACAGT  
CTGGGGAAGCGATCACATCTGGTGACCAGGCTGCTTCACTCAACACTGTGTAAACACCAAGCCTTAAC  
TAGCAACAGTTGTTAGAAGTGGGACACTCCAACCACATTTCCAAGCTGAGATAAAATCAAATCACAAATG  
TTTAACCACTTTGCTGCTGACTTGAGTTATTTATCCAAATATATTAACATAGACTTTTACCAATGGGTA  
GCTATAAGGTTACAGCTTATTTTGTAACTATTTTATATCTCAATATCTTTAATATAAATCTTTTTACTGA  
50 GAGATCATTATAGAAACATGTTAAAGTTGGTTAGGATCATATCTTCACATATGGCCCTTTCTGAATCAA  
GTGCGGCAAGTAATATTGTCTAAGCTTTAATCCACTGTGTTAGGTCAAACTTCAAATACATGCATTT  
TTCAATATAGGGTATATTTCTTAACGTAGTGAAGAGGCTTAGACATGAGTGTGTAGTCTTCTTCAATGC  
GTGTATGTAATCTTTGTTAGTATAAAAGATATTAAATATAGGTGCCAAGAATTAATGTATAATTTGTTT  
55 AATAAGAGATGGATATATTAATTTACATTCATCAAGGCATGATTTTTGTTTCACTACAAATAATGCAAA  
CTGTTTTCAATAAAAAGAGGAGACTGTTAATGTGTACTTATAAATTCACATTGTCAGTATT

&gt;DEX0360\_028.nt.1

AGTGATGGCCCGCGTCCCCGTGCACCCAGTGATGGCCCGCGTCCCCGTGCACACCAGTGATGGCCCGCG  
60 TGCCCGTGCACCCAGTGATGGCCCGCGTCCCCGTGCACACCAGTGATGGCTCTGTCCCCCATGCACTC  
CCAGACAGGCAATGTCCCTGTGGGCTGTCCAGGCTCTGTTCTCAGCAGGCTGGGCTCAGCCCTGGTGC

[illegible]

DEX-0360

190

PATENT

AATTGGCAACTATGATAAATACCTTCAAAGGATGTAGATATAATGGAGATGTTTAAAAGTTTAGTTTCA  
 TTAATTGTAAAATTAGCATGTTATATTTACTCAATATAGTGAAGACTAGGTGATTCTTACATGTATCTA  
 CTTATGGTACTGTACTGGTTTGTAGTGAATTTACATAGAATAAATTTACTTCACTTTCATGTCTCGAC  
 5 ATGAATGACACAAAAGCTACTTCATAATACTACTTTACAATAGTTTTCACATTTCCATATGGTGCGACC  
 CCTTTGCTCTCATCAATTTTGGGTGTCATGAGAACAATAGGTATCCCGTTGGACATGATGTATTGCGAAG  
 AGCATATAAAGCAGAGGGGAAAATGAAAAAGCAAGAGAAACTCATTTCAATGCTTTTTCTAAAAGGTAACA  
 AATATAAATTTAATCAACTTCCTTGGAAAATATTTTAAAACAGGTATCAATAGAAAATTTACAAAACA  
 TCATATGAAGCTATAAATAATTTTGA AAAACTATATCATCATATAAGCATAAGTAATAATCTTAAAAATAC  
 10 ACTCTTAAGAAGGTATGTAATTTGCAAAGGAAAATGGCTAGATATCTGATGGGACAGTAAACCTTGAAAG  
 AAACCTGGCTAAAGAGTAAGTGTGTATATTTCTGAACCTAAGTAATTTTGTACGACTTTTAAAATTT  
 AGCCAGTTACAAATATTTTAAAATCCTAACCTTAAAGTTATCTAAAAAGGCAATATGGAGGAAATAGTA  
 ATTTTGTTTTTGAAAGATGTTGAAAACCTGATCACCATTTAGAGGCTTCAAATTCATAATTCATAATAA  
 GAACAAGAAGTAGAAAGCATATGGGCAAGGAACAAATATGTGGCCAGCCAGTCCCTTAGACGAACTAAT  
 15 TTTGTCTTATTAAAAATGCCAATACAATTGACTTTCTCTTTAAATTTCTTCACTATGATTGAAGACCACT  
 CCATATATACATCATTAAGAAATGCTGTTAACACATGGACAGACAAGACAGTAACAGTCTAGTGGCTTTT  
 GTTATGCAGCACA

&gt;DEX0360\_030.nt.1

CCCGTTAGGGGTTACCCCTTCCATCTTAAGCAGGATATTCTAGGATCTCTCAGTCTCACAGCCTTGCCCA  
 20 CCAATAACCAGCAGAAAGCGGTTTCGACAATTGGTCCTTCTTTTGGCCCCCTCTGCGATGCCCGCGGATTG  
 GACGGCTGAGTCTGGCTACGCGGGCTCCGCGGAGCGCATGGGCGCAATCAAGAGCTTGGCGTATTTT  
 ACAAACTGAGAAAGTAGCTCCAGCAGCACCAGAGGGTTCAGGAGAAAAGCGGAGGAACTGGGTAGGCC  
 CTGAGGGGCTCGGTAAGCCATCATGACCACCCGCAAGCCACGAAGGATCCCTCTCCGGGGTGTATC  
 25 TCCTACCCCTAGCAAGATTCCGGTACGCTCTCAGAAACGCACGCTTTCCCTACTGTTACATCGTGCGCC  
 GTGGACACAGGAGAACAAGATCCAAGGAGATGGGTGCAGAAACCACCGCTCAATATTCAACGCCCCCTCG  
 TTGATTTCAGCAGGCCCCAGGCCGAAAGCCAGGCACAGGCAGAGACATCAAAAGATTGGTGGGGATCAG  
 TCAGCCTCGGAACCCCTTGGAAGAGCTCAGGCCTAGCCCTAGGGGTCAAATGTTGGGGCTGGGCCCCCT  
 GCCCAGACAGAGGCTCCAGGGACCATAGAGTTTGTGGCTGACCCTGCAGCCCTGGCCACCATCCTGTCAG  
 30 GTGAGGGTGTGAAGAGCTGTACCTGGGGCGCCAGCCTAGTCTGGCTAAAAGAGTACTGGTTTCAGGAAG  
 TCAGGGAGGCCACCCAGAGGGTCCAGGGTGTTCGGGCTCTGCATATTTGGCCCCCAGAACCCCCACC  
 CACCGACTGGACCTGCCAGGGCTTCTGCTCTTAGGCTGGAGGGACAGGACCTCGAGGCGGACAT  
 TGTGCCCCCAGAGGCTACAGGCTCTGATTTACCTTCAGGACCTTCTTTTACCCTTCCACTCGCCCCAG  
 TTTCCAGGAGCTAAGAAGGGAGACAGCTGGCAGCAGCCGACTTCAGTGAGCCAGGCTCAGGATTGCTC  
 35 CTGGAGACCCAGTCCAGCCTGCTTTCTCTCTTCTAAAGGAGAACCGAGGTTGTCACTCACTCAGATG  
 AAGGAGGTGTGGCTCTCTTGGTCTGGCCCCAGCAGTACCATTAAAGAGAAAACCGAGAAATGTCACATAC  
 CAGGGACAGCCATGACTCCCACCTGATGCCCTCCCCCTGGCCCTGTGGCCAGCCCTTGCCCTGGCCATGTG  
 GTGCCATGTCCATCACCTTTGGACGGGCTCAGCGTGTACCTCCCCAGGCCCCCAACTCTGACCTCAT  
 ATTCAGTGTTCGGCGCTCTACCGTTCAACCTAAAACCCGGTTTACACCCATGCCATCAACCCCCAGAGT  
 40 TCAGCAGGCCAGTGGCTGCGTGGTGTCTCCCTCAGTCTGCTCTGAAGATCCTGCCCTGCCCTGGGAG  
 CAGGTTGCCCTCCGGTTGTTTGAACAGGAGTTGTATAAGGTCACTGGAGGGTTCTGGGAAACCCACCG  
 TGGCCACTCCTTCTGGACCCCACTCTAACAGAACCCCAAGCCTTCAGGAGGTGAAGATTCAAGTGAGTCT  
 GTGTGGCCACAGCTTTGATGTCTATTGAACAGTGAAGTGGGCTGAGGAAGAGGGAAGATGGGGGAT  
 CAGGAATAGGACAGTGTGGGTAGACTACTGAACGCACATCTTGATGTCACTGGGGTGTCTCTCCAC  
 45 CACAGCCATCGGTATCCTGCAACAGCTGTTGAGACAGGAAGTAGAGGGGCTGGTAGGGGGCAGTGTGT  
 CCTCTTAATGGAGGCTCTTCTCTGGATATGGTTGAAGTTCAGCCCCCTGCTGACTGAGATTTCTAGAAGT  
 CTGAATGCCACAGAGCATAACTCTGGGACTTCCACCTTCTTGGACTGTTAAAACACTCAGGGCTGCCAA  
 AGCCCCGTCTTCCAGAGGAGTGGGGGAACACAGCCCTGCCCTCCGGCAGAGCTGGGGCCCCAGAGGC  
 CTTCTGTAGGAGTGAGCTTGAGATACCAGAGCCCTCCCTCCAGGAACAGCTTGAAGTACCAGAGCCCTAC  
 50 CCTCCAGCAGAACCCAGGCCCTTAGAGTCTGCTGTAGGAGTGAGCTGAGATACCGAGTCTCTCGCC  
 AGGAACAGCTTGAGGTACCTGAGCCCTGCCCTCCAGCAGAACCCAGGCCCTTAGAGTCTTACTGTAGGAT  
 TGAGCCTGAGATACCGGAGTCTCTCGCCAGGAACAGCTTGAGGTACCTGAGCCCTGCCCTCCAGCAGAA  
 CCCGGGCCCCCTTACGCCAGCACCAGGGGAGTCTGGACCCCCAGGGCCCTGAGGTAGAGTTAGG  
 GGGCATCAGAGCCCTGCACCTGGAACATAGAAGTCTAGAGTCCAGTCTACCACTGCTGCAGTCACTG  
 55 GGCTCCAGCAACCACAGCCTGATCTTCTCTTCCCAACACCCGCTTTGTGCCAGCCCCCTATCTGCTCA  
 CTCAGTCTTTGAGACCCAGCAGGCCAGGCCTCAGCAATCTGGCCCCCTCGAACCTTAGCCCTGA  
 GGGAGCGCTCAAATCGTGTTTAACCGCCATCCACTGCTTCCACGAGGCTCGTCTGGACGATGAGTGTG  
 CTTTACACAGCCAGCCCTCCCTCAGGCCCAACCGGGTCTGCACCAACCTGTGGCTACATTACTC  
 GAATGGCAGGATGCCCTGTGTTTCAATCCAGTTGGTTCTGCTGCCCCCCAGGGCTCTCCATGATGAGACA  
 60 ACCACTCTGCCCTGCCGTACTTCTCTCTTTAGCCCTTATTTATGTGCGTCTGCCCATGGGACTGGGA  
 GCGGCCCACTTTTGTCTCAATAAAGTTTCTAAAGTAAACAC

DEX-0360

191

PATENT

&gt;DEX0360\_030.nt.2

CGCCAGGAACAGCTTGAGGTACCTGAGCCCTGCCAGCTCCAGCAGCACCCGAGAGGGTCAGGAGAAAAGC  
GGAGGAAGCTGGGTAGGCCCTGAGGGGCCCTCGGTAAGCCATCATGACCACCCGGCAAGCCACGAAGGATC  
5 CCCTCCTCCGGGTGTATCTCCTACCCCTAGGGTAGAGCTGGGGGCATCAGAGCCCTGCACCCTGGAAC  
ATAGAAGTCTAGAGTCCAGTCTACCACCCTGCTGCAGTCAGTGGGCTCCAGCAACCACCAGCCTGATCTT  
CTCTTCCCAACACCCGCTTTGTGCCAGCCCCCTATCTGCTCACTCCAGTCTTTGAGACCCCCAGCAGGC  
CAGGCAGGTAAGGAGTTGGCTGGGAAGGAGTGTGAACACAAGAGGTCCTCACCTCACTGTGAGCTGCACA  
CCTGCCCTGCCCTACCCAGGCAATCTCATGCTTCCACACCTTCCACCCTGGCCCCAGCCTGGCTCTCCC  
10 TCAGGAAGAGGGGAGGGGCTGCACCTCCAGCCCTGTGCTCCTAATTGGCTTGGCCGTTGGTGGGGGAGGA  
GGAGAGGACAGTACATGGTGGAAAGTATAGGACCCAGACCTCCCTCTAAATTTTCCATGCCCCCTCAGGCC  
TCAGCAATCTGGCCCCCTCGAACCCTAGCCCTGAGGGAGCGCCTCAAATCGTGTTTAACCGCCATCCACTG  
CTTCCACGAGGCTCGTCTGGACGATGAGTGTGCCTTTTACACCAGCCGAGCCCCCTCCCTCAGGCCCCACC  
CGGGTCTGCACCAACCCCTGTGGCTACATTTACTCGAATGGCAGGATGCCCTGTGTTTTCATTCTAGTTGGTT  
15 CTGCTGCCCCCAGGGCTCTCCATGATGAGACAACCACTCCTGCCCTGCCGTACTTCTTCTTTTAGCCC  
TTATTTATTGTCGGTCTGCCCATGGGACTGGGAGCCGCCCACTTTTGTCTCAATAAAGTTTCTAAAGTA  
AAACAC

&gt;DEX0360\_031.nt.1

CCCAGGCTGTGGCCTCTGCACTACGTGCGCCCCACACAGGCCCTGGGTGACCTCTGCTGGTGGCCCCCT  
TCCCCACCCCTCCTCCGCCTCGGTGCCCGGCGCTGCTCCGGACCACTATGACCATGAGATCCGCGGTGT  
TCAAGGCGGGCGCGGCCCTGCGGGCGGCAATCCTGAGCAGCGACTGGACTACGAGCGGGCTGCGGGCGCT  
GGGCGGGCCCCGAGGACGAGCCTGGGGCGGGCGAAGCCCACTTCCCTCCCCCGGCACCGTAAGCTCAAGGAG  
CCGGGGCCCCCGCTGGCCTCCTCCAGGGCGGGAGCCCCGCGCCTTCCCCGGCCGGCTGCGCGGCAAGG  
25 GCGGGGCTTGTACTCCCGCGGGGCGGCCCGGGCAGCAGGAAGAGAGCTGGGGCGGTTCCGTGCC  
CTTGCCCTGTCCGCCCCGGCCACCAAGCAAGCCGGCATTGGGGGGAGCCTGCCGACGCGGAGCCGGC  
TGCAGCCCCCGGCCCAAGTATCAGGCGGTGCTGCCCATTCAGACGGGCTCTCTCGTGGCGGGGCCAAAG  
AGCCTACGCCCTGGGCTGGGACAAGGGTGGGGCGGGCTCCCCGCTGCCACCGCCTCGGACCCGGCGGG  
ACCCCCACCACTACCTCTGCCCGGGCGGCCACCCCTCGCGCCCCACGCCACCGCCGCGGAGCTGGCGGCC  
30 AGCGAGGGCAGATGGAAGACTATGAGGAAGAGCCCTCTCGGGGTGGTGGCGGCTCGGGAGCCTCCAGTC  
AGGCCGCTGCTCAACAGATCCTTCTGTGCAATTGGACCTCATCGAACAGCAGCAGCAGCAGCTGCA  
GGCCAAGGAAAAGGAGATCGAGGAGCTGAAGTCAGAGAGAGACACGCTCCTTGCTCGGATGAACGTATG  
GAAAGGCGGATGCAGCTGGTAAAGAAGGATAACGAGAAAAGAAAGGCACAAGCTGTTTCAGGGCTATGAAA  
CTGAAGAGAGAGAGGAAACAGAGCTATCTGAGAAAATTAACTGGAGTGCCAGCCGGAGCTTTCCGAGAC  
35 ATCCAGACTCTGCCTCCCAAGCCCTTCTCATGTGGGCGGAGTGGAAAGGGACATAAAAGGAAATCCCCA  
TTTGGAAGTACAGAAAGAAAGACTCCTGTAAAGAGCTGGCTCCTGAATTTTCAAAAGTCAAAACAAAAA  
CTCTAAGCACTCTCCTATTAAGAGGAACCTGTGGTTCTTATCTGAAACTGTTTGTAAACGTGAATT  
GAGGAGCCCAAGAAACCCAGAAAAGCCCCGGTCTTCAAGTGACACCCACCAAGACTCTCCACTCCCCAA  
AAGGACCCAGCACCCATCCCAAGGAGAAAAGCCTTCTCAAGTGAGATAGAAGATTGCGCTACTTTTCCA  
40 CCACAGAAATGTATTTGTGTCGTTGGCACCAGCCTCCCCATCACCGTTACCATTACGGGAATCCTCTCC  
AAAGAAGGAGGAGACTGTAGCAAGTAAGGCATAGAGAACACTTGCTCTTATACCCTAGTGGTGGCGGTCA  
AGCTAACAAGTGTGAAAATGCCTTTGGCATTTTAAAAAAGTGCAATCAATAAAGCAGAGTTCTGTCAAG  
AATGAGTAAGTTAACAGCCAGAGACAGACACTGTGCAGGCATTGCAATAGATGGAATTACAGCAAAATG  
TGCTCAATGTATTTGCCCTGCTTACAACACTGGGAGATGTGTTTGCCAGTAAGTTGCTCATCACAAAGAGCA  
45 CCAGACTTGGGGGTGTAATCTCCGGCAACTTGCACTGCCCTCTGAAAGAAGGGTTTTCTGTGCTGTGAAAT  
GCATAGAACTATACTTTGCCATGCACGACTGTTCTGCAATTGATATTGTGTGAAATCTGGGAGGGTGGT  
CTTTGGGTGTTCTCAGGGGCCAATGGTAATTTTGGGGTGGGGAGCCAGCTTGGGGTGGGGAATTTTAC  
CTGGGCCTCCGCTCTTAACTATATAAACATTTATCTGTATATCTATGTCCCTGTCTGGGGGCGAGGAGG  
AATCTGCCAAAGACCAACAGTCTTACTTTATCTTACTATACTTACAAAAGGTTTAAATGTGAAGGTT  
50 TACTTGGATTGCAGTAGCCCATTTGGTTGTTTCAATATTTAAATAAAATGGTCTACAACTATTTTCAA  
CAAAAGAAAATCTTGGGATATCTGAGCTGCTTGGGGAGGGTGTGGGGTGTGGGACCTTGGTCTTCATTC  
CCTTTTCTTTTCTTTATGGCTTCCACACAGAGATGCTCCCTATCTTCTACATCAACCACTAAGTGGAA  
TGTGCCCTCAATCATGTAATATTAGTCTATGTCACTGCGGTTACTCTGGGGTAATGGTTGGGGAGG  
CCTTCTAGGATAGAGCCGAGTCCCAAGTTTCTACCACTGTGTCTTGCCTAGCAGGATGGGGATAGAAAT  
55 CCATTCCAGTGAGACAAGAGCGTTCTCCAGGCCTTGTGTTGGCTGTCT

&gt;DEX0360\_031.nt.2

CCCTGCTGATACGATTCGAGCTCGTACCCCTCCAGCTGGCCCCAAGGAGAAAAGCCTTCTCAAGTGAGATA  
GAAGATTGCGGTACCTTTCCACCACAGAAATGATTTGTGTCGTTGGCACCAGCCTCCCCATCACCGT  
60 TACCATTACGGGAATCCTCTCCAAAGAAGGAGGAGACTGTAGCAAGTAAGGCATAGAGAACCTTGCTCT

## DEX-0360

192

## PATENT

TATACCCTAGTGGTGGCGGTCAAGCTAACAAGTGTGAAAATGCCTTTGGCATTTTTAAAAAGTGAATC  
AATAAAGCAGAGTTCTGTCAAGAATGAGTAAGTTAACAGCCAGAGACAGACACTGTGCAGGCATTGCAAA  
TAGATGGAATTACAGCAAAATGTGCTCAATGTATTTGCCTGCTTACAACACTGGGAGATGTGTTTGCCAG  
TAAGTTGCTCATCACAAAGAGCACCAGACTTGGGGGTGTAATCTCCGGCAACTTGCATGCCCTCTGAAAGA  
5 AGGTTTTCTGTGCTGTGAAATGCATAGAACTATACTTTGCCATGCACGACTGTTCTGCAATTGATATT  
GTGTGAAATCTGGGAGGGTGGTCTTTGGGTGTTCTCAGGGGCCAATGGTAATTTTGGGTGGGGAGCCA  
GCTTGGGGTGGGGAATTTTACCTGGGGCTCCGCTCTTTAACTATATAAACATTTATCTGTATATCTATG  
TCCCTGTCTGGGGGGCAGGAGGAATCTGCCAAAGACCAACAGTCTTACTTTATCTTACTATACTTCACAA  
AGGTTCTAAAATGTGAAGAGTTTACTTGGATTGCAGTAGCCCATTTGGTTGTTTCATATATTTAAATAAAAT  
10 GGTTTACAAACTATTTTTCAAACAA

&gt;DEX0360\_032.nt.1

CCCCGCGCGCCCTCGCTCCCTCCCGTCAGCCCCCGCCCCCTCGGCGAAGGGAGCGGCGTGCCGTCCGGGTC  
GCCTAGGCCTGGGGTGGGAGCGCGCACGCTGTGCGCCCTGGGCGCGCTCGGGATTCTCGCCTGGCGCGG  
15 CTGGGGAAGGTGAACAGTGTGGCCCGCCATGTTCTTCTCCGCGGCGCTCCGGGCCCGGGCGGCTGGCCCTC  
ACCGCCCACTGGGGAAGACATGTAAGGAATTTGCATAAGACAGCTATGCAAAATGGAGCTGGAGGAGCTT  
TATTTGTGCACAGAGATACTCCTGAGAATAACCTGATACTCCATTTGATTTACACCCAGAAAACATATAA  
GAGGATAGAGGCAATTGTAAAAAACTATCCAGAAGGCCATAAAGCAGCAGCTGTTCTCCAGTCCCTGGAT  
TTAGCCCAAAGGCAGAATGGGTGGTTGCCCATCTCTGCTATGAACAAGGTTGCAGAAGTTTACAAAGTAC  
20 CTCCAATGAGAGTATATGAAGTAGCAACTTTTATACAATGTATAATCGAAAGCCAGTTGGAAAGTATCA  
CATTCAGGTCTGCACTACTACACCTGCGATGCTTCGAAACTCTGACAGCATACTGGAGGCCATTTCAGAAA  
AAGCTTGAATAAAAGGTTGGGGAGACTACACCTGACAAACTTTTCACTCTTATAGAAGTGGAAATGTTTAG  
GGGCTGTGTGAACGCACCAATGGTTCAAATAAATGACAATTACTATGAGGATTTGACAGCTAAGGATAT  
TGAAGAAATTTATGATGAGCTCAAGGCTGGCAAAATCCCAAAACCAGGGCCAAGGAGTGGACGCTTCTCT  
25 TGTGAGCCAGCTGGAGGTCTTACCTCTTTGACTGAACGCCCAAGGGACCTGGATTTGGTGTACAATGTG  
TTCACCTCCACAGGAAATTCAGGTGCAATAGCGGTGTTGTGTAATCATAGGATCTCTGTTGGGATGGC  
TGAAGGTGAACAGGGCTGGGGTGCAGAGAGCTGGTGAAGTTGTGCAGCCGTACCTGCCCGGGCGGCGG

&gt;DEX0360\_032.nt.2

CCCCGCGCGCCCTCGCTCCCTCCCGTCAGCCCCCGCCCCCTCGGCGAAGGGAGCGGCGTGCCGTCCGGGTC  
GCCTAGGCCTGGGGTGGGAGCGCGCACGCTGTGCGCCCTGGGCGCGCTCGGGATTCTCGCCTGGCGCGG  
CTGGGGAAGGTGAACAGTGTGGCCCGCCATGTTCTTCTCCGCGGCGCTCCGGGCCCGGGCGGCTGGCCCTC  
35 ACCGCCCACTGGGGAAGACATGTAAGGAATTTGCATAAGACAGCTATGCAAAATGGAGCTGGAGGAGCTT  
TATTTGTGCACAGAGATACTCCTGAGAATAACCTGATACTCCATTTGATTTACACCCAGAAAACATATAA  
GAGGATAGAGGCAATTGTAAAAAACTATCCAGAAGGCCATAAAGCAGCAGCTGTTCTTCCAGTCCCTGGAT  
TTAGCCCAAAGGCAGAATGGGTGGTTGCCCATCTCTGCTATGAACAAGGTTGCAGAAGTTTACAAGTAC  
CTCCAATGAGAGTATATGAAGTAGCAACTTTTATACAATGTATAATCGAAAGCCAGTTGGAAAGTATCA  
40 CATTCAGGTCTGCACTACTACACCTGCGATGCTTCGAAACTCTGACAGCATACTGGAGGCCATTTCAGAAA  
AAGCTTGGAAATAAAGGTTGGGGAGACTACACCTGACAAACTTTTCACTCTTATAGAAGTGGAAATGTTTAG  
GGGCTGTGTGAACGCACCAATGGTTCAAATAAATGACAATTACTATGAGGATTTGACAGCTAAGGATAT  
TGAAGAAATTTATGATGAGCTCAAGGCTGGCAAAATCCCAAAACCAGGGCCAAGGAGTGGACGCTTCTCT  
TGTGAGCCAGCTGGAGGTCTTACCTCTTTGACTGAACGGCTCCAGTATGCTGTCAGAGTTTCGAAGCAT  
45 GCAGGTGTAGTAGTGCAGACCTGAATGTGATACTTTCCAACCTGGCTTTCGATTATACATTGTATAAAAA  
GTTGCTACTTCATATACTCTCATTTGGAGGTACCTGCCCGGGCGGCGG

&gt;DEX0360\_032.nt.3

CCCCGCGCGCCCTCGCTCCCTCCCGTCAGCCCCCGCCCCCTCGGCGAAGGGAGCGGCGTGCCGTCCGGGTC  
GCCTAGGCCTGGGGTGGGAGCGCGCACGCTGTGCGCCCTGGGCGCGCTCGGGATTCTCGCCTGGCGCGG  
50 CTGGGGAAGGTGAACAGTGTGGCCCGCCATGTTCTTCTCCGCGGCGCTCCGGGCCCGGGCGGCTGGCCCTC  
ACCGCCCACTGGGGAAGACATGTAAGGAATTTGCATAAGACAGCTATGCAAAATGGAGCTGGAGGAGCTT  
TATTTGTGCACAGAGATACTCCTGAGAATAACCTGATACTCCATTTGATTTACACCCAGAAAACATATAA  
GAGGATAGAGGCAATTGTAAAAAACTATCCAGAAGGCCATAAAGCAGCAGCTGTTCTTCCAGTCCCTGGAT  
TTAGCCCAAAGGCAGAATGGGTGGTTGCCCATCTCTGCTATGAACAAGGTTGCAGAAGTTTACAAGTAC  
55 CTCCAATGAGAGTATATGAAGTAGCAACTTTTATACAATGTATAATCGAAAGCCAGTTGGAAAGTATCA  
CATTCAGGTCTGCACTACTACACCTGCGATGCTTCGAAACTCTGACAGCATACTGGAGGCCATTTCAGAAA  
AAGCTTGGTAGGGAATACATGATATTTGTAACACTGATAAAAAGTAGAATTTGTCTCTTAGATTTGGTAC  
ATTTCTATCTAAAAATTTCCAACCTCTGCCATCTTATTGGATCTGTACTTACCTAGTAATATTTTGTGTTA  
CTGTGTTTCCACATCTTTATTTCTTCTATTTGGTATTTCTCTCAGTTCTTAGTGTTAAAGCTGAGTTT  
60 TTAATTTTTTCTTTTAAATCAGT

DEX-0360

193

PATENT

&gt;DEX0360\_033.nt.1

GGTCCAACGCCAGCCTGCGGCTGCCAGGCCCCACGCCGGCCAGGAAGTGCTCGCCGCCCGCGGCCGACGG  
GACCCGCCACGCCCGCCTCTTAAAGGGGGCAGTGACTGCGGCTGGGCGGGAGTCCGGGTCGGCTTGGC  
5 TGAGCGGGGGCGGTGCTGGGCAGGGCGCGCGCCGCTCCCTCCCGACTCCCGGCCCTCCCGCCTCCCTGG  
TCCCGCCTGGGAAGGGATGCAAGGAAGCCCTCCGGCGCTGCGCTCCGAGGCGGGAGACAGCGTCCCCCTC  
CGCCCCTCGGGTCTTGGCCCTCAGAGCCCGGCCAGGCCCGGAACGGTGATGCTCGGGCCGACGGGC  
GGGCGCGGATCCCTGCGTCCCGCTGAAAATGTGTCTGACATGCAAGCTCAGTGGGGCAGAGACCCGTG  
GATTGCTGTGCCCTGCCCTCCGGACCTGGATCATGAAGGTGTTGGGAAGAAGCTTCTTCTGGGTGCTGTT  
10 TCCCGTCCCTTCCCTGGGCGGTGCAAGGCTGTGGAGCACGAGGAGGTGGCGCAGCGTGTGATCAAAGTGCAC  
CGCGGGCGAGGGGTGGCTGCCATGCAGAGCCGGCAGTGGGTCCGGGACAGCTGCAGGAAGCTCTCAGGGC  
TTCTCCGCCAGAAGAATGCAGTTCTGAACAACTGAAAAGTGAATTGGAGCAGTGGAGAAAGACGTGGG  
CCTGTCGATGAAGAGAACTGTTTCAGGTGCACACGTTTGAAATTTCCAGAAAGAGCTGAATGAAAGT  
GAAAATTCGTTTCCAGCTGTCTACGGACTGCAGAGAGCCCTGCAGGGGATTACAAAGATGTCGTGA  
15 ACATGAAGGAGAGCAGCCGGCAGCGCCTGGAGGCCCTGAGAGAGGCTGCAATAAAGGAAGAAACAGAATA  
TATGGAACCTCTGGCAGCAGAAAAACATCAAGTTGAAGCCCTTAAAAATATGCAACATCAAAACCAAAGT  
TTATCCATGCTTGACGAGATTCTTGAAGATGTAAGAAAGGCAGCGGATCGTCTGGAGGAAGAGATAGAGG  
AACATGCTTTTGACGACAAATAATCAGTCAAGGGGGTCAATTTTGAGGCAGTTCTGAGGGTGGAGGAAGA  
AGAGGCCAATTCTAAGCAAAATATAACAAAACGAGAAGTGGAGGATGACTTGGGTCTTAGCATGCTGATT  
20 GACTCCCAGAACCAACAGTATATTTTGACCAAGCCAGAGATTCAACCATCCACGTGCAGATCACCACT  
TTATAAAGGACATTGTTACCATAGGAATGCTGTCTTGCCCTGTGGCTGGCTATGTACAGCCATAGGATT  
GCCTACAAATGTTTGGTTATATTTTGTGGTGTACTTCTGGGACCTTCAGGACTAAATAGTATTAGTCT  
ATTGTGCAAGTGGAGACATTAGGAGAATTTGGGGTGTTTTACTCTTTTCTTGTGGCTTAGAATTTT  
CTCCAGAAAAGCTAAGAAAGGTGTGGAAGATTTCTTACAAGGGCCGTGTTACATGACACTGTTAATGAT  
25 TGCATTTGGCTTGCTGTGGGGCATCTCTTGCGGATCAAACCCACGCAGAGCGTCTTCAATTTCCACGTGT  
CTGTCTTGTCAAGCACACCCCTCGTGTCCAGGTTCCCTCATGGGCAGTGTCTGGGGTGACAAAGAAGGCG  
ACATTGACTACAGCACCGTGTCTCTCGGCATGCTGGTGACGCAGGACGTGCAGCTCGGGCTCTTCATGGC  
CGTCATGCCGACTCTCATACAGGCGGGCGCCAGTGCATCTCTAGCATTGTCTGGAAGTTCTCCGAATC  
CTGGTTTTGATTGGTCAGATTCTTTTTCATAGCGGCGGTTTTTCTTTTATGCTTGTATTAAGAAGT  
30 ATCTCAATGGACCCCTATTATCGGAAGCTGCACATGGAAGCAAGGGGAACAAAGAAATCCTGATCTTGGG  
AATATCTGCCCTTATCTTCTTAATGTTAACGGTCACGGAGCTGCTGGACGCTCTCCATGGAGCTGGGCTGT  
TTCTTGGCTGGAGCGCTCGTCTCTCAGGGCCCCGTGGTCACCGAGGAGATCGCCACCTCCATCGAAC  
CCATCCGCGACTTCCTGGCCATCGTTTCTTTCGCTCCATAGGGCTCCACGTGTTCCCCACGTTTGTGGC  
GTACGAGCTCACGGTGTGGTGTCTCTCACCTTGTCTAGTGGTGGTGATGAAGTTCTCTGGCGGCGGCTG  
35 GTCCTGTCTCTCATTTCTGCCGAGGAGCAGTACATCAAGTGGATCGTCTCTGCGGGGCTTGCCGAGG  
TCAGCGAGTTTTCCTTTGTCTTGGGGAGCCGGGCGCGAAGAGCGGGCGTCATCTCTCGGGAGGGTGAGTG  
GCTTCCCCCGCGGAGCGCTTCTCGGGCGGCACGGGCTGCACTCTGGGTTTGTAGTCCGGGTGTGGCGAAGG  
CGGCTCGGCAGCACAGCGGGGCCCTGGGGGCGAGGGTCTCTCCAGGGGGGACGCAGAGGCTTGGCTGCT  
CTCTGCTCATCCAGCATGTGGCGTTTTTCAGAGGAAGTTGCAGTTAGTACTGTTGAACATTGCAATTAA  
40 CTTTAAACAAAGTCTAATTAATGTTCAGATATTTTCTTCTGAAAGAAAACCTAATTTTAAAGCTGAAC  
TGCCAGTGTGCACATAAGTAGCACCCAGAAACGTGAAATACCCGTAATGGCAGTGTGCCCCGAGAGCTG  
GGTGGAGGTTCTGTGGACACTGAGATGGCCCTGGGCATTCCGACTCACGGCTTGTCTCTTGCATTGT  
GTAAGTGTGAGCGGGTAGAAGTCCAGGTGTTGAGTGCAGTGAAGTAATGTGAAAGGTAGAATTGCT  
TACAGGAAGCTCCACCTGAGGCCTGACCAAGGCCGATCCCCAGGGTCAGGGAAGCTGTGGGGCAGGCT  
45 GGCTTGTACTGTGGCCCGGGGTTGGCCCTCAGGCAACACAGGCTAAAGCTGTTATCTGTGGCCCATC  
AGGACTAACCATGCATCACTGATCTTGAATACAGTCTCTCTTACATCCC

&gt;DEX0360\_033.nt.2

GGGACACAGCTGTCCAGCTCAGCTGAGAGCACAGGAGCCTCCGGGGCATCAGCGACTGGCCGGGGTGAGG  
50 GATGCCACCAGGTGCAGAGGTGGAGGCTCAGGGCGTGTGGGGAGGAAGAGAGGCTTGTGGAAAAGTCCA  
GAGGGCTCCACGTGTTCCACGTTTGTGGCGTACGAGCTCACGGTGTGGTGTCTCTACCTTGTGAGT  
GGTGGTGATGAAGTTCTCTGCGGGCGTGGTCTGTCTCTATCTGCGGAGGAGCAGCCAGTACATC  
AAGTGGATCGTCTCTGCGGGGCTTGCCGAGGTCAGCGAGTTTCTCTTGTCTGCGGAGCCGGGCGGAA  
GAGCGGGCGTCTCTCTGCGGAGGTGTACCTCTTATACTGAGTGTGACCAGCTCAGCCTCTGCTCGC  
55 CCCGGTGTGTGGAGAGCTGCAATCACGAGGTGTGTGCCAGACCGGAGAGACGGTCCAGCTCTGATGG  
CTCGGAGATGATGGACCGTGAAGGGAAGCGTCTGTGGGGAGTGAGCGCTTAGATGGCCAGCAGCTGCTC  
CTTCTGGGAAGCTCGCACCTTGGCAACAGAACAGCCCTCTAGCAGAGCGTCAAGTGCAGTCTGTTATCCC  
GGCTTTTACAGAAATATCTTGTCTTATTTAGAAATTTCCGGAGTAGTTTATTTGCACTGCTGTTGATTAT  
60 GTGCAGTAGACCCGGGACACTGCGTTTTTACCAGTACCTTGAATGTGGTGGCTGGATGTGCTTTTTTTT  
TTTTCCCTGAAATTATTTATTAATTTTCTATTGTGAGTTCATCAGTTTCATAGTTTTTTTAGTAAAGAAGCA

DEX-0360

194

PATENT

AAATTAAAAGGCTTTTAAAAATGTACAACCTCAGAATTATAATCTGTTAGTCAAATATTTGTTATTAAAC  
ATTTCTGTAATATGAAGTTGTAATCCTGGCCGTGAGCTTGAAGCTTACTTTTGATTCTTAAAGCCTATG  
TTTCTAAAATGAGACAAATACGGATGCTATTTGCCCTTTTATTGTAACCTTTTAAATGAAATAATTTTCAT  
GTCAATTTCTATTAGATATATCACTTAAATATTTGGTTTTTAAATCACAAGAATATGTATTCTTTAATAA  
5 AGATAATTTATGATCATGGTATAATTAATTGAAATTTATTAAAAATCTGTTTTATTAA

&gt;DEX0360\_033.nt.3

GAGCGGCGCAGTGTGATGGATTTCGCGGCCGAGGTACATCCCCTTCAAGCAGTATGCTGGCAAATACGTCC  
TCTTGTCAACGTGGCCAGCTACTGAGGCCGTGACGGGCCAGTACATCAAGTGGATCGTCTCTGCGGGGCTT  
10 GCCCAGGTGAGCGAGTTTTCCTTTGTCCTGGGGAGCCGGGCGGAAGAGCGGGCGTCTCTCTCGGGAGG  
TGTACCTCCTTATACTGAGTGTGACCACGCTCAGCCTCTTGCTCGCCCCGGTGTGTTGAGAGCTGCAAT  
CAGGAGGTGTGTGCCAGACCGGAGAGACGGTCCAGCCTCTGATGGCTCGGAGATGATGGACCGTGAAG  
GGAAGCGTCTGTGGGGAGTGAGCGCTTAGATGGCCAGCAGCTGCTCCTTCTGGGAAGCTCGCACCTTTGGC  
AACAGAACAGCCCTCTAGCAGAGCGTCAGTGCAGTCTGTTATCCCGGCTTTTACAGAATATTCTTGTTC  
15 TATTTTAGAAATTTCCGGAGTAGTTTATTTGCAGTCTGTTGATTATGTGCAGTAGACCCGGGACACTGCG  
TTTTACCGATCACCTTGAATGTGGTGCCTGGATGTGCCCTTTTTTTTCCTGAAATATTATTAATT  
TTCTATTGTGAGTTCATCAGTTCATAGTTTTTTTAGTAAAGCAAAATTAAGGCTTTTAAAAATGT  
ACAACTTCAGAAATATAATCTGTTAGTCAAATATTTGTTATTAACATTTCTGTAATATGAAGTTGTAAT  
CCTGGCCGTGAGCTTGAAGCTTACTTTTGATTCTTAAAGCCTATGTTTTCTAAAATGAGACAAATACGG  
20 ATGTCTATTTGCCCTTTTATTGTAACCTTTAAATGAAATAATTTTCATGTCAATTTCTATTAGATATATCAC  
TTAAATATTTGGTTTTTAAATCACAAGAATATGTATTCTTTAATAAAGATAATTTATGATCATGGTATAA  
TTAATTGAAATTTATTAAAAATCTGTTTTATTAA

&gt;DEX0360\_034.nt.1

TGGGTAAATTGGATTCTCACCCCTCCGCCCTACGCACTGCACTNCGACTCTTAGAGATCCCCGGGGAGCCG  
GGGCAGACGTCCGTAGCGCCCCCTCCCGAGGAGGTCGAGCCGGGCAGTGGGGTCCGCATCGTGGTGGAGT  
25 ACTGGTGAGCGGCCCCGGCTGGAGGACCCGCACCCTGGTCCCGCGGGCCGACGGAGGTGGGTCCACGGG  
AGGCCCCACCCCCGAATCCCCAGCCAGCCCATCTCTTGACTCCCCAGTGAACCCTGCGGCTTCGAGGC  
GACCTACCTGGAGCTGGCCAGTGTGTGAAGGAGCAGTATCCGGGCATCGAGATCGAGTCCGCGCTCGGG  
30 GGCACAGGTGCCCTTTGAGATAGAGATAAATGGACAGCTGGTGTCTCCAAGCTGGAGAATGGGGCTTTTC  
CCTATGAGAAAGATCTCATTTGAGGCCATCCGAAGAGCCAGTAATGGAGAAACCCTAGAAAAGATCACCAA  
CAGCCGTCTCCCTGCGTCATCTGTGACTGCACAGGACTCTGGGTTCTGCTCTGTTCTGGGGTCCAAA  
CCTTGGTCTCCCTTTGGTCTGCTGGGAGCTCCCTGCTCTTTCCCTACTTAGCTCCTTAGCAAAGA  
GACCCTGGCCTCCACTTTGCCCTTTGGGTACAAAGAAGGAATAGAAGATTCCTGGCCTTGGGGGCAGGA  
35 GAGAGACACTCTCCATGAACACTTCTCCAGCCACCTCATACCCCTTCCCAGGGTAAGTGCCACGAAAG  
CCAGTCCACTCTTCGCTCGGTAATACCTGTCTGATGCCACAGATTTTATTATTCTCCCTTAACCCAG  
GGCAATGTCTAGCTATTGGCAGTAAAGTGGCGCTACAAACACT

&gt;DEX0360\_034.nt.2

TAAATGAAGCCATGAAGTCCAGCGGACACCGGGAGTGGGGAGTGGGGAAGCCCGGCACTCCGGGAGACCG  
GGCCAGGGAAGGAGGGTCTGGACCGGACCCAGCCCCCTGCCCGGGGAGCGAGCTCCGGAGCTGCCCTACGA  
GGTCAAAACGTAGCAGTGGCGGAGACCCGAGGGGGCGCCGAAACGCCACCCTCGGCCCTCCCGCTCC  
AGAGGCCCCCGCCCGTACGTGCCCGCGGTTTCGCGTCAACCCGGAAGCAGGGGGCCGAGCGGACCGGCC  
40 GCGATGAGCGGGGAGCCGGGGCAGACGTCCGTAGCGCCCCCTCCCGAGGAGGTCGAGCCGGGCAGTGGGG  
TCCGCATCGTGGTGGAGTACTGTGAACCCTGCGGCTTCGAGGCGACCTACCTGGAGCTGGCCAGTGTGT  
45 GAAGGAGCAGTATCCGGGCATCGAGATCGAGTCCGCGCTCGGGGGCAGAGTGCCTTTGAGATAGAGATA  
AATGGACAGCTGGTGTCTCCAAGCTGGAGAATGGGGGCTTTCCCTATGAGAAAGATGTGAGTATTTACA  
GCGTTGGGAGGACCTCTTGGTCACCTACCCCAACAGTGCATCATCTGTCTATCCACTCCTTAGCTCA  
TTGAGGCCATCCGAAGAGCCAGTAATGGAGAAACCCTAGAAAAGATCACCAACAGCCGTCTCCCTGCGT  
50 CATCCTGTGACTGCACAGGACTCTGGGTTCCTGCTCTGTTCTGGGGTCCAAACCTTGGTCTCCCTTTGGT  
CCTGCTGGGAGCTCCCCCTGCCCTTTTCCCTACTTTAGCTCCTTAGCAAAGAGACCCTGGCCTCCACTTT  
GCCCTTTGGGTACAAAGAAGGAATAGAAGATTCGCTGGCCCTTGGGGGCAGGAGAGACACTCTCCATGA  
ACACTTCTCCAGCCACCTCATACCCCTTCCCAGGGTAAGTGCCACGAAAGCCAGTCCACTCTTCGCC  
TCGGTAATACCTGTCTGATGCCACAGATTTTATTTATCTCCCTAACCAGGGCAATGTCTAGCTATTGG  
55 CAGTAAAGTGGCGCTACAAACACT

&gt;DEX0360\_034.nt.3

TGGGTAAATTGGATTCTCACCCCTCCGCCCTACGCACTGCACTNCGACTCTTAGAGATCCCCGGGGAGCCG  
GGGCAGACGTCCGTAGCGCCCCCTCCCGAGGAGGTCGAGCCGGGCAGTGGGGTCCGCATCGTGGTGGAGT  
60 ACTGGTGAGCGGCCCCGGCTGGAGGACCCGCACCCTGGTCCCGCGGGCCGACGGAGGTGGGTCCACGGG

DEX-0360

195

PATENT

AGGCCCCACCCCGAATCCCCAGCCAGCCCATCTCTTGACTCCCCAGTGAACCCCTGCGGCTTCGAGGC  
GACCTACCTGGAGCTGGCCAGTGTGTGAAGGAGCAGTATCCGGGCATCGAGATCGAGTCGCGCCTCGGG  
GGCACAGGTGCCTTTGAGATAGAGATAAATGGACAGCTGGTGTCTCCAAGCTGGAGAATGGGGGCTTTC  
CCTATGAGAAAGATGTGAGTATTTACAGCGTTGGGAGGACCTCTTGGTCACCCCTACCCCAACAGTGCATC  
5 ATCCTGTCTATCCACTCCTCTAGCTCATTTGAGGCCATCCGAAGAGCCAGTAATGGAGAAACCCCTAGAAAA  
GATCACCAACAGCCGCTCCTCCCTGCGTCATCTGTGACTGCACAGGACTCTGGGTTCTGCTCTGTTCTG  
GGGTCCAAACCTTGGTCTCCTTTGGTCTGTGGGAGCTCCCCCTGCTCTTTCCCTACTTAGCTCCT  
TAGCAAAGAGACCCTGGCCTCCACTTTGCCCTTTGGGTACAAAGAAGGAATAGAAGATTCCTGGCCTTG  
10 GGGGCAGGAGAGAGACTCTCCATGAACACTTCTCCAGCCACCTCATACCCCTTCCCAGGGTAAGTGC  
CCACGAAAGCCAGTCCACTCTTCGCCTCGGTAATACCTGTCTGATGCCACAGATTTTATTATTCTCCC  
CTAACCCAGGGCAATGTCAGCTATTGGCAGTAAAGTGGCGCTACAAACACT

&gt;DEX0360\_035.nt.1

GACAGTCTGGCTGTGGCAGGGTCTCGGAAACCATGGGTTATTGCAGTGGCAGGTGCACGCTTATCTTTA  
15 TCTGTGGCATGCAACTGCCCTGGATTGTGGTATCATTTCTATCACTGTCATTAGCCTGCTTTCCTTGCTA  
GGCGTGATCTTGGTTCTTATCATTAACCAAGGATGCTTCAAATTCCTTCTTACATTCTTGTGCAATTAG  
CTGTAGGAACAATGAGTGGAGACGCCCTTCTTCACTACTGCCCATTCCTCAGGGTGGACATGATCACAG  
TCACCAACATGCACATGGGCATGGACATTCTCATGGACATGAATCTAACAGTTTTTGGAGAATATGAT  
GCTGTATTGAAAGGACTTGTGTCTTAGGAGGCATTTACTTGTCTATTATCATTGAACACTGCATTAGAA  
20 TGTTTAAGCACTACAAACAACAAAGAGGAAAACAGAAATGGTTTATGAAACAGAACACAGAAGATCAAC  
TATTGGAAGAAAGCTTTCAGATCACAAGTTAAACAATACACCAGATTCTGACTGGCTTCAACTCAAGCCT  
CTTGCCGGAAGTGTGACTCGGTGTGTTCTGAAGATCGACTTAATGAACTGAACTGACAGATTTAGAAG  
GCCAACAGAATCCCTCTTAAAAATTACCTTTGTATAGAAGAGGAGAAAATCATAGACCATTCTCACAG  
TGATGGATTACATACCATTATGAGCATGATCTCCATGCTGCTGCACATAACCCAGCCGAGAACAAA  
25 TATGTGCTGAGGAAGCATAATCACCAGTGGCACCACAGCATTCTCATCATTTCCCATGGCCCTGTCAAT  
CTGGATCCGATCTGAAAGAACAGGAATAGCTAATATAGCCTGGATGGTGTGATCATGGGGGATGGCATCCA  
CAACTTCAGTGATGGGCTCGCAATTGGTGCAGCTTTCACTGCTGGATTGACAGGAGGAATCAGTACTTCT  
ATAGCCGCTCTCTGTGATGAACCTGCCACATGAATTAGGAGATTTTGCAGTTCTTCTTAAAGCAGGCATGA  
CTGTAAAGCAAGCAATTGTATACAACCTCCTCTTGCCATGATGGCTTACATAGGCATCATATAGGCAC  
30 AGCTGTTGGTCAAGTATGCCAATAACATCACACTTTGAGATCTTTGCAGTCACTGCAGGCATGTTCTCTAT  
GTAGCCTTGGTGGATATGCTTCCAGAAATGTTGCATGGTGTGATGGTGACAATGAAGAACATGGCTTTTGTCT  
CTGTGGGGCAATTCATCCTTCAGAAATTTAGGATTGCTCTTTGGATTGTCATTTATGCTGGTGTGCTTCT  
CTATGAAGATAAAATTTGTGTTTGACATCCAGTTTGGACCTTTCCAGTAATCACTGTTGATTACGAGAAT  
GTTACCATGCACTTTGCACTGTCTCTGTACTGTATGCACATTGCTCAAAGGAAAGTCACTAGTGGCTTGC  
35 ACTACTTACAGTTTTCATAGATTTGAGCCTAACACAGAGGCTGGTGTCTAGTACTGTTTCCCTGCAC  
GTAGGGGCTCTTTAAAAATATAAGCTTGTGATAAAGAGAGGAGAATATGGGACTCCATGAACAGTGT  
GATATGTTTGTATTAAGACTTTTACAAAATAATCATATAAAACACTAGTCTCTTTATTAGTAGAACTTC  
TGTGGCTATGCGAATAAGAGATCGAACAAAAAATCATTTAAACTTTAAAAATATTTTAAATGGACT  
TTGGGGAGACATTTTGTGTGTTTAAAGATGAATGTAGTGCTCTTTAATTCAGTACATATATTCAT  
40 TGGGTGATAGGGATCAACTTGACACAACCTTGAACCTGCATAAAGTAGACATAGGAACTAGAGGAAGCT  
CAGGCTGCATTAGAGTATGAATTTAGCATTGGGAAAAGCCCTTATTCTTGAATCTAGAGTTACTATTTT  
GTATATATTTGCATAGTGTTTAAACCTGCAGCCTAAACTACTGAAATTTGTGATTTGTATGTTTGTGTGAG  
CTTCAGTTTAAATGAAAGATTCTAATGGTCTCTTGTATTATTATAATACTTGGTGTGGGGTGTCTTCT  
45 TGTCTTGTCTTCTTACTTTAATTTTGTCTTGTGATTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT  
GGAGCATGTGGTCTTTTAAAAAATGTAAACCTCTAGAAAAATATCAAAGAAATGAACAGACGTGGT  
AAATAGTTGATTTCTCTATTTTAAACAGTACCAACTAGTTAATTTGGGAAATGTAAGTCTGAATGTTTCA  
TTGCTTTTACCAGTTTGGCACTGGAACCAAGAGCACATGTCGTGGCTGGCTACAGGTTGTAAAGCAGAAA  
ATCGAAGTTTACCATGTCTGTAATGTGTACATGAAGTGTCAATTTAGAACAGTTACTAGGATAAACTCCA  
50 TTATTGCCATGGCTGTGATGGTACCAAGTGAAGTGAAGATGCATTTAAATTTACTCAGCTGAAATCACT  
TGATCATCTTGTGCCAAGATATGCTGTTGGTGCCTGATAGGGATTAGTCTTTTGGTGGCCTGTTCTCTCT  
ACCATAATTGTGAATGATTTGTGAGAAGTGAAGCCATGTTTATCCTGAATTTTACTTAAATAATTTGTA  
TTACTAGTCATATGCATGTAGCTTCTGTTTACATCCTATGCCACATGGCTTCTATTTATGCCAGGTAAA  
CTGTATTTGAACATATGTGCAGCTAGCTTGTGTTTAAATCTGCTTGGCAACCAAGTGTAGCTGCTGTAACAT  
55 CTATCTTATTGTTCAAATATATAAGAGCCAACTCTTTCCATTCCATCTAAATGTTTCTTCTTCTTCTTCT  
TCTCT  
ATTTATAGATTATTGCCAGTGTCTTTTCTGTATGCTATAAGCAAGGGAGCTTAGGTGTTATTTCTTTAAT  
TTATGCTTGAATCTGAAAAATTATTTCTGACTTACTCCATGGCCTCCTTATAATAGTAGAAGTTTATA  
TATAATTAATTTTCTAGCATTGGGCACTGAATTAGGACAGTCTCATCTCATTTGCTTGGCCCTTCAAGCAA  
60 CCTAGCTAAAAGGTGCTGATATTTTATTAGTACTGCCAACTTCAAGTGATTTAGATATCTATCTATA  
TCTAGATTTCTGAACCAAGATATATTTATAGTTCACTTTTGGGTTTATACCCAGGTAGGATTTCTGCA

DEX-0360

196

PATENT

TTCCAGCATTAAATCTGCTTCATTTTAGAACCCTTTATAAAAGCAATAGCTGGAATATACTCCCAGTTTAA  
 AAATAAATAAATGCCTGATTGATTTAAAGCAAGTAGGTTATGCTGAAGTATATAAAGAAGTTTATATTC  
 TCTCAAAAATGGTATATCTTTCTTTATTTGCTAGATTCTTACAAATCTTTTAAGAGGGCTGTAACAGTT  
 5 GCTGCTAGTATTAGGGTCCACATCATTCTAATGTATAGTTTCAAGTCTTAATAGACAATCTGAATTTCCA  
 CTACATTTCTTTTGGCTCCAACATTCTTTTAGCTTGACCAGTCTAATTTAAATGTGTTTGTGGAGGT  
 CATTAACGTTACTTGTACAATGCTGTCTCATGATCCATATGAATTTTGGTATATATCAATCAATC  
 AATCAATCAATCACATTGCATTCAATCAATCAGCTGTGATTGATTGATTATGCTTAGAAATACTATAGTA  
 ACTAGATGCAGTGTGAATTTTTCATTAAACAAACAAACAGTCAAGTGGCTTAAATGTGATTATGGTCCCT  
 10 GCAAGGTGATTCTTGTCTAAAATATCTAAACTTTTGTGTTGTTTAACTGAATCATTTTAACTTAAAAA  
 GCTGGAATAATCAAAATGCTGTTTTTTTTTTCATTGTCAACAGTGGTGTGTCATTTTATGTATGTTCCCTA  
 ATGCTTATGGAACCTCTCCAAAATAAAGTTACTCAAAGAGAGCAAA

&gt;DEX0360\_036.nt.1

GGAGAGATCGTCCAGGAGCGGTGTTGATGCGGCAAAGGGCAACAGGAAGGGCATTAGGACTTGAAATCG  
 15 GAGACGCACGCAGGGGAGGGAGTCAGTGTGCGAACCTGGTAGGCCCTGGGAGAACTCCGGCTTTTCGTCT  
 GCGTGAGCTGGAGAAGAGCCGAAGGTTTCTGCGACAGCACGGACCTGCGTGCCTCAGCTTTAAGGAAAT  
 CACCGTGGCCGCCGCTGTGAACGCAGAGAAGGGCGGAGCGTGGGAGCAGGAACCAAGGCGGTGGGAAA  
 CGGTGGGGCTTTCTGAGTGTATTGGAAAGTAGAGCCACAGATCTGCTGCAGACCAGAAAGGGGCGCGAG  
 20 AAAGAGCGGACAGAGGCGAGACGCCGGGGCTGGCGGCGATGGAGCAGCAGTCCGAGGACGCGGAAGGCCTG  
 CGAGAGTCGCCCCGCGGCCAGCGCCGGCTTCGGGTCCCACCTTGGCGGTGATGTTGTGCACGTAGGGGC  
 ACGTGTTCAGGCGAAGCGGTGGCAGCGTTGTCCCTCCTCCACGATCAGCCCCGTTCGCCGAGCCGGGGCA  
 GAACAGCAGCATGGTCTCGAACTCCGCGAGGCTCCAACCTCCGGCGAGTCCCACTGCCGCTCAGCGCCGAT  
 GCGCCGCCCGCCTCGAGCTCACATTGGTCTTGGCAGCCTTCCCGGCACACCAACCAACCAATAGACAGGG  
 25 CGATTCTGCGCTCCCGGCCCTGCTGCAGGCTGTCTCGCACTTGTCTCATTTGGTCACTGCAGCCGCCACCCC  
 CCGGCGCGCCAGTGGCTGGGCGGCCCTCGCTGGGGCGGCGCAGTTCTCGCGCTGCGCGCTTGGCCTC  
 CCTAGTGCGGGCTGGCAGTGCGGGCGAGGCCCGCTGAGAGGGGCGGCCCTGGAGGAGACGGAGGCGGCG  
 GGTGGGCCCCGAGGCGCAAGAGGAAGATGAGGACGAAGAAGAGGCGCTGCCGCACTCCGAGGCCATGGACG  
 TGTTCAGGAGGGTCTGGCTATGGTGGTGCAGGACCCGCTGCTCTGCGATCTGCCGATCCAGGTTACTCT  
 30 GGAAGAAGTCAACTCCCAAATAGCCCTAGAATACGGCCAGGCAATGACGGTCCGAGTGTGCAAGATGGAT  
 GGAGAAGTAATGCCGTGTTGTAGTGCAGAGTCCACAGTCCCTGGACCTGAAGAAGGCCATCCAGAGAT  
 ACGTGCAGCTCAAGCAGGAGCGTGAAGGGGGCAATTCAGCACATCAGCTGGTCTTACGTGTGGAGGACGTA  
 CCATCTGACCTCTGCAGGAGAGAACTCACGGAAGACAGAAAGAAGCTCCGAGACTACGGCATCCGGAAT  
 CGAGACGAGGTTTCTTTCATCAAAAAGCTGAGGCAAAAGTGAGCCTCCAGACAGGACAACCTCTTTCATC  
 35 ACTGGTGGCTGAGCTTTTTCAGCAGGAATGGGTCTCGAATCATCGTGCTCTTTCACAGAAAGGACG  
 TTGTGGTGGCCTCACCCAGGCATGCCCAACAGGAAGTGTGAGCATTAAACCTGGGGGCCCTCAGGACATA  
 GGACAGGCTGAGCAGTGTCTCCCTCCTTTTCATGTACTTGGCCTGAGACTGACCTCTCCCTAGGTCCAAAT  
 GCCCTAGTCACATGGAGACACGGCTGGCACTGTTAATAAACTGTTGGTTAGTTGAAGGACAAAAA  
 GGGGGCGGTGAAGTTACTCTGGGGCGAGTAGGACCAAGTTTGGAAAGGGCATGTGGGATTAAGAGAAGGGG  
 40 GGTAAAGTGCAGAAAGCATGGTTTGGAGAGATTGGGGGGAGAGAGCGAGAGGAGGGGAAAGGTGAGAAGG  
 GGGAGGTGTATAAGAGAGG

&gt;DEX0360\_037.nt.1

GGCACGAGGAGAGATCGTCCAGGAGCGGTGTTGATGCGGCAAAGGGCAACAGGAAGGGCATTAGGACT  
 45 TGAATTCGAGACGCACGCAGGGGAGGGAGTCAGTGTGCGAACCTGGTAGGCCCTGGGAGAACTCCGGCT  
 TTTCTGCTGCGTGAGCTGGAGAAGAGCCGAAGGTTTCTGCGCACAGCACGGACCTGCTGCTCAGCTTT  
 AAGGAAATCACCGTGGCCGCCGCTGTGAACGCAGAGAAGGGCGGAGCGTGGGAGCAGGAACCAAGGCG  
 GTGGGAAACGGTGGGGCTTTCTGAGTGTATTGGAAAGTAGAGCCACAGATCTGCTGCAGACCAGAAAGG  
 GCGCGAGAAAGAGCGGACAGAGGCGAGCGCCGGGGCTGGCGGCGATGGAGCAGCAGTCCGAGGACGCGG  
 50 AAGGCCCTGCGAGAGTCGCCCCGCGGCCAGCGCCGGCTTCGGGTCCCACCTTGGCGGTGATGTTGTGCAC  
 GTAGGGGACAGTGTGTCAGGCGAAGCGGTGGCAGCTGTGCTCCCTCCTCCACGATCAGGCCCCCTCCGCGAG  
 CCGGGGCGAGAACAGCAGCATGGTCTCGAACTCCGAGGCTCCAACCTCCGGCGAGCTCCCACTGCCGCTCA  
 GCGCCGATGCGCCGCCCGCCTCGAGCTCACATTGGTCTTGGCAGCCTTCCCGCCACACCAACCAACCAAT  
 AGACAGGGCGATTCTGCGCTCCCGGCCCTGCTGCAGGCTGTCTCGCACTTGTCTATTTGGTCACTGCAGCCG  
 55 CCCCACCCCCCGGCGCGCCAGTGGCTGGGCGGCCCTCGCTGGGGCGGGCGCGAGTTCTTGGCGGTGCGC  
 GCTTGGCCTCCCTAGTGCGGGCTGGCAGTGCGGGCGAGCCCCGGCTGAGAGGGGCGGGCCCTGAGGAGAC  
 GGAGGCGGCGGTGGGGCCGAGGCGCAAGAGGAAGATGAGGACGAAGAAGAGGCGCTGCGCACTCCGAG  
 GCCATGGACGTGTTCCAGGAGGGTCTGGCTATGGTGGTGCAGGACCCGCTGCTCTGCGATCTGCCGATCC  
 AGGTTACTCTGGAAGAAGTCAACTCCCAAATAGCCCTAGAATACGGCCAGGCAATGACGGTCCGAGTGTG  
 60 CAAGATGGATGGAGAAGTAATGCCCGTGGTTGTAGTGCAGAGTGCCACAGTCCCTGGACCTGAAGAAGGCC  
 ATCCAGAGATACGTGCAGCTCAAGCAGGAGCGTGAAGGGGGCATTACAGCACATCAGCTGGTAAGTGAAC

DEX-0360

197

PATENT

AACATTCCTTCATTATAGCCCTTCGTGGGGCTAGTGCCCTTCTTGCCACTGTCAACAGGCACCACCTGG  
 AAACAGCTCTCAGCTCTGCATGAGTACAGACCACTGAAAGTGATGAGCTCCCTGTCAAGAGTGATGAG  
 CTCCCTGTCAAGACAGTGCCTGCTTCTGTGCTGGGACTCCTGCCTCGGCCATCCCCAACATTCTGC  
 TCTTCCATCGGCATACCCCCATCCGAGCTGCTGGGTATCTTCACTTGCGGACACTGTGCGGAATTTCCAG  
 5 TGTGCTGGAAGTGGCTCCCTAGTTTTGGATGGTACACCTGTAGGGGCTCCCATCCCCTTCTCACCTGG  
 GTGCTGTCAAGCCCTCACTCTCCTATTGGATCAACTATCTGTTCACGTAGTCTCAACACTGTGCGCTGTT  
 GCATTAGCAAGTTTTGTTGGCCAAGCCGCCCCAGACAGCCCTCTGAGAACAGAGCCTCCTGTAGCTGC  
 CTCAGACCCAATCTGCACATTGTACAGAACAGCCAGGTAGGGAGGACAGCTGCCCCAGGTCCCATAGGA  
 CTGCATGCCTCAAGCCCACGTCATGCAGAGCCACTCAGCTCACCTGTCTAGGGCACGTGGTTTACCTGC  
 10 ATCCCCCTCTTGACAGTCCCTACGTGTGGAGGACGTACCATCTGACCTCTGCAGGAGAGAACTCACGGAA  
 GACAGAAAGAGCTCCGAGACTACGGCATCCGGAATCGAGACGAGGTTTCTTTCATCAAAAAGCTGAGGC  
 AAAAGTGAGCCTCCAGACAGGACAACCTCTTTCATCACTGGTGGCTGAGCTTTTCCAGCAGGAATGGG  
 TCCTCGAATCATCGTGCCTCTTTCACAGAAAGGACGTTGTGGTGGCTCACCCAGGCATGCCCAACAGG  
 AACTGTCAAGATAAACCTGGGGGGCCCTCAGGACTAGGACAGGGTGAGCCAGTGCTCCCTCTCTTTCATGTA  
 15 CTTGGCCTGAGACTGACCTCTCCCTAGGTCCAAATGCCCTAGTCACTGGCAGACCCACGGCTGGCCCCA  
 CTGTATAAAATAAACCTGTGTTGCTTCTTATCTTAGTTTGAAGTAGAAAGCCACAGTAACCTGGGTAGC  
 AAAGACTGAGATTGCCCCATCACAGAGGTGAGTTAAGGGGAGAGAATTGGTACAGGCGAGTCTTATAGTC  
 CAAGATGGCGCCACACCACCAAGCCTTGAGGCCACACCCTCCCCAAACCACACAACCTGTGTACCATG  
 ATCTCCACAGCAAGGAGGAAATAAAAGCAGAGCGGCTTTAGGGTTTGCATCTTGAGCTCACAGTG  
 20 >DEX0360\_037.nt.2  
 GGCACGAGGGAGAGATCGTCCAGGAGGCGGTGTGATGCGGCAAGGGCAACAGGAAGGGCATTAGGACT  
 TGAAATCGGAGACGCACGAGGGGAGGGAGTCACTGTGCGAACCTGGTAGGCCCTGGGAGAACTCCGGCT  
 TTTCTGCTGCGTGAGCTGGAGAAGAGCCGAGGTTTCTGCGCACAGCACGGACCTGCGTGCTCAGCTTT  
 25 AAGGAAATCACCGTGGCCGCGCTGTGAACGACAGAGAAGGGCGCGAGCGTGGGAGCAGGAACCAAGGCG  
 GTGGGAAACGGTGGGGCTTTCTGAGTGTATTGGAAAGTAGAGCCACAGATCTGCTGCAGACCAGAAAGG  
 GGCGCGAGAAAGAGCGGACAGAGGCAGACGCGGGGCTGGCGCGATGGAGCAGCAGTCGGAGGACGCGG  
 AAGGCCTGCGAGAGTGCCTCGCGCGCCAGCGCGGGCTTCGGGTCCACCTTGCGGGTGATGTTGTGAGC  
 GTAGGGGACAGTGTGTCAGGCGAAGCGGTGGCAGCGTTGTCCCTCCTCCACGATCAGCCCGTTCCCGCAG  
 30 CCGGGGACAGAACAGCAGCATGGTCTCGAATCTCCGAGGCTCCAACTCCCGGCAGTCCCACTGCGCGCTCA  
 GCGCGATGCGCGCGCCCGCTCGAGCTCACATTGGTCTTGGCAGCCTTCCCGCCACACCAACCAACCAAT  
 AGACAGGGCGATTCTGCGCTCCCGGCCCTGCTGACAGGCTGTCTCGCACTTGTCAATTGGTCACTGCGC  
 CCCCACCCCCCGCGCGCCAGTGGCTGGGCGGCCCTCGCTGGGGCGGGCGCAGTTCTTGCGCGTCCGCG  
 GCTTGGCCTCCCTAGTGGCGGCTGGCAGTGGCGGCGAGCCCGGCTGAGAGGGGCGGCCCTGGAGGAGAC  
 35 GGAGGCGGCGGGTGGGCCCGAGGCGCAAGAGGAAGTAGGAGCAGAAAGAGGGCCTGCCGCACTCCGAG  
 GCCATGGACCTGTTCCAGGAGGCTGTGCTATGGTGGTGCAGGACCCGCTGCTCTGCGATCTGCCGATCC  
 AGGTTACTCTGGAAGAAGTCAACTCCCAAATAGCCCTAGAATAAGGCCAGGCAATGACGGTCCGAGTGTG  
 CAAGATGGATGGAGAAGTAATGCGTAAGTGCTACCCCTCCTCCCTTCAGGTTATGTGGTCCAGGCTTTTAC  
 AGCAGGAAGACCTAACAGTGCTGGTTCAGCCTGCTCAGAACTCACAGGCCATGCCAGGGGTACTGGGGC  
 40 AACCACAAACCTGCCCTGTGCACAGAGGTGTTGGTTCTCTTCTGCCATCGGAGGCTGTGGCTTTGGGTT  
 CTCACCATGGATCTTCTCCCATCTGTGTCCGTATGGTGGTGCAGCCGTGGTTGTAGTGCAGAGTGCCACAGTCC  
 TGGACCTGAAGAAGGCCATCCAGAGATACGTGCAGCTCAAGCAGGAGCGTGAAGGGGCAATTCAGCACAT  
 CAGCTGGTAAAGTGAACAACATTCCCTTCATTATAGCCCTTCGTGGGGCTAGTGCCCTTCTTGGCACTGT  
 CACCAGGCACCACCTGGAACAGCTCTCAGCTCTGCATGAGTACAGCACCCTGAAGTGATGAGCTCCCT  
 45 GTCACAAGAGTGATGAGCTCCCTGTACAGACAGTGCGGGTGGTTCTGTGCTGGGACTCTGCTCGGC  
 CATCCCCAACATTCTGCTCTTCCATCGGCATCACCCATCCGAGCTGCTGGGTATCTTCACTTGGGGACA  
 CTGTGCGGAATTTCCAGTGTGTCTGGAAGTGGCTCCCTAGTTTGGATGGTACACCTGTAGGGGCTCCC  
 ATCCCCCTTCTACCTGGGTGCTGTACAGCCCTCACTCTCCTATTGGATCAACTATCCTGTTCACTGAGCT  
 50 CAACACTGTGCGCTGTGTCATTAGCAAGGTTTGTGGCCAAGCCGCCCCAGACAGCCCTCTGAGAACAG  
 AGCCTCCTTGTAGCTGCCTCAGACCCAATCTGCACATTGTACAGAACAGCCAGGTAGGGAGGACAGCTG  
 CCCCAGGTCCCATAGGACTGCATGCCTCAAGCCACGTCATGCAGAGCCACTCAGCTCACCTGTCTCAGG  
 GCACGTGGTTTACCTGCATTCCCTCTTGCAGGTGCTACGTGTGGAGGACGTACCATCTGACCTCTGCAG  
 GAGAGAAACTCACGGAAGACAGAAAGAAGCTCCGAGACTACGGCATCCGGAATCGAGACGAGGTTTCTT  
 CATCAAAAAGCTGAGGCAAAAGTGAGCCTCCAGACAGGACAACCTCTTTCATCACTGGTGGCTGAGCTTT  
 55 TTCCAGCAGGAATGGGTCTCGAATCATCGTGCCTCTTTCACAGAAAGGACGTTGTGGTGGCTCACCC  
 CAGGCATGCCCAACAGGAACCTGTCAGATAAACCTGGGGGGCTCAGGACTAGGACAGGGTGAGCCAGTG  
 CTCCCTCCTTTTCATGTAATTGGCTGAGACTGACCTCTCCCTAGGTCCAAATGCCCTAGTCACATGGCAG  
 ACCCAGGCGCTGGCCCACTGTATAAAATAAACCTGTTTGTCTCTTA

60 &gt;DEX0360\_038.nt.1

45 ATCTAGCTCTGCATGCCACCCAGGGAGCTCAGGAGGGGAATTGCACTGAAGATTGTGCCATCGTGAAG  
CAAGAGCACTGGAACCTTAACTCCACCATCAGGCCCTGTACAGGAGAACAAAGAAGGAAGGCAGAGGAG  
ATCATGCTCCGGCCAGCAGGGAATCTCCATTTTTTTTCAGCCTCATACCTTGGAAAGTACAAAGGAGTGAG  
AGCTGGGACTACCAGCCAGAGGGTTCACTGGAGGTAGTGGGAGGGGAAGATGGGTTCTGCATGGAGCCACT  
CCAGGGACTTTTCTTCTGTCTACAGCCTGCAATCACTCTAGCTGTCTCAGTCCCATCTCATCAAT  
50 GACCTCGTCTCCTGATTTTGTCAATATCTAGGTGACCTTCTCTCTTTCCATCTTCAAACGCTTGATCA  
TTGATGCTCCCTTTTCTCTCTCTCTCCTCCTGGGAAAAGAGAAGGACCAACATCCCCCTTTCCCTTGCT  
CCTGTGCTGTCCCGAACCCCTCTGAGACCTGGCTCTAGCAGTAAGTCCCTCTCTCTTCTGCAGCACCAGCC  
TCTGCCCATCCCTGCCCTCTGCAGACAAAGCTCTCACAAATGGTCTTGCACTTTAAGAACCTTTTGTGGCAAAC  
CCTGGCAAATCCTGCCACTTGTTTCCACTTCTCAAAATGGCTTTGAGGTCAACTTACCTATCCCAT  
TGACCCGTGCTCCTGTATCTGATGTTTGTACCCCTTCTCCTTGATCCACTCTGGCAACTCTCCCACCTCCCT  
55 TTCTTGGATCAACTGTCTTGCTCCTCAGTCTTGATCAATGCCTCCTTCTCTCTCTTTAGCCTTGGCCCTT  
TTTGGCCAGGGAAATAAATGTGAAATACATAAAGCTTCATTTTATCTTATGATTATAGCTATGTTGATGT  
TACCCAAGACCTAAAGTCAACACTCTAATTACACTTCCCTCCTGTGTTCTGGGTCTCTTGGACCAGT  
CCTTACTCTGGCTCCCTCCTGGATGTCTCCAGACTTCTAATTAGAATTACTGTTTCCATATATCAAGCT  
AATTATCTTTCCACCAACCTCCTCCATCCTTGGGTGAAAGTCACTTGGTGTCAAAGTCAAGAACTCT  
60 GGGTTTCATTCTTGCGGTAGGTAGAATAATGCCCCCAGGCCCCAGGTTTTTGACATCCGAATCCCTGGGAC

DEX-0360

199

PATENT

TTTGCAGATGTGATTTCAGTTTATAGGATTTTGTAGATGGGGAGATTATCTGGGAGAGCCTGATGTCATCATAA  
GGTTCCTTATAAGAGGGAGGCAGGAGGGTTAGAGTGTAGTAGTAAGAGATGCAACAGTGGGAAGCAAGAGGTT  
GGGGTGATGTGGCCACAAGCCCAGGAGTGTGACAGACATCAGAAGCTGGAAGGGACAAGGAATGGTTTC  
TCTCTGGAGCCTCCAGAAAGAACAGCCCTGCTGACACCTTGATTTTAGCCTTGGGAAGACTCATTTTGG  
5 ACTTCTGACCTTGAACGTTGTAAGAGAAATAAATTTACATATTTTAACTGGAATGTTTAT

&gt;DEX0360\_039.nt.1

TAAGCCTCATAGTCTAAGAAAGCCCTCAAGCAAGGCTAACATTTTGGTCATCTGCGAGAAGATTGAGCAC  
TCGGTGTCTTGTCTCTTTCAGCTTCGACAGCATCTTCTGGAGCAGCATGAGCTTCTCACTCTGACTCATA  
10 AGTCTCCCACCCTCATAAGCCCCACTGGGGAGTTTGGGGGCCCTTATTTGCCATGTCCCTGGAATTATTAT  
ATGCTCATCACTTTATGAASAAYAAATTTGTCTTKCCTGCCCTTAAAGTTACATTCGTTCTTCCGCTCAA  
ATCTGATCTGGTCCATTAAAGAGTGTTCGCAGACAAAGTTTCTGAAAGATTAGAGAAGAATCCCCCCCA  
AGATTGCCCCAACACTGAACCTACAGACAAACACTATTTTATTTAAATAAGGAGACAGCTTTCTAAAAGTA  
TACATTTCTCTAATAAAAATAGTTTATTATTTTGAATGATTTAATGGTTTCTACACAATTTACATCACAA  
15 CATGTAAATTTTAGCAGTAACATCTGATTTCAACAGCACATCATGCTATTCTTTCATAGAGCCTTCAGA  
GATTCAGTCTAAACAAAATTTCTTAGTTGGCATCAAGGCATGATCACTTTAGAGGCTTTTAAAGAAATT  
ATTTAAAGATGCAAATGCCCTCTGAGTGAAGTGTACTATCCCATCACTGAAGCCACAGGAACAAGTCCCTA  
CAATTTTAAAAGGCTCGATGGAATAATTTCTCAATCCTGAAATCCCTAGGGAAGGGGTCAGGAGAAAG  
TGCCATGGTTGATATTTAAGAACTCCACAGCTCTTAAAAATAAGCACTTATCCCTAACATGCAATACTGC  
20 AGATGCAAGTTAAACTTATCTGTTAACAGCTGCCTGCTGTTTCTGCTCCAGATGAAATGAAGCAACTC  
TTCTGATAACGAAGAGATACCTGTCTGAGGCAACGAAACATTGGCACACAGCACAGCCTCCTCAATCCA  
CTTGATCCCAACTCATCTCTCATTTATTTTCGGCTTCTTTTATTCCAGGATTAATGTAGTGAACATTTTC  
ATTTCTTTTCGCTTTTATTCTGCTTTTGTAAAAGCAGTATTTTGAGATGGACATTGCCTTTCATTGTAT  
TTCTCATCAATTCATTATTTTGTGGTTATAGCTTGACAAGCAATTAACTTTAAAATGGTAGATTCCGTA  
25 ACTTTAAATTTGGTAGCTTTTCAATTTGCTTAAATTTTGTGGCATATGCAGATAATGTTCTCATCAGTAGTA  
AGAATCTCAGGGTTATGCTTATTTCCCAATGGAGGATAGCATATAATCTTTTCTGCCTTACTTATCAA  
TTCACCAAGGAGCTGTTTTCTCTGCATCTAGGCCATCATACTGCCAGGCTGGTTATGACTCAGAAGATGT  
TATCTGAAAAAGTCTATAGAAAAAARATKTCCTCCCTCATCAACAAAAGCCACCCTCTAAGA  
GACATTCAGCTGAACCTATCACAATTTCTTAATCAGTTACAATTTACAAAACAGATAAGTTTAAAAATAACA  
30 ATTTACAAAAATTTTGAAGCATACCTTAACATCTTGTTTTGGCAGTTAAACAATGGAAAAGTATTTCTCCT  
ACACTAAAAAAGAACTTGCTTACACACAACCTGAAAATAGAATCTTACTTGATAATACAAAAGCTACCATC  
AGAAGAAATCCCTTCAGGATCATTAAGCCACTTCTTTGCTCTGCAGTTTCTATAGTAGTTTAAATTTAT  
TATTAATACCTGAAAAAATTTCCAAAAGAGAACACACACTACCATATCCAAACAACCTTTTGCATTTT  
CCATAATTGTAGTTAATGTCAGCCAGTAGGCCAGACCAACCCCCAGTTCAATACTTTCTTCCCCAAAA  
35 GCTCTATACCTTTGAAGGAAAACAGATACAGTATCAAAATATGACACTTTCTTGCCTTAAAGTATGCACT  
GGTACACCCAGTGGCTCATATTTAACTTCCCCAGCTTCCCAATTCAAACCTGGGGGAAAAAAGCTAAAT  
CATTGGGAGTTACTTGCCAACTTGAAGTTGATATTTCTTTACTTTTCCATTTCTAAGACTTTAAGTTCT  
CTGGCATGAGTTTATCTGCAATCATAACTAAACAATTACCTAAACCCACCCACCAATCCCAACCGTAA  
CAGGCCACTGCCAACTAATTGCCAATATTTGCCCTTCCCTTTAATAAACTTTTAAAGATCAGATTAT  
40 TGGAAAACCTTAACTTCAACATTTGGCCTACTCAAGCTTCTCTGAAGTTCTCTGAGATGATGAATGA  
ACCAAAGCTGCACTGTGCTGTACTTTTCAGCTTCAACTGGGAATACTCTTCCAAGGATAAAAGCAGCTCC  
AGTCCCTGAAGGTGTTCTGTGCCAACAGCACAGCGGTACATTACCAAATCGCACTGGCTCCTGGACTCTT  
TTCTATCTTTCACCACGAACCTGCTGCTTGTCTGCTTGTCTCTCAGTCTTAGCTTCATCAACACTGGTTC  
CTGGAATCCTGTCTGCTGCTGCTTCTTAGATTCACTGAATCCACTTCTGTGTAGCACCTGGGTCAGCTG  
45 TCAATTAATGCTAGTCTCAGGATTTAAAAAATAATCTTAACTCAAAGTCCAATGCAAAAAACATTAAAGTT  
GGTAATTACTCTTGATCTTGAATTACTTCCGTTACGAAAGTCTTACATTTTTCAAACTAAGCTACTAT  
ATTTAAGGCTTCCAAATCTTCTAACTCTTCCAAAAGCCTTCTGCCTTAGTTTCTTAAATTACACCA  
GTCTTTTGTAGTCTTTTGTATGTGATTTTAAACCAACTTCCCTTCTAGCTTCAAGTATTTCTTAAAT  
TGGTTCTGGTCTACGTAAACACCCCTCATCTTCTCAAGCTTTACCTTCTAAGTTCTGCAACACAGAAAT  
50 AAATTGATGGGCTTTTAAATAAATTTGGTTACCAATAATTTCTCATTTTTCAGTCTAGTTTATCCAA  
TTTTTGGCTTTATATTTTCTATCTTCTATACTTCTCCAATACTTGTCTTAGCTTGTTTTCTATTTCTA  
TCTGAAACTCTTGACAATATTTTCTATCTTGTCTTCTATCTTCCAATTTCTTCTAAGTTTGTAC  
ATTTTGGCCCTTAGCTTTTGTCTTCTAGCTTGTCTTTTCTTCTGCTTCTTCTTCTAGGTTTAAAT  
TATCTTTTCTTCTTAAAGTATGTTTATCTTCTAATTTCCCTATCTTCTTCTTCTTCTTCTGCTT  
55 TCCCGTATCTGTCTTCCAGTTTCCACTTCAACTTCTATCTTCTTCCAAATTTGTTTCTATCTTACCAC  
CCCAATTAATCTTCCATTTTCTGCTGCTTGTAGTAAAGCGTTAACTAGGCTTTAAATGACGCAATCTCT  
CCCTGCGTCATGGATTTCAAGGCTTTTAAATCACCTTCCGTTTAAATCTCTTTTAAAGA

&gt;DEX0360\_039.nt.2

60 TAAGCCTCATAGTCTAAGAAAGCCCTCAAGCAAGGCTAACATTTTGGTCATCTGCGAGAAGATTGAGCAC

DEX-0360

200

PATENT

TCGGTGTCTTGCTCCTTTCAGCTTCGCAGCATCTTCTGGAGCAGCATGAGCTTCTCACTCTGACTCATA  
AGTCTCCCACCCTCATAAGCCCCACTGGGGAGTTGGGGGCTCTATTGCCATGTGCCTGGAATTATTAT  
ATGCTCATCACTTTATGAASAAYAAAATTTGTCTTKCCTGCCTTAAAGTTACATTTCGTTCTTCCGCTCAA  
ATCCTGATCTGGTCCATTAAAGAGTGTTCGCAGACAAAGTTTCTGAAAGATTAGAGAAGAATCCCCCCA  
5 AGATTGCCCCAACACTGAACTACAGACAAACACTATTTTATTTAAATAAGGAGACAGCTTTCTAAAAGTA  
TACATTCTCTAATAAAAATAGTTTATTATTTTGAATGATTTAATGGTTTCTACACAATTTACATCACAA  
CATGTAAATTTTAGCAGTAACATCTGATTCTAACAGCACATCATGCTATTCTTTATAGAGCCTTCAGA  
GATTCAATGCTAAACAAATTTCTTAGTTGGCATCAAGGCACGTGATCACTTTAGAGGCTTTTAAAGAAAT  
ATTTAAAGATGCAAATGCCTCTGAGTGAAGTGTACTATCCCATCACTGAAGCCCACAGGAACAAGTCTTA  
10 CAATTTTAAAAAGGCTCGATGGAATAATTTCTCAATCCTGAAATCCCCTAGGGAAGGGGTGAGGAGAAAG  
TGCCATGGTTGATATTTAAGAACTCCACAGCTCTTAAAAATAAGCACTTATCCCTAACATGCAATACTGC  
AGATGCAAGTTAACTTATCTGTAAACAGCTGCCTGCTGTTTTCTGCTCCCAGATGAAATGAAGCAACTC  
TTCTGATAACGAAGAGATACCTGTCTGAGGCAACGAAACATTGGCACACAGCACAGCCTCCTCAATCCA  
CTTGATCCCAACTCATCTCTCATTATTTTCGGCTTCTTTTATTCCAGGATTAATGTAGTGTAAACATTTTC  
15 ATTTCTTTTCGCTTTTATTCTGCTTTTGTAAAAGCAGTATTTTGAGATGGACATTGCTCTTTCATTGTAT  
TTCTCATCAATTCATTATTTTGTGGTTATAGCTTGACAAGCAATTAACCTTTAAATGGTAGATTCCGTA  
ACTTTAAATTTGGTAGCTTTTCATTGCTTAAAAATTTTTTGGCATATGCAGATAATGTTCTCATCAGTAGTA  
AGAATCTCAGGGTTATGCTTATTCCCCAATGGAGGTATGACATATAATCTTTTCTGCTTTACTTATCAA  
TTCACCAAGGAGCTGTTTCTCTGCATCTAGGCCATCATACTGCCAGGCTGGTTATGACTCAGAAGATGT  
20 TATCTGAAAAAAGTCTATAGAAAAAARTKTCCTCCCTCATCAACAAAAGCCACCCTCTAAGA  
GACATTCAAGCTGAACATACAAATCTTAATCAGTTACAATTTACAAACAGATAAGTTTAAATAAACA  
ATTTACAAAATTTTGAAGCATACTTAAACATCTTGTTTTTCAGTTAAACAATGGAAAAGTATTTCTCCT  
ACACTAAAAAATTTGCTTACACACAATGAAAATAGAATCTTACTTGATAATACAAAAGCTACCATC  
AGAAGAAATCCCTTCAGGATCATTAAGCCACTTCTTTGCTCTGCAGTTTCTATAGTAGTTTAAATTTAT  
25 TATTAATCACCTGAAAAAATTTCCAAAAGAGAACACACACTACCATATCCAAACAATTTTGCATTTC  
CCATAATGTAGTTAATGTAGCCAGTGGCCAGCAACCCCAAGTTCAATACTTTCTTCCCCAAAA  
GCTCTATCTTTGAAGGAAAACAGATACAGTATCAAATTTATGACACTTTCTTCCCTAAATTAATGCACT  
GGTACACCCAGTGGCTCATATTTAACTTCCCCCAGCTTCCAATTCAAACCTGGGGGAAAAAATCTAAAT  
CATTTGGGAGTTACTTGCCAATTTGGAAGTTGATATTTCTTTACTTTTCCATTCTAAGACTTTAAGTTCT  
30 CTGGCATGAGTTTATCTGCAATCATAACTAAACAATTACCTAAACCCACCCCAATCCCAACCTTAA  
CAGGCCACTGCCAATAATTGCCAATATTTGGAGGGATGAGCATAAGGAGGGATGAGCATATGAGGGT

>DEX0360\_039.nt.3

TAAGCCTCATAGTCTAAGAAAGCCCTCAAGCAAGGCTAACATTTTGGTCACTCTGCAGAGAAGATTGAGCAC  
35 TCGGTGTCTTGCTCCTTTCAGCTTCGCAGCATCTTCTGGAGCAGCATGAGCTTCTCACTCTGACTCATA  
AGTCTCCCACCCTCATAAGCCCCACTGGGGAGTTGGGGGCTCTATTGCCATGTGCCTGGAATTATTAT  
ATGCTCATCACTTTATGAASAAYAAAATTTGTCTTKCCTGCCTTAAAGTTACATTTCGTTCTTCCGCTCAA  
ATCCTGATCTGGTCCATTAAAGAGTGTTCGCAGACAAAGTTTCTGAAAGATTAGAGAAGAATCCCCCCA  
AGATTGCCCCAACACTGAACTACAGACAAACACTATTTTATTTAAATAAGGAGACAGCTTTCTAAAAGTA  
40 TACATTCTCTAATAAAAATAGTTTATTATTTTGAATGATTTAATGGTTTCTACACAATTTACATCACAA  
CATGTAAATTTTAGCAGTAACATCTGATTCTAACAGCACATCATGCTATTCTTTATAGAGCCTTCAGA  
GATTCAATGCTAAACAAATTTCTTAGTTGGCATCAAGGCACGTGATCACTTTAGAGGCTTTTAAAGAAAT  
CAATTTTAAAAAGGCTCGATGGAATAATTTCTCAATCCTGAAATCCCCTAGGGAAGGGGTGAGGAGAAAG  
45 TGCCATGGTTGATATTTAAGAACTCCACAGCTCTTAAAAATAAGCACTTATCCCTAACATGCAATACTGC  
AGATGCAAGTTAACTTATCTGTAAACAGCTGCCTGCTGTTTTCTGCTCCCAGATGAAATGAAGCAACTC  
TTCTGATAACGAAGAGATACCTGTCTGAGGCAACGAAACATTGGCACACAGCACAGCCTCCTCAATCCA  
CTTGATCCCAACTCATCTCTCATTATTTTCGGCTTCTTTTATTCCAGGATTAATGTAGTGTAAACATTTTC  
ATTTCTTTTCGCTTTTATTCTGCTTTTGTAAAAGCAGTATTTTGAGATGGACATTGCTCTTTCATTGTAT  
50 TTCTCATCAATTCATTATTTTGTGGTTATAGCTTGACAAGCAATTAACCTTTAAATGGTAGATTCCGTA  
ACTTTAAATTTGGTAGCTTTTCATTGCTTAAAAATTTTTTGGCATATGCAGATAATGTTCTCATCAGTAGTA  
AGAATCTCAGGGTTATGCTTATTCCCCAATGGAGGTATGACATATAATCTTTTCTGCTTTACTTATCAA  
TTCACCAAGGAGCTGTTTCTCTGCATCTAGGCCATCATACTGCCAGGCTGGTTATGACTCAGAAGATGT  
TATCTGAAAAAAGTCTATAGAAAAAARTKTCCTCCCTCATCAACAAAAGCCACCCTCTAAGA  
55 GACATTCAAGCTGAACATACAAATCTTAATCAGTTACAATTTACAAACAGATAAGTTTAAATAAACA  
ATTTACAAAATTTTGAAGCATACTTAAACATCTTGTTTTTCAGTTAAACAATGGAAAAGTATTTCTCCT  
ACACTAAAAAATTTGCTTACACACAATGAAAATAGAATCTTACTTGATAATACAAAAGCTACCATC  
AGAAGAAATCCCTTCAGGATCATTAAGCCACTTCTTTGCTCTGCAGTTTCTATAGTAGTTTAAATTTAT  
TATTAATCACCTGAAAAAATTTCCAAAAGAGAACACACACTACCATATCCAAACAATTTTGCATTTC  
60 CCATAATGTAGTTAATGTAGCCAGTAGGCCAGCAACCCCAAGTTCAATACTTTCTTCCCCAAAA

DEX-0360

201

PATENT

GCTCTATACTTTGAAGGAAAACAGATACAGTATCAAATTATGACACTTTCCTTGCCCAAATTAATGCACT  
GGTACACCCAGTGGCTCATATTTAACTTCCCCAGCTTCCCAATTCAAACTGGGGGAAAAAACTAAAT  
CATTGGGAGTTACTTGCCAACCTTGAAGTTGATATTTCTTTACTTTTCCATTCTAAGACTTTAAGTTCT  
CTGGCATGAGTTTATCTGCAATCATAACTAAACAATTACCTAAACCCACCCACCAATCCCAACCGTAA  
5 CAGGCCACTGCCAATAATTGCCAATATTTTACCTCGCCGCGACCACGCTAAGGGC

&gt;DEX0360\_040.nt.1

TGCTTTGTTGTCTACTTCCTTGTGCCCTMCGGAGTCGAGCTCTGTCAGTGCATGATTCTTGCCAATCGCT  
AAACGTAGGACTCGAGGAAGGCCATTGGCAATTCGCTAAGAAGACAGTGCAAGTGCCATATAAAAAACGAC  
10 AGTTTAGGGGAAAAACAAACCAATACCCGAAAGCTGAGAGGCCAGCTTTTTAATCGTCATGGTTTTATG  
TAAATAAAACAGCACGTGGAAGGTATTGTAAGCGCTTGGTGGCTGCTCGAGCCCCAGAAAGGTGCTTG  
GTTCTTCCACCTCTGCCACTAATTCGACATCAGTTTCATCGAGGAAAGCTGAAAATAAATATGCAGGAGG  
GAACCCCGTTTGGCTGCCGCCAACTCCCAAGTGGCAAAAAGGAATTGGAGAATTCTTTAGGTTGTCCCT  
AAAGATTCGAAAAAGAGAATCAGATTCTGAAGAGGCAGGAAGCAGTGGCTTAGGAAAAAGCAAGAGAA  
15 AAGCATGTCCTTTGCAACCTGATCACACAAATGATGAAAAAGAATAGAACTTTCTCATTCATCTTTGAAT  
AACGTCCTCTTGTTTACCTGGTATTCTAGAATGTAATTTACATAAATGTGTTTGTTCCAATTAGCTTT  
GTTGAACAGGCATTTAATTAAAAAATTTAGGTTTAAATTTAGATGTTCAAAAGTAGTTGTGAAATTTGAG  
AATTTGTAAGACTAATTATGGTAACTTAGCTTAGTATTCAATATAATGCATTGTTGGTTTCTTTTACCA  
AATTAAAGTGTCTAGTTCTTGCTAAAAATCAAGTCATTGTCATTGTGTTCTAATTACAAGTATGTTGTATTG  
20 AGATTTGCTTAGATTGTTGTACTGCTGCCATTTTATTGGTGTGTTGATTATTGGAATGGTGCCATATTGT  
CACTCCTTCTACTTGCTTTAAAAAGCAGAGTTAGATTTTTGCACATTAAAAAATTCAGTATTAAATTAAC  
A

&gt;DEX0360\_041.nt.1

CCCCCCCCCGCCTACTTATCTATAAGGGCCANTGGTTATCCTAGATGCTGCTCGAGCGGCGCAGTGTG  
ATGGATTGGTCGCGGCCGAGGTACCAGATTATAATGCCAGAATATAATGTGCAAGGCAATCGTGGATGTCT  
CTGACAAAGTGTGTCTCAAAAATAATATACTTTTACATTAAAGAAATTTAATGTTTCTCTGGAGTTGGGG  
CTCTTGGCTTTCAGAGTTTGGTTAATCAGTGTGATTCTAGATGATCAACATAATGGACCACCTCTGAAT  
GAGACTTAATTTTGTCTTTCAAAATTTACTGCTTAAATCAGTTTATTAATCTGAATTTTAAACATGCT  
30 GTTTATGACACAATGACACATTTGTTGCACCAATTAAGTGTGAAAAATATCTTTGCATCATAGAACAGA  
AATATATAAAATATATGTTGAATGTTAACAGGTATTTTACAGGTTTGTGTTCTTGATAGTTACTCAGAC  
ACTAGGGAAGGTAAATACAAGTGAACAAAATAAGCACTAAATGAGACCTAATAATTGGCCTTCGATTT  
TAAATATTTGTTCTTATAAACCTTGTCAATAAAAAATAAATCTAAATCAGAAAAAACAACAAAAA  
AAAAGGTTGGGGAAACCAGGGCCAAAGGGTCCCTGTGTGACTTGGTTTTCCGTCCAATTCCCCAAGT  
35 AGGCAC

&gt;DEX0360\_041.nt.2

AATTCCCCTTTCACTGTTGCCCTACTGTTAAAGTTCTTCCCGCTCGGGAATCCCTGGACGGCGGCGCG  
GAGCGGGAGGGAAGCCCGCCCTGGGGACTGAGCGCTGCGGTCCCGGCTATGGGAGGAGGCAACTTTCAGG  
40 GCAGGTGTCCCGCGGGAAGGGTAGCATCATTCAGGGTGGCCGCCCCGCTCCTGCTGCGGGAGTAGGAGGA  
CCGAGACGTCCGGCTTTCTTCCCGCATGCAGGTGTTTCACAGCATGTCCGCCTCGGCCCTGCTGCGGAGG  
GGGAGGGAACCCCCACCCAGCCCGCTCCGAGAAAGAACCAGAAATGCCCGGTCCAGAGAGGAGAGCGGA  
GGAGGAAGAGGACGAGGACGACGAGGAGGAGGAGGAGGAAAAAGAAAGAGTCTCATCTGTTGAAGGC  
AAGAGGGAAGAAAGAAAAAGTAGAGAGGTTGACAATGCAAGTCTTCTTCTTACAGAGAGAGCCATTTACAA  
45 TTGCACAAGGAAAGGGGCAGAACTTTGTGAAATTGAGAGGATACATTTTTTTCTAAGTAAGAAGAAAAAC  
CGATGAACTTAGAAATCTACACAACTGCTTTACAACAGGCCAGGCACTGTGTCTCATTAAGAAGAAAT  
GTGGGTCAAGTTCAAGTGGCTTTCCATTTGAAAAAGGAAGTGTCCAATATAAAAAAGGAAGAAATGTTGA  
AAAAATTTAGAAATGCCATGTTAAAGAGCATCTGTGAGGTTCTTGATTGAGAGATCAGGTGTAATAG  
TGAACCTAGTGAAGAGGATCTTGAATTTCTTAAATGCATCCAAAGCCTTCTGGCAAAACCATTGCCGAAATCT  
50 AAAAAAATTTAGCAAGGCAGTAAAAAGGAACGGAACAGTTCTGGAATGGCAAGGAAGGCTAAGCGAA  
CCAAATGTCTGAAATTTCTGTGAGATGAATCTAGTAGTGATGAAGATGAAAAGAAAAACAAGGAAGAGTC  
TTCAGATGATGAAGATAAAGAAAGTGAAGAGGAGCCACCAAAAAAGACAGCCAAAAGAGAAAAACCTAAA  
CAGAAAGCTACTTCTAAAAGTAAAAATCTGTGAAAAGTGCCAAATGTTAAGAAAGCAGATAGCAGCACCA  
CCAAAGAAATCAAAACAGTTCCAAAAAGAAAGTGAAGTGTGAGGATAGTTCAAGTGAACCTTTAAT  
55 TAAAAAGTTGAAGAAACCCCTACAGATGAAGAGTTAAAGGAAACAATAAAGAAATTTACTGGCCAGTGCT  
AACTTGGAAGAGTCACAATGAAACAGATTTGCAAAAAGGTCTATGAAAATTATCTTACTTATGATTTTA  
CTGAAAGAAAGATTTCATAAAAACAACCTGTAAAAGAGCTAATTTCTTGAGATAGAGGACAGAGAAGATG  
ACTCGTTCCCATAGATTTGAAGATCTGATTTATACCATTATACCAGCAAAGAGAATGTATTTCTTTTCT  
AAATCCTTGTAAAGCAACGTTAGTAGAAGTTACTGCTGACCTTTTATCTTGAAGTGTATGTGAATTTGA  
60 GTTTGCTGTTTTAAATTCATTTCTATGCCATTTTATGTTTAAATCTTGCATGGCATTAATTTGTTCTT

DEX-0360

202

PATENT

GCTTTTATAGTTGTATTTTGTACATTTTGGATTCTTTTATATAAGGTCATAGATTCTTGAGCTGTTGTGG  
TTTTTAGTGCACCTTAATATTAGCTTGCTTAAGGCATACCTTTAATCAAGTAGAACAAAACTATTATCAC  
CAGGATTTATACATACAGAGATTGTAGTATTTAGTATATGAAATATTTTGAATACACATCTCTGTCACTG  
5 TGAAAAATTCAGCGGCAGTGTGTCCATCATATTAATAATATACAAGCTACAGTTGTCCAGATCACTGAATT  
GGAACCTTTCTCCTGCATGTGTATATATGTCAAATTGTGAGCATGACAAAAGTCAGATGTTATTTTTTG  
TATTTTAAAAAACAAATGGTTGTATATAAAGTTTTTTTATTTCTTTTGTGCAGATCACTTTTTAACTC  
ACATAGGTAGGTATCTTTATAGTTGTAGACTATGGAATGTCACTGTTTCAGCCAAACAGTATGATGGAACA  
GTGAAAGTCAATTCAGTGATGGCAACACTGAAGGAACAGTTACCCTGCTTTGCCCTCGAAAGTGTCTACAA  
10 TTTGTAATTTTAGTATTAACCTGTGTAAGGTGTCTGTAGGTACGTTTATATATATAAGGACAGACCAA  
AAATCAACCTATCAAGCTTCAAAAACCTTTGGGAAAGGGTGGGATTAAGTACAAGCACATTTGGCTTACA  
GTAAATGAAGTATTTTATTAACCTGCTTTTGCCCATATAAAATGCTGATATTTACTGGAACCTAGCCA  
GCTTCACGATTATGACTAAAGTACCAGATTATAATGCCAGAAATATAATGTGCAGGCAATCGTGGATGTCT  
CTGACAAAGTGTGTCTCAAAAATAATATACTTTTACATTAAAGAAATTAATGTTTCTCTGGAGTTGGGG  
CTCTGGCTTTTCAGAGTTTGGTTAATCAGTGTGATTCTAGATGATCAACATAATGGACCACTCTGAAT  
15 GAGACTTAATTTTGTCTTTCAAATTTACTGTCTTAAATCAGTTTATTAATCTGAATTTTAAAAATGCT  
GTTTATGACACAATGACACATTTGTTGCCAATTAAGTGTGAAAAATATCTTTGCATCATAGAACAGA  
AATATATAAAATATATGTTGAATGTTAACAGGTATTTTCACAGGTTTGTCTTGTAGTTTACTCAGAC  
ACTAGGGAAGGTAAATACAAGTGAACAAAATAAGCAACTAAATGAGACCTAATAATTTGGCCTTCGATTT  
TAAATATTTGTTCTTATAAACCTTGTCAATAAAAATAAATCTAAATCA  
20 >DEX0360\_041.nt.3  
AATTCCTCTTCACTGTTGCCCTACTGTTAAAGTTCTTCCCGCTCGGGAATCCCTGGACGGCGGGCGG  
GAGCGGGAGGGAAGCCGCCCTGGGGACTGAGCGCTGCGGTCCCGCTATGGGAGGAGGCAACTTTCAGG  
GTTACAGCATGTCCGCTCGGCCCTGCTGCGGAGGGGAGGGAACCCACCCGCGCTCCGAGA  
25 AAGAACCCGAAATGCCCGTCCAGAGAGGAGGAGGAGGAAGAGGACGAGGACGACGAGGAGGAGGA  
GGAGGAGGAAAAAGAAAGAGTCTCATCGTGAAGGCAAGAGGGAAGAAAAAGTAGAGAGGTTGACA  
ATGCAAGTCTCTTCTTACAGAGAGAGCCATTTACAATTGCACAAGGAAAGGGGAGAACTTTGTGAAA  
TTGAGAGGATACATTTTCTTAAGTAAGAAGAAACCGATGAACCTAGAAATCTACACAACTGCTTTA  
CAACAGGCCAGGCACTGTGTCTCATTAAAGAAGATGTGGGTCAAGTTCACTGAGTTCAGTTGAAAAA  
30 GGAAGTGTCCAATATAAAAAGAAAGGAAGAAATGTTGAAAAAATTTAGAAATGCCATGTTAAAGAGCATCT  
GTGAGGTTCTTGATTTGGAGAGATCAGGTGTAATAGTGAAGTAGTGAAGAGGATCTTGAATTTCTTAAT  
GCATCCAAAGCCTTCTGGCAACCATTTGCCGAAATCTAAAAAACCTGTAGCAAGGCAGTAAAAAGGAA  
CGGAACAGTTCTGGAATGGCAAGGAAGGCTAAGCGAACCAATGTCTGAAATTTCTGTCAAGTGAATCTA  
GTAGTGATGAAGATGAAGAAAGAAACAAAGGAAGAGTCTTCAAGATGATGAAGATAAAGAAAGTGAAGAGGA  
35 GTACCAAAAAAGACAGCCAAAAGAGAAAAACCTAAACAGAAAGCTACTTCTAAAAGTAAAAAATCTGTG  
AAAAGTGCCAATGTTAAGAAAGCAGATAGCAGCACCACCAAGAAGAAATCAAAACAGTTCCAAAAAGAAA  
GTGAGTCTGAGGATAGTTTCAAGATGATGAACCTTTAATTAAGAAAGTTGAAGAAACCCCTACAGATGAAGA  
GTTAAAGGAACAATAAAGAAATTAAGTGGCAGTGTCACTTGAAGAAAGTCAATGAACAGATTTGTC  
AAAAAGGCTATGAAATTTATCTTACTTATGATTTAACTGAAAGAAAGATTTTCAATAAAACAACTGTAA  
40 AAGAGCTAATTTCTTGAGATAGAGCAGAGAAAGATGACTCGTTCCCATAGATTTGAAGATCTGATTTAT  
ACCATTATACCAGCAAGAGAAATGTATTTCTTTTCTAAATCCTTGTAAAGCAACGTTAGTAGAATTTAC  
TGCTGACCTTTTATCTTGTGATGTTATGTGAATTTGAGTTTGTCTGTTTAAATTTGATTTCTATGCCATT  
TTTAGTTTAAAACTTGCATGGCATTAATTTGTTCTTGTCTTTTATAGTTGTATTTGTACATTTTGGATT  
TCTTTATATAAGGTCATAGATTCTTGAGCTGTTGTGGTTTATAGTGCACTTAATATTAGCTTGTCTTAAGG  
45 CATTCTTTAATCAAGTAGAACAAAACTATTATCACCAGGATTTATACATACAGAGATTGTAGTATTTA  
GTATATGAAATATTTGAATACACATCTCTGTCACTGTGAAATTCAGCGGAGTGTGTCCATCATATTA  
AAAATATACAAGCTACAGTTGTCCAGATCACTGAATTTGGAACCTTTCTCCTGCATGTGTATATATGTCAA  
ATTGTCAAGTACACAAAGTACAGATGTTATTTTGTATTTTAAAAAACAAATTTGGTTGTATATAAAGT  
TTTTTTATTTCTTTTGTGCAGATCACTTTTAAACTCACATAGGTAGGTATCTTTATAGTTGTAGACTAT  
50 GGAATGTCACTGTTTCAAGCAACAGTATGATGGAACAGTGAAGTCAATTCAGTGTGCAACACTGAAG  
GAACAGTTACCTGCTTTGCCCTCGAAAGTGTCAATTTGTAATTTTAGTATTAACCTCTGTAAGGTGT  
CTGTAGGTACGTTTATATATATAAGGACAGACCAAAAATCAACCTATCAAGCTTCAAAAACCTTTGGG  
AAAGGGTGGGATTAAGTACAAGCACATTTGGCTTACAGTAAATGAAGTATTTTATTAAGTGTCTTTGTC  
CCATATAAAATGCTGATATTTACTGGAACCTAGCCAGCTTACAGATTATGACTAAAGTACAGATTATA  
55 ATGCCAGAAATATAATGTGCAAGCAATCTGGATGTCTCTGACAAAGTGTGTCTCAAAAATAATATACCTT  
TACATTAAGAAATTTAATGTTTCTCTGGAGTTGGGGCTCTGGCTTTTCAGAGTTTGGTTAATCAGTGT  
GATTTCTAGATGATCAACATAATGGACCACTCCTGAATGAGACTTAATTTTGTCTTTCAAATTTACTGTCT  
TAAATCAGTTTATTAATCTGAATTTTAAAAATGCTGTTTATGACACAATGACACATTTGTTGCCACAA  
TTAAGTGTGAAAAATATCTTTGCATCATAGAACAGAAATATATAAAATATATGTTGAATGTTAACAGG  
60 TATTTTCACAGGTTTGTCTTGTATAGTTTACTCAGACACTAGGGAAGGTAATAAAGTGAACAAAAATA

DEX-0360

203

PATENT

AGCAACTAAATGAGACCTAATAATTGGCCTTCGATTTTAAATATTTGTTCTTATAAACCTTGTCAATAAA  
AATAAATCTAAATCA

&gt;DEX0360\_042.nt.1

5 GTTGAGAAAAGTTTCACCTTCAGATGACGCCGGGAATGTAAACCGTTTTCTCTTCCATTCTAACTCGGAGC  
CATCCCCGCTTTCTCCGCCAGCTGGAATTTTTGAAGCGAGAAAATCGACTCGCTCGGTGTTCCGCCGCC  
GACGCCGCACGGCTTGCTGGGGCTGGGCTCTTCCCTCGCGAAGTGGGAGGAGCGGTTGCGGTTAGTGG  
ACCGGGACCGGTAGGGGTGCTGTTGCCATCATGGCTGACCCCGACCCCGGTACCCCTCGCTCCTCGATCG  
AGGACGACCTCAACTATGGCAGCAGCGTGGCCTCCGCCACCGTGCACATCCGAATGGGTTCTCTTAACATA  
10 CAGTGACCTCAACAGTTTTTTTATACCTTTGAGTCTGTACGGACATTTGTACATGAGAGTCTGCGCTTAAT  
TTTGCTGTTTGGCCTCGGATCTCTGGGTTTGATTTTTGCGTTGACTTTAAACAGACATAAGTATCCCCCTT  
AACCTGTACCTACTTTTTTGGATTTACGCTGTTGGAAGCTCTGACTGTGGCAGTTGTTGTTACTTTCTATG  
ATGTATATATTATCTGCAAGCTTTCATACCTGACTACTACAGTATTTTTTGGTTGACTGTGTATACTCT  
ACAATCTAAGAAGGATTTTCAGCAAATTTGGAGCAGGGCTGTTTGCTCTTTTGTGGATATTGTGCCTGTCA  
15 GGATCTTTGAAGTTTTTTTTTATAGTGAGATAATGGAGTTGGTCTTAGCCGCTGCAGGAGCCCTCTTTT  
TCTGTGGATTTCATCATCTATGACACACACTCACTGATGCATAAACTGTACCTGAAGAGTACGTATTAGC  
TGCCATCAGCCTCTACTTGGATATCATCAATCTATTCCGACCTGTTACGGTTTCTGGAAGCAGTTAAT  
AAAAAGTAATTTAAAGTATCTCAGCTCAACTGAAGAACAACAAAAAAATTTAACGAGAAAAAAGGATTA  
AAGTAATTTGAAGCAGTATATAGAACTGTTTCATTAAGTAATAAAGTTTGAACAATGATTAAATACTGT  
20 TTACAATCTTTATTTGTATCATATGTAATTTTGGAGAGCTTTAAATCTTACTATTCTTTATGATACCTCA  
TTTCTAAATCCTTGATTTAGGATCTCAGTTAAGAGCTATCAAAATTTCTATTAAAAATGCTTTTCTGGCTG  
GGCAGAGTGGCTCAGCCTGTAATCCACCACCTTTGGGAGACCGAGGCAGGTGGATCAGGAGTCAAGAG  
GTTGAGACCATCTTGGCCAACATGGTGAAACCCGCTCTCTACTAAAAATACAAAAATTAGCTGGATGTGG  
25 TGGCACACACCTGTAGTCCCAGCTAGTCAAGAGGCTGAGGCCAGAGAATCGCTGAACCTGGGAGGTGGA  
GGTTGCATTGAGCCAAGATCAGCCCACTGCATTCCAGCCTGGTGACAGAGCGAGACTCAGTCTCAAAAAA  
AAAAAAATTTTCTTCTTAAATTAGCCACGCATAGCGGTTTCGTTTGAATTTCAAAAAATATTTTAT  
GAGTAGATAAGAAATATCAGTTTACCCTGTGTCTAGTGATTTTATCTAAATTTTCCCTGAATTTAAGTAA  
TATTGATTTGGCTTTGATTCTGAAGTAGTAGAGCTTTTACCATTATAAACTGTAAATCTCTTTTGTCTTA  
30 AAAGGAAAAAATGTAAAGATAAATTTCCACAGAGAATTTATTCAGTATTACATTAATGATGACTTT  
TTTATTTTAAATTTGACTAACATTTAAAGTTGGCCTGAAAGTCAGATATTATGACAAAAATTTGACATTAA  
TTGTTTTTAAAGTATAGATTTTCAATTTGAAATTTATAGAATGGTAATGTGGTTAGAGGACACCAAAGTACT  
GGGTCATCAGCCATTAAGTATATCTATTTCAAAATTTAAATATTTGGGAAGTAT

&gt;DEX0360\_043.nt.1

35 ATGCTGCTCGAGCGGCGCAGTGTTGATGGATCGTGGTCCGCGCCGAGGTACATCGACTTCACTGCAGACC  
AGGTGGACCTGACTTCTGCTCTGACCAAGAAAATCACTCTTAAGACCCCACTGGTTTCTCTCCCATGGA  
CACAGTCACAGAGGCTGGGATGGCCATAGCAATGGCGCTTACAGCGGTTATGGCTTCATCCACCACAAC  
TCCTAAGTATATGATTGCGAGTGGAATAATAGGGGACAGAAATCAGGTATTGGCAGTTTTCATTTTCA  
40 TTGTGTGTGAATTTTAAATATAATGCGAGAGCGTAAGCATTAATGCAAGTTAAATGTTTCACTGAA  
CTAAGTTTCAGCGGTTCAACTTTATAATAATTATAAATAAACCTGTAAATTTTCTGGACAATGCCAGCA  
TTTGGATTTTTTTAAACAAGTAAATTTCTTATTGATGGCAACTAAATGGTGTGTTGTAGCATTTTTATCA  
TACAGTAGATTCCATCCATTCATATACTTTTCTAACTGAGTTGTCTTACATGCAAGTACATGTTTTTAA  
TGTTGTCTGTCTTCTGTGCTGTTCTGTAAAGTTTGCTATTAAATACATTAACTATAAAAA

45

&gt;DEX0360\_044.nt.1

TGCGGAACAAACAATTTTAAACAAAACATTTTCCATTTTCTGTTCTTTAAAGCCTGTCTGTACAAGAC  
CCAGCTGAAGCTGACCAGGGCATTCACACTTCACACACAACCCCAAGCCACCTGCTCCAGGCTTTCGGT  
GGGGGGCGGAGGGTACTGCTGGGAGCTGCATTTGGGGGTTGCACCTGAGGGTGCTGGTCCATGCTTGGC  
50 TAGCATGACTCTGGCTGTGTTTCTCCCTACAGGAAGCCCTGGCCAGCCTCCACCTGAGCCAGTGAGC  
TCAGCTTTAAGGATGGAGTCAGGCAGGGGTCCTCAACCCCTCCAGGACCCATTGCTGCCCTAGGGATGC  
CAGACACTGGGCCTGGCAGTTCTCTCCCTAGGGAAGCTTCAGGCGCTCCCTGTTGGGCCCAGAGCCACTG  
TGGGGACCCCTGTCAGCCTGGCTGCAGCAGGGGACGGCTCTCCAGACATAGGCCCCACGGGAGAGCTGAGT  
GGTAGCTTAAAGATCCCCAACCGGGACAGCGGATCGACAGTCCATCTCCAGTGTGGCTGGAGAGAAT  
55 TTCCCTGCGAGGAGGGCTTGGAGGCTGGCCCAAGCCCCACTGTACTGGGGGCGCAGCAGAGATGGCCCT  
GGACAGCCAGGTCCCAGAGGTACCCCCCAGGAGGAGGCGGACAGCGACGTGGGTGAGGAACCTGACTCT  
GAGAACACCCCCCAGAAGGCTGACAAGGATCGCGGCTGGCCAGCACTCTGGCCCCCAGAAGCTTCTCC  
ACATTGCCCAGGAGCTCTGACACACCGAGGAGACCTATGTGAAGCGGCTGCACCTGCTGGACCAGGTTTT  
60 CTGCACCAGGCTGACGGATGCGGGGATCCCTCCAGAAGTCATCATGGGCATATTCTCTAACATCTCTCTCC  
ATCCACCGCTTCCACGGGAGTTTCTGCTGCCGGAGCTGAAGACGCGGATCAGGAGGAGTGGGACACAA

DEX-0360

204

PATENT

ACCCACGGCTCGGGACATCCTGCAGAAGCTGGCCCCATTCTGAAGATGTACGGCGAGTATGTCAAGAA  
CTTTGACCGAGCCGTAGGGCTGGTGAGCACGTGGACCCAGCGCTCCCCACTGTTTAAAGACGTCTCCAC  
AGCATCCAGAAGCAGGAGGTATGTCGGGAACCTGACGCTGCAGCACCACATGCTGGAGCCCGTGCAGAGGG  
TCCCCCGGTACGAGCTGCTGCTCAAGGACTATCTGAAGAGGCTCCCGCAGGACGCCCCAGACCGGAAGGA  
5 TCGCGGAGAGGTCCCTGGAGCTCATCTCCACAGCCGCCAACCACTCCAATGCTGCCATTGGAAAGTGGAG  
AAAATGCACAAGCTCTTGGAGGTGTACGAGCAGCTGGGTGGGGAAGAAGACATTGTCAACCCGGCCAATG  
AACTGTATCAAGGAGGGCCAAATCCAGAAACTGTACGCCAAGAACGGCACCCCCAGGACCGCCACCTCTT  
CCTGTTCAACAGCATGATCCTTTACTGTGTGCCCAAGCTGCGGCTCATGGGCCAGAAGTTACAGCGTCCGG  
GAGAAGATGGACATCTCAGGCCCTCAGGTGCAGGATATCGTCAAGCCAAACACAGCACATACATTATCA  
10 TAACGGGAAGAAAAAGGTCCCTGGAGCTGCAGACGCGGACAGAGGAAGAGAAGAAATGGATTTCAGAT  
CATCCAGGCCACCATCGAGAAGCACAAACAGAACAGCGAAACCTTCAAGGCTTTTGGTGGCGCCTTCAGC  
CAGGATGAGGACCCAGCCTCTCTCCAGACATGCCTATCAGAGCACCAGCCCTGTGGAGCCTGTGGTGA  
CCACCGAAGGCAGTTTCGGGTGCAGCAGGGCTCGAGCCAGAAAACATCTCTTAAGACCAGACGTGACAA  
GGAGAAGCAGAGCTGTAAGAGCTGTGGTGAGACCTTCAACTCCATCACCAGAGGAGGCATCACTGCAAG  
15 CTGTGTGGGCGGTTCATCTGTGGGAAGTGCTCCGAGTTCAAGGCCGAGAACAGCCGGCAGAGCCGTGTCT  
GCAGAGATTGTTTCTGACACAGCCAGTGGCCCCTGAGAGCACAGAGAAGACACCCACTGCAGACCCCCA  
GCCCAGCCTGCTCTGCGGCCCCCTGCGGCTGTGAGAGCGGTGAGACCTGGAGCGAGGTGTGGGCGGCC  
ATCCCCATGTGAGATCCCCAGGTGCTGCACCTGCAGGGAGGCAGCCAGGACGGCCGGCTGCCCCGACCA  
TCCCTCTCCCCAGCTGCAAACTGAGTGTGCCGGACCCTGAGGAGAGGCTGGACTCGGGGCATGTGTGGAA  
20 TCTGCAGTGGGCCAAGCAGTCCCTGGTACCTGAGCGCCTCCTCCGCAGAGCTGCAGCAGCAGTGGCTGGAA  
ACCCTAAGCACTGCTGCCCATGGGGACACGGCCAGGACAGCCCGGGGGCCCTGCAGCTTCAGTCCCTA  
TGGGCGCAGCTGCTCCGTGAGCTGAGTCTCCCACTGCCCTGCACACCACCACATTGGACCTGTGTGTCC  
TGGGAGGTGTGTTGGAGGCCCATGAAGAGCGCCCTGGACTGCTGAGGTTGGGCCAACAGCCAGAGCT  
CAGGACACTTGGCTTTGGGGGAAGGAAACTGAGGCCCCAGAGAGGGGCAACCACTGGCCAAAGGTCACCC  
25 AGCAAGTTTGGCTAAGAGCCTGGCCCTCCAGCCCCAGCAGTGTGGCCAGAGCGGGCCGATGCCAAA  
GTAACCATCATCATATGGGCCGTGTGGTGTGCTGGCCCGAAGGCAGAAAGAGGCAGCATGGGCACTG  
CCAGGGACAGCCACATCCTGCTGGTCTGCAGCGTGGTCCACCCCGCCTCTGCCACGCTGTCTACACCGT  
GTGAGCTGAATCGTGAATTGCTTCCCACTCCTTCTCTGTCTCTCTGAGGTTCTGCCTGCAGCCCC  
AGGAGGTGGGCTGCCCCATCTAGCTGGAATCATGGTTCTAAATAAACACGCTCAGAAGCTCTGCTAG  
30 GATTACCCAGCCACTGAGTGGCAGCGCATGAGATTTGTGGCTGTTCTGATGCTAGTGGCACACAGT  
GCTTATCTGCATAAAATAAACACTGGCCACCA

&gt;DEX0360\_044.nt.2

GCCCCCTTAGGATTTTCTATGCACATGCACATATATCTATGTTTAAATCACAGATGGCTGTTTACTGT  
35 ATAACCTGTCTGCACCTTGCTTTTTCACTTAATTTGTCAAGAATCATCCATATCTGCACACCATTCCT  
AAAGCAACACAATTTTCCATTATGATCATTAGCTAGTTCCCACTGACGAGGACCTGCGCTCCTCCCGAAC  
CTGGCCATCACAAATGCGGCTGCAAGCAGTGTCTTGTGTTTATAGGTGTTTCTGCATATGTGTAATTGTAG  
CCGTACAGATTGCTGACATAGATTGTGCTGGTTCACAGGGTAGTGATCTGTTTGAATGTTGGTGGCTGTG  
TCACACTACCTTTAAGGTGATGTACGGCTGTGCTCTGACTAGCCATAACATGGGAGTTCTGTTCTCCAC  
40 ACCCAACCAAGTGGGATCTTATAATGACCATATGTTTCAAGGAGGCATTGAATTACAGCCACTGC  
AGAGGGCTCCACATGGCTCACCTGGCCCCACAGGCCACGAGTGTGTTGAGGCCCTTGGGGCAATCTTC  
CAATCCTTGAGCTGCGTTGACAAGCCAGTGCCTGGCTCGGCTGTGCTGCAGGGTTGAGAGAGGGCTGGTC  
ATTTAGAGTCAGTATCCAAGACTGGATTAAATAACAAGACCGTTTGGTGTGTTAGGACAGAGGAAGAGAAG  
AAAGAATGGATTTCAGGTGAAGCTTCTAAAGTTGTAAAGTAACCAATGACCAAGTATTGAGCAGTAAGG  
45 CCATTATGTTGGTTTCAGAGGGTGGGGGCCCTGGCCCTCCGGGACTGCTGGCCCTGTGCTGTACCTGCAG  
GGATGCAGTGACCACACTGTGCCTTCATAAGCAGCTTCAGATGCCACAAGCCCTTCAACCCATTATTTTC  
TTTGAGGGCCCCCAAATAACATGAGCGGGCCTGGTGGAGTCACAGGCCAGGTTCCCGCTCAGGGTGGGA  
TCTCCTCAATCTGGACAGCTCCAAGGGGAGACCACATCATGGTAGGGGGGAAGGGAGATGGCCAGTGGC  
50 CTGGGCATTGTTCTGGGAACGCCAAGGCCGCTCCTCGGGACAGAGGCAGGCGCTCCCTCTGTGGGTAG  
CATGCTCCCATGCCCTTTATAGTCTCTACTGTTGTGTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG  
GAAGCACAAACAGAACAGCGAAACCTTCAAGGCTTTTGGTGGCGCCTTCAGCCAGGATGAGGACCCAGC  
CTCTCTCCAGACATGCTATCAGAGCACCAGCCCTGTGGAGCCTGTGGTGAACACCGAAGGCAGTTCGG  
GTGCAGCAGGGCTCGAGCCAGAAAACATCTCTTAAGACCAGACGTGACAAGGAGAAGCAGAGCTGTAA  
GAGCTGTGGTGAGACCTTCAACTCCATCACCAGAGGAGGCATCACTGCAAGCTGTGTGGGCGGTCATC  
55 TGTGGGAAGTGCTCCGAGTTCAAGGCCGAGAACAGCCGGCAGAGCCGTGTCTGCAGAGATTGTTTCTGA  
CACAGCCAGTGGCCCCTGAGAGCACAGAGGTGGGTGCTCCCACTCCTGCTCCCCCTCTGGTGGCGCGGC  
AGAGCCTCCAGACACCTGCTCCTGTGCCACAGCAGCTCTAGCTGCCTCTGCTTTTCGGAGTGTCCCTGGGA  
CCAGGATAGATGTGGGTGTGTCTAGTGGGCCCCCAGGCTGGGAACACACTCGGAAGATCCCGTGTGTG  
60 CACGCTGGCTTCTCGGGACAGCCAGGGCCAAGGCTTGGGAACCATTTGCATCCAGGAGTTAGATGGGA  
CAAGTGTCACTCCTGGTACCTGGTTGGAGGGCATGGATTGAAGCTGCCCTCAAGTCCAGGCCCTTGAGGC

>DEX0360\_045.nt.2  
TGGGCTGGACTCAGGGACCGACTCTTCCCGTCTCATGACTGTGTTTACTGGGCTGGATTTTGGGAAGGGG  
CCAGATTGCATCAGACAGGGCCTGATGGGCTGGAGCCAGACTGTGGTCTGAGGAGGAGACACAGCCTTAT  
AAGCTGAGGGAGTGGAGAGGCCCGGGCCAGGAAGCAGAGACAGCAAGCGTTAGGAGAGAAGAGAGAG  
50 CAGGGAAGACAAGCCAGGCACGATGGGCCACCTTCCCACCAGCAACCAGCGCCCCCAGCAGCCCCCAGG  
CCCGGAGGACGAGGACTCCAGCCTGGATGAATCTGACCTCTATAGCCTGGCCCCATTCTTACCTCGGTAAG  
GCCCACCTAGCCATCTCCACGGTCTTCTCTCTCTCCCGAAATCAGGACCCACCCCTCTGTGTTTCTCTC  
ATTTCTCTTCTCTTCTCTCTCGTTTCTTTCTTTCTTTTGTGAGAGAGTCACTCTGTCACCACGGCTG  
GAGTGCGAGTAGTGATGATCAACAACCACTCAACGAGCCTGAACTCCTGGGCTCAAGTGATC  
55 GTCCTCTGCTTACGCTCCTGAGTGCTGGAATCTCAGTGATACACCACCTGCGAGTGGTGAGATGGGGTCTC  
ACTATGTTTCCAGGCTGATCCCAAATTCTTGGGCTCAAGCAATTCTCTGCTTGGCCTCCCAAAGTGC  
TGAGATTACAGGAGTGAGCCACCCTGCCAGCCCACTCACCCTTTTCTAGCCAACCTGTTCTTGGACCC  
TCACGTCACCCCTGTCTAATCCCTTATCCAGGAGTGCTATGTTACTCAGCCTGGGACCTCACACATC  
TGGGGTCCCAATCCACAGAGGGGAAGCAGGCTTCTCCCTGCTCTTCCCATCCCAACCCCTGAA  
60 CCGCTGCCCTCTCTCTGACAGGGGCTCTCATCATGCTATGCCACCTTACCTCTGACTCTGCCTTGGT

DEX-0360

206

PATENT

TACAGGAGGTGGAGGCCGAAAGGTGCGACCAAGAGAGAAGCTGCTGCCAACACCAACCGCCCCAGCCCT  
GGCGGGCAGCAGAGGAACTGGTGACCAAGCTGCAGAATTCAGAGAGGAAGAAGCGAGGGGCACGGCGCT  
GAGACAGAGCTGGAGGGTAAGGAGTCCGGGGGCCAGAGAGCTCAAGGTGGTGTCTCTGCCATGAAGGAC  
AGGCCGGAAGGTGTGTGATTGGGTGGGGAGGAGGGATCAGGCAACTGTTGTCTTGATGCAGAATAAAACG  
5 AGACATATGTTTGAATTGTGAGTTTCTTAGTGCCAGAGCAAAGTGGGAACACAGAACCTTTCCAATTGAA  
GGGAAATTTGACTTACAGAGACAGAAATTGAGGATAGAGAGGGTGGGTCTTCTCCCTGGAGTCAAAATCA  
AGTGAGTGGGAGAGGCAGAATTAGAACCCAGATCTCTGTCCCTTTTACCACCTGCTTTCTCACCCTCC  
AGATGAGGCCAGACCATGGACACTACACCAGCAATAGAGACGGGACTGCGGAGGAAGGAGGACCCAGGA  
10 CAGGATCCAGGCCGGCTTGCCACACCCCCCACCCTAGGACTTATTTCCGCTGACTGAGTCTCTGAGGGG  
CTACCAGGAAGCGCTCCAACCCTAGCAAAAGTGCAAGATGGGGAGTGAGAGGCTGGGAATGGAGGGGC  
AGAGCCAGGAAGATCCCCCAGAAAAGCTACAGAAGAACTGGGGCTCTCCAGGTGGCAGCAACA  
ATAAATAGACACGCACGGCAGC

&gt;DEX0360\_046.nt.1

15 TAGATGCATGTCGAGCGGCGCAGTGTGATGGATGTGGTTCGCGGCCGAGGTGGGGAGCTGAATTCGGGAAG  
ATCCCCACATCGATGAAAGCAAAGCGAAGCCACCAAGCCATCATGTCCACGTCGCTACGAGTCAGCC  
CATCCATCCATGGCTACCACTTCGACACAGCCTCTCGTAAGAAAGCCGTGGGCAACATCTTTGAAAACAC  
AGACCAAGAATCACTAGAAAGGCTCTTCAGAACTCTGGAGACAAGAAAGCAGAGGAGAGCCAAAGATC  
ATTTTTGCCATAGATCAAGATGTGGAGGAGAAAACGCGTGCCCTGATGGCCTTGAAGAAGAGGACAAAAG  
20 ACAAGCTTTTCCAGTTTCTGAACTGCGGAAATATTCCATCAAAGTTCACTGAAGAGAAGAGGATGGATA  
AGGACGTTATCCAAAGATGGACATTCAAAGACCAAGTGAGTTTGTGAGATTCTAACAGATGCAGCATTTT  
GCTGCTACCTTACAAGCTTCTCTCTGTGTCAGGACTCCAGAGGCTGGAAAGGGACCGGACTGGAAAGGGA  
CCAGGACTGAACAGACTGGTTACAAAGACTCCAAACAATTTTCATGCCCTGTGCTGTTACAGAGGAGAACA  
AAATGCTTTTCAGCAAGGATTTGAAAACCTCTTCCGTCCTGCGAGGAAAGGATTGATGCTGATAGAAGAGCC  
25 TGGACAGATGTAATGAGAACTAAAGAAAACAGATGGCTGGAGATGACATTTATCCAGGGTCATTTGTCA  
GGCCCTAGGACTTAAATCGAAGTTGAACCTTTTTTTTTTTTAAACCAATAGATAGGGGAAGGGAGGAGG  
GAGAGGGAGGACAGGGAGAGAAAATACCATGCATAAATTTGTTTACTGAATTTTATATCTGAGTGTTCAA  
AATATTTCCAGCCTGAGTATGTCTATTGGTATAGATTTTTAGAAATCAATAATTGATTATTTATTGTC  
ACTTATTACAATGCCTGAAAAAGTGCACCACATGGATGTTAAGTAGAAATCAAGAAAGTAAGATGTCTT  
30 CAGCAACTCAGTAAACCTTACGCCACCTTTTGGTTTGTAAAAGGTTTTTTATACATTTCAAACAGGTTG  
CACAAAAGTTAAAATAATGGGGCTTTTTATAAATCCAAAGTACTGTGAAAACATTTTACATATTTTTTAA  
ATCTTCTGACTAATGCTAAAACGTAATCTAATTAATTTTACATAGTTACTGAGTAAGCATTAGGAAGT  
GAATATGATATACAAAATAGTTTATAAAGACTCTATAGTTTCTATAATTTATTTTACTGGCAAAATGTCAT  
GCAACAATAATAAATTATTTGTAACCTTTTGTGGCTTTTGGTCTGTGATGCTTGGTCTCAAAGGAAAAATA  
35 AGATGGTAAATGTTGATATTTACAACTTTTCTAAAGATGTGTCTTAACAATAAAAGTTAATTTTAGAG  
TAGTTTATATTAATTACCAACTTTTTTCAAACCAATTTACGTCAAATATCTGGGAAGTTTCTCTGT  
CCCAATCTTAAAATATAAAATATAGATATAGAAGTTTATAGATTGACTCCTTGGCATTCTATTTATGTA  
TCCATTAAGGATGAGTTTTAAAGGCTTTCTCTTACACTTTTGA AAAAATTTCTTCTATGATACAGTAG  
CTATGTACATGTGTACATCTATTTTTCCCAAGCAATATGTTTTGGGTTTAGAGTCTGAGTGATGACCAAG  
40 ATCTGTGTGTTACTACTGTTTGTTTAATAGGAACAAATATAGAAATAATATTATCTCTTTGCTTATTTT  
CCGTTAAAACATAATAAATGTTTCTAAGACAGCATACGTAA

&gt;DEX0360\_046.nt.2

45 GCGGCCGCCTACTACTACTACTACTAAATTCGCGSCCGGCCGAGGTGGGAGCTGAATTCGGGAAGAT  
CCCCACATCGATGAAAGCAAAGCGAAGCCACCAAGCCATCATGTCCACGTCGCTACGAGTCAGCCCA  
TCCATCCATGGCTACCACTTCGACACAGCCTCTCTTAAGAAAGCCGTGGGCAACATCTTTGAAAACACAG  
ACCAAGAATCACTAGAAAGGCTCTTCAGAACTCTGGAGACAAGAAAGCAGAGGAGAGGCAAGATCAT  
TTTTGCCATAGATCAAGATGTGGAGGAGAAAACGCGTGCCCTGATGGCCTTGAAGAAGAGGACAAAAGAC  
AAGCTTTTCCAGTTTCTGAACTGCGGAAATATTCCATCAAAGTTCACTGAAGAGAAGAGGATGGATAAG  
50 GACGTTATCCAAGATGGACATTCAAAGACCAAGTGAGTTTGTGAGATTCTAACAGATGCAGCATTTTGC  
TGCTACCTTACAAGCTTCTCTCTGTGTCAGGACTCCAGAGGCTGGAAAGGGACCGGGACTGGAAAGGGACC  
AGGACTGAACAGACTGGTTACAAAGACTCCAAACAATTTTCATGCCCTGTGCTGTTACAGAGGAGAACAAA  
ATGCTTTTCAGCAAGGATTTGAAAACCTTCTCCGTCCCTGCAGGAAAGGATTGATGCTGATAGAAGAGCCTG  
GACAGATGTAATGAGAACTAAAGAAAACAGATGGCTGGAGATGACATTTATCCAGGGTCATTTGTTCAGG  
55 CCTAGGACTTAAATCGAAGTTGAACCTTTTTTTTTTTTTTAAACCAATAGATAGGGGAAGGGAGGAGGA  
GAGGGAGGACAGGGAGAGAAAATACCATGCATAAATGTTTACTGAATTTTTATATCTGAGTGTTCAAAA  
TATTTCCAAGCCTGAGTATGTCTATTGGTATAGATTTTATAGAAATCAATAATTGATTATTTATTTGCAC  
TTATTACAATGCTTGA AAAAGTGCACCACATGGATGTTAAGTAGAAATCAAGAAAGTAAGATGTCTTCA  
GCAACTCAGTAAAACCTTACGCCACCTTTTGGTTTGTAAAAGGTTTTTTATACATTTCAAACAGGTTGCA  
60 CAAAAGTTAAAATAATGGGGCTTTTTATAAATCCAAAGTACTGTGAAAACATTTTACATATTTTTTAAAT

DEX-0360

207

PATENT

CTTCTGACTAATGCTAAACGTAATCTAATTAAATTTTCATACAGTTACTGCAGTAAGCATTAGGAAGTGA  
ATATGATATACAAAATAGTTTATAAAGACTCTATAGTTTCTATAATTTATTTTACTGGCAAATGTCATGC  
AACAAATAATAAATTATTGTAAACTTTGTGGCTTTTGGTCTGTGATGCTTGGTCTCAAAGGAAAAAATAAG  
ATGGTAAATGTTGATATTTACAAACTTTTCTAAAGATGTGTCTCTAACAATAAAAGTTAATTTTAGAGTA  
5 GTTTTATATTAATTACCAAACCTTTTCAAACAAATTCCTTACGTCAAATATCTGGGAAGTTTCTCTGTCC  
CAATCTTAAATATAAAATATAGATATAGAAGTTCATAGATTGACTCCTTGGCATTTCCTATTTATGTATC  
CATTAAAGGATGAGTTTTAAAGGCTTTCTCTCATACTTTTGAAAAATTTCTTCTATGATTACAGTAGCT  
ATGTACATGTGTACATCTATTTTTCCCAAGCAATATGTTTTGGGTTTAGAGTCTGAGTGATGACCAAGAT  
TCTGTGTGTTACTACTGTTTGTTTAATAGGAACAAATATAGAAATAATATTATCTCTTTGCTTATTTCCC  
10 GTTAAACTATAATAAATGTTTCTAAGACAGCATACGTAA

&gt;DEX0360\_046.nt.3

AGATGCTGCTCGAGCGGCGCAGTGTGATGGATGGGCAGGTAAAGGGAGCTGAATTCGGGAAGATCCCCAC  
ATCGATGAAAGCAAAGCGAAGCCACCAAGCCATCATCATGTCCACGTCGCTACGAGTCAGCCCATCCATC  
15 CATGGCTACCACTTCGACACAGCCTCTCGTAAGAAAGCCGTGGGCAACATCTTTGAAAACACAGACCAAG  
AATCACTAGAAAGGCTCTTCAGAAACTCTGGAGACAAGAAAGCAGAGGAGAGAGCCAAGATCATTTTTGC  
CATAGATCAAGATGTGGAGGAGAAAACCGCTGCCCTGATGGCCTTGAAGAAGAGGACAAAATGCTTTTCAG  
CAAGGATTTGAAAACCTTCCGTCCCTGCAGGAAAGGATTGATGCTGATAGAAGAGCCTGGACAGATGTA  
ATGAGAACTAAAGAAAACAGATGGCTGGAGATGACATTTATCCAGGGTCACTTTGTCAGGCCCTAGGACT  
20 TAAATCGAAGTTGAACCTTTTTTTTTTTTAAACCAATAGATAGGGGAAGGGAGGGAGAGGGAGGAC  
AGGGAGAGAAAATACCATGCATAAATGTTTACTGAATTTTATATCTGAGTGTTCAAAATATTTCCAAG  
CCTGAGTATTGCTATTGGTATAGATTTTATAGAAATCAATAATGATTATTTATTTGCACCTATTACAAT  
GCCTGAAAAAGTGCACCACATGGATGTTAAGTAGAAATCAAGAAAGTAAGATGTCTTCAGCAACTCAGT  
AAAACCTTACGCCACCTTTTGGTTTGTAAAAGGTTTTTTATACATTTCAAACAGGTTGCACAAAAGTTAA  
25 AATAATGGGGTCTTTTATAAATCCAAAGTACTGTGAAAACATTTTACATATTTTTTAAATCTTCTGACTA  
ATGCTAAAACGTAATCTAATTAAATTTTCATACAGTTTACTGCAGTAAGCATTAGGAAGTGAATATGATATA  
CAAAATAGTTTATAAAGACTCTATAGTTTCTATAATTTATTTTACTGGCAAATGCTGCAACAATAATA  
AATTATTGTAAACTTTGTGGCTTTTGGTCTGTGATGCTTGGTCTCAAAGGAAAAAATAAGATGGTAAATG  
TTGATATTTACAAACTTTTCTAAAGATGTGTCTCTAACAATAAAAGTTAATTTTAGAGTAGTTTATATT  
30 AATTACCAAACCTTTTCAAACAAATTCCTTACGTCAAATATCTGGGAAGTTTCTCTGTCCCAATCTTAAA  
ATATAAAATATAGATATAGAAGTTCATAGATTGACTCCTTGGCATTTCCTATTATGTATCCATTAGGAT  
GAGTTTTAAAGGCTTTCTCTTCATACTTTTGAAAAATTTCTTCTATGATTACAGTAGCTATGTACATGT  
GTACATCTATTTTTCCCAAGCAATATGTTTTGGGTTTAGAGTCTGAGTGATGACCAAGATTCTGTGTGTT  
ACTACTGTTTGTTTAATAGGAACAAATATAGAAATAATATTATCTCTTTGCTTATTTCCCGTTAAACTA  
35 TAATAAATGTTTCTAAGACAGCATACGTAA

&gt;DEX0360\_047.nt.1

AGATGCATGTCGAGCGGGCCGAGTGTGATGGATACAAGGCCGTGAGGTTCTCCAGCCCCCTCCAGAGCA  
TTGTTGGGGACCCGTGAGATCTGGTTGTGGTTCGAGATGGAGCTCTCTCACACCCACAGAGCTAATCTAA  
40 ATCTTGTGCTAGAAAAAGCATTTCTCTAACTCTACCCACCCCTACAAAATGCATATGGAGGTAGGCTGAAA  
AGAATGTAATTTTTATTTTCTGAAATACAGATTGAGCTATCAGACCAACAAACCTTCCCCCTGAAAAGT  
GAGCAGCAACGTAAAAACGTATGTGAAGCCTCTCTGAATTTCTAGTTAGCAATCTTAAGGCTCTTTAAG  
GTTTCTCCAATATTAAAAAATATCACCAGAAAGTCTCTGCTATGTTAAAAACAACAACAAAAACA  
CAACAAAAAATTAATAAAGCCTGTTTCTAACTATGAATATGAGAAGTTCTAGGAAACATCCAGGAGG  
45 CGGCATTTCCTTTTTAAAAAGCCTGTTTCTAACTATGAATATGAGAAGTTCTAGGAAACATCCAGGAGG  
TATCATATAACTTTGTAGAAGCTTAAATACTTGAATATTCAAATTTAAAGACACTGTATCCCCATAAATA  
TTCTGATGGTGCACACTCTGAGGCCGTGATGGCCCCCTTTCATCAATATCTATTCAAATATACAGGTGC  
ATATATACTTGTAAAGCTCTTATATAAAAAAGCCCCAAAATATTGAAGTTCTATCTGAAATGCAAGGTGC  
TTTCATCAATGAACCTTTTCAAACCTTTCTATGATTGCAGAGAAGCTTTTATATACCCAGCATAACTTG  
50 GAAACAGGTATCTGACCTATTCTTATTTAGTTAACACAAGTGTGATTAATTTGATTTCTTTAATTCCTTA  
TTGAATCTTATGTGATGATTTTCTGGATTTACAGAACATTAGCACATGTACCTTGTGCCTCCCATTC  
AGTGAAGTTATAATTTACACTGAGGGTTTCAAATTCGACTAGAAGTGGAGATATATTATTATTATG  
ACTGTACTGTATTTTATATTGCTGTTTAAACCTTTTAAAGCTGTGCCTCACTTATTAAAGCACAAATGT  
TTTACCTACTCCTTATTTACGACGCAATAAATAACATCAATAGATTTTTAGGCTGAATTAATTTGAAAG  
55 CAGCAATTTGCTGTCTCAACCATCTTTCAAGGCTTTTCATTSKWCAAAKWWAATAAAWMARTAGAYWW  
TWARG

&gt;DEX0360\_048.nt.1

TCCTCCCTCCCTCCCATCCCAATCCTGATTCTGTTTACAAAGAATGTTGAAAAACAAGGAATTATGT  
60 ATAACAGTTCAGTTTGTCTCAGGAAATCTCAGATTATAAAGAGACATTACAAATGAACAAGTGAAGAG

DEX-0360

208

PATENT

AAGAACCTTGGTGGTTCCAACATAGTATGGCCATTGTTTTATACTCAAAATATAGAAAGACAACCTCAGA  
ATAAGAAAACCTTTTGGAAATGGAATAAATCAAGTTTATCATTAAAATGCAAAGAAAACCTCTCCAAATG  
TTGCTGATCTTCTGTTTTAACTACTGTTAGACCGGAGAGAGCAGGGGAATCCGCCAAAGAGTT  
5 TTGGATGAAAATTAATCAGCCCTGTCTACCGTAGTCACACCCACTGCCCTTGAGACCCAATCTCTCGGA  
AGGAGTGTCCAAGAGGTATAAAGCAAAACGAAAAACAGTTTCGCAAATTCAGAGTTCTGTTTTCTCTCAT  
TAAAAATATAAATATCAGGCTAACACATGTTGACACACAATAACAGGGACACAGAATCCCTCTCGGAAGA  
CCGACGGGCCACGGACCCACGGGTGCCACGGTGGTGGACGAGGTTAAGTAACTTGGTTTCAGGGTGTCT  
GGGCACACCTCTGCGTGAGACTCTGTCTCTGCTCCTCTCATCTCTACGCCGATTCTCCCCACAATC  
10 CTCCCTTTTCTTGGGCCCCGACGCCTCTCCGACCAACAGTCTCCCCAGCCCCGAGCTTCTCTCTTTC  
AGACCTTTACTTCTTGATCCTCACTCCATAGTGAGATGTGGCCTTTCAGCAAATAAATTGTCTCAGGGA  
GACAGCCAATTGTCCCTTGCCGTCTCTGAGGGTGCCTGGAGCTTAAGCACTGTGTGCTCTTGGCCTCC  
ACACTGGGGATGCCGTGACTCCCACTGTCCAGGGCTTCCAGTGGATTCTCCGAGGCCCTGATGTAGAAA  
CTTCCCCATTGGGTGCACCAAGAGCAGCTCATATGGTGTGGGTGACATCAAGAGCTGCCAGATCCAAC  
15 AGGAAGATGGCCAATCTTTCCTAAGCTGCTCACCTTACAAGAAAACGAATCGTACTGCTAAGAAATCAAA  
CTTCAGCAGTCATGGGAGCCTTGAAGGAGCCGAATCACTGATGGAATTGGACAGTGCATGGAGATGG  
TTCAGCAGGACAAGGGTAAGTGCAGGGGCAAGTCCAGGTCTACTGAGAGACAACGAGTGGCGCTGACAG  
AGACAGACAAAAGATAAAATCAAAAGTTTGTGCTTCATCTTCAAAAACCTCAAACTAATAACAAACTTGGCC  
TTATGAGAAATAAAGTATTTTTCTATTACATGAGAAATTAATCTCAAAACAGGAATCAGAAACATAT  
TAAGTCCAGGGCATAAAACCTAAACCACTGCTCATATTTATCTTTCTAAATAGAGCAAAGTGTAAATC  
20 TTCTCCATAAAATGCACATTGTGCTTATGAAAAGGCCAGTCTTAGTGAGAATCATTTGGTATTCCATAGAA  
GAGTGAATTAACACAGCCAAGGGAAGACCCAAGTCTCATCTTCTTGTATATTCCAGAGTTCCAGGG  
GAATTCAGGTGATAGAGGTGATCTCCCATCTGTTAAAGCAAGGTTGCAGACACTTGGGAATTTTGGTCT  
CCAGTACTCTAGGAGGTACACCTCTGTCTGGAAATACTACAGGAATGTATCTTCTCATGACTTGC  
25 TTCTGGTCATTCTTCCAGCATCACAAAAACAAAAAAGGAAATATGTCCAAATACATGATTTCG  
TATCCCTCTCTTTCAGGTTTCTTACCTGTTACTTACGGATAACAGCATTACCACAGGATTATGATGAAGA  
TACAATGTCCAAATATAAACACAGTTTTCAGCAAAATGCCCTGTACGAATTGGTCAATGAACAACCTAGTA  
AATAATTATGTGAATATTTACTGAATTATATGGATCTTATGAATAATTACTGAATAATTCTATGTGATTGC  
TTTTATTGGCAGTGCTGAAAACCTATCCCGTGTGACCTCAAGTAAGCCATGTAACCTCTGTGAACCTGCA  
30 GTTTTATCATTTTTTAAATAAAGAAACATGACAGATTTTCATTATGACACAGAATGTCAAGTCTCCGCA  
TGCCAGAAAATACATTTACTTAAAGCCGTGATACGCTTAAAGCGGTTTCTTACAGTGTCTATTGGAGG  
ACAGTGTGGAGTGCAGAGAGACATGCTTTGAAATGGGATGATCCAGTCTCTCTTCTTCACTACCACAT  
GAATGCTGGGCAGCCAGGGTCAACCCACCGCACCTCAACTCAGGCAAGTCCAGCAGCCAATCTTAGGA  
GACCTGGGCTACAGAACAGTCTCCCAAGTTCCAGGCTCACAAAACCTAGGTGGGGTGAAAGCTGAGAAAG  
CGAGGAGTTGGTTTCAGGGGATCACTCTTCTTCTACTCATTTCTCTCATCTCAACTCACCTTCTACTGCAA  
35 CACTGAGGATCACCAACCAACCGTGACCATAACCTTGATCTTGCCATGTTCTGTTAGTGGAAATGCAACCC  
AAAATCAATGGTGTAGGTCACTGTAACAAAATATATATCAAACCATATTGCATAAGAACCCTCATGGC  
CCTGTTCTTTTTCAGTATATGGGAAAACAAAATGGAAACAACAAAATAGCATCAGGTTTATGAAACTTCCC  
AAGATAGATGGTACACATGTTTTTCAGGAGATCTCTATATAAATGATTTTGATCACTTGATACCTTGAAA  
AGAGCTCTGTGACACTAGAATGACATCCATAAGTGACAAGTATAAATGTAGCGCTCAGTGACATCAAAA  
40 AACCAAATCAACCCACATAGAGGAAGAGCTCTGGACATAGGGATGTCAAACCTGGTCTAGAGTGTAAATGAA  
AAGCAAAGATGGTGGCCAGTGAGAAAAAGAAATCAACATAAACAATGGGAAACAGCAAGAAGAACTAGT  
AGACAGGAAAGACAACATTTTTTACAAATGAATTATTCATTCACTTTCTAGTGGATACAGACAAAACCTGC  
AGAAGACCCAGAGGAAATCAGGGCAGGCTAAAAGTTTGATATCTTACACCTGTGGAAAAGGCCCTAAGCT  
CTGTTTAACTGAGAGCAGGTGGGGTGACTTCATGACTACCATTAAAGAAAATACAACCTGTTGGGAAACT  
45 GTTCTGCTTGTGATGATGTGTACAGACAAGAGATAAACAGTGAGGAATATGCTTAGATGTATTGGGAAA  
GACACGGGTCTGTGGCATCATCAAGGGTACACGAATACTGAGAGTGAATGCTGAAGGAATGATCCCCA  
TTGGTGGTGACCTCAGGTGAGACTAGGGTGCTGTGTTTCAGGAAAGCCTGGGCAATTGGAATGCAGGG  
CTCCTAAGATTCCATGACACCCCCACCTTCTAATTGCTTATTGCAACTGCAGACGGTTACCTGGCAGCG  
50 TGCCACAGTCTACCTCACTCTTATCAGAGTCTGAGCTACTGGCAGTGCTTTTCAGCTCTGAGTTCAGGCA  
CCTCGAACCTTGTTTTTGTGGTGAAGGATCTTAAAGTGTGTGGGGAGTGATCACATTTTTTCAACATC  
CCTGGCTCCACCTCTTCTGCCACAAACGTCAGCATGGTGGTATCAGCTGGCCCTTGGTCCAGCGAGAAGG  
CAGAGACGAACATTTAGAAATCAACGAGAAATTTGCGCCCCAGCTGGCAGAGAACAAACAGCAGTTTCA  
55 AAACCTCAAAGAGAAATGTTTTGTAATCACTGGCGGCTTCTTGGCCAACCGACAGAGAAATACAAG  
TATGAAGAGTGTAAAGACCTCATAAAATTTATGCTGAGGAATGAGCGACAGTTCAAGGAGGAGAGCTTG  
CAGAGCAGCTCAAGCAAGCTGAGGAGCTCAGGCAATATAAAGTCTGGTTCACTCTCAGGAACGAGAGCT  
GACCCAGTTAAGGGAGAAGTTACGGGAAGGGAGAGATGCCCTCCGCTCATTGAATCAGCATCTCCAGGCC  
CTCCTCACTCCGATGAGCCAGACAAGTCCAGGGGAGGACCTCCAAGAACAGCTGGCTGAGGGGTGTA  
GACTGGCACAGACCTTGTCCAAAAGCTCAGCCGAGAAAATGACAACGATGACGATGAAGATGTTCAAGT  
60 TGAGGTGGCTGAGAAAGTGCAGAAATCGTCTGCCCCAGGGAGATGCCGAAGGCTGAAGAAAAGGAGT  
CCTGAGGACTCACTGGAGGAATGTGCCATCACTTGTTCAAATAGCCATGGCCCTTATGACTCCAACCCAGC

CACATAGGAAAACCAAATCACCATTGAGGAAGACAAAGTCGACTCAACTCTCATTGGCTCATCCTCTCA  
 TGTGTAATGGGAGGATGCTGTACACATTATCCCAGAAAATGAAAGTGATGATGAGGAAGAGGAAAGAAAA  
 GGGCCAGTGTCTCCAGGAATCTGCAGGAGCTGAAGAGGAGGAAGTCCCCAGGAGTCTGGGATGAAG  
 GTTATTGCACTCTCTCAATTCCTCCTGAAATGTTGGCCTCGTACCAGTCTTACAGCGGCACATTTCACTC  
 5 ATTAGAGGAACAGCAAGTCTGCATGGCTGTTGACATAGGCGGACATCGGTGGGATCAAGTGAAAAGGAG  
 GACCAAGAGGCAACAGGTCCCAGCCAGGCTCAGCAGGGAGCTGCTGGATGAGAAAGGGCCTGAAGTCTTG  
 CAGGACTCACTGGATAGATGTTATTCAACTCCTTCAGGTTATCTTGAAGTCACTGACTCATGCCAGCCCT  
 ACAGAAAGTGCCTTTTACATATGAGAGCAACAGCGTGTGGCTGGGCTCTTGACATGGATGAAATTGAAAA  
 GTACCAAGAGTGGAAAGAGACCAAGACCCATCATGCCCCAGGCTCAGCAGGGAGCTGCTGGATGAGAAA  
 10 GAGCCTGAAGTCTTGCAGGACTCACTGGATAGATGTTATTGCACTCCTTCAGGTTATCTTGAAGTGCCTG  
 ACTTAGGCCAGCCCTACAGAAGTGCTGTTCACTCATTTGGAGGAACAGTACCTTGGCTTGGCTCTTGACGT  
 GGACAGAATTAAGGACCAGGAAGAGGAAGAAGACCAAGGCCACCATGCCCCAGGCTCAGCAGGGAG  
 CTGCTGGAGGCAGTAGAGCCTGAAGTCTTGCAGGACTCACTGGATAGATGTTATTCAACTCCTTCCAGTT  
 GTCTTGACAGCCTGACTCCTGCCTGCCCTATGGAAGTTCCTTTTATGCATTGGAGGAAAAACATGTTGG  
 15 CTTTCTCTTGACGTGGGAGAAATTGAAAAGAAGGGGAAGGGAAGAAAAGAGGGAAGAAGATCAAAACCCACC  
 ATGCCCCAGGCTCAGCA  
 GGGAGCTGCTGGATGAGAAAGGGCCTGAAGTCTTGCAGGACTCACTGGATAGATGTTATTCAACTCCTTC  
 AGGTTATCTTGAAGTCACTGACTCATGCCAGCCCTACAGAAGTGCCTTTACTYATTGAGSACAGCRY  
 RTTSAGCTTCGCCCTTGACGTGGACAATAGAGTTTCTTTACTTTGATGGGAAGAAGTCTCCACCTGAGT  
 20 CTTCCAGATGGGAGTCAATTTCCACAGTAAGCAGCCCTTACTAAGCCGAGAGATGTCATTCCTGCAGGC  
 AGGACCTATAGGCACGTGAAGATTGAATGAACTMTAGTTCCAYTTGGAAGCCAGRCARWGATGGGT  
 CAGTGRGCAKGGCTCTMTTCTAKTCTCAGRCCATGCCWGTGGCAMCCTGTGCTCAGTCTGAAGACAATG  
 GACCCAAGTTAGGTGTGACACGTTACATAACTGTGCAGCACATGCCGGGAGTGATCAGTCAGACATTTT  
 AATTTGAACCACGTATCTCTGGGTAGCTACAAAGTTCTCTCAGGGATTTCATTTTGCAGGCATGTCTCTGA  
 25 GCTTCTATACCTGCTCAAGGTCAAGTGTCTCTTTGTGTTAGCTCATCCAAGGTGTTACCTTGGTTTCA  
 ATGAACCTAACCTCATTCTTTGTATCTTTCAGTGTGTAATTGTTTTCAGTGTATCCATCTTTAACGCAGGAG  
 GGATCCTTGGCTGAGGATTGTATTTCAAGAACCAACTGCTCTTGACAATTGTTAACCCGCTAGGCTCC  
 TTTGGTTAGAGAAGCCACAGTCTTTCAGCCTCAATTGGTGTGAGTACTTAGGAAGACCACAGCTAGATG  
 GACAAACAGCATTTGGGAGACCTTAGCCCTGCTCCTCTCGATTCCATCCTGTAGAGAACAGGAGTCAGGAG  
 30 CCGCTGGCAGGAGACAGCATGTCAACCAGGACTGTCCCGTGCAGAAATATGAACAACGCCATGTTCTTGC  
 AGAAAACGCTTAGCCTGAGTTTTCATAGGAGGTAATCACCAGACAAGTGCAGAAATGAGAACACTGAGCAG  
 GACAAGTACCTGTCTCTTTCACATAGTCCATATCACCACAAATCACACAACAAAAGGAGAAGAGATAT  
 TTTGGGTTCAAAAAAGATAAAGATAATATAGCTGCATTCTTTAGTTATTTTGAACCCCAATATTTTC  
 CTCATCTTTTGTGTTGTGTCATTGATGGTGGTGACATGGACTTGTATTATAGAGGACAGGTCAGCTGTCTG  
 35 GCTCAGTGATCTACATTCTGAAGTTGTCTGAAGATGTCTTCAAGCTTTCATGATTAAATTCAGCCTTAAACGTTTTCG  
 GGAACACTGCAGAGACAATGCTGTGAGTTTCCAACCTTAGCCCATCTGCGGGCAGAGAAGGTCTAGTTT  
 GTCCATCAGCATTATCATGATATCAGGACTGGTTACTTGGTTAAGGAGGGGTCTAGGAGATCTGTCCCTT  
 TTAGAGACACCTTACTTATAATGAAGTATTTGGGAGGGTGGTTTCAAAAGTAGAAATGTCCTGTATTCC  
 GATGATCATCCTGTAAACATTTTATCATTTATTAATCATCCCTGCCTGTGTCTATTATTTATTTATATC  
 40 TCTACGCTGGAACTTTCTGCCTCAATGTTTACTGTGCTTGTGTTTGTGTTTGTGTTTGTGTTTGA  
 AAAAAACATTCTGCTGAGTTTAAATTTTGTCCAAAGTTATTTTAACTATACAAATTAAGCTTTTG  
 CCTCTAGATCGCGGGCGGCCGC

>DEX0360\_048.nt.2

45 CGGGGCTGTGTTCCCGCGCTGGATTCTTCGCTGCGCTGCGCGCCGAGCCCAACTCTCGTGGGCGC  
 TGGGGAAGAACTCGCTGGCGGGTGTCTGTGGCATCCAGGGGGTGGAGGGACGGAGCAGCTTCGGGGG  
 CACGTCTCTATATCCTGTAGAGGACACTGACCCCGACCCACCCCTCCAGGCCAGAAATCCGTTCCCT  
 CTGCGGACCTGAGAGCGAGCGCGCTCGCGCCCTGACTTGCAAGTTGGGGTCTTTACTGGCCTCCGGG  
 CTCTGCTCCTGGCGTTGTCTCCAGGCTGGTGTAGGGCAAGCCAGGTGTGCCAGCTCCAGGATGCACATG  
 50 AGCAGCATTTGTAGCATCGCTGAATCACCTCTCAGCTAGCGGGCAAGCCTCAAAATGAACCCGAGGATT  
 TCGGGCAATCTGAAGGCAAACTCCTGTTTAGACCCAGGCGAAGGTTCCCGGTGACCCGGGCTCTCACCAGC  
 CAATTGTCCCTTGGCGTCTCCTGAGGGTGCCTGGAGCTTAAGCACTGTGTGCTCTTGGCTCCACACTG  
 GGGATGCCGCTGACTCCCACTGTCCAGGGCTTCCAGTGGATTCTCCAGGGCCCTGATGTAGAACTTCCC  
 CATTTGGGTGCACCAAGAGCAGCCTCACATGGTGTGGGCTGACATCAAGAGCTGCCAGATCCAACAGGAAG  
 55 ATGGCCAATCTTTCCTAAGCTGCTCACCTTACAAGAAAACGAATCGTACTGCTAAGAAATCAAACTCAG  
 CAGTCATGGGAGCCTTGGAAAGGAGCCGAATCAAGTATGGAATTGGACAGTGCATGGAGATGGTTTCAGC  
 AGGACAAGGGTAAGTGCAGGGGCAAGTCCAGGTCACTAGAGACAACGAGTGGCGCTGACAGAGACAG  
 ACAAAGATAAAATCAAAGTTTGTGCTTCATCTTCAAAAACCTCAAACTAATAACAACTTGGCCTTATGA  
 GAAATAAAGTATTTTCTATTTACATGAGAAATTAATCTCAAAACAGGAATCAGAAACATATTAAGTC  
 60 CAGGGCATAAAACCTAAACCACTGCTCATATTTATTCTTTCTAAATAGAGCAAAGTGTAATCTTCTCC

DEX-0360

210

PATENT

ATAAAATGCACATTGTGCTTATGAAAAGGCCAGTCTTAGTGAGAATCATTGGTATTCCATAGAAGAGTGA  
ATTAAACACAGCCAAGGGAAGACCCAAGTCTCATACTTCTCTTGATATCCAGAGTTCAGGGGAATTC  
CAGGTGATAGAGGTGATCTCCCATACTGTTAAAGCAAGGTTGCAGACACTTGGGAATTTTGGTCCCAGTA  
CTCTAGGAGGTACACCTCTGTCTGGAAAATACTACAGGAATGTATACTCTTCTATGACTCATTCTGG  
5 TCATTCTTCCAGCATCACAAAAACAAAAAAGGAAATATGTCCAAATACATGATTGCTATCCC  
TCCTCTTCAGGTTTCTTACCTGTTACTTACGGATAACAGCATTACCACAGGATTATGATGAAGATACAAT  
GTCCAAATATAAACACAGTTTGTAGCAAAATGCCTTGATACGAATTGGTCAATGAACAACCTAGTAAATAAT  
TATGTGAATATTTACTGAATTATATGGATCCTATGAATAATTACTGAATAATTCTGTGATTGCTTTTAT  
TGGCAGTGCTGAAAACCATCCCCGTGTGACCTCAAGTAAGCCATGTAACCTCTGTGAACCTGCAGTTTAA  
10 TCATTTTAAATAAAGAAACATGACAGATTTTCAATTATGACACAGAATGTCAGGTCTCCAGATGCCAG  
AAAATACATTTTACTTAAAGCCGTTGATACGCTTAAAGCGGTTTCTTACAGTGTCAATTGGAGGACAGTG  
TGGAGTGCAGAGAGACATGCTTTGAAATGGGATTGATCCAGTCCCTCTTCACTACCACATGAATGC  
TGGGCAGCCCAGGGTCAACCCACCGCACCTCAACTCAGGCAAGTCCAGCAGCCAATCTTAGCAGCCCTG  
GGCTACAGAACAGTCTCCCAAGTTCAGGCTCAAAAACCTAGGTGGGGTGAAGCTGAGAAAGCGAGGA  
15 GTTGGTTCAGGGGATCACTCTTCTTCTCATCTCTCAAACTCACCTTCTACTGCAACACTGA  
GGATCACCACCAACCGTGACCATAACCTTGATCTTGCCATGTTCTGTTAGTGAATGCAACCCAAAATC  
AATGGTGTAGGTCTATCTGAACAAAATATATATCAAAACCATATGCAATAAGAACCGCTCATGGCCCTGTT  
CTTTTCAGTATATGGGAAAACAAAATGGAACAACAAAATAGCATCAGGTTTATGAACTTCCCAAGATA  
GATGGTCAACATGTTTTCAGGAGATCTCTATATAAATGATTTTGATCACTTGATACCTTGAAAAGAGCT  
20 CTGTGACACTAGAATGACATCCATAAGTGACAAGTATAAATGTAGCGCTCAGTGACATCAAAAACCAA  
ATCAACCCACATAGAGGAAGAGCTCTGGACATAGGGATGTCAAACCTAGTGAATGAAAAGCAA  
AGATGGTGCCCCAGTGAGAAAAAGAAAATCAACATAAACAATGGGAAACAGCAAGAATACTGAGACAG  
GAAAGACAACATTTTACAAATGAATTATTCATTCACTTTCTAGTGGATACAGACAAAACCTGCAAGA  
CCCAGAGGAAATCAGGGCAGGCTAAAAGTTTGATATCTTACACCTGTGAAAAGGCCCTTAAGCTCTGTTT  
25 TAAGTGAGAGCAGGTGGGGTGACTTTCATGACTACCATTAAGAAAATACAACCTGTTGGGAAACTGTTTCT  
GCCTTGATGATGTTGTACAGACAAGAGATAAACAGTGAGGAATATGCTTAGATGTATTGGGAAAGACACG  
GGTCTGTGGCATCATCACAAGGGTACACGAATCTGAGAGTGAATGTGAAGGAATGATCCCCATTGGTG  
GTGACCTCAGGTGAGACTAGGGTGCTGTGTTTTCAGGAAAGCCTGGGCAATTGGAATGCAGGGCTGCTA  
AGATTCCATGACACCCCCACCTTCTAATTCTGTTATTGCAACTGCAGACGGTTACCTGGCACGCTGGCCA  
30 CAGTCTACCTCACTCTTATCAGAGTCTGAGCTACTGGCAGTGCTTTTCAGCTCTGAGTTTCAGGCACCTCGA  
ACCTTGTTTTTGTGGTGAAGGATCCTAAAGTGCTGTGGGAGTGATCACATTTTTCACAACATCCCTGGC  
TCCACCTCTTCTGCCACAAACGTCAGCATGGTGGTATCAGCTGGCCCTTGGTCCAGCGAGAAGGCAGAGA  
CGAACATTTTAGAAATCAACGAGAAATTCGCGCCCCAGCTGGCAGAGAACAAACAGCAGTTTCAGAAACCT  
35 CAAAGAGAAATGTTTTGTAACCTAAGTGGCGGGCTTCTGGCCAACCGACAGAAGAAATACAAGTATGAA  
GAGTGTAAGACCTCATAAAATTTATGCTGAGGAATGAGCGACAGTTCAAGGAGGAGAAGCTTGCAGAGC  
AGCTCAAGCAAGCTGAGGAGCTCAGGCAATATAAAGTCTGGTTCACTCTCAGGAACGAGAGCTGACCCA  
GTTAAGGGAGAAGTTACGGGAAGGGAGAGATGCCCTCCGCTCATTGAATCAGCATCTCAGGCCCTCTCT  
ACTCCGGATGAGCCAGACAAGTCCCAGGGGAGGACCTCCAAGAACAGCTGGCTGAGGGGTGTAGACTGG  
40 CACAGCACCTTGTCCAAAAGCTCAGCCCAGAAAATGACAACGATGACGATGAAGATGTTCAAGTTGAGGT  
GGCTGAGAAAGTGCAAAATCGTCTGCCCCCAGGGAGATGCCGAAGGCTGAAGAAAAGGAAGTCCCTGAG  
GACTCACTGGAGGAATGTGCCATCACTTGTTCAAATAGCCATGGCCCTTATGACTCCAACCAGCCACATA  
GGAAAACCAAAATCACATTTGAGGAAGACAAAAGTCGACTCAACTCTCATTTGGCTCATCTCTCATGTTGA  
ATGGGAGGATGCTGTACACATTATCCCAGAAAATGAAAGTGATGATGAGGAAGAGGAAGAAAAGGGCCA  
45 GTGTCTCCAGGAATCTGCAGGAGTCTGAAGAGGAGGAAGTCCCCAGGAGTCTGGGATGAAGGTTATT  
CGACTCTCTCAATTCTCTGAAATGTTGGCTCGTACCAGTCTTACAGCGGCACATTTCACTCATTAGA  
GGAACAGCAAGTCTGCATGGCTGTTGACATAGCGGACATCGGTGGGATCAAGTGAAGGAAGGAGGACCA  
GAGGCAACAGGTCCCAGCCAGGCTCAGCAGGGAGCTGCTGGATGAGAAAGGGCCTGAAGTCTTGCAGGAC  
TCACTGGATAGATGTTATTCAACTCCTTCAGGTTATCTTGAAGTCACTGACTCATGCTTACAGAA  
50 GTGCCCTTTTACATATTGGAGCAACAGCGTGTGGCTGGGCTCTTGACATGGATGAAATTGAAAAGTACCA  
AGAAGTGGAAGAAGACCAAGACCCATCATGCCCCAGGCTCAGCAGGGAGCTGCTGGATGAGAAAGAGCCT  
GAAGTCTTGCAGGACTCACTGGATAGATGTTATTCGACTCCTTCAGGTTATCTTGAAGTCCCTGACTTAG  
GCCAGCCCTACAGAAGTGCTGTTCACTCAATTGGAGGAACAGTACCTTGGCTTGGCTCTTGACGTGGACG  
AATTAAGAAAGGACCAGGAAGAGGAAGAAGACCAAGGCCACCATGCCCCAGGCTCAGCAGGGAGTCTG  
55 GAGGCGATAGAGCTGAAGTCTTGCAGGACTCACTGGATAGATGTTATTCAACTCCTTCCAGTTGTCTTG  
AACAGCCTGACTCCTGCCTGCCCTATGGAAGTTTCTTTTATGATTTGGAGGAAAACATGTTGGCTTTTC  
TCTTGACGTGGGAGAAATTGAAAAGAAGGGGAAGGGGAAGAAAAGAAGGGGAAGAGATCAACGAAGAAA  
AGAAGGAGAAGGGGAAGAAAAGAAGGGGAAGGGGAAGAAAAGAAGGGGAAGAGATCAACGAAGAAA  
TGCTGGATGAGAAAGGGCCTGAAGTCTTGCAGGACTCACTGGATAGATGTTATTCAACTCCTTACGGTTA  
TCTTGAAGTCACTGACTCATGCCAGCCCTACAGAAGTGCCTTTTACTYATTKGAGSAACAGCRYRTTSAG  
60 CTTCCGCCCTTGACGTGGACAATAGAGTTTCTTTACTTTGATGGGAAGAAGGTCTCCACCTGAGTCTTCCA

DEX-0360

211

PATENT

GATGGGAGTCATATTTCCACAGTAAGCAGCCCTTACTAAGCCGAGAGATGTCATTCTGCAGGCAGGACC  
TATAGGCACGTGAAGATTTGAATGAACTMTAGTTCCAYTTGGAAGCCAGRCARWGATGGGTCAGTGR  
GCAKGGCTCTMTTCTCTAKTCTCAGRCCATGCCWGTGGCAMCCTGTGCTCAGTCTGAAGACAATGGACCCA  
AGTTAGGTGTGACACGTTACATAACTGTGCAGCAGCATGCCGGGAGTGATCAGTCAGACATTTTAATTTG  
5 AACCACGTATCTCTGGGTAGCTACAAAGTTCCCTCAGGGATTTTCATTTTGCAGGCATGTCTCTGAGCTTCT  
ATACCTGCTCAAGGTCAAGTGTATCTTTTGTGTTTAGCTCATCCAAAGGTGTTACCCTGGTTTCAATGAAC  
CTAACCTCATTCTTTGTATCTTCAGTGTGTAATTTAGCTGATCCATCTTTAACGCAGGAGGGATCC  
TTGGCTGAGGATTGTATTTACAGAACCACTGCTCTTGACAATTGTTAACCCGCTAGGCTCCTTTGGT  
10 TAGAGAAGCCACAGTCCCTCAGCCTCCAAATTTGGTGTACGTACTTAGGAAGACCACAGCTAGATGGACAAA  
CAGCATTGGGAGACCTTAGCCCTGCTCCTCTCGATTCCATCCTGTAGAGAACAGGAGTCAGGAGCCGCTG  
GCAGGAGACAGCATGTACCCAGGACTGTCGGGTGCAGAATATGAACAACGCCATGTTCTTGAGAAAA  
CGCTTAGCCTGAGTTTCATAGGAGGTAATCACCAGACAACCTGCAGAATGTAGAACACTGAGCAGGACAAC  
TGACCTGTCTCCTTCACATAGTCCATATCACCACAAATCACACAACAAAAAGGAGAAGAGATTTTGGG  
15 TTCAAAAAAAGTAAAAAGATAATATAGCTGCATTTCTTTAGTTATTTTGAACCCCAATATTTCTCATC  
TTTTTGTGTTGTCTGATGGTGGTGACATGGACTTGTTTATAGAGGACAGGTCAGCTGTCTGGCTCAG  
TGATCTACATTCTGAAGTTGTCTGAAAAATGTCTTCATGATTAAATTCAGCCTAACCTTTTGGCCGGGAAC  
ACTGCAGAGACAATGCTGTGAGTTTCCAACCTTAGCCCATCTGCGGGCAGAGAAGGTCTAGTTTGTCCAT  
CAGCATTATCATGATATCAGGACTGGTTACTTGGTTAAGGAGGGGTCTAGGAGATCTGTCTTGTAGAG  
ACACCTTACTTATAATGAAGTATTTGGGAGGGTGGTTTTCAAAAGTAGAAATGTCTGTATTCCGATGAT  
20 CATCTGTAAACATTTTATCATTTTATTAATCATCCCTGCCGTGTCTATTATATATTCATATCTCTACG  
CTGGAACATTTCTGCCTCAATGTTTACTGTGCCTTTGTTTGTCTAGTTTGTGTTGTAAGAAAAAAC  
ATTCTCTGCCTGAGTTTAAATTTTGTCCAAAGTTATTTAATCTATACAATTAAGCTTTTGCTCTA  
GATCGCGGGCGGCCG

25 >DEX0360\_049.nt.1  
GCGTCCGCTGAGGCGCCCATGGCCTTCGCCCCGCGGCTCCTGCGCGGGCCACTGTGCGGGCCGCTGCTCGG  
GCGGCGCGGGGTCTGCGCTGGGGCCATGGCTCCGCCGCGCGCTTCGTCTGGAGCTTCCGACTGCACC  
CTGGCTCACTTCGCCCTAGGCGCGGACGCCCCGGCGCAGCAGACGCCCCGCTGCGCGGCGC  
TGCTGGGGCCCCCGGAGCGCAGCTACTCGCTGTGCGTGCCTGACCCCGGACGCGCGCTGCGGGCCCCG  
30 GTCCGGGCGGCGCGGCTGCACCAGCGCCTGCTGCACCAGCTGCGCCGCGGCCCCCTTCCAGCGGTGCCAG  
CTGCTCAGGCTGCTCTGCTACTGCCCCGGCGGCCAGGCCGGCGGCGCACAGCAAGGCTTCTGCTGCGCG  
ACCCCTGGATGACCCTGACACCCGCAAGCGCTGCTCGAGCTGCTGGGCGCCTGCCAGGAGGCACCAGC  
CCCGCACCTTGGGCGAGTTTCGAGGCGGACCCGCGCGGCCAGCTGTGGCAGCGCCTCTGGGAGGTGCAAGAC  
GGCAGGCGGCTGCAGGTGGGCTGCGCACAGGTGCTGCCCGTCCCGGAGCCCCGCTGACCCGGTGGTGC  
35 CAGACTTGCCAGTTCGCTGGTCTTCCCGGACCGGGAAGCCCGCGGCGGCTTTTGGAGGAGTGTACCTC  
CTTTATTCTGAAGCCCGGCGAGTGCTTGACCTGGTTCGACCAAGTGCACCAAAACAGATCCAGAAAGGAAAG  
TTCCAGGTTGTTGCCATCGAAGGACTGGATGCCACGGGTAAACACCGGTGACCCAGTCAGTGGCAGATT  
CACTTAAGGCTGTCTCTTAAAGTCAACACCCCTCTTGCAATTGGCCAGTGGAGGAAGATCTTTGATGATGA  
ACCAACTATCATTAGAAGAGCTTTTTTACTCTTTTGGGCAATTATATTGTGGCCTCCGAAATAGCTAAAGAA  
40 CTGCCAAATCTCTGTGATGTAGACAGGTAAGTGGCACAGCAGGCCACCTATGCCATAGCCACTGAGG  
TGAGTGGGGTCTCCAGCACCTGCCCGGAGCCATCACCCTGTGTACCAAGTGGCCAGAGGACCTGCTCAA  
ACCTGACCTTATCTGTGCTCACTGTGAGTCTGAGGAGAGGTTGCAGAGGCTGCAGGGCCGGGGCATG  
GAGAAGACCAGGGAAGAAGCAGAACTTGAGGCCAACAGTGTGTTTCGTCAAAAGGTAGAAATGTCCTACC  
AGCGGATGGAGAATCCTGGCTGCCATGTGGTTGATGCCAGCCCCCTCCAGAGAAAAGGTCTGCAGACGGT  
45 ATTAAGCCCTAATCCAGAATAGTTTGTAGTGAACCGTAGTTACTCTGGCCAGGTGCCACGTCTAACTAGATT  
AGATGTTGTTTGAACATCTACATCCACCATTTGTTATGCAGTGTTCCTCAATTTCTGTTCTACAAGCAT  
GTTGTGTGGCAGAAAACCTGGAGACCAGGCATCTTAATTTTACTTCAGCCATCGTACCCTCTTCTGACTGA  
TGGACCCGTCATCACAAAGGTCCCTCTCATCATGTTCCAGTGAGAGGCCAGCGATTGCTTTCTTCTTGGC  
50 ATAGTAAACATTTTCTTGAACATATGTTTCACTTAATCACTACCAATATCTGGAAGACCTGTCTTACT  
CAGACAGCACCAGGTGTACAGAAGCAGCAGACAAGATCTTCCAGATCAGCAGGGAGACCCCGGAGCCTCT  
GCTTCTCCTACACTGGCATGTGATGAGATCGTGACATGCCACATTTGGCTTCTTCCACATCTGGTTGCA  
CTCGTCATGATGGGCTCGCTGCACTCTCCCTCAGTCCAAATTTAGAGCCAAGTGTTCCTGCAGAGGCTG  
TCTATGTGTCTGCTGCCCCAAGGACACTCCTGCAGAGCCATTTTGGGTAAGGAACACTTACAAAGAG  
GCATTGATCTTGTGTCTGAGGCTCAGAGCCCTTTTGATAGGCTTCTGAGTCATATATAAAGACATTCAG  
55 CCAAGATGCTCCAACCTGCAATATACCAACCTTCTCTGAATATATTTTGTCTTATTTATATTTCTTTCT  
TTTTTTCTAAAGTATGGCTCTGAATAGAATGCACATTTTCCATTGAACTGGATGCATTTTCAATTTAGCCAA  
TCCAGTAATTTATTTATATTAATCTATACATAATGTTTCCCTCAGCATAGGAGCTATGATTCATTAATT  
AAAAGTGGAGTCAAAACGCTAAATGCAATGTTTGTGTGTTTTCATTACACAACTAATTTGTCTGT  
TTAAATAAGTACAGTGGATCTTGGAGTGGGATTTCTTGGTAAATATCTTGCACCTGAATGTCTCATGAT  
60 TACATATGAAATCGCTTTGACATATCTTTAGACAGAAAAAGTAGCTGAGTGAGGGGGAATTTATAGAGC

DEX-0360

212

PATENT

5 TGTGTGACTTTAGGGAGTAGGTTGAACCAGGTGATTACCTAAAATTCCTTCCAGTTCAAAGGCAGATAAA  
TCTGTAAATTATTTTATCCTATCTACCATTTCTTAAGAAGACATTACTCCAAAATAATTAAATTTAAGGC  
TTTATCAGGTCTGCATATAGAATCTTAAATCTAATAAAGTTTCATGTTAATGTCATAGGATTTTAAAA  
GAGCTATAGGTAATTTCTGTATAATATGTGTATATTAAATGTAATTGATTTGAGTTGAAAAGTATTTTAA  
10 AGCTGATAAATAGCATTAGGGTTCTTTGCAATGTGGTATCTAGCTGTATTATTGGTTTTATTACTTTAA  
ACATTTTGAAAAGCTTATCTGGCAGCCTAGAAAAACAACAATTAATGTATCTTTATGTCCTGGCACA  
TGAATAAACTTTGCTGTGGTTTACTAATCTATGCTGTATCTGCTGGGTACATATTGATTTGTCTGAAAAGT  
GCTTTCTCAGATTTCCCTTTTAATATTGTATGTAAAGGAGGAAATTTTGGTAAAGGAAGTTGAAAGGT  
GTGAGCTGGCAGGCTAAGTGAATTTGTGGTCAGAGTGCTTTCAGAGAAA

15 >DEX0360\_050.nt.1  
GAAAAGTACTGGAAGTAAAGTCTGACCTAAAGCAAATGAACAGCTTAAACGGAGATCAGAAAGGCTACAA  
CAATTAACAGAGGTTTCAAGAAGGTCGTTACGCAGTAGAGAAATTCAGGGTCAAGTTCAAGCAGTTAAAC  
AGAGTTTGCCACCACTAAAAAAGAGCAGTGTAGCAGTACTCAGAGTAAATCTAATAAAACAAGTCAAAA  
20 ACATGTGAAGAGAAAAGTACTGGAAGTAAAGTCTGACTCTAAAGAAGATGAAAATCTAGTAATTAATGAA  
GTAATAAATTTCTCCAAAGGGAAAAACGCAAGGTAGAACATCAGACAGCTTGTGCTTGTAGTTCTCAAT  
GCATGCAAGGATCTGAAAAGTGTCCCTCAGAAGACTACTAGAAGAGACGAAACGAAACCTGTGCTGTAAAC  
TTCTGAGGTGAAAAGATCAAAAATGGCTACTTTCAGTGGTCCCGAAAAAGAATGAGATGAAGAAGTCGGTT  
CATAACAAAGTGAATACTAACACAACACTCCCAAAAGTCCACAGCCATCAGTGCCTGAACAAAGTGATA  
25 ATGAGCTGGAGCAAGCAGGAAAGAGCAAACGAGGTAGTATTCTCCAGCTCTGTGAAGAAATTGCTGGTGA  
AATTGAGTCAGATAATGTAGAGGTAAAAAGGAATCTTCACAAATGGAAGGTGTAAGGAAGAAAAGCCC  
ACAGAAATAAAAATTGGAAGAGACCAGTGTGAAAGACAAATACCTTCATCAGAAGGAAACAAATCAGGATG  
TGCAATGTAATCGTTTTTTTCCCAAGTAGAAAAACAAAGCCTGTGAAATGTATACTAAATGGAATAAACAG  
CTCAGCCAGAAGAAGTCCAACTGGACTAAAATTAACCTCTCAAAATTTAACTCTGTGCAGCACAATAAG  
30 TTGGACTCTCAAGTTTCCCTTAAATTAGGCTTATTACGAACCAAGTTTTTACCACCAGCTTTAGAAATGC  
ATCATCCAGTGACTCAAAGTACATTTTTAGGGACAAAGCTACATGATAGAAATATAACTTGCCAGCAGGA  
AAAAATGAAAAGAAATTAATTTCTGAAGAAGTGAATTAATGATATTACAGTAGAAATTAATAAAACCACA  
GAAAGGGCTCCTGAAAATGTCTATTGGCCAAATGAGATAAAACCTTCTGACCCACCATTGGATAATCAGA  
TGAACATTTCTTTTGATTTCAGCATCAAATAAGAATTTTCAGCCAATGTTTGGAAATCCAAGCTAGAAAACAG  
35 TCCAGTGGAATGTTACTGCTGCTTTCGACTCTGCTCAGTCAAGCAAAATGATACAGGAGAGAATAAAA  
TTTCCAGGTTTCAGCTCCCCAACAGCATAGTATTCTCAGTAACCAGACATCTAAAAGCAGTGATAACAGGG  
AGACACCACGAAATCATTTCTTGCCTAAGTGTAAATTTCCATTTGGAGATAACAATTCAAAGGACTTGAA  
ACTAAAAGAAGCAGAGAAAAGTATGAAAACAGTTGATTATAGATGCAGGACAAAAAGATTGGAGCA  
GTTTCTTGTAATGTTTGTGGAATGCTGTATACAGCTTCAAATCCAGAAGATGAAACACAGCATCTGCTTT  
40 TCCACAACCAAGTTTATAAGTCTGTTAAATATGTGGTTCTGCTCATTAAATCACCACGAGTGTGGATCTGA  
AGAAGAGTTTATTACCTCTCTTTTTTTGAGTATGTTAACTTCAGATACACACAACGTAGCTTCTCCTTC  
CCTATTAGATTCTTAGAAGGGCTGGAAGAAAGAAAGTTCTGGCTGAATACCCTGATGGCAGGATAATA  
ATGGTTCTTCTTGAAGACCCAAAGTATGCCCTGAAAAGGTTGACGAGATTAGAGAGATGGTTGACAATG  
ATTTAGGTTTTTCAACAGGCTCCACTAATGTGCTATTCCAGAACTAAAACACTTCTCTCATTTCCAATGA  
45 CAAAAAGTAGTTGGCTGCCTAATTGCGGAACATATCCAATGGGGCTACAGAGTTATAGAAGAGAACTT  
CCAGTTATCAGGTCAGAAGAAGAAAAGTCAGATTTGAAAGGCAAAAGCCTGGTGTGCTCAACATTAC  
CAGAGCCTGCAATCTGCGGGATCAGTCGAATATGGGTATTGAGCATGATGCGTCCGGAAGAAAATTGCTTTC  
TCGATGATTGAATGCCCTAAGGAGTAACCTTATATATGGCTCATATTTGAGCAAAGAAGAAATGCTTTTC  
TCAGATCCCACTCCTGATGGAAGCTGTTTGCAACACAGTACTGTGGCACTGGTCAATTTCTGGTATATA  
50 ATTTTATTAATGGACAGAATAGCACGTAAAACAAATTTCTTGCCTACACCACTAGAAGACATCTATTGAAG  
AGAATGGATTGGTTGCTGACTTTAACAGGAAGTAGGGCCATTTTTATTACAATGAATCAGGACTGGCA  
ACAACCATATGGTTGTTCCATTTTCATAAAATTTGAAACAAATGCAGTAATAGCTTATTGTTTTGTTTTT  
AAAGAAGATATTTTATTATCTTTTACAGAAATTTATGATTGATGTTTATCTATAGTTATTTAGACAT  
GTTTACATGCAGCAGATAATTGTTTATAGTGGACTGAAAACCTAATGCAAGGACTATGGTCTCAGTGATAA  
55 GTATATTTTGAAGTTCTTAATATGGAATATACCAGTGTAGCTTGGTACTGTATTTTTTTATATTGATCT  
GCTGATACCAGTGATAGGCTTAAAGATTGTATTTTACAGAGTGGAAACCAATTTTTTTAGTTATTTGTTTC  
AAGGAGGGTGCAATATTAAGTGTTTTGAATTTGAAGCTAATTTTTTAAAGGCTGAACTATACTTTGAA  
GAAACCCCTATAGAAAAGGAAAGCTCCAGCTAAATAGGAAGAATTAGAATATTGAGCTTTTTTTTCTCTGA  
TTTTTCTCTTCTCTATCTTTGATGGAAGGAGGAAGTAGAAAAGTGGTAAAGAATTGAGGCTTCTCTCTTC  
60 GAGAGCTGTAAATGACAAGCATTAGGAAAGGTACCCTCCTAGATTCATTATTCTTTTCATTCTGGTTTCAG  
TTTTAAATAAATGGCAACTTGGCACACCTAGGCTGTAAACAAATCTCAAAGAGGTTTATAAAAACGTAT  
AGAATACCTGGAAGCAAAGTATGGATGACTCGGTATCTGCTTTGTTATTCTCTCAGAAATCTGCACTGAG  
TATATGCCCTCATTACTGGACTTCATTTTGATACCTTATGCTATCTTCATAGTGCCCTCTACTTTTAAAGG  
GTTTATATGTTGAAAACCTGCTGTGGCCTTTTATGACCTGTATATAATGTAGAATAAATAAATAAATA  
CTTGATAGCTTTTTCTAAGTGACCAATGTACTAACTGAGAATAATGGTGTGTTGTCATTTGTGCTTTTTTC

DEX-0360

213

PATENT

AGGGTGTTTTTTGGTTTGATATCTTGAAATATGATTAACAAATTTGGCTTCCTAAAGGCAGTTTCCACCA  
GTTTGCCAAAGGATCATTGTGTGTCAGCAGCAAATCAGCTGAACCTTTATTTCCAAAGGCCAAATCCTTTCTG  
ATTATTTTAGTAACATAGTACTTTTATGATGTTGCAAATAAATGAAGGGCCCCACAGCCCCAAGAATGAATT  
5 ACCACTGTGGTTCAACTTAGGTTATTTTGTGAGCTGAAATGATCATATCTCAGTTGAAAACCTGGCTAAA  
ATTTAGGGCCTTAAATTAACAGGTATACATTTTATTTCCCTATAAAATTTTGGCTTTTACAATTTCTAGGC  
CACTGCACCTGGCCCTAGCTTTTGATACTGTCAATTTCCCTTTGGGCTTGAGACTGTTCTAGTCAATCCTG  
GTCTCATTTGTTTGCCTGACAGGTACCATGATTTAA

&gt;DEX0360\_051.nt.1

10 CTGTTATTTACCTCATGAGCTAAAACCTCTTGAATTTACTAGTTTCTTATTACTTATGAGGGTGTGTTT  
TTTGTGTGCTTATAGAACTTTTCTAAGTGTCTTATAGCAGTGAAGCCTACAAAGTAAGAGTTTCCAGAT  
TCCATCCGTTCTTTAGCTGACTTGAATGACTCTAATGCAGTGGGTTGCAGGTTTGGCTACTTACCTATG  
TACTCTGTAAACATCCAGAGGCCAGGGATATTCTGAGCCACTGTGTGTGAATGGAGTTTGGCCATCTGT  
AGATTTCCGCAGTCTCTCCAGGTGATCGCACTGTGCAGCCTCATTGCTCATAAACAAAACCTTTAATATGC  
15 TTTTAATGATCTTTCAAGTGTGTTGAGGATTTCTTTCTTGATTTTGAGGAATATATGTCAGTATATTTTT  
CAACTTTAAGTGTTCGTATATATATTTAGTAAAAACATTGAACTGAAGTCTGGGGGAAGTTTGTGGAAC  
AGAATATTAGAATCAAAAGTTTGGATTTAAAATCTAATGTGACTATCGAGTGGCATGCTGGAAATTTTTTA  
ATTTATTTGGCCATCTTTAGTATGCCATTTCTTAATCTCATCTGTCAAAGAAACAAAATATGTTTTTC  
TAGTAGCTGTTTCCGGTTTTCAAACCTTATGCATGCTTTCTTGCCCTCTTTAGTCAATGTTTCTTTCATGTT  
20 TCTGGTTTTAAACATGCAAAAATGTGTAATATTACAGAGGTCTGCTGTACTAGCCACCAAGCAGCTGC  
TGGTACTAAGAAATATGATCTTAGTAAATGGAATATGCAGAACTACGTGATACCATCAATACTTCTTGT  
GATATTGAGCTCCTGGCAGCTTGCAGAGAAGATTTTCATAGGAGACTAAAAGTGTATCATGCTTGGAAAT  
CTAAGAACAAGAGAGAAATACTGAAACAGAGCAACGTGCTCCAAAGTCTGTTACTGATTTATGCTCAGCA  
AAACCCAGCAGCTCAGATTCCTGCCAGGCAGCGGAGATTGAAATGAACCGACAGCAACGCTTCTTCCGC  
25 ATCCCCATTCACCGCCCTGCCGACCAGTACAAAGACCTCAGAGTAAGAAAAAGGCTGGTGGTATGCC  
ATTTTGATGGACCATGGATTGCCCGGCAATGGAACCTCCATCCTGACAAGCCACCCATCCTACTTGTGGC  
TGGTAAGGACGACATGGAGATGTGTGAGCTGAATCTTGAGGAGACTGGCCTGACTCGGAAGCGTGGTGTCT  
GAGATCTTGCCAAAGACAGTTTGAAGAAATCTGGGAACGCTGTGGAGGCATCCAGTACCTTCAGAATGCGA  
TTGAGAGCAGACAGGCTCGGCCCCACCTATGCAACAGCCATGCTGCAGAGTCTGTTAAAGTAGATGTTGCA  
30 CACCAGCCTTACAGCTGGGAGCCTTTGCCATGGTACTTAGGTAGGGTGTGTGCCCCAGATTAAACCAT  
CCATAATCATGTTAGAGTTACTTCTATAAAGTGAACAGATTTTATTAATCACGGCTTTTGGTGAATTTGT  
TTAAGGTTAATTATGGTAGCAAATTTTGGACCTAAACATTATTTTCTGTATCCCGCTGTAATTCCTAAA  
ACTCTCATTATTTCTAATCTAATACATGGGCATATTCTGATGTTTCTCATCTTTTCCAGAAAGACTAC  
CTTACATCCATCGTAATTGTTCTCTAGGAAAAGAGAACTTTTTTCAAAATTCAAAATACTTTTTAAGGAT  
35 GGCACAGTACCATATAACTGGAGTAATAAAACATGAGCTTACATTCTTACAATAACTAAACCACTTAAAA  
TGATCAAGGCACATAATGTTTTGGTCTGAAAAGCTGTGTACTTTATAGACATTTTCAGACATTTTGGAAA  
TTTCCATTAAAGGTGAAAATCTATTTTTTCTCCTTTGCAGTGTCTTAGTTTGAATGAAACACTTCGA  
AGTTCTAGAATTCTAGAAAGAGCCTTAATGTATTTGATGTATTCTGTGATAAGAGGTACTAATAGTATCC  
AGCACAGATTTGCTTTTCTTTGTCTAGCACAAATGTGTGTGTGCTGTCAGAAATATTCTTTTATATTCTGTGG  
40 AAAAATAAGGAAATTCAGATTGTTTAAATGCTTAAAGTTTGTGATAAGTTTGTGTTTCAATTAGAAAA  
GGAAATAGGTTTTAGGTGGCATAAGTGGCTTAACTGGACTGAATTCAAATATTCTTTCAACTTCATCTCAA  
TAGTGATTTTTGTATCAGAATCTTGTCCAAGTTGTTTCATTGATTAGTAAGTGTCTGCTTCCAACATC  
TTCTTTTTTAAGAAATTCCTAGTGTCTTTTTTGGCCTTTGAGGTTTGGTAATTGTAGACCTGTTTCATA  
AGCTTTGTAATTCAGAAATCCTTGTATTTAGTAAGTGCTTGTTTTACATAACTGATAATTTTAAATGTT  
45 TTCTTTGTGTGCTGTTAGTATTGATTCAATGTGACAGCTTTAAGCCTAATATTTATGACTTTTCAATTT  
GGAATTTAAAGACAAAAATACATCAAGGAGTTATGCTGACATAATTTCTAAGGAGTTTGTGTGATTTTAG  
AATAAAATTATAAAGTAAAA

&gt;DEX0360\_052.nt.1

50 AGGATGATAGATATATAGGCCAATGGKCTCTAGATCATGCTCGAGCGCGCAGTGTGATGGATGCGTGGT  
CGCGGCCGTACAGCGTGGAGTGGGATGGCTCTCTTCCCTCAGCCACGCGCTTGTGAGGACAGAGGTGGG  
GGAGTGGGAAGTGGGAAGTCACCAGAGAACAGGAGAGGGATTGAGGGCGCGACCCAGCGCTCTCCACG  
GACCAGCCAGAGGGACTGGAGCCAGGTGTGCATGGGTTCAAGGCCCTGGCCCTGCCAGCCTCTGTCTTG  
GGAGCTCAGCCCCAGGGTTCCGTCGTGACGAGTTTCCCAAGAACAGATGTGATGGCATCTGCTGTGAA  
55 ACCCTGATGAGGACCAGGCCCTTGCACCGCTGACGCTGAGGAATTAAGGCTTTGGTGTCTGGGAAGAG  
CATTTATCTCTGAGGAGCCGCTGTGCTTCTTCTGAAAGTGAGGGCGTGCCCCGGGTCCCATTTCTCCT  
TTCACTTGAGTCGGGAAGCACAGCAACTTTAAGGCTCGCGCCAGCAACATGGCTCCCCCTGCATCTGCA  
TCTCCCTCCTGCTCTGGTGTGCGCGCTGCACCTGTCTCGGAGGACAGCAGAGGTTTGGACGGAGACTC  
AGGGAGGGAGGGAAGGAGGCAAGGACGCCTGTGGAACATCTTTCAGGCAGCTCTAGGGTCTGGGGGCCA  
60 GGATGCTTGGGTCTCCCAAGGCCTGTCTGTCTCTGCCACCTCAGCGGCTGCCAGAAGCAGCGTGTG

60 >DEX0360\_053.nt.1  
TGATGGATCGGCCGCCGGGCAGGTCAAAGCGGCAACAAGTGATCTGGAACACTATGACAAGACTCGTCA  
TGAAGAATTTAAAAAATATGAAATGATGAAGGAACATGAAAGGAGAGAATATTTAAAAACATTGAATGAA

45 AAAAAGCAAAGAGTACCAGACTCACAAGTATGGTTATGAGAGCTACATGATATAGTATATAGCAAAGGAA  
TTTATTAGTTTTAAAGTACTATGGAAATGTTAATTTTGGAAATGTGAGGTAATATTTATAAGGCACCTTAG  
AACAAATGCTAGCCACATAGTGTTTGTAAATAGATTAAACAGTCCTAGTAATATCGTTATCTAGGAATA  
CACAGTTTCATGTTATTGCAACAAAGCTACTTCTGAAATGACTAAAGATAGCCACTTGGTTCAATATACCT  
GAGAAATAGAGTGTAAGTTTATTAAAAATGTTAGTCTGTAATGCACAACTTCAGTCACTTGGGAAATCC  
50 CTTTCCCCACAAACAGTTTAGTAGTGAAGTTGCACCTTAGGACAAATTAACCTACTACTACGACAAATAAA  
AAAGTGTATATTACGCGCTCTGAGGGCCAGAAATACTCGGAGATCAATTAAACTAGATGGAAAGGAGAA  
CCCAAAGGGGCGAAGAGAGCGAAGCCAGTGAAGTACACTGCAGCAAAGCTGCATGAGAAAGGTGTCCTGC  
TAGATATAGATGATCTTCAACAAACCAAGCTTTAAGAATGTTACATTTTGATATCATAGCTACTGAAGATGT  
AGGCATTTTCGATGTAAGATCAAATTCTTGGTGTGAGATGGAAAGGTGCAACTCAATATTCTAGGAT  
TTACTTCAGATGCAATATGAAGGAGTAGCTGTAATGAAATGTTTGAATGAAGTTAAAGTGAATGTAAACC  
55 TTCTCATATACCTGCTGAACAAGAAGTTCTATGGAAAGTGAAGTGCCACAGAAATTTCTTGGATTCTGT  
ATCATCTGGGATTAGGAAATGAATTTGTTTAATATTTTTGTTTTTAAACATGATTGAAATCACTGCTTATA  
AATGTGTGATTTTTTTTAAACGACCAAACTGTTCTGAAGAATGTATCCAGGTGCCTTTTTGCTAATTTG  
ATACTATAATAGAATGAGACATAAAATGAATTAATGGAACATATCCACACTGTACTGTGATATAGGTAC  
TCTGATTTAAAACTTTGGACATCCTGTGATCTGTTTTTAAAGTTGGGGGTGGGAAATTTAGCTGACTAGG  
60 GACAAACATGTAAACCTATTTTCCTATGAAAAAATTTTAAATGTCCCACTTGAATAACGTAATTCCTCA

DEX-0360

216

PATENT

1 TAGTTTTTTAATCTATGGATAAATGGAAACCTAATTATTTGTAATGAATTATTTAGACAGTTCTAAGCC  
CTGCTCTCTGGGAGTTATCAATTTTAAAGAGAACTTTTGTGCAATTCAAATGAAGTTTTTATAAGTAATT  
GAAAATGACAACACAATAACACTTTCTGTATAAAAGTATATATTTTATGTGATTTATTCCTACTAAATGA  
5 AAGTGCACACTACTGCCCTCATGTAAAGACTCTTGCACGCAGAGCCTTTAAAGTACTAAGGAACAACATAGAT  
AGTGAGCATAGTCCCCACCTCCACCCCTCACAATTTATTTGAATACCTCAATTGTGCCCTCAATTTTTT  
GTAATGCTAAAAAATCAGTATCTAGATGGTTTTTAAATGTATTCTCTGGAAATTGTTTTATGTAAATAA  
ATGTTACTTAATTC

&gt;DEX0360\_055.nt.1

10 GCAAAGCAGCGCGGAGCGGGGGGGCGACGAGCGAGAAATTAACACGTATGGGCGATGGGCCCTAATG  
CAATGCGAGCGGCGCAGTGTGATGGATGTCCGCGGCGAGGTACTTCGAGCTGCCTTAATGCAAGGTCAT  
TTATATTTTGTAAAGAGGAAATAATCAAGTCACTCATATCCCACTGAATCTGAGGTTTTATAAATCCCT  
CAAACGATTGCTGAGAGCCTGATTGTGGAAAGAAGTGAATGCACCTTATTTTCAAGAAGTCTGGGAAG  
CGCTCTCCTAGCACGTCCATTTCCAGGAGGAGAAGCAAGCAGATGAGAGGTTTTCCATTTGTGCATCCAA  
15 GGTAGCTGTGCACCTGCCTTGTGTGCTGAAGTTCCAATAATGTGAAAACCAAGTAGAGGTTTTTTTCTTC  
TTCTTTTTGTTTTCTATTAATTTCACTTATACCAAAGTGTGAAAGTATGAAATGTGTGCTTCTGAGT  
TATATAAGGCTACTTCATGACAAGACTGCTTTGTAATATTTCACTTTGTTTTACTACAAATTCAGATCAC  
TTGTTTTACTATAAATTCAGATTATCCAAATATTTTCTAATACTATGTGGGAATGCTGATTTTCTTTT  
GTTACGTAGTGGAAACATTTTGCATTGTTTACATAGTTCTCATGGAACATGGAATTTTGAAGTGATA  
20 TATGATACACATTTTTTGTGTATGTATTCTAATTAGTGTGAATAAAGCAGTAACATTAATGCATTTTTTA  
AG

&gt;DEX0360\_056.nt.1

25 GGCACCTGGCCTTCCATGGCACAGCACCCCTGCCCAACTGGCGCTGGCTGGTCTACGACAAGCTCAGCCCC  
ATCCCCAACACAACCGCTTCATCAACCAGGACTTCGTGGTGTGGATGCGCATGGCAGCGCTGCCACGCT  
TCCGCAAGCTGTTCCGCAAGCTGTACGGGCACATCCGCGCAGGCACTACTCAGCTGGGCTGCCGCGGTG  
TGTCTACTGTGTCAACATCACCTACAACCTGGTAAGAAGCGCAATTCACACTCTACATAACCATGT  
TACTCATTGTTCCAGTCATCGTCGCAGGTGCAATCATAGTACTCCTGCTTTACCTAAAAAGGCTCAAGAT  
TATTATATTCCTCCCAATTCCTGATCCTGGCAAGATTTTTTAAAGAAATGTTTGGAGACCAGAATGATGAT  
30 ACTCTGCACCTGGAAGAAGTACGACATCTATGAGAAGCAAAACAGGAGGAAACCGACTCTGTAGTGCTGA  
TAGAAAACCTGAAAGAAAGCCTCTCAGTGATGGAGATAATTTATTTTTACCTTCACTGTGACCTTGAGAAG  
ATTCTTCCCATCTCCATTTGTTATCTGGGAACCTATTAAATGGAACCTGAAACTACTGCACCATTTAAA  
AACAGGCAGCTCATAAGAGCCACAGGTCTTTATGTTGAGTCGCGCACCGAAAACTAAAAATAATGGGCG  
CTTTGGAGAAGAGTGTGGAGTCATTCTCATTGAATTATAAAGCCAGCAGGCTTCAAACCTAGGGGACAAA  
35 GCAAAAAGTGATGATAGTGGTGGAGTTAATCTTATCAAGAGTGTGACAACCTCCTGAGGGATCTATACT  
TGCTTTGTGTTCTTTGTGTCAACATGAACAAATTTTATTTGTAGGGGAACCTATTGGGGTGCAATGCT  
AATGTCAAACCTGAGTCACAAAGAACATGTAGAAAACAAATGGATAAAATCTGATATGTATTGTTGGG  
ATCCTATTGAACCATGTTTGTGGCTATTAAAACTCTTTTAACAGTCTGGGCTGGGTCCGGTGGCTCACGC  
CTGTAATCCCAGCAATTTGGGAGTCCGAGGCGGGCGGATCACTCGAGGTGAGGTTCCAGACCAGCCTG  
40 ACCAAAATGGTGAACCTCCTCTCTACTAAAACTACAAAAATTAACCTGGGTGTGGTGGCGCGTGCTGTA  
ATCCCAGCTACTCGGGAAGCTGAGGCAGGTGAATTTGTAACCTGGGAGGTGAGGTTGCAGTGAGCAG  
AGATCACACCACTGCACTCTAGCCTGGGTGACAGAGCAAGACTCTGTCTAAAAAACAAAAACAAAA  
CAAAACAAAAAACCTCTTAATATTCTGGAGTCATCATTCCTTCGACAGCATTTTCTCTGCTTTGAAA  
GCCCCAGAAATCAGTGTGGCCATGATGACAACCTACAGAAAAACAGAGGCAGCTTCTTTGCCAAGACCT  
45 TTCAAAGCCATTTTAGGCTGTTAGGGGCAGTGGAGGTAGAATGACTCCTTGGGTATTAGAGTTTCAACCA  
TGAAGTCTCTAACAATGTATTTTCTTCACTCTGCTACTCAAGTAGCATTACTGTGTCTTTGGTTTGTG  
CTAGGCCCCCGGTGTGAAGCACAGACCCCTTCCAGGGGTTTACAGTCTATTTGAGACTCCTCAGTTCTT  
GCCATTTTTTTTTTAATCTCCACAGTCATTTTTCAGACCTTTTAACTCCTCAATTCCAACACTGATTT  
CCCCTTTTGCATTCTCCCTCCTTCCCTTCTTGTAGCCTTTTGACTTTCATTGGAAATTAGGATGTAAAT  
50 CTGCTCAGGAGACCTGGAGGAGCAGAGGATAATTAGCATCTCAGGTTAAGTGTGAGTAATCTGAGAAACA  
ATGACTAATTCTTGATATTTTGTAACTTCCATGTGAGGGTTTTTCAGCATGATATTTGTGCATTTTCTA  
AACAGAGATGAGGTGGTATCTTACGTAGAACATTTGATTCGCTTGAGAAAAAAGAATAGTTGAACCT  
ATTTCTCTTCTTTTACAAGATGGGTCCAGGATTCCTCTTTTCTCTGCCATAAATGATTAATTAATAGCT  
TTTGTGTCTTACATTGGTAGCCAGCCAGCCAAGGCTCTGTTTATGCTTTTGGGGGCATATATTTGGGTTT  
55 CATTTCTACCTATCCACACAACATATCCGTATATATCCCTCTACTCTTACTTCCCCCAAATTTAAAGAA  
GTATGGGAAATGAGAGGCATTTCCCCACCCATTTCTCTCTCACACAGACTCATATTTACTGGTAGG  
AACTTGAGAACTTTATTTCCAAGTTGTTTCAACATTTTACCAATCATATTAATACATGATGCTATTTGCA  
ATTCCTGCTCCTAGGGGAGGGGAGATAAGAAACCCCTCACTCTCTACAGGTTTGGGTACAAGTGGCAACCT  
GCTTCCATGGCCGTGTAGAAGCATGGTGCCCTGGCTTCTCTGAGGAAGCTGGGGTTCATGACAATGGCAG  
60 ATGTAAAGTTATTCTTGAAGTCAGATGAGGTGGGAGACAGCCGTAGTAGATGTTCTACTTTGTTCTGC

DEX-0360

217

PATENT

5 TGTCTCTAGAAAGAATATTTGGTTTTCTCTGTATAGGAATGAGATTAATTCCTTTCCAGGTATTTTATAA  
TTCTGGGAAGCAAAACCCATGCCTCCCCCTAGCCATTTTTACTGTTATCCTATTTAGATGGCCATGAAGA  
GGATGCTGTGAAATCCCCAACAAACATTGATGCTGACAGTCATGCAGTCTGGGAGTGGGGAAGTGATCTT  
10 TTGTTCCCATCCTCTTCTTTTAGCAGTAAATAGCTGAGGGAAAAGGGAGGGAAAAGGAAGTTATGGGAA  
TACCTGTGGTGGTGTGATCCCTAGGCTCTGGGAGCTCTTGGAGGTGTCTGTATCAGTGGATTTCCCATC  
CCCTGTGGGAAATTAGTAGGCTCATTACTGTTTATAGGCTAGCCTATGTGGATTTTTCTTAACATACC  
TAAGCAAACCCAGTGTGAGGATGGTAATCTTATTCTTTCTCAGTTAAGTTTTCTTCATCTGGGC  
ACTGAAGGGATATGTGAAACAATGTTAACATTTTTGGTAGTCTTCAACCAGGGATTGTTTCTGTTAACT  
TCTTATAGGAAAGCTTGAGTAAATAAATATTGTCTTTTTGTATGTCA

>DEX0360\_057.nt.1  
CGGGCTGCAGGAATTGGCAGCAGGAGCGCGACATCCTGGAGCTGGCGGGCGCCGACGAAATGGGACC  
AACCAGCTCCAGCCCCACTTCTCTTCCCTCCCGCAGCGGCCCCAGGTGGGGAGGTCAACCAGCAGTGGGGG  
AAGTCTGGGGGACACAGCTGCTCCTTCAGGAGCCTTGGATGCTGCTGCTGCTGTGGCTGCCAAGATT  
15 AATGCCATGCTCATGGCAAAAGGGAAGCTGAAACCAACTCAGAATGCTTCTGAGAAGCTTCAGGCTCCTG  
GCAAAGGCCTAACTAGCAATAAAAGCAAGGATGACCTGGTGGTAGCTGAAGTAGAAATTAATGATGTGCC  
TCTCATGTAGGAACTTGCTGACTCGAGGACAGACTCAAGACGAGATCAGCCGACTTAGTGGGGCTGCA  
GTATCAACTCGAGGGAGGTTTCATGACAACCTGAGGAAAAAGCCAAAGTGGGACCAGGGGATCGTCCATTAT  
ATCTTCATGTTTCAGGGCCAGACACGGGAATTAGTGGACAGAGCTGTAAACCGGATCAAAGAAATTATCAC  
20 CAATGGAGTGGTTCACCAGCCAGCACCCTATCGCTCAGTTGTCTCCAGCTGTTAGCCAGAAGCCTCCCTTC  
CAGTCAGGGATGCATTATGTTCAAGATAAATTATTTGTGGGTCTAGAACATGCTGTACCCACTTTTTAATG  
TCAAGGAGAAGGTGGAAGGTCCAGGCTGCTCCTATTTGCAGCACATTGAGATTGAAACAGGTGCCAAAGT  
CTTCTGCGGGGCAAGGTTTCAGGCTGCATTGAGCCAGCATCTGGCCGAGAAGCTTTTGAACCTATGTAT  
ATTTACATCAGTCACCCCAAACAGAGGCTGGCTGTGCCAAGAAGCTTTGTGAGAATCTTTTGCAAA  
25 CAGTTCATGCTGAATACTCTAGATTGTGAATCAGATTAACTGCTGTACCTTTACCAGGCTATACACA  
ACCCTCTGCTATAAGTAGTGTCCCTCCTCAACCACTATTTATCCATCCAATGGCTATCAGTCTGGTTAC  
CCTGTTGTTCCCCCTCCTCAGCAGCCAGTTCAACCTCCCTACGGAGTACCAAGCATAGTGGCACCAGCTG  
TTTCATTAGCACCTGGAGTCTTGCCGGCATTACCTACTGGAGTCCACCTGTGCCAACACAATACCCGAT  
AACACAAGTGCAGCCTCCAGCTAGCACTGGACAGAGTCCGATGGGTGGTCTTTTATTCTGCTGCTCCT  
30 GTCAAAACTGCCTTGCTGCTGGCCCCAGCCCCAGCCCCAGCCCCAGCCCCACTCCCAAGTCAGCCCC  
AGGCACAGAAGAGACGATTACAGAGGAGCTACCAGATGAACGGGAATCTGGACTGCTTGGATACCAGGT  
TAAATAAAATACCCTGTTTTCTCTACCTTATCTTCTACTATATTCTCCCTTTAAAAAAGATAAA  
TTCACATCATTTCTCCAGTACTAGGATTTCTGCTTTCTGGAATTCATTTTGGTTAGGTTTTTTATCCTAT  
TCAACAGACTCTTGAAAGCCTCTGAGAGTTCTTACTTTCTTATACATCTCACTCAAAGCTCTTGATCTAC  
35 CAGTATGTGGTTTTGTATTTAAACCTTTGGCTTTTCAGTGGTGTCTCTCTTTTACCCTCCACCTAAAAAAG  
AGAGTGATATCTCCCTCCAGTCTCCCCACCCCTCAAGACTGCTAGAAAAGGAGTGATTCTGTACATGTAA  
TTGTAAAGTTAGCCACTAAAGTTAAAAAGATTCTTAATTTGTAGTTTTTGGTGCAATTTTATCAGAAGTAC  
CTTTCCATTTTGCCAGAATCCTTGAATCATTCTTTAAACCAAAGCATTTTTTTATAGTTTCTAGCTAGGT  
TTATAGAACTAGTGGAGCTATGGGCAGTCAGTTAAAAACAGGCCATAGATAGCATAATGAATTATAACA  
40 CCCCTGTCCAAGTCTTATAGAGAAAAAATCCCTACTTTTGACTACAGTTACACAGCAGATCCCAA  
AGAGCTTTGTAGTAGTTTAACTACTACAATTATCAGAAAGATGAGGCACCTTGACAGTTACATTAAGGA  
GCTAAAGTCAATACGGCAGTTGTAGATTGTCTAATGCCACTGTATTTTCTGCTCATAGCATGGACCAT  
TCATATGACTAATTTAGGTACAGGCTTCTCCAGTCAGAATGAGATTGAAGGTGCAGGATCGAAGCCAGCA  
AGTTCTCAGGCAAAGAGAGAGAGAGGGACAGGCAGTTGATGCCTCCACCAGCCTTTCCAGTGAAGTGGAA  
45 TAAAAACAGAGTCCGATGAAAGGAATGGGTCTGGGACCTTAACAGGGAGCCATGGTGAGTGTGATATAGC  
TGGGGGAACAGGGGAGTGGCTAAGACTGGTCTAAAGCTATTAGTTTTCTCAGCCGGGCGCAGTGGCTCAC  
GCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACCTAAGGTCAGGAGTTCAAGACCAGCT  
TGGCCAAACATAGTGAATCCCATCTCTACTAAAAATACAAAACTAGCGGGCATGGTGGTGGGCCCTGT  
AATTCAGCTACTCAGGGGGTGGAGGCAGGAGAAATCGCTTCAACCTGGGAGGCAGAGGTTGCAGTGAGCC  
50 AAGATCAGACCCTGCCCTCCAGCCTGGGCAATAGAGCAAGACTCCATCTCATAAATAAATAAATACATA  
AATAAAGCTATTAATTTCTAACCTGATGTTTCATTACAGGTGTTAATCCAACCTCTATAATCTGTTGGCC  
AGTGAATAATCTTTTGGGCTGGGCACGGTGGCTCACGCCGTGAATCCAGCACTTTGGGAGGCCAAGGTG  
GGCGGATAACCTGAGGTGAGGAGTTTGAAGCAGCGTGGCTAACACGGTGAAACCCGCTCTCTACTAAAA  
ATAGAAAAATTAAGCTGGGCATGGTGGTGCATGCTGTAATTCAGCGGCTTGAAGGCTGAGGCAGGAG  
55 AATCACTTGAACCTGGGAGGTGGAGGTTGAGTGAGCCAAGATCACACCCTGCATTCCAGCCTGGGCAC  
TAGAGTGAGACTCTGTCTCAAAAAAAGAAAGAGAAAGAGAAAAATAGTTTCTAAAAAATTTGTATACAGA  
CAACCTTTTATTTCCAACAAACGTGTGCCGAGAGAGAGAGAAAAATAGTTTAAAAAATTTGTATAC  
AGACAACCTTTTGTTCCTCAACCAACGTGTATCTAGAAAAAGAGTTAGTCGACTTATTTTATACATGATC  
AGTGAATAGTAATGAGTGGTAGGTCATTTCAAAATCCTGTTGCCCTATATTATGTGAATACCAGGAGGTCA  
60 TCTGATACGGACTTAATAAAGGTTGATTTTGTCTTATATTGGGAGCTGAGCCACACCTCCCTTATAACT

30 CACCCAGCTTGCCCCATTGATTTGGATAGACGAGACCACATTTGTTTATAACCTATTAGACAACCAGCAA  
AAAGGAATCTGTGTTCTTAAATATTGGGTTATCTCAATAGACTGGAAAATAATGGTAGTGAATCCATAAGA  
ACAGATTGTGATCTGAACCTCTGTGGGCCAGTTGACTTTTAAATCAAGAAGTTTATTGTTTCCCCAGCTGT  
TAAAGCATGTTCTGAGACATTAGCTAGCAAAAACCCCTCTAATGTATATAGTCCCTTTTGGTTATTGGGA  
AACTTGAAACATTACAAATTAGATCTGGTGACCCATTGACTCCCTTTTGGTTTTTGACCAACATTGAGAT  
35 CATCCCTTTTGTGTTCTCTTTATAGGGATCGTCCATTATATCTTCATGTTTCAGGGCCAGACCGGAATT  
AGTGGACAGTAAGTAATGTTTTTGGCTCACGTAGCATTCTTTTGTAAGAGCAAAGTACAGGGCTCTGTAT  
AGCAAGTTGGCAAAGTGTCCTGTAGTGGCTGTTCTAACCTTGTTTCATGAACATAACGAATTTGTATGG  
GAGTTTATAGAGGATGGAGAGCCACATATTTGGGTAAACGTATAAAGCAGATTATACGGTGAAATAATTGAACA  
CTGGCCTGCCTGGGCAC TAGTCAGTTTCAATCCATTAGTCTTACTGTCTGTGTTTTCTAAGGAGCTGTA  
40 AACCGGATCAAAGAAATTTATACCAATGGAGTGGTAAAAGCTGCCACAGGAACAAGTCCAACCTTTTAATG  
GTGCAACAGTAACTGTCTATCACCAGCCAGCACCCATCGCTCAGTTGTCTCCAGCTGTAGGCCAGAAGCC  
TCCCTTCCAGTCAGGAGTCATTATGTTTCAAGATAAATTATTTGTGGGTCTAGAACATGCTGTACCCACT  
TTTAATGTCAAGGAGAAGGTGGAAGGTCCAGGCTGCTCCTATTTGCAGCACATTAGATTGAAAACAGGTG  
CCAAAGTCTTCTGCGGGGCAAAGGTT CAGGCTGCATTGAGCCAGCATCTGGCCGAGAAGCTTTTGAACC  
45 TATGTATATTTACATAGTCACCCCAAACCAGAAGGCCCTGGCTGCTGCCAAGAAGCTTTGTGAGAATCTT  
TTGCAACACAGTTCATGCTGAATACTCTAGATTTGTGAATCAGATTAATACTGCTGTACCTTTACAGGCT  
ATACACAACCCCTCGCTATAAGTAGTGTCCTTCTCAACCACCATATATCCATCCAAATGGCTATCAGTC  
TGGTTACCCCTGTTGTTCCCCCTCCTCAGCAGCCAGTTCAACCTCCCTACGGAGTACCAAGCATAGTGCCA  
CCAGCTGTTTCATTAGCACTTGGAGTCTTGCCGGCATTACCTACTGGAAGTCCCACCTGTGCCAACACAAT  
50 ACCCGATAACACAAGTGCAGCCTCCAGCTAGCACTGGACAGAGTCCGATGGGTGGTCTTTTATCTCTGCT  
TGCTCTCTGTCAAAACGTGCTTGCTGCTGGCCCCAGCCCCAGCCCCAGCCCCAGCCCCACTCCCAAT  
CAGCCCCAGGCACAGAAGAGACGATTACAGAGAGAGCTACCAGATGAACGGGAATCTGGAGTCTGGAT  
ACCAGGTTAAATAAAATACCCTGTTTTCTCTATCTTACCTTATCTCTCTACTATATCTCCTCTTAAAAA  
AGATAAATTCACATCAATCTCCCAGTACTAGGATTTCTGCTTCTTGGAAATTCATTTTGGTTAGGTTTTTT  
55 ATCTTATCAACAGACTCTTGAAAGCCTCGAGAGTCTTCACTTTCTTATACATCTCACTCAAAGCTCTT  
GATCTTACCAGTATGTGGTTTGTAAATTTAAACCTTGCTTTACGTGTGCTCTCTTTTACCCTCCACT  
AAAAAAGAGAGTGATATCTCCCTCCAGTCTCCCCACCCCTCAAGACTGCTAGAAAAGGAGTGATTCTGTA  
CATGTAATTTGTAAAGTTAGCCACTAAAGTTAAAAAGATTCTTAATTTGTAGTTTTGGTGCAATTTTATCA  
GAAGTACCTTTCCATTTTGCCAGGAATCCTTGAACTCATTTTAAACCAAAGCATTTTTTATAGTTTCTA  
60 GCTAGGTTTATAGAAACTAGTGGAGCTATGGCAGTCAGTTAAAAACAGGCCATAGATAGCATATAATGAAT  
TATAACACCCCTGTCCAAGTCTATAGAGAAAAAATAATCCCTACTTTTGAAGTACAGTTACACAGCAG

DEX-0360

219

PATENT

ATCCCAAAGAGCTTTGTAGTAGTTTAACTACTACAACCTTATCAGAAAGATGAGGCACCTTGACAGTTACA  
TTAAGGAGCTAAAGTCAATACGGCAGTTGTAGATTGCTAATGCCACTGTATTTTCTGCTCATAGCATG  
GACCCATTTCATATGACTAATTTAGGTACAGGCTTCTCCAGTCAGAATGAGATTGAAGGTGACAGGATCGAA  
GCCAGCAAGTTCTCAGGCAAAGAGAGAGAGAGGGACAGGCAGTTGATGCCTCCACCAGCCTTTCCAGTG  
5 ACTGGAATAAAAACAGAGTCCGATGAAAGGAATGGGTCTGGGACCTTAACAGGGAGCCATGGTGAGTGTG  
ATATAGCTGGGGGAACAGGGGAGTGGCTAAGACTGGTCTAAAGCTATTAGTTTCTCAGCCGGGCGCAGT  
GGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCACCTAAGGTGAGGAGTTCAAG  
ACCAGCTTGGCCAACATAGTGAATCCCATCTCTACTAAAAATACAAAACTAGCGGCATGGTGGTGGG  
CGCTGTAATTCAGCTACTCAGGGGGTTGAGGCAGGAGAATCGCTTCAACCTGGGAGGCAGAGGTTGCA  
10 GTGAGCCAAGATCAGACCACTGCCCTCCAGCCTGGGCAATAGAGCAAGACTCCATCTCATAAATAAATAA  
ATACATAAAATAAAGCTATTAAATTTCTAACCTGATGTTTCAATTCAGGTGTTAATCCAACCTCTATAATCT  
TTTGCCAGTGAAATATCTTTTGGGCTGGGCACGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGC  
CAAGGTGGGCGGATAACCTGAGGTGAGGAGTTGAGACCAGCGTGGCTAACACGGTGAAACCCCGTCTCT  
ACTAAAAATAGAAAAATTAAGCTGGGCATGGTGGTGCATGCCGTGAATTCAGCGGCTTGAAGGCTGAG  
15 GCAGGAGAATCACTTGAACCTGGGAGGTGGAGGTTGCAGTGAGCCAAGATCACACCACTGCATTCCAGCC  
TGGGCATAGAGTGAGACTCTGTCTCAAAAAAAGAAAGAGAAAGAGAAAAATAGTTTCAAAAAATGT  
ATACAGACAACCTTTTATTTCCCAACAAACGTGTGCCGAGAGAGAGAGAGAAAAATAGTTTAAAAAAAT  
TGTATACAGACAACCTTTTGTTCACCAACCGTGTATCTAGAAAAAGAGTTAGTCGACTTATTTTATACA  
TAGCATCAGTGAATAGTAATGAGTGGTAGGTCATTTCAAAATCCTGTTGCCTATATTATGTGAATACCAG  
20 GAGGTCATCTGATACGGACTTAATAAAGGTTGATTTTGTCTTATATTGGGAGCTGAGCCACACCTCCCT  
TATAACTCTATTGGTCAGTAATGGTCAGTTTGTGGCTGTTAGGAAAAATGTTGCCTTTTAGCATCCAGAA  
CTCTAAATCCTGTAGAGGTACATGGGATATTTTATCTTTTGCCTGTACTCATAAAAAATGACAGAA  
ATACGTTTTTTTTCTTTCTTAACCTCTTTCTTTTAACTCTTTAAAAAGGTGAAATATCAGCCCTCAAGAG  
ACTCACTTGCTAACCTTCTTTTTTTCTTTTTTTTTCTTTTTTTGTGTTTCTTTTTCTCTGTCT  
25 TCTTACATGGTCTGTGGTGGATTACATTTGCTGATGCTGGTGTGTTTTTCTGTGTATCTCAACGTTTT  
TGGGTGACCAATTGACCTGTGACCTCAAAATGGTGTCCAACCTAACCACTTAAATTAACATCTTTTTTT  
AATTAACGAATTTATGGTATTTTTTTTTTTCCCTTGGCGGGGATGGGTTGGGTTGTTTTCTCTATT  
CTAGATTATCCAGCCAAGAAGATGAAACTACAGAGAAGGGATTGGCTTGGTGGCTTATGCTGCAGATT  
CATCTGATGAAGAGGAGGAACATGGAGGTCAAAAAATGCAAGTAGTTTCCACAGGGCTGGAGTTTGGG  
30 ATACCAATATCCTTCATCACAACCACGAGCTAAACAACAGATGCCATTCTGGATGGCTCCCTAGGAAACA  
GTGGAACAGAGTTTTGACCTCAGTGACTCTTCTTAGCAATAATGCATGCATTGATTTAACAAGACTCT  
GGGCCTGTGCTGGGAACCATCTGGACCTTGCAGAAAGTTAGAGATTGAGTGCCCTTTCTTAAAGGG  
GTTCTTAACAACCACAAAAATCCTTATTTCTGCAGTGGCATAGAATCTGTTAAAAATTAATTAGAATCA  
CAAATTTATCTCAGAAGCTTTTTTAACAGTTGGTGAAATGTGCTTGTCCAACAAGCATCCTAACAGGGTC  
35 GTTCCCATACATTTGACCTGGTCAGCCTTTTCCAGGTGAATAGCCCCAGTTCTGCATAAAGAAAGTT  
TTATTTGTATTTTACTACTGTTTGGTCAATTTTGATATATACTGGTTACAACAGAGCCTTACTATTTA  
TTAGTGGGGAATGATTTTAAGACCGTCTTTTTCAGTATTTAATTTCTGACAGATCTGCATCCCTGTTTTG  
TTTTGGATTATTTCTGTTTTGAAAAATGCTGTCTCATTAAAACTGTTGGATATAGCTGGATCCTGGATA  
GGAAAAATGAAATATTTTTTCATTGTGTTTTTAATTGGGGTGATCCAAAGCTGGCACCTTCAGGCACAT  
40 TGGTCTCATAGCCATTACTGTTTTTATTTGCCCTTCTAAGATCCTGTCTTCAGCTGGGTCAGAGAACTT  
CTTGACATAAACTGGTCAGAACTCATCAGAAATGAAATACAGTGGTCTCTCTCTCCAGAACTGGTTG  
CAGCTAAAAACAGAGAGATCTGACTGCTGCTTATAGGATTTTGGACTTAATGACTGAAATGCAAAATGTC  
CTTTTTCTTGGCATTACAGATTTTGCCAAAATAACTTTTTGTATCAAATATTGATGTGTGAAGTGAAGG  
AGCTAGTCTGCTGAACCAGGAATAGTTTGAGATATTGAACGTGATTTTTGACATTTGAATACTTTGCA  
45 GGCTGGCTTTGTATAAACTTATCTCTGGTTTCTATATGTTGTAAATATTTAGACCATAATTTCAATTAT  
AAATAAATCTATAAATATTC

&gt;DEX0360\_058.nt.1

GGCAAAAAAAATTTAATTTTGGCAGATTGTGCTATTTAGAATCTTTGAAGTTTCTCTTGTAAAGATGG  
50 ATTGCATTTTACTTTTGACTAAAATTTCCAGAATTATGTGTGGACTCTTGATATCTGGTATGTTAAGGTC  
CTACTCCCTTACAATAAAAAATTTTAAATTAAGTAACAAAACTAGATAATCTTTATTTCTTAACCATCAT  
CTGTTTTTGGCACTCTACCACCTAGGTACCATAACTGAACAACCTATATGCTCTGGTTTCTTAACCTTTT  
ACTAGTTGTGCTAATATTTTACTTGTAGTCAAGGAAATGAAGTCATAATAGTTTCTCTCTTACA  
GAGACTTTAGAAGACAGCTTTCCATCGACACTAGGCCCTTTAGACCAGCCTCTGAAGGGAATCCTAGCGA  
55 TGATCCTGAGCCTTTGCCAGCACATCGGCAGGCACCTTGGAGAGAGGCTTTATCCTCGTGTAACAGCAATG  
CAACCACTGTACTGTGTACTGTACCTCTTAACCTGGCTGTGTTATTTTTTGTCTTTGAATTAAG  
ATGGTGTTTAAAAAAATTTGTCAGCTACTGGCAAAACCATGATTGAGGACTCTTTTGTAGCTTGCAGT  
AAGAAGGAAGCTCAGGAGAGAATAAGGCAGTGTCTTACTGAAGGGTAAGTGTATAGCTTGAATTTATTTT  
TCCTCCACCCACCTTATGTTGGGACACTGTCTCCATTCTACCTTCTTGCATGCTAAAGAATTTGCTGTG  
60 CATTATATTTATTTGATCTTCAATTTGAACAAATATTACTACTTTTGGAGCAGACTTTATCTGTTAGCAA

GCTGTAGTTGGAACACATTAATGCTGATTAGTATTGCAGGAAGAATTTTATTTTGAATGTTCTATCAAGA  
GTTTTTCTTTATATGATATGAAACACAAATTAGTTATGTTTTTTGTCCTTTATGCATAACTGTATGTACAC  
ATTTTATAGTGAAAGAATAACAGAAAACATTTATTTCTTCCAGCAAGTCCCTCAGCCTTAAACATAGGTAT  
ATTTTCTCTACCCCTACCCCTTCTTTTTTCTACCTAAATAAAAGATATTTCTGGCTCTCTGTATGAAG  
5 AAAAAATATGGAATTGAGTATATGTATGTTTAACTCAGAGATATAAAAAACCTAAAAAGAAAACCTTG  
TCATACAAATATTATAAGTAGCCTTAACAAGATGTGGTACTGCATGGACTGTTTATTCCTGCCAAGTTT  
CTCTATAATTGATCTTCCAGTTTCATAAAAGACCTTACTGGTTCTGAAATTTTGTATTTGTTACCCAAGT  
TTCTTATTTTATTTTTTTTTTAAATAAAAGATTGTAGATGTAATTAGACAAGAGGTTTTAGAGAGTAGTC  
AAGTAACATTTGTTTCATCATTTACAGGCATTTGCAAGTAAATCAC TGGCATGTTGTTGGAATTATCCCC  
10 AGCTCAGCTGCTTCTCTCTCTAGCAAGTGAGGATTTCTCTGAGAGCAAGAGTGGATGAGGCCATGGAACCTC  
ATTAATTGCACATGGACGGGAAAATGGAGCTGATAGTATCCTGGATCTTGGATTAGTAGACTCCTCAGAAA  
AGGTACAGCAGGAAAACCGAAAGCGCCATGGCTCTAGTCGAAGTGTAGTAGATATGGATTTAGATGATAC  
AGATGATGGTGATGACAAATGCCCTTTGTTTTACCAACCTGGGAAAAGAGGATTTTATACCTCAAGCCCT  
15 GGCAAGAACACAGAAGCAAGGTTGAATTGTTTCAGAAACATTGGCAGGATTTCTGGACTATGTCTGTTAC  
AGAATGAACATATGCTCTATCACATTGAATAGACATGTAATTAAAGTATTTGCTTGGTAGAAAAGTCAATTG  
GCATGATTTTGGCTTTTTTTGATCCTGTAATGTATGAGAGTTTGGCGCAACTAATCCTCGCCTCTCAGAGT  
TCAGATGCTGATGCTGTTTTCTCAGCAATGGATTTGGCATTGCAATTGACCTGTGTAAGAAGAAGGTG  
GAGGACAGGTTGAACATCTCTAATGGTGTAAATATACCAGTCACTCCACAGAATGTATATGAGTATGT  
20 GCGGAAATACGCAGAACACAGAATGTTGGTAGTTGCAGAACAGCCCTTACATGCAATGAGGAAAGGTCTA  
CTAGATGTGCTTCCAAAAATTCATTAGAAGATTTAACGGCAGAAAGATTTTAGGCTTTTGGTAAATGGCT  
CGCGTGAAGTCAATGTGCAATGCTGATCAGTTTTACCTCTTTCAATGATGAATCAGGAGAAAATGCTGA  
GAAGCTTCTGCAGTTCAAGCGTTGGTTCTGGTCAATAGTAGAGAAGATGAGCATGACAGAACGACAAGAT  
CTTGTTTACTTTTGGACATCAAGCCCATCACTGCCAGCCAGTGAAGAAGGATTCCAGCCTATGCCCTCAA  
25 TCACAATAAGACCACAGATGACCAACATCTTCTACTGCAATACTTGCATTTCTCGACTTTACGTCCC  
ACTCTATTCTCTAAACAGATTCTCAAACAGAAATTGTTACTCGCCATTAAGACCAAGAAATTTTGGTTTT  
GTGTAGATATAAAAAAGTGTGTATTGCTGTGTAATATTACTAGCAAAATTTGTAGATTTTTTCCATTTG  
TCTATAAAAGTTTATGGAAGTTAATGCTGTATACATCCCCCTGGTGGTACCTTAAAGAGATAAAATGCAGA  
CATTCCTTGGCTGAGTTTATAGCTTAAAGGCCCTAAGGAGCACTAGCAACATTTGGCTATATTGGTTGCTA  
30 GTCACCAACTTCTGGGTCTAACCCAGCCAAAGATGACAGCAGAACACATAATTTACACTGTGATTTAT  
CTTTTTGCTGAGGGGAAAAAATGTAATGTTCTGAAATTCAGTGTGCCTTTGTGAAACTGTTTCAG  
CAAAGGTTCTTGTATAGAGGGAATAGGGAATTTCAAAATAAAAAATTAAGTATGTTCTGTGTTTTCAAT  
TAATTTTTTTTTATGGTGTTAATTTGTGGTTGGCTGCAACTGTGTATCATGTATATGGAAGTTGAAAA  
AGTTCTCGACATTCAGATCTTAAGAGATGAAATCACTTTTACCTATAAAAAACCACTTTTATTGCGGTTTTG  
35 ACTGCATTGAGCTCTAGGATATTAAATGATATCACTAATATTTTGCATGTAATTTGCTCATTGAGTGAG  
GGCACTTTTTTGTACATATGATGGGGCAATGCACAATACTTTTATCACAATCAACTTTTTCTTTGTAT  
CCCTATTTCAATGAGCAGTCAGTCTCAAGAGGTTACTGCATTCACTTCACTAGACATTTGTACTAAG  
GTATTTCACTTATGTAAACTCAGCCTGGGCATTTCTGATAACTGTAAATGTTTATAAGATCATGATT  
ATTGAAGATACATTTTGGAAAATTTTAAATGTTCTGTGAGCAGCTTAACCTTTTGTATCTAGCCTTTTT  
40 TAAGTATCTTGTACATTTACTTTTTTAAATAAAGAAATTACAGAAGAAATGTCAAGTAATATTGAAGAA  
ACAATAGTTTTTATTTATGTAGTTGTACATTTTTTAACTAAGGGCAATCACTGACATGGTTATGTGCAT  
AAAAATTTTGACTTAAAGAACTGGAAAGTTTATATACCTGGACTATAAGAAACAGAAGAAAATCAGTCC  
ACATTTTACAGTTAGCAGAGAATCCTAAATGGCAGTGGCCCTGGCCACCCTTTTCAATTTTACAAATGGGGGA  
AGTGAAGTGTGACCCCTTACTTGGCATAGGAAGTTAACTTACACCTAATAACTGACAGGTTTTTGTGTTG  
45 ATGACCTATTAATTATGTAGCCTAGGATTAATATCCAAAATTACTCTGGTTTAAAGTAGCTTTATTCAGT  
GGCATAATAACACTGTTTTCTTCCCTAAGTCTTCAATGAAGTGACTTAAACAGTCACTTTACATATTAA  
AAATGAGGAGAGCAATCTCTGGAATCTCTCTTCACTTCTTTGTAGGATTTCTGGCCTTGAGGATAG  
TCTTCATGTTCAAAGGCATATGCTTTTATTATATAAATCTCTTCAAGAGCTGAACCACATGATATTCT  
CAGCCCTGTTAAACATAAAAAATTTTAAACTGAATGATAGTAGTACTCATTGTATTACTTTAAACTTA  
50 TATAACACGCTGTATTAGATGTGTGTAATTAGCCAAAGGTTATTTTACAAAGTGAGACATTTGGTTTTTA  
TGTTTAAATGCTATTTCTGAATAAATGAAATAGTAATTAGATCAAGAGCTGATTAGCATCAATGTGTTTG  
AAAGATATAAAATTTATACATCAACCTTCTGTATGCACATGATGGGATTGATAAAATATTAAATGA  
GAACAACTAGATATGATTAGGACATTTGAAACCTTAATTTGTGAATTTATTTTTAATAGTTACTGAAATG  
AAAATATTTTAAATAATGCACAATGTCTTAAGTCTTCTAAATCAAGATTTTGGTTAAAAAATACTCTA  
55 ATAATAGTAAAGATTTTTTTTTTAAAGTAAATCATAAACGGTTCTAAATGTAAATAAAGACATGTAAA  
ATAAGTTCTCTTTTGGTCTTGTGTTAGTGTAAATCTAACATTTGAAAACAAATTTAGGAAGAGAAGAC  
CAAGAATGAACCTTTACTGAGTGTTTTCAAGTGTGCTACTACTATTTTTTCCCTAAATCATCTGGATAC  
CAAGACTATCCAGTAAATGGATAAAGTGGGACAGCTTGGAGGGGATTTTAAAGGAATGATTTCACTAT  
TTAGTAGCTGCCCCAAACACATCCCTCCCAATAAGATACTATTTTTTACATTTTAAAGGTAGTCAGCAA  
60 TTCTATGTTTAACTCAAGTTGAGATAATCCCTTGAGGCAGTAGTTCCATGCTTCTGTATGTTGTAAG  
ATTCATTTGTAAAGTTGTTAATGCAGATTTCAAGCATTCCTCATCCTCTTGCCCTCTTCTGATTACG

DEX-0360

221

PATENT

TAAGTCTTTGGTGGAGGCCAGGAATCTTCATGCAGATCATCCCAGGTGATTCTGAAACACTGCCCAAAGA  
ATAATTCCTTTTATTTACAAATATAAATGTCCCGCTGAAAGCTCCTGAGAGCCAAACCTTTCCTACTTA  
GAACTGCTTACAATCTATGGAAAAGTACATCTATTGATAAACTAGTCTAGGTTGGATTCTTCTACTGA  
TAAGGGGCTGGTTGGAAAGTC

5

&gt;DEX0360\_059.nt.1

TGGGTTGACCGATGCTGGGCAGCTGAGCGGACCAATCGGCCCCCTAGACTGAGACGTTGGCGTTTGAAAT  
CAGCCAATGGCAGGTCTACACTGGAGCTTCTCTCCGCCCTCTTCGCCCTAGCCTGCGAGTGTCTGAGGG  
AAGCAAGGAGGCGGCGCGCGCCGACGCGAGTGGCGAGTAGTGAAACGTTGCTTCTGAGGGGAGCCCAAG  
GTAGGGAGGCGAGGCGACGGTGTGCGGGAGCGGGCTCTCCAGGGAAGTCCCGGGTCCGCAACTGGCAGGG  
10 CCGTTCGATTTCGAGGGGATCCCGTTTCGTTTCTGTTGTTTCCCTTTATTTTATTTTATTTTATTTTATTTT  
ACGGGACCCCGGAGAGGGGAAAGGGAACAGTCTGGGGTCCGGGCATCGCTGTGGGCCGGGCTGGGTTTA  
GGGGGACGGCGGTGCGGGCTGGGCCGGTTTGGGCGCGGGGGGGCGGATGATGGGGCGAGTCCGGACCT  
TGGCGGGCGAGTGTCTGGCGCAGGCGCAAGCGCAGAGTCTCTCGCGGTGCTCTCTCGGCCCTCCCTC  
15 TGGGGGACCCCAAGTGCAGGCTGTCTAGTGCAGCGCCAGCCGCGGGACCCCTGGGGACTCTGGGCG  
CCTGTTCTGCAGATGACCGGTTCTAACGAGTTCAAGCTGAACAGCCACCCGAGGATGGCATCTCTCCG  
TGAAGTTCAGCCCCAACACCTCCCAGTTCTGCTTGTCTCTCTCTGGGACACGTCCTGCGTCTCTACGA  
TGTGCCGGCCAACTCCATGCGGCTCAAGTACCAGCACACCGCGCGCTCTGGACTGCGCTTCTACGAT  
CCAACGCATGCTCGAGTGGAGGACTAGATCATCAATTGAAAATGCATGATTTGAACACTGATCAAGAAA  
20 ATCTTGTGGGACCCATGATGCCCCATCAGATGTGTTGAATACTGTCCAGAAGTGAATGTGATGGTCAC  
TGAAGTTGGGATCAGACAGTTAAACTGTGGGATCCCAAGTCCCTTGTAACTGCTGGGACCTTCTCTCAG  
CCTGAAAAGGTATATACCTCTCTAGTGTCTGGAGACCGGCTGATTGTGGGAACAGCAGGCCGCGAGTGT  
TGGTGTGGGACTTACGGAACATGGGTTACGTGCAGCAGCGCAGGGAGTCCAGCCTGAAATACCAGACTCG  
CTGCATACGAGCGTTTCCAACAAGCAGGGTTATGTATTAGCTCTATTGAAGCCGAGTGGCAGTTGAG  
25 TATTTGGACCCCAAGCCCTGAGGTACAGAAGAAGAAGTATGCCCTTCAAATGTCACAGACTAAAGAAATA  
ATATTGAGCAGATTTACCCAGTCAATGCCATTTCTTTTCAATATCCACAATACATTTGCCACAGGTGG  
TTCTGATGGCTTTGTAAATATTTGGGATCCATTTAACAAAAGCGACTGTGCCAATTCATCGGTACCC  
ACGAGCATCGCATCACTTGCCCTTCAGTAATGATGGGACTACGCTTGCAATAGCGTCATCATATATGTATG  
AAATGGATGACACAGAATCTCTGAAGATGGTATCTTCAATTCGCCAAGTGACAGATGCAGAAACAAACC  
30 CAAGTACCATGTACTTGACAAGATTTCAATTTACTTTAAGTGCCATGTTGATGATAATAAAACAATTCGTA  
CTCCCCAATGGTGGATTTATTTACTATTTAAAGAAACCAGGAAAAATATTAAATTTATAACAACCT  
GAAAATAATGAAAAGAGGTTTTTGAATTTTTTTTTTTTAAATAAACACCTTCTTAAGTGCATGAGTGGT  
TTGATGGTTTGCTGCATTAAAGGTATTTGGGCAACAAATTTGAGGGCAAGTGAAGTGCAGTTTGTAGAA  
TCAGTTTTGACCTTGATGATTTTTTGTTCCTCTGTGGAATAAATGTTTGTAAATAAGTGTAAATAAAA  
35 TCCCTTTGCAATCTTTCTGGACCTTAAATGGTAGAGGAAAAGGCTCGTGAGCCATTTGTTTCTTTGCTG  
GTTATAGTTGCTAATTTCTAAAGCTGCTTCAGATGCTTCATGAGGAGGTTAATCTACAATTAACAATAT  
TTCTCTTTGGCCGCTCATTATTTCTGAAGCAGATGGTTCATCATTTCTGGGCTGTTAAACAAAGCGAG  
GTTAAGGTTAGACTCTTGGGAATCAGCTAGTTTTCAATCTTATTAGGGTGCAGAAGGAAAACATAAGA  
AAACCTCCTAATATCATTTGTGACTGTAAACAATTTATTATTAGCAACAATTTGATCCAGAGGGCAA  
40 ATTGTTTGAAGTCAGTAATGAGCTGAGAAAAGACAGAGCATATCTGTGATTTGGAAAAATAATTGTAACG  
TAATTGCAGTGCATTTAGACAGGCTATTTGGACCTGTTTCTATCTCTAAATGAATTTTGGAAACAT  
TAATGAGGTTTACATATTTCTCTGACATTTATATAGTTCTTATGTCCATTTCAAGTTGACCAGCGCTGGT  
GATTAAAGTTAAAAAGAAAAAATATAGTGAGAATGAGATTCAATTTCAATGTAATGCACTAAAGCAGAA  
CACGAACCTAGCTTGGCCATTTCTAGGTAGTTCCAAATAGTATTTTTGTTGTCAAACCTTTAAATTTATA  
45 TTAATTTGCAAAATGTATGTCTCTGAGTAGGACTTGGACCTTTCTTGAGATTTATTTATCCGTGATGTAT  
TTTTTTTAATTTCTTTGTATACAGAGAAGGGTCTTTTTTTTTTTTAAAGTATTTCAAGTGAACCTTGGTGTAA  
GTCTGAACCCATCTTTTGAATGTATTTTCTTCATTGTCAGGTCCACCTAATCATCTGTGAAAGTGGTTT  
CTCTATGGAAGCTTTGTTGCTTCTTACAAATACATGCTTATCTCTAAGGGATGTGTAGAGTTACTG  
TGGATTTCTCTGTTTCTGTCTTACAAGAACTTGTCTATGTACCTTAATACTTTGTTTGGATGAGGAG  
50 TCTTTGTCTCCCTGTACAGTAGTCTGACGATTTCCCTTCTGTCCCTAGTAAGCCAGTTGCTGTATC  
TGAACAGTTTGAAGCTCTTTTGTAAATATACTCTAAACCTGTTATTTCTGTGCTAATAAACGAGATGCAGA  
ACCTTTGAA

&gt;DEX0360\_060.nt.1

GGCGGTTCCGTACAGGTATATAAAGCTGTCCGCGCGGGAGCCAGGCCAGCTTTGGGGTTGTCCCTGGAC  
TTGTCTTGGTTCCAGAACCTGACGACCCGGCGCGGCGAGCTCTCTTTTGAATAAAGACAGTGTCCAGT  
GCTCCAGCCTAGGAGTCTACGGGGACCGCCTCCCGCGCCGCCACCATGCCCAACTTCTCTGGCAACTGGA  
AAATCATCCGATCGGAAAACCTTCGAGGAATTGCTCAAAGTGCTGGGGGTGAATGTGATGCTGAGGAAGAT  
TGCTGTGGCTGCAGCGTCCAAGCCAGCAGTGGAGATCAAACAGGAGGGAGACACTTCTACATCAAACCC  
60 TCCACCACCGTGCACACCACAGAGATTAACCTTGAAGGTTGGGGAGGAGTTTGAAGGACAGACTGTGGATG

DEX-0360

222

PATENT

GGAGGCCCTGTAAGGTGAGTGCCAGAAGGGGCTCCAGGGTCATGGCGTCATTGCCCTGCCCTCTCAACCTG  
 CCATTTTCCAGGCTAGCAGTTAACTCCTAGCTTCTCTCTGTCCAGTAGGGAAAATCCCTAGGTGGTGGT  
 GGGGGCTAGAAAAGGGGCTCTCTCCCTTATCCCTCTCACTGCATTGCCCTGCTATGGGCCCAGCTCACTT  
 5 GGCCACCTGTCTCTTGCAAGAGCCTGGTGAAATGGGAGAGTGAGAATAAAATGGTCTGTGAGCAGAAGCTC  
 CTGAAGGGAGAGGGCCCCAAGACCTCGTGGACCAGAGAAGTACCAACGATGGGGAACTGATCCTGACCA  
 TGACGGCGGATGACGTTGTGTGCACCAGGGTCTACGTCCGAGAGTGAGTGGCCACAGGTAGAACCAGCGGC  
 CGAAGCCCACCACTGGCCATGCTCACCGCCCTGCTTCACTGCCCCCTCCGTCCCACCCCTCCTTCTAGG  
 ATAGCGCTCCCCCTACCCCACTCACTTCTGGGGGTCACTGGGATGCCTCTTGCAAGGCTTGTCTTTCTTT  
 GACCTCTTCTCTCTCCCCCTACACCAACAAAGAGGAATGGTGCAGAGGCCAGATACCCATTCCGGGT  
 10 TCACTCCCCGCCCTCCCAAGTCAGCAGTCTAGCCCCAAACCAGCCAGAGCAGGGTCTCTCTAAAGGGG  
 ACTTGAGGGCCTGAGCAGGAAAGACTGGCCCTCTAGCTTCTACCCCTTGTCTCCCTGTAGCCTATACAGTTT  
 AGAATATTTATTTGTTAATTTTATTTAAATGCTTTAAAAAATAAAAAAATAAAAAAATAAAAAAATAA  
 AAGAGCCCGGCGCGGAAACCCGCGTGGCCATGGCGCGGCGACCCGCGGGGCGGAAACAGTGGCGTAC  
 CTCGCGGCCTCCCCAAATTCTCCCCACCCACCTTTAGCGCAGCGACCAACGTGCGCGCCGCGCAGCGGGG  
 15 GCGGCCGCGACGAGCGCCGACGCTACGCGACGCGCGCGCGCGGCCGCCACCACGCCACACGTCACGGG  
 CAGCCCGCAGCGCAGCCCGGGCGGCGCCTGTACACAACGAGGTCTGCCTAGTTGCTGCTCCCGGTGCC  
 GAGCCAAGGCCCGCTACGACGCGCCACGAGGGCTGAGGCGCGGCGACGCGCGCGCGTGAACGCGCGG  
 GGCACCCGGCTGGAGGGGGGAGGCACCGCAACACGGCCGACGCGCGGCGAAGAGCGGGGAACAAACGACAC  
 GACCCACACCGCAACGGGTGAGCAACGACCGAGCGGCCAGCGCGGCGACCGCGCGTGGCAGCAGGCGACGAC  
 20 GCCACGAGACGCGCGAGAGCGAGAGACCACTCCGAGGCGCGGCCCGGGGTGTGCCAGGCCCGACGCGTGG  
 TGGCC

&gt;DEX0360\_060.nt.2

GGCGGTTCCGTACAGGGTATAAAAGCTGTCCGCGCGGGAGCCAGGCCAGCTTTGGGGTTGTCCCTGGAC  
 25 TTGTCTTGGTTCCAGAACCTGACGACCCGCGCAGCGCGACGTCTCTTTTGAATAAAAGACAGTGTCCAGT  
 GCTCCAGCCTAGGAGTCTACGGGGACCGCTCCCGCGCCACCATTGCCAACTTCTCTGGCAACTGGA  
 AAATCATCCGATCGGAAAACCTTCGAGGAATTGCTCAAAGTGCTGGGGGTGAATGTGATGCTGAGGAAGAT  
 TGCTGTGGTGCAGCGTCCAAGCCAGCAGTGGAGATCAAACAGGAGGGAGACACTTCTACATCAAACCC  
 TCCACCACCGTGCACACCACAGAGATTAACCTTCAAGTTGGGGAGGAGTTTGAGGAGCAGACTGTGGATG  
 30 GGAGGCCCTGTAAGAGCCTGGTGAAATGGGAGAGTGAGAATAAAATGGTCTGTGAGCAGAAGCTCCTGAA  
 GGAGAGGGCCCAAGACCTCGTGACCAAGAGAACTGACCAACGATGGGGAAGTATCCTGGTAAGTCCT  
 GCCTCCTCCCCACTAATAGCAAAACCCAGTGCTACCTTCCAAGATTCTCTGGGAGACCCAGGGTGCAGGA  
 GACTCAAGAAACACCATGGCTGGACTCCGACCCCTGCTGATGGGACTGCTTGAACAGAACTAAGGTGTCC  
 CTATCCCATACAGTGCCCTGTGTGAATTAGAAATGGTGTTCCTTTTATGCAAGCAAAGGGCATGTACTGA  
 35 GGGATCCCAAGCAGTTCTTCAGGGAGATCTTCTGGCTTGAGGAGGAGGACGGGCCCCAGGGGCTCTATTG  
 TATCTCTCCCTCCATTGATGCTTGGCATTCTGGGACACAGCTCCTGCTTGTGGTCTTGAGCCAAGAAGC  
 AGGTTTGGACCTGGAGGCCAAGCAGAGTACCTCCATTCAACCTCCTCTCCAAAGCCACAGGACCCAGG  
 GGCCTCTCAGGCTAACAACCTACTTCTGTCTTCCAGACCATGACGGCGGATGACGTTGTGTGCACCAGGG  
 TCTACGTCCGAGAGTGAGTGGCCACAGGTAGAACCAGCGGCCGAAGCCACCACTGGCCATGCTACCGCC  
 40 CTGCTTCACTGCCCCCTCCGTCCCAACCCCTCCTTCTAGGATAGCGCTCCCCCTTACCCCACTCACTTCTG  
 GGGGTCACTGGGATGCCTCTTGACGGGTCTTGCTTTCTTTGACCTTCTCTCTCTCCCCCTACACCAACAA  
 AGAGGAATGGCTGCAAGAGCCAGATCACCCATTCCGGGTTCACTCCCCGCTCCCCAAGTCAGCAGTCC  
 TAGCCCCAAACAGCCAGAGCAGGGTCTCTCTAAAGGGGACTTGAGGGCTGAGCAGGAAAGACTGGCC  
 CTCTAGCTTCTACCCCTTTGTCCCTGTAGCCTATACAGTTTAGAATATTTATTTGTTAATTTTATTTAAAT  
 45 GCTTTAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATAAAAAAATA  
 ATGGCGCGGCGACCCGCGGGGCGGAAACAGTGGCGTACCTCGCGGCTCCCCAAATTCTCCCCACCCA  
 CCTTTAGCGCAGCGACCAACGTGCGCGCGCGCGACGCGGGGCGGCGCGACGCGCGGACGCTACGCG  
 ACGGACGCGCGGGGCGGCGACCAACGCCACACGTCACGGGCGAGCGCCAGCGCACGCGCGGGGCGGCGCT  
 GCTCAACAACGAGGTCTGCCTAGTTGCTGCTCCCGTGCCGAGCCAAGGCCGCTACGCACGCCACGCA  
 50 GGGCTGAGGCGAGCGGCGCGCGCGCGGCTGCAACGCCGCGGCGCACCCGGCTGGAGGGGGGAGGCACCGC  
 AACACGGCCGACGCGGCGAAGAGCGGGAACAAACGCACACGACCCACACCGCAACGGTGAGCAACGACCG  
 AGCGGCCAGCGGCGACCGCGCGTGGCAGCAGGCGACGACGCGCAGAGACGCGGAGAGCAGAGACCAC  
 TCCGAGGCGCGGCGCGGGTGTGCCAGGCCGACGCGTGGTGGCC

&gt;DEX0360\_060.nt.3

GCCCACCCCAAGCGGTTTCACAAACTCCGTTTCTTACCGTAAGGTTTCTCCCCCTCTCGCCGCTCGGGCA  
 AGCTGATCACAGGTGTGTGCGGAGCCTAGGAGTCTACGGGACCGCTCCCGCGCCGACCATGCCCAA  
 CTTCTCTGGCAACTGGAAAATCATCCGATCGGAAAACCTTCGAGGAATTGCTCAAAGTGCTGGGGGTGAAT  
 GTGATGCTGAGGAAGATTGCTGTGGCTGCAGCGTCCAAGCCAGCAGTGGAGATCAAACAGGAGGGAGACA  
 60 CTTTCTACATCAAACCTCCACCACCGTGCACACAGAGATTAACTTCAAGGTTGGGGAGGAGTTTGA

DEX-0360

223

PATENT

GGAGCAGACTGTGGATGGGAGGCCCTGTAAGAGCCTGGTGAAATGGGAGAGTGAGAATAAAATGGTCTGT  
GAGCAGAAGCTCCTGAAGGGAGAGGGCCCCAAGACCTCGTGGACCAGAGAAGTACCAACGATGGGGAAC  
TGATCCTGACCATGACGGCGGATGACGTTGTGTGCACCAGGGTCTACGTCCGAGAGTGAGTGGCCACAGG  
TAGAACCGCGGCCGAAGCCCACTGGCCATGCTCACCGCCCTGCTTCACTGCCCCCTCCGTCCACCC  
5 CCTCCTTCTAGGATAGCGCTCCCCCTACCCAGTCACTTCTGGGGGTCACTGGGATGCCTCTTGCAGGGT  
CTTGCTTTCTTTGACCTCTTCTCTCCTCCCCACCAACAAAGAGGAATGGCTGCAAGAGCCAGATCA  
CCCATTCGGGTTCACTCCCCGCTCCCCAAGTCAGCAGTCTTAGCCCCAACCCAGCCAGAGCAGGGT  
TCTCTAAAGGGGACTTGAGGGCCTGAGCAGGAAAGACTGGCCCTCTAGCTTCTACCTTTGTCCCTGTAG  
CCTATACAGTTTAGAATATTTATTTGTTAATTTTATTAAATGCTTTAAAAAATAAAAAAAAAAAAAACA  
10 AAAAAAAAAAAGAAGAGCCCGCGCGCGAAACCCGCGTGGCCATGGCGCGCGACCCGCGGGCGCGGAA  
ACAGTGGCGTACCTCGCGGCCCTCCCCAAATTTCCCCACCCACCTTTAGCGCAGCGACCAACGTGCGGCC  
CGCGCAGCGGGGCGCGCGCAGCAGCGCGGACGCTACGCGACGCGCGCGCGCGCGCGCGCCCA  
CCACGTACCGGCGAGCCCGCAGCGCAGCCCGGGCGCGCTGCTCACAACCGAGGTCTGCCTAGTTGCT  
GCTCCCGGTGCGGAGCCAAGGCCCGCTACGCGCGCCACGCGAGGGCTGAGGCGAGCGGCGCGCGCGCG  
15 TGCAACGCGCGCGCGCACCCGGCTGGAGGGGGGAGGCGACCGCAACAGCGCCGACGCGCGGAGAGCGGGA  
ACAAACGCGACCGACCCACCGCAACGGTGAGCAACGAGCCGAGCGGCCAGCGGCGACCGCGCGGTGGCA  
GCAGGCGACGCGCCACGAGACGCGCGAGAGCGAGAGACCACTCCGAGGCGCGCGCGCGGTGTGCCAGG  
CCCCGCGGTGGTGGCC

20 >DEX0360\_060.nt.4  
GGCGGTTCCGTACAGGGTATAAAAGCTGTCCGCGCGGGAGGCCAGGCCAGCTTTGGGGTTGTCTCTGGAC  
TTGTCTTGGTTCCAGAACCTGACGACCCGCGCAGCGCGACGTCTCTTTTGACTAAAAGACAGTGTCCAGT  
GCTCCAGCCTAGGAGTCTACGGGGACCGCTCCCGCGCGCCACCATTGCCAATTTCTCTGGCAACTGGA  
AAATCATCCGATCGGAAAATTCGAGGAATTGCTCAAAGTGCTGGGGGTGAATGTGATGCTGAGGAAGAT  
25 TGCTGTGGCTGCAGCGTCCAAGCCAGCAGTGGAGATCAAACAGGAGGGAGACATTTCTACATCAAAACC  
TCCACCACCGTGGCGACCAAGAGATTAACTTCAAGGTTGGGAGGAGTTTGGAGGAGCAGACTGTGGATG  
GGAGGCCCTGTAAGAGCCTGGTGAAATGGGAGAGTGAGAATAAAATGGTCTGTGAGCAGAAGCTCTGTAA  
GGGAGAGGGCCCCAAGACCTCTAGGATAGCGCTCCCCCTACCCAGTCACTTCTGGGGGTCACTGGGATG  
CCTCTTGCAGGGTCTTGCTTTCTTTGACCTCTTCTCTCTCCCTACACCAACAAAGAGGAATGGCTGCA  
30 AGAGCCAGATCACCCATTCCGGGTTCACTCCCCGCTCCCCAAGTCAGCAGTCTTAGCCCCAACCCAGC  
CCAGAGCAGGGTCTCTCTAAAGGGGACTTGAGGGCCTGAGCAGGAAAGACTGGCCCTCTAGCTTCTACCC  
TTTGTCCCTGTAGCCTATACAGTTTAGAATATTTATTTGTTAATTTTATTAAAAATGCTTTAAAAAATAA  
AAAAAAAAAAACAAAAAAAAAAAGAAGAGCCCCGCGCGCGAAACCCGCGTGGCCATGGCGCGCGACCC  
35 CGGGGGCGCGAAAAAGTGGCGTACCTCGCGGCCCTCCCCAAATTTCTCCCCACCCACCTTTAGCGCAGCGA  
CCAACGTGCGCGCGCGCAGCGGGGCGCGCGCAGCGCGCGGACGCTACGCGACGCGCGCGCGCGCGG  
CGGCACACGCGCCACCGTACGG  
CTGCCTAGTTGCTGCTCCCGGTGCGGAGCCAAGGCCGCTACGCGCGCCACGCGAGGGCTGAGGCGAGCG  
CACGCGCGCGCGCGTGAACGCGCGCGCGCACCCGGCTGGAGGGGGGAGGCGACCGCAACAGCGCGAGCGG  
CGGAAGAGCGGGAACAAACGCACACGACCCACACCGCAACGGTGAGCAACGAGCGCGCGCGCGCGG  
40 CGCGCGCGTGGCAGCAGCGACGCGCACGAGACGCGCGAGAGCGAGAGACCACTCCGAGGCGCGCGCGG  
CGGGTGTGCCAGGCCCCGACGCGTGGTGGCC

>DEX0360\_060.nt.5  
GTTCACFCCCCGCTCCCCAAGTCAGCAGTCTTAGCCCCAACCCAGCCAGAGCAGGGTCTCTCTAAAGG  
45 GGACTTGAGGGCCTGTAAGAGCCTGGTGAAATGGGAGAGTGAGAATAAAATGGTCTGTGAGCAGAAGCTC  
CTGAAGGGAGAGGGCCCCAAGACCTCGTGACCCAGAGAAGTACCAACGATGGGGAAGTATCTTGACCA  
TGACGGCGGATGACGTTGTGTGCACCAGGGTCTACGTCCGAGAGTGAGTGGCCACAGGTAGAACCAGGCG  
CGAAGCCCACTGGCCATGCTCACCGCCCTGCTTCACTGCCCCCTCCGTCCACCCCTCTCTTAGG  
50 ATAGCGCTCCCCCTACCCAGTCACTTCTGGGGGTCACTGGGATGCCTCTTGAGGGTCTTGCTTTCTTT  
GACCTCTTCTCTCTCCCCACCAACAAAGAGGAATGGCTGCAAGAGCCAGATCACCCATTCCGGGT  
TCACTCCCCGCTCCCCAAGTCAGCAGTCTAGCCCCAACCCAGCCAGAGCAGGGTCTCTCTAAAGGGG  
ACTTGAGGGCCTGAGCAGGAAAGACTGGCCCTTAGCTTCTACCTTTGTCCCTGTAGCCTATACAGTTT  
AGAAATATTTATTTGTTAATTTTATTAAATGCTTTAAAAAATAAAAAAAAAAAAAACAAAAAAG  
AAGAGCCCGCGCGCGAAACCCGCGTGGCCATGGCGCGCGACCCGCGGGGCGCGAAACAGTGGCGTAC  
55 CTCGCGGCTCCCCAAATTTCTCCCCACCCACCTTTAGCGCAGCGACCAACGTGCGCGCGCGCGAGCGGG  
GCGCGCGCGAGCGCGCGCGACGCTACGCGACGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG  
CAGCCGCGCAGCGCAGCGG  
GAGCCAAGGCCCGCTACGG  
GGCACCCGGCTGGAGGGGGGAGGCGACCGCAACAGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG  
60 GACCCACACCGCAACGGTGAGCAACGACCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGG

DEX-0360

224

PATENT

GCCACGAGACGCGGAGAGCGAGAGACCACTCCGAGGCGCGGCCCGGGTGTGCCAGGCCCGACGCGTGG  
TGGCC

>DEX0360\_060.nt.6

5 GATTCAAGTGTGGCTTTGCGTCCGCTTCCCCATCCACTTACTAGCGCAGGAGAAGGCTATCTCGGTCCC  
CAGAGAAGCCTGGACCCACACGCGGGCTAGATCCAGAGAACCTGACGACCCGGCGACGGCGACGTCTCTT  
TTGACTAAAAGACAGTGTCCAGTGTCTCCAGCTTACGGGGACCGCTCCCGCGCCGCCACCAT  
GCCCAACTTCTCTGGCAACTGGAATAATCATCCGATCGGAAAACCTTCGAGGAATTGCTCAAAGTGTGGG  
10 GTGAATGTGATGCTGAGGAAGATTGCTGTGGCTGCAGCGTCCAAGCCAGCAGTGGAGATCAAACAGGAGG  
GAGACACTTCTTACATCAAACCTCCACCACCGTGCACACACAGATTAACCTCAAAGTGTGGGGAGGA  
GTTTGAGGAGCAGACTGTGGATGGGAGGCCCTGTAAGCACTGCCCCCTCCGTCCCACCCCTCCTTCTAG  
GATAGCGCTCCCCCTTACCCAGTCACCTTCTGGGGGTACCTGGGATGCCTCTTGCAAGGTCTTGCTTTCTT  
TGACCTCTTCTCTCTCCCTACACCAACAAAGAGGAATGGCTGCAAGAGCCAGATCACCATTCCGGG  
TTCACCTCCCCGCTCCCCAAGTCAGCAGTCTTAGCCCCAAACAGCCAGAGCAGGGTCTCTCTAAAGGG  
15 GACTTGAGGGCTGAGCAGGAAAGACTGGCCCTCTAGCTTCTACCTTTGTCCCTGTAGCCTATACAGTT  
TAGAATATTTATTTGTTAATTTTATTAATGCTTTAAAAAATAAAAAAAAAAAAAACAAAAAAGAGT  
GAAGAGCCCGCGCGCGAAACCCGCGTGGCCATGGCGCGCGACCCGCGGGGCGGAAACAGTGGCGTA  
CCTCGCGGCCCTCCCAATTCTCCCCACCCACCTTTAGCGCAGCGACCAACGTGCGCGCGCGCGCGG  
GGCGGGCGCGACGAGCGCGCGGACGCTACGCGACGGACGGCGCGGGCCGGCACCACGCCACCACGTACGG  
20 GCAGCCGCCAGCGCAGCCCGGGCGCGCTGCTCACAACCGAGGTCTGCCTAGTTGCTGCTCCCGGTGC  
CGAGCCAAGGCCGCTACGCACGCCACGCGAGGGCTGAGGCGCGCGACGCGCGCGCGCGGCGTGAACGCCG  
CGGCACCCGGCTGAGGGGGGGAGGCACCGCAACACGCGCGACGCGCGCGGGAAGAGCGGGAACAAACGCACA  
CGACCCACACCGCAACGGTGAGCAACGACCGAGCGGGCAGCGCGACCGCGCGCGGTGGCAGCAGCGCACGA  
CGCCACGAGACGCGGAGAGCGAGAGACCACTCCGAGGCGCGGCCCGGGTGTGCCAGGCCCGACGCGTG  
25 GTGGCC

>DEX0360\_060.nt.7

CCCTCTCTGAGTACGGAGTGGTCCCACTGGATCCAGTTTCAAGGTTCAGGGTTCATGGAGCTAGGGCCAGCTACGGC  
TCAAGATCTGGGGTCCGCCTGCGGGTGGGGTTCGCCAGGTGTCCGGCACCAGGAGTTGAATGCACCGAGT  
30 CAGAACCTGACGACCCGGCGACGGCGACGTCTCTTTGACTAAAAGACAGTGTCCAGTGTCTCCAGCCTAG  
GAGTCTACGGGGACCGCTCCCGCGCCGCCAGTCCCAACTTCTCTGGCAACTGGAATAATCATCCGAT  
CGGAAACTTCGAGGAATTGCTCAAAGTGTGGGGTGAATGTGATGCTGAGGAAGATTGCTGTGGCTGC  
AGCGTCCAAGCCAGCAGTGGAGATCAAACAGGAGGGAGACACTTTCTACATCAAACCTCCACCACCGTG  
CGCACCACAGAGATTAACCTTCAAGGTGTGGGGAGGAGTTTGAGGAGCAGACTGTGGATGGGAGGCCCTGTA  
35 AGCACTGCCCCCTCCGTCCCACCCCTCCTTCTAGGATAGCGCTCCCTTACCCAGTCACTTCTGGGGG  
TCAGTGGGATGCCTCTTGCAAGGTCTTGCTTTTGACCTCTTCTCTCTCCCTACACCAACAAAGAG  
GAATGGCTGCAAGAGCCAGATCACCCATTCCGGGTTCACCTCCCGCTCCCAAGTCAAGCAGTCTTAGC  
CCCAACAGCCAGAGCAGGCTCTCTTAAAGGGGACTTGAGGGCTGAGCAGGAAAGACTGGCCCTCT  
AGCTTCTACCTTTGTCTCTGTAGCCTATACAGTTTGAATATTTATTTGTTAATTTTATTAATAATGCTT  
40 TAAAAAATAAAAAAAAAAAAAACAAAAAAGAGAGCCCGCGCGCGGAAACCCGCGTGGCCATGG  
CGCGCGACCCGCGGGCGCGGAAACAGTGGCGTACCTCGCGGCTCCCAAAATTCTCCCCACCCACCTT  
TAGCGCAGCGACCAACGTGCGCGCGCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG  
ACGGCGCGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG  
45 ACAACCGAGGTCTGCCTAGTTGCTGCTCCCGGTGCGGAGCCAAGGCCGCTACGCACGCCACGCGAGGGC  
TGAGGCGAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG  
CGGCCGACGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG  
GCCAGCGG  
AGGCGCGG

50 >DEX0360\_060.nt.8

51 GTTTGGAAGGTTGGGGNCCCCCAACCCAAAGGGGGTTAAAGGGAAAAACCCCCCGGCNCCCGGGG  
GCCCCAAAAAGCCCACTGGCCATGCTCACCGCCCTGCTTCACTGCCCCCTCCGTCCCACCCCTCC  
TTCTAGGATAGCGCTCCCTTACCCAGTCACTTCTGGGGTCACTGGGATGCCTCTTGCAAGGTCTTG  
TTCTTTGACCTCTTCTCTCTCCCTACACCAACAAAGAGGAATGGCTGCAAGAGCCAGATCACCCAT  
55 TCCGGGTTCACTCCCGCTCCCAAGTCAAGCAGTCTAGCCCCAAACAGCCAGAGCAGGGTCTCTCT  
AAAGGGGACTTGAGGGCTGAGCAGGAAAGACTGGCCCTCTAGCTTCTACCTTTGTCTCTGAGCCTAT  
ACAGTTTGAATATTTATTTGTTAATTTTATTAATAATGCTTTAAAAAATAAAAAAAAAAAAAACAAAAA  
AAAAAGAAGAGCCCGCGCGCGGAAACCCGCGTGGCCATGGCGCGGCGGCGGCGGCGGCGGCGGCGG  
GGCGTACCTCGCGGCTCCCAAAATTCTCCCCACCCACCTTTAGCGCAGCGACCAACGTGCGCGCGGCG  
60 AGCGGGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG  
AGCGGGGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG

DEX-0360

225

PATENT

TCACGGGCAGCCGCCAGCGCACGCCCCGGGGGGCGCCTGCTCACAACCGAGGTCTGCCTAGTTGCTGCTCC  
CGGTGCCGAGCCAAGGCCCGCTACGCACGCCCACGCAGGGCTGAGGCAGCGGCACGCGCGGGCGTGCAA  
CGCCGGCGGCACCCGGCTGGAGGGGGGAGGCACCGCAACACGGCCGACGCGCGAAGAGCGGGAACAAA  
CGCACACGACCCACACCGCAACGGTGAGCAACGACCGAGCGGCCAGCGGGCAGCGGGCGTGGCAGCAGG  
5 CGACGAGCCACGAGACGCGCGAGAGCGAGAGACCCTCCGAGGCGCCGCGCCGGGTGTGCCAGGCCCGA  
CGCGTGGTGGCC

&gt;DEX0360\_060.nt.9

GCGGCGCCAGTGTGATGGATGCGGCCGCCGGGCAGGTCCCAGTCACTTCTGGGGGTCACTGGGATGCCT  
10 CTTGCAGGGTCTTGCTTTCTTTGACCTCTTCTCTCTCCCTACACCAACAAAGAGGAATGGCTGCAAGA  
GCCCAGATCACCCATTCCGGGTTCACCTCCCCGCTCCCAAGTCAGCAGTCTCTAGCCCCAAACCGCCCA  
GAGCAGGGTCTCTCTAAAGGGGACTTGAGGGGCTGAGCAGGAAAGACTGGCCCTCTAGCTTCTACCCCTT  
GTCCCTGTAGCCTATACAGTTTAGAATATTTATTTGTTAATTTTATTAATAATGCTTTAAAAAATAAAAA  
15 AAAAAAACAAAAAAGAGAGCCCGGCGCGGAAACCCGCGTGGCCATGGCGCGGCGACCCGCG  
GGGCGGAAAACAGTGGCGTACCTCGCGGCTCCCAAATTTCTCCCAACCCACCTTTAGCGCAGCGACCA  
ACGTGCGCGCCGCGCAGCGGGGGCGCGACGAGCGCCGACGCGCCCGGGCGCGCTGCTCACAACCGAGGTCTG  
CCTAGTTGCTGCTCCCGGTGCGGAGCCAAAGGCCGCTACGCACGCCCACGCAGGGCTGAGGCAGCGGCAC  
15 CCGCGCGGCGTGAACGCGCGGCGCACCCGGCTGGAGGGGGGAGGCACCGCAACACGGCCGACGCGGCG  
AAGAGCGGGAACAAACGCACACGACCCACACCGCAACGGTGAGCAACGACCGAGCGGCCAGCGGCGACCG  
20 CGCGTGGCAGCAGGCGACGACGACGAGACGCGCGAGAGCGAGAGACCCTCCGAGGCGCCGGCCCGG  
GTGTGCCAGGCCGACGCGTGGTGGCC

&gt;DEX0360\_001.aa.1

MWTFNQNYPLCFLGRFRSLTTAFFRDAMGFLMFDLTSQQSFLNVRNWSQLQANAYCENPDIVLIGNKA  
25 DLPDQREVNERQARELADKYGCKLSTLGINKFDEACLSLHQWSECCS

&gt;DEX0360\_002.aa.1

MATASPRSDTSNNHSGRLQLQVTVSSAKLKRKNWFGTAIYTEVVVDGEITKTAKSSSSSNPKWDEQLTV  
30 NVTFQTTLEFQVWSHRTLKADALLGKATIDLKQALLIHNRLERVKEQLKLSLENKNGIAQTGELTVVLD  
GLVIEQENITNCSSSPTIEIQENGDALENHENGEPARTTARLAVEGTNGIDNHVPTSTLVQNSCCSYVNG  
DNTFSSPSQVAARPKNTPAPKPLASEPADDTVNGESSFAPTDNASVTGTPVSEENALSPNCTSTTVED  
PPVQEILTSSENNCEIPSTSAELESEARSILEPDTNSNRSSSAFEAAKSRQPDGCMDFVRQQSGNANTET  
35 LPSGWEQRKDPHGRTYVVDHNTRTTTWERPQPLPPGWERRVDDRRRVYVDHNTRTTTWRPTMESVRNF  
EQWQSQRNLQGAMQQFNQRYLYSASMLAAENDPYGPLPPGWEKRV DSTDRVYFVNHTKTTQWEDPRTQ  
GLQNEETLGRRLRQFRIFSVKVLRSPPCTHSTQOPTFPRLRLMRKPTDTSNGGPANCPTEERRLQVKPAK  
YPKMGPSLMAYPRTGTNTASPGQQSATEPPPTKMGQTPQDREGRHRLTAEPSTNQGTREKPPHNVPPTV  
QTHNQLSNDNNTNTIRNNTSN

&gt;DEX0360\_003.aa.1

MGGPGPLLSRSGFLLCKTGWHSNRLGDCGPHTPVSTALSFIAGVMAAPSMKERQVCWGARDEYWKCLD  
40 ENLEDASQCKLRSSFESSCPQQWIKYFDKRRDYLKFKEFAGQFEPSETTAKS

&gt;DEX0360\_003.aa.2

FFLEPCAPLLAEPLLERDEAEVGGADAGPALLYGLVGDGELAQVVANHLGLDLHLVEGLAVVDAHHAH  
45 HLGQDDHVPQVRLHHFRLLHGRRLLLGLAQALQQGVLLPPQAPVQPPPLARTVQLHQLLVGHVQQLVEVH  
AALHRSRNGSPIYEGKTGLLGPG

&gt;DEX0360\_004.aa.1

DPRWALYSLYVYKFLHFSYSSAKNPDGCFQKVLNGFTKFFCKEQYCKLLKLYFYRLFALLWILCLSGFL  
50 KFFFYSEIMELVLAAGALLFCGFIYDTHSLMHKLSPEEYVLA AISLYLDIINFLHLLRPLEAVNKK

&gt;DEX0360\_005.aa.1

MGDLELLLPGEAEVLVRGLRSFPLREMGSEGNQHENLEKLNMQAILDATVSQGEPIQELLVTHGKVPT  
55 LVEELIAVEMWKQKVPVFCRVEDFKPQNTFFIYMVVHHEASIIINLETVFFHKEVCESAEDTVLDLVDY  
CHRLTLLVAQSGCGGPEGEQSQDSNPMQELQKQAELEMEFEIALKALSVLRYITDCVDSLSTLSRML  
STHNLPCLLVELLEHSPWSRREGGKLQFEGSRWHTVAPSEQQKLSKLDGQVWIALYNLLSPEAQARYC  
LTSFAKGRLLKVRLPPHQPQPQYRPPHPTPTASLLFIHPPQPCSFQSLGLSDTPASGTWAPTGILS  
60 PTQPLPPFPWPGQLHHTGLHWTPLQLRAFLDTLLDQLPNLAHLQSFLAHLTLTETQPPKKDLVLEQIP  
EIWERLERENRGKWAIAKHQLQHVFSPEQDLRLQARRWAETYRLDVLEAVAPERPRCAYCSAEASKRC

DEX-0360

226

PATENT

SRCQNEWYCCRECOVKHWEKHGKTCVLAAGDRAK

&gt;DEX0360\_006.aa.1

5 MDEIEKYQEVEEDQDPSCPRLSRELLDEKEPEVLQDSLDRCYSTPSGYLELPDLGQPYSSAVYSLEEQYL  
GLALDVDRIKKDQEEEDQGPCPRLSRELLEVVEPEVLQDSLDRCYSTPSSCLEQPDSCQPYGSSFYAL  
EEKHVGFSLDVGEIEKKGKGKRRGRRSKKERRRGRKEGEEDQNPCCPRLSRELLDEKGPEVLQDSLDR  
YSTPSGCLSLTDSQCPYRSFYVLEQQRVGLAVDMDEIEKYQEVEEDQDPSCPRLSRELLDEKEPEVLQD  
SLDRCYSTPSGYLELPDLGQPYSSAVYSLEEQYLGLALDVVDKIEKKGKGKRRGRRSKKERRRGSKEGEE  
10 DQNPCCPRLSGVLMEVEEPEVLQDSLDRCYSTPSMYFELPDSFQHYRSVFYSFEEQHISFALDVNDRFLT  
LMGTSLHLVFQMGVIFPQ

&gt;DEX0360\_007.aa.1

15 MRRRSHSTRLSAGGSWSPHLLSPSYSVKSRRDRKMVGDTVGAQAYASTAKCLNIWALILGILMTIGFILL  
LVFGSVTVSHIMFQNTGKTGLLVAHSLQLHSTVQCWPCNAVAVAPAPLVLPLNTAVYTHTPVYSVIQ

&gt;DEX0360\_008.aa.1

20 MEEMKNEAETTSMVSMPLYAVMYPVFNELERVNLSAAQTLRAAFIKAENENPGLTQDIIMKILEKKSVVE  
NFTESLLRMAADDDVEEYMIERPEPEFQDLNEKARALKQILSKIPDEINDRVRFLQTIKALEHQKKEFVKY  
SKSFSOTLTKTYFKDGKAINVFSANRLIHQTNLILQTFKTVA

&gt;DEX0360\_009.aa.1

25 GRVPLALGVQTLPTCDEPKAHTSFQISLSVSYTGSSGRPGRYELFKSSPHSLFPEKMWSSCLDAHTGIS  
HEDLIQVGGPPISLQIHDSPALASAPPLSPVPPLYVVERAKSQSCVTGDSHPCLSSISFFY

&gt;DEX0360\_009.aa.2

30 MELDLSPHLLSSPEDLCPAPGTPPGTTPRPPDTPLPEEVKRSQPLLIPTTGRKLREEERRATSLPSIPNP  
FPFLCSPPSQSPILGGPSSARGLLPRDASRPVVKVYSEDGACRSVEVAAGATARHVCEMLVQRAHALSD  
ETWGLVECHPHLALERGLEDHESVVEVQAAPVVGDSRFVFRKNFAKYELFKSSPHSLFPEKMWSSCLDA  
HTGISHEDLIQVGGPPISLQIHDSPALASAPPLSPVPPLYVVERAKSQSCVTGDSHPCLSSISFFY

&gt;DEX0360\_010.aa.1

35 MSREPTPPLPGDMSTGPPIAESWCYTQVKVVKFSYMWTTNNFSFCREEMGEVLKSTFSGSPDKMKWCLR  
VNPKGLDDESKDYLSTYLLLVSCPKSEVRKFKFSLNNAKREETKAMESQRAYRFVQGDWGFKKFIRRD  
FLLDEANGLLPDDKLTLCFEVSVVQDSVNISSGHTNTNTLKVPECRLAEDLGNLWENTRFTDCSFFVRGQE  
FKAHKSVLAAARSPVFNAMFEHEMESKKNRVEINDLDPEVFKEMMRFIYTGRAPNLDKADNLLAAADKY  
ALERLKVMECEALCSNLSVENVADTLVLADLHSAEQLKAQIDFINRCSVLRLQGLCKDGKNWNSNQATDI  
METSGWKSMIQSHPHLVAEAFRALASAQCPQFGIPRKRLKQS

&gt;DEX0360\_011.aa.1

40 MFLVLARACQLLQICLKESLFAYLGLSPPSYTFPAPAAVPTAAIYQPSVILNPRALQPOSTAYYPAGTQ  
LFMNYTAYYSPSPGSPNSLGYFPTAANLSGVPPQPGTVVRMQGLAYNTGVKEILNFFQGYQYATEDGLIH  
TNDQARTLPKEWVCI

&gt;DEX0360\_012.aa.1

45 MVKLNSNPSEKGTKPPSVEDGFQTVPLITPLEVNHLQLPAPEKVIVKTRTEYQPEQKNKGKFRVPKIAEF  
TVTILVSLALAFACIVFLVYKAFTYLLKELNS

&gt;DEX0360\_013.aa.1

50 MPEFLEDPSVLTKDKLSELVANNVTLPAGEQRKDVYVQLYLQHLTARNRPPLPAGTNSKGGPPDFSSDEE  
REPTFVLGSGAAAAGRSRAAVGRKATKTKDPRQEDKDDLDVTELTDNEDLLDQLVKYGVNPGPIVGTTRK  
LYEKKLLKLRBQGTESRSSTPLPTISSAENTRQNSDSDRYSDNEEDSKIELKLEKREPLKGRKTPV  
TLKQRRVEHNQSYSQAGITETETWTSOSSKGGPLQALTRSTRGSRRTPRKRVETSEHFRIDGPVISESTP  
IAETIMASSNESLVNVRVTGNFKHASPILPITEFSDIPRAPKKPLTRAUVGEKTEERRVERDILKEMFP  
55 YEASTPTGISASCRRPIKGAAGRPLELSDFRMEESFSSKYVPKYVPLADVKSEKTKKGRSIPVWIKILLF  
VVAVFLFLVYQAMETNQVNPFNSNHLHVDPRKSN

&gt;DEX0360\_014.aa.1

60 MELGRPLEVLASALSPAPPLLPDYILCVVSLQMKDLGAEHLAGHEGVQLLGLLNVYLEQEERFQPR  
EKGLSLIEATPENDNTLCPGLRNAKVEDLRSLANFFGSCSTETFLAVNILDRLALMKVKPKHLSCIGVC

DEX-0360

227

PATENT

SFLLAARIVEEDCNIPSTHDIIRISQCKCTASDIKRMKEIISEKLHYELEATTALNLFHLHYHTIILCHTS  
ERKEILSLDKLEAQLKACNCRILIFSKAKPSVLALCLLNLEVETLKSVELLEILLVKKHSHKINDTEFFYW  
RELVSKCLAEYSSPECCKPDLKKLVIVSRRTAQNHLNSYYSVPELPTIPEGGCFDESESEDSCEDMSCG  
EESLSSSPSDQECTFFFNFKVAQTLCFPS

5

&gt;DEX0360\_014.aa.2

MLLERRQCDGLRRGRGTASDIKRMKEIISEKLHYELEATTALNLFHLHYHTIILCHTSERKEILSLDKLEA  
QLKACNCRILIFSKAKPSVLALCLLNLEVETLKSVELLEILLVKKHSHKINDTEFFYWRELVSKCLAEYSS  
PECCKPDLKKLVIVSRRTAQNHLNSYYSVPELPTIPEGGCFDESESEDSCEDMSCGEESLSSSPSDQEC  
TFFFNFKVAQTLCFPS

10

&gt;DEX0360\_015.aa.1

MCCWQATFFKALSETLIFGVSFQETFLWRENEYEDNFQLIIWVTQNRVYGYRIDFLIMASDVALGKGALC  
TVCACMCVLYKFSFGMTVCLSRKPINSKF

15

&gt;DEX0360\_016.aa.1

MACRLILLPFVMSLSHWGDALLLALCPQLILPHVDIQLKYFDLGLPNRDQTDQVTTIDSALATQKYSVA  
VKCATITPDEARVEEFKLKKMWKSPNGTIRNILGGTVFREPIICKNIPRLVPGWTKPITIGRHAHGDQYK  
ATDFVADRAGTFKMVFTPKDGSQVKEWVYNFPAGGVGMGMNTDESISGFAHSCFYAIQKKWPLYMST  
KNTILKAYDGRFKDIFQEIFDKHYKTDFDKNKIWEHRLIDDMVAQVLKSSGGFVWACKNYDGDVQSDIL  
AQGFGLGLMTSVLPCPDGKTIEAEEAHGTVTRHYREHQGRPTSTNPIASIFAWTRGLEHRGKLDGNQD  
LIRFAQMLEKVCVETVESGAMTKDLACCIHGLSNVKLNEHFLNTTDFLDTIKSNLDSSPGQAVGGGATHG  
CSGGARAEPAGPPERGRG

20

25

&gt;DEX0360\_016.aa.2

MKNFRTPVWLCCCLGFKFWLKDGGCSGTTIISVLTEFKLKKMWKSPNGTIRNILGGTVFREPIICKNIPR  
LVPGWTKPITIGRHAHGDQVGGGEGIHRRPGHPPTGAPRLAILLSLQYKATDFVADRAGTFKMVFTPKDG  
SGVKEWVYNFPAGGVGMGMNTDESISGFAHSCFYAIQKKWPLYMSTKNTILKAYDGRFKDIFQEIFD  
KHYKTDFDKNKIWEHRLIDDMVAQVLKSSGGFVWACKNYDGDVQSDILAQGFGLGLMTSVLPCPDGKT  
IEAEEAHGTVTRHYREHQGRPTSTNPIASIFAWTRGLEHRGKLDGNQDLIRFAQMLEKVCVETVESGAM  
TKDLACCIHGLSNVKLNEHFLNTTDFLDTIKSNLDSSPGQAVGGGATHGCSGGARAEPAGPPERGRG

30

&gt;DEX0360\_016.aa.3

MSTKNTILKAYDGRFKDIFQEIFDNKASSMYSVAFLPFPPCCSHPTLGRSLLECIIWLSSEAQGGIPNLSA  
FCPLPITDLPTRHYKTDFDKNKIWEHRLIDDMVAQVLKSSGGFVWACKNYDGDVQSDILAQGFGLGL  
MTSVLPCPDGKTIEAEEAHGTVTRHYREHQGRPTSTNPIASIFAWTRGLEHRGKLDGNQDLIRFAQMLE  
KVCVETVESGAMTKDLACCIHGLSNVKLNEHFLNTTDFLDTIKSNLDSSPGQAVGGGATHGCSGGARAEP  
AGPPERGRG

35

40

&gt;DEX0360\_016.aa.4

MAATILGCRGQQGSAGWPQERRGPERKAFYPPGFGSLGLMTSVLPCPDGKTIEAEEAHGTVTRHYREHQ  
GRPTSTNPIASIFAWTRGLEHRGKLDGNQDLIRFAQMLEKVCVETVESGAMTKDLACCIHGLSNVKLNEH  
FLNTTDFLDTIKSNLDSSPGQAVGGGATHGCSGGARAEPAGPPERGRG

45

&gt;DEX0360\_016.aa.5

MAGYLRVVRSLCRASGRPAWAPAALTAPTSQEQPRRHADKRIKIVAKPVVEMDGDDEMTRI IWQFIKEKC  
EAERALPEHHGLPRHHQEQPGQPWAGSRGRRHFWLQWRGQG

50

&gt;DEX0360\_017.aa.1

MPWRAPSASSASAGRILLRPTEEEGGAERSFSGPRGSSGRIPRFVSISITNGPVFCGVGAVARHEYTVI  
GPKVSLAARMITAYPGLVSCDEVTYLRSMLPAYNFKKLPEKMMKNI SNPGKIYEYLGHRRCIMFGKRHLA  
RRRNKNHPLLGLVGLAPCLSTDWEKELEAFQMAQQGCLHQKKQAVLYEGGKGYKSQLAEINFLAQKEG  
HSYPSQVLWKPTLFEVLQDQLSKDVLLFHVLFQKEEENSKWETLSANAMKSIMYSISPANSEEGQELV  
CTVKDDVNLDTVLLPFLKEIAVSQDQLSPPEQLLVKCAAIIGHSFHIDLLQHLLPGWDKNKLLQVLRA  
LVDIHVLCWSDKSQELPAEPILMPSSIDIIDGTKEKKTLDGGSASLLRLQEELSLPQTEVLEFGVPLLR  
AAAWELWPKEQQIALHLEACACFLQVLACRCGSGCHGGDFVPFHHFAVCSTKNSKGTSRFCTYRDTGSVLQ  
VITEKLQLPSPQEQRKSS

55

&gt;DEX0360\_017.aa.2

MITAYPGLVSCDEVTYLRSMLPAYNFKKLPEKMMKNI SNPGKIYEYLGHRRCIMFGKRHLARKRNKNHPL

60

DEX-0360

228

PATENT

5 LGVLGAPCLSTDWEKELEAFQMAQQGCLHQKKGQAVLYEGGKGYGKSQLLAEINFLAQKEGHSYPSQVLW  
 KPTLFEVLCDLLSKDVLVLFVLOKEEEENSKEWETLSANAMKSIMYSISPANSEEGQELYVCTVKDDVNL  
 DTVLLLPFLKEIAVSQDLQSPQELLVKCAAIIGHSFHIDLLQHLPGWDKNKLLQVLRALVDIHVLCW  
 SDKSQELPAEPILMPSSIDIIDGTKEKKTCLDGGASALLRLQEEELSLPQTEVLEFVPLLRAAAWELWPK  
 EQQIALHLEACFLQVLACRCGSGHGGDFVFFHHFAVCSTKNSKGTSRFCTYRDTGSLTVQVITEKLQLP  
 SPQEQRKSS

>DEX0360\_018.aa.1

10 MRSTRERRPQERRRQGSVRQGRGTGGSRFAIIPGSRLCFVGPSHCILAHTGEFWPWNWSQHAAKLSHGRQ  
 RIPTHCRSKPCWKQNSSPSVELRGDWSRAPADTKIQVAQVSHRKWRSICT

>DEX0360\_019.aa.1

15 MQSSLYFERIKYDLQKLHGGLSKTLNLYLFFVEKSYFRHHFIPQQLAVKPLLCCMPVTLDDCGDYQCSRL  
 RARVGWGIKTGKIATILYCECLCWRYRELLEHLRGAPTLNLGVSRLKVKAKPQSISSLGIEQNV  
 GEEMPKARREEYSKQEGFQREKSI PNINICTNLMGRENVGWGWMMRLKKKARSEIISGLVHHVKECRDLSV  
 VNRKAAQFIMNILEDHWNMENKVGDDYILEAGRTFLRKLHYFGENDGHKHEELEVTMTSSLIQKGFGR  
 YNIGTLTGLTKGDEIHHINCQTQGGMSNYFAYDVEITNFSSGNQKLQNLVFPSPRILSVQTICTTPPISL  
 PLHVCPSTKSRSIHTGKTRAVQVSENEKEELSCAEPIONKHILCIDSWNLERNSPNSIGIWMVCNPLWGS  
 20 AFKKPYLEIPSMEPSSIKAHLKAYIKNKILAALYTNNDVMIKLSDAIKWNKMYVPLQKKKAKFSVEHC  
 DFMSLHSLGAEEGALVSSEVEEKTWRLIYAMFFHLKEAFFLDYLIQFPSRKLVLPLTRQQLGRQKLYCM  
 YMAVAVGRRFLSPGPHWPTYSPLLVMPGHRPPVAII SYLSLWLVNLSILSASALQSAGTLLTSISCWLSTF  
 LIGPALFSSGPAVESPCPFRRAMAYHCLLSLHSAATTLNPSFSKDVADFTGKHRLDLPLPFTCLNLTS  
 FNFQSQNVGIVSSLPYIFLLLNHESLSLPLAMCWRLLSGFRMSSHLVLVAFDASSPPFKDTFEI

25 >DEX0360\_020.aa.1

VRAPSPGQAGRAEGADPQPGPAHLHDGSELLRGKLRQLSEDNVRPRGARLSSGPGTGVSVLFRDGEHLHF  
 PACHRALRACDGKSSSQPNVISAALLGPRSVVVSGLLVWRPVSFGDGDSDAITARQGVSRGVKAAMNRVL  
 CAPAAGAVRALRLIGWASRSLHPLPGSRDRAHPAAEEEDDPDRPIEFSSKANPHRWSVGHMTMGKHQRP  
 30 WWKVLPLSCFLVALIWCYLRESEADQWLRQVWGEVPEPSDRSEEPETPAAYRART

>DEX0360\_021.aa.1

MVRAGAVGAHLPASGLDIFGDLKMMNKRLQLYYQVLNFAMIVSSALMIWKGLIVLTGSESPIVVVLGSME  
 PAFHRGDLFLTNFREDPIRAEIMETSNF

35 >DEX0360\_022.aa.1

MSKTFRQTEGSQGDRRVHASKATASPDALPSLLWTQEKSNPHSEFSHQNLIIINTLSLFFAGTETTSTTLR  
 YGFLMLKYPHVAERVYKEIEQVVGPHRPPALDDRAKMPYTEAVIREIQRFADLLPMGVPHIVTQHTSF

>DEX0360\_023.aa.1

40 MLLERRSVMDDPPGQVQTYEEGLFYAQSKKPLMVIHLEDCQYSQALKKVFAQNEEIQEMAQNKFIMLNL  
 MHETTDKNLSPDGQYVPRIMFVDPSTVRADIAGRYSNRLTYEPRDLPLLIENMKALRLIQSEL

>DEX0360\_024.aa.1

45 MEGNGPAAVHYQPASPPRDACVYSSCYCEENIWKLCYIKNHDQYPLEECYAVFISNERKMPIWKQAR  
 PGDGPVIWDYHVLLHVSSGGQNFYDLDTVLFPCLFDTYVEDAFKSDDDIHPQFRKFRVIRADSYLK  
 NFASDRSHMKDSSGNWREPPPPYPCIEGTGINPVDNFLTFKKIKGSPYCYCLAFI

>DEX0360\_025.aa.1

50 RERERERERESGHKNCFVKVKDSKLPAYKDLGKNLPFPTYFPDGDEEELPEDLYDENVCQPGAPSITFA

>DEX0360\_026.aa.1

55 MESRTLLGQLWVPLASGWARGQRTCRRRLRYGLVKVEMDGRMDSLGHMARSWEDGHRPKSVLVYHCTSGN  
 LNPENRGKMGFQVLATFEIPIPFERALTTPYADFTTSNFRQYWNNAISQAPAIYDFYLWLTGRKPRQG  
 QDGSKSNQPLQPATSCWQDLFLHPVKSQGGTRA

>DEX0360\_027.aa.1

MQQARETAVQYKLEEEIQTLRVYYSLHKSLSQEEENLKDQFNYTLSTYEEALKNRENIVSITQQQNEEL  
 ATQLQQUALTERANMELQLQHAREASQVANKEVQKLERLVDVLRKKVGTGTMRVTI

60 >DEX0360\_028.aa.1

DEX-0360

229

PATENT

MPQSRQWDFEGGKRRQAGHALRGARTHLLHPHVFRALSLWEAFFRTALVNWKRNPSPWWPCSDLDLSE  
VTLPLRALQSLLAGGGSFSPSHSHFLTSLCITGSSL

&gt;DEX0360\_028.aa.2

5 MPGPAPGRGGSGVGLRGLSSLOAPQPSRVPMMAAYSYPGPGAGPGPAAGAALPDQSFLWNVFORVDKD  
RSGVISDTTELQQUALSNGTWTFFNPVTVRSIISMFDRENKAGVNFSEFTGVWKYITDWQNVFRTYDRDMSG  
MIDKNELKQALSGFGYRLSDQFHDILIRKFDQRGRQIAFDDFIQGCIVLQTLAPSPRECEGGANTAHCS  
LDEQAQAILTPRTPKVLGSQARVTMLA

10 &gt;DEX0360\_029.aa.1

KDQSAEDPARARTRARRRSKEHNTHRACKAAARAPHAYPAHTVQEDDVAVHTPWHQPTPRTSASL

&gt;DEX0360\_030.aa.1

15 MTTRQATKDPLLRGVSPTPSKIPVRSQKRTFPFTVTSCAVDQENQDPRRWVQKPPLNIQRPLVDSAGPRP  
KARHQAETSQRLVGISQPRNPLEELRPSPRGQNVGPGPPAQTEAPGTIEFVADPAALATILSGEGVKSCH  
LGRQPSLAKRVLVRGSQGGTTQRVQGVASAYLAPRTPTHRLDPARASCFSRLEGPGPRGRTLCPQRLQA  
LISPSGSPSFHPSTRPSFQELRRRETAGSSRTSVSQASGLLLETVPQPAFSLPKGEREVVTHSDEGGVASLG  
LAQRVPLRENREMSHTRDSDSHLMPSAPVAQPLPGHVVPCCSPFGRAQRVSPGPPPTLSYSVLRRLT  
20 VQPKTRFTMPSTPRVQQAQWLRGVSPQSCSEDPALPWEQVAVRLFQESCIRSLESGKPPVATPSGPH  
SNRTPSLQEVKIQVSLCQQLCCLLNSDWAEEGKEMGDQEDSVGRLLNAHLDTLGCSLPPQIRIGILQ  
QLLRQEVEGLVGGQCVPNLNGSSLDMLVELQPLLTEISRTLNAATEHNSGTSHLPGLLKHSGLPKPCLPEEC  
GEPQPCPPAEPGPPEAFCRSEPEIPEPSLQEQLEVPEPYPPAEPRLPESCCRSEPEIPESSRQEQLEVPE  
PCPPAEPRLPLESYCRIEPEIPESSRQEQLEVPEPCPPAEPGLPQSTQGGSGPPGPCPRVELGASEPCTL  
25 EHRSLSSLPPCCSQWAPATTSLIFSSQHPLCASPPICSLQSLRPPAGQAGLSNLAPRTLALRERLKSCL  
TAIHCFFHEARLDDECAFYTSRAPPSGPTRVCTNPFVATLLEWQDALCFIPVGSAAPOGSP

&gt;DEX0360\_030.aa.2

30 MLPHLPPWPSLALPQEEGRGCTSSPVLLIGLAVGGGGEDSTWWKYRTPDLPLNFPCCPSGLSNLAPRTLA  
LRERLKSCLTAIHCFFHEARLDDECAFYTSRAPPSGPTRVCTNPFVATLLEWQDALCFIPVGSAAPOGSP

&gt;DEX0360\_031.aa.1

35 MTMRSAVFKAAPAGGNPEQRLDYERAAALGGPEDEPGAEEAHFLPRHRKLKEPGPPASSQGGSPAPS  
PAGCGKGGRGLLLPAGAAPGQEEESWGGSVPLPCPPPATKQAGIGGEPAAGAGCSPRKYQAVLPQTG  
SLVAAAKEPTPWAGDKGGAASPAATASDPAGPPPLPLPGPPPLAPTATAGTLAASEGRWKS MRKSPLGGG  
GGSGASSQAACLKQILLQLDLIEQQQQQLQAKEKEIEELKSERDTLLARIERMERMQLVKKDNEKERH  
KLFQGYETEEREETEELSEKIKLECOPELSETSQTLPPKPFSCGRSGKGHKRKSPPFGSTERKTPVKKLAP  
FSKVKTTPKHSPKEEPCGSLSETVCKRELRSQETPEKPRSSVDTPRLSTPQKGPSTHPKEAFSSEI  
EDLPYLSTTEMYLCRWHQPPPSPLPLRESSPKKEETVASKA

40 &gt;DEX0360\_031.aa.2

MRARTPPAAPKEKAFSSEIEDLPYLSTTEMYLCRWHQPPPSPLPLRESSPKKEETVASKA

&gt;DEX0360\_032.aa.1

45 MFFSAALRARAAGLTAHWGRHVRNLHKTAMQNGAGGALFVHRDTPENNPDTPFDFTPENYKRIEAIKVNY  
PEGHKAAAVLPVLDLAQRQNGWLPISAMNKVAEVLQVPPMRVYEVAFTYTMYNRKPVGKYHIQVCTTTTPC  
MLRNSDSILEAIQKKLGIKVGETTPDKLFTLIEVECLGACVNAPMVQINDNYEDLTAKDIEEIDELKA  
GKIPKGPGRSGRFSCEPAGGLTSLTEPPKGPFGVQCVHLHRKFQGAIAVVVNHRI SVGMAEGETGLGCR  
ELVEVVQPYLPGRP

50 &gt;DEX0360\_032.aa.2

MFFSAALRARAAGLTAHWGRHVRNLHKTAMQNGAGGALFVHRDTPENNPDTPFDFTPENYKRIEAIKVNY  
PEGHKAAAVLPVLDLAQRQNGWLPISAMNKVAEVLQVPPMRVYEVAFTYTMYNRKPVGKYHIQVCTTTTPC  
MLRNSDSILEAIQKKLGIKVGETTPDKLFTLIEVECLGACVNAPMVQINDNYEDLTAKDIEEIDELKA  
GKIPKGPGRSGRFSCEPAGGLTSLTERPPVCCQSFEACRV

55

&gt;DEX0360\_032.aa.3

60 MFFSAALRARAAGLTAHWGRHVRNLHKTAMQNGAGGALFVHRDTPENNPDTPFDFTPENYKRIEAIKVNY  
PEGHKAAAVLPVLDLAQRQNGWLPISAMNKVAEVLQVPPMRVYEVAFTYTMYNRKPVGKYHIQVCTTTTPC  
MLRNSDSILEAIQKKLGREYMI FVTLIKSRIVSLDLVHFYLFKPTSAILLDLYLP SNILCYCVSTSLFLP  
IYWSSSVLSVKA EFLIFSFLIS

DEX-0360

230

PATENT

- >DEX0360\_033.aa.1  
MKVLGRSFFWVLPVLPVAVQAVEHEEVAQRVVKLHRGRGVAAMQSRQWVRDSCRKLSGLLRQKNAVLNK  
LKTAIGAVEKDVGLSDEEKLQVHTFEIFQKELNESENSVFQAVYGLQALQGDYKDVNMKESSRQRLE  
5 ALREAAIKEETEYMEMLAAEKHQVEALKNMQHONQSLSMLEILEDVRKAADRLEEEIEEHAFDNKSVK  
GVNFEAFLRVEEEEANSKQNTKREVEDDLGLSMLIDSQNNQYILTKPRDSTIPRADHHFIKDIVTIGML  
SLPCGWLCTAIGLPTMFGYIICGVLLGPSGLNSIKSIVQVETLGEFGVFFTLFLVGLFESPEKLRKVWVKI  
SLQGPCYMTLLMIAFGLLWGHLLRIKPTQSVFISTCLSLSTPLVSRFLMGSARGDKEGDIDYSTVLLGM  
LVTQDVQLGLFMAVMPPTLIQAGASASSSIVVEVLRLVLIGQILFSLAAVFLLCVLKYLIGPYRKLH  
10 MESKNGKEILILGISAFIFLMLTVTELLDVSMELGCFLAGALVSSQGPVVTEEIATSIPIRDFLAIVFF  
ASIGLHVFPPTFVAYELTVLVFLTLSSVVMKFLAALVLSLILPRSSQYIKWIVSAGLAQVSEFSFVLGSR  
ARRAGVISREGEWLPPAERFSGGTGCTLGLSRVWRRRLGSTAGPGGRVLLQGGTQRPSCSLLIQHVAFSE  
ESCS
- 15 >DEX0360\_033.aa.2  
GHSCPAQLRAQEPGHQRLAGVRDATRCRGGGSGRAGEEERLVEKSRGLHVFPPTFVAYELTVLVFLTLSSV  
VVMKFLAALVLSLILPRSSQYIKWIVSAGLAQVSEFSFVLGSRARRAGVISREVYLLILSVTTLSLLLA  
PVLWRAAITRCVPRPERRSSL
- 20 >DEX0360\_033.aa.3  
MDSRPRYIPFKQYAGKYVLLSTWPATEA
- >DEX0360\_034.aa.1  
25 WVIGFSPLRPTHCTXTLRDPRGAGADVRSAPSRRGRAGQWGPHRGGVLVSGPGWRTRTLVPAGRRWVHG  
RPHPRIPSPAPSLDSPVNPAASRRPTWSWPVL
- >DEX0360\_034.aa.2  
MKSSGSHREWVGKPGTPGDRAREGGSGDPAPARGASSGAALRGQNVAVAETRRGRPNATLGPSPLQRP  
PVTCPRFASHPEAGARAEPAMSGEPQTSVAPPPEEVEPGSGVRIVVEYCEPCGFATYLELASAVKEQ  
30 YPGIEIESRLGGTGAFIEIEINGQLVFSKLENGGFPYKDVSIYSVGRTSWSPYNSASSCHSTPLAH
- >DEX0360\_035.aa.1  
MSGDALLHLLPHSQGGHDHSHQHAGHGHSHGHESNKFLEEYDAVLKGLVALGGIYLLFIIEHCIRMFKH  
YKQQRGKQKQWFMKQNTTEESTIGRKLSDHKLNNTPDSDWLQKPLAGTDDSVVSEDRLNETELTDLEGQQE  
35 SPCKNYLCIEEEKIIDHSHSDGLHTIHEHDLHAAAHNHGGENKTVLRKHNHQQWHKHSHSHSGPCHSGSD  
LKETGIANIAWMVIMGDGIHNFSDGLAIGAAFSAGLTGGISTSIIVFCHELPHELGDFAVLLKAGMTVKQ  
AIVYNLLSAMMAYIGMLIGTAVGQYANNITLWIFAVTAGMFLYVALVDMLEPEMLHGDGDNEEHGFCPVGQ  
FILQNLGLLFGFAIMLVIALYEDKIVFDIQF
- 40 >DEX0360\_036.aa.1  
MVSNSAGSNSRQLPLPLSADAPPASSSHWSWQPSRHTNQPIDRAILRSRPPCRLSRTCHWSLQPPPPPPA  
RQWLGGLAGAGRSSCACALGLPSAGCSAGRARLRGAALTEEAAGGPEAQEEDEDEEEALPHSEAMDVFQ  
EGLAMVVQDPLLCDLPIQVTLLEVNSQIALEYGQAMTVRVCKMDGEVMPVVVVQSATVLDLKKAIQRYVQ  
45 LKQEREGGIQHISWSYVWRTYHLTSAGEKLTEDRKKLRDYGIRNRDEVSFIKKLQK
- >DEX0360\_037.aa.1  
MVSNSAGSNSRQLPLPLSADAPPASSSHWSWQPSRHTNQPIDRAILRSRPPCRLSRTCHWSLQPPHPPRR  
ASGWAASLGRAAVPARARLASLVRAGSAGRARLRGAALTEEAAGGPEAQEEDEDEEEALPHSEAMDVFQ  
50 EGLAMVVQDPLLCDLPIQVTLLEVNSQIALEYGQAMTVRVCKMDGEVMPVVVVQSATVLDLKKAIQRYVQ  
LKQEREGGIQHISW
- >DEX0360\_037.aa.2  
MVSNSAGSNSRQLPLPLSADAPPASSSHWSWQPSRHTNQPIDRAILRSRPPCRLSRTCHWSLQPPHPPRR  
ASGWAASLGRAAVPARARLASLVRAGSAGRARLRGAALTEEAAGGPEAQEEDEDEEEALPHSEAMDVFQ  
55 EGLAMVVQDPLLCDLPIQVTLLEVNSQIALEYGQAMTVRVCKMDGEVMRKCYPPPPFRMWSRLSQQEDLT  
VLVSLLRNSQAMPRTGATTNLPQACQRCWFLSCHRRLLWLWLTMDLLPSVSVVAAVVVVQSATVLDLKKAI  
IQRYVQLKQEREGGIQHISW
- 60 >DEX0360\_038.aa.1  
MPAYTATAGTLRDTQLHTHIAVHNPTYNQKTKHETFPWALNPHVNVHTQTHALLSHFLFHTPSSRPPTPD

DEX-0360

231

PATENT

- FRHPQSQSELAPAQPSLDTHAPPTHALPSPAGGGGFGREPAEPASDSRCGSDSALHVLQAATVSEARRGR  
ELE
- 5 >DEX0360\_038.aa.2  
SSSACHPGSSGGGIALKICPIVKQEHWNHSTIRPCHRRTKKEGRGDHAPASRESPPFFSASYLGKYKGV  
AGTTSQRVHGSGRGRWVLHGATPGTFLLSHSLTITSSCSQSHSHQ
- 10 >DEX0360\_039.aa.1  
KPHSLRKPSSKANILVICEKIEHSVSLLLSASQHLLEQHELLTLTHKSPTLISPTGEFGGLYCHVPGIII  
CSSLYEE
- 15 >DEX0360\_040.aa.1  
MVLCKIKQHVGEIVSAWWLLEPPERCCGSSTSATNSTSVSSRKAENKYAGGNPVCVRPTPKWQKGIGEFF  
RLSPKDSEKENQIPEEAGSSGLGKAKRKACPCAT
- 20 >DEX0360\_041.aa.1  
PPPRLLIYKGQXVILDAARAAQCDGLVAAEVPDYNARI
- 25 >DEX0360\_041.aa.2  
MSASAPAAEGEGTPTQPASEKEPEMPGPREESEEEEEDEDEEEEEKEKSLIVEGKREKKKVERLTMQV  
SSLQREPFTIAQGGKQKLCEIERIHFFLSKKKTDELRLNLHKLLYNRP GTVSSLLKNVQFSGFPFEKGSV  
QYKKKEEMLKKFRNAMLKSICEVLDLERSGVNSELVKRIILNFMHPKPSGKPLPKSKKTCSKGSKKERNS  
SGMARKAKRTKCPEILSDESSSDEDEKKNKEESSDDEDEKSEEEPPKKTAKREKPKQKATSKSKSVKSA  
NVKKADSSTTKKNQNSSKKESESEDSSDDEPLIKKLKPPPTDEELKETIKKLLASANLEEVMTMQICKKV  
YENYPTYDLTERKDFIKTTVKELIS
- 30 >DEX0360\_041.aa.3  
MSASAPAAEGEGTPTQPASEKEPEMPGPREESEEEEEDEDEEEEEKEKSLIVEGKREKKKVERLTMQV  
SSLQREPFTIAQGGKQKLCEIERIHFFLSKKKTDELRLNLHKLLYNRP GTVSSLLKNVQFSGFPFEKGSV  
QYKKKEEMLKKFRNAMLKSICEVLDLERSGVNSELVKRIILNFMHPKPSGKPLPKSKKTCSKGSKKERNS  
SGMARKAKRTKCPEILSDESSSDEDEKKNKEESSDDEDEKSEEEPPKKTAKREKPKQKATSKSKSVKSA  
NVKKADSSTTKKNQNSSKKESESEDSSDDEPLIKKLKPPPTDEELKETIKKLLASANLEEVMTMQICKKV  
YENYPTYDLTERKDFIKTTVKELIS
- 35 >DEX0360\_042.aa.1  
MAAAWPPPPCTSEWVLLTTVTSTVFLYFESVRTFVHESPALILLFALGSLGLIFALTILNRHKYPLNLYLL  
FGFTLLEALTVAVVVTFYDVYIILQAFILTTTVFFGLTVYTLQSKKDFSKFGAGLFALLWILCLSGFLKF  
FFYSEIMELVLAAGALLFCGFIIYDTHSLMHKLSPEEYVLA AISLYLDIINLFLHLLRFLEAVNKK
- 40 >DEX0360\_043.aa.1  
MLLERSVDGWSRPRYIDFTADQVDLTSALTKKITLKTPLVSSPMDTVTEAGMAIAMALTGGIGFIHNS  
S
- 45 >DEX0360\_044.aa.1  
MESGRGSSTPPGPAAALGMPDTGPGSSSLGKLQALPVGPRAHCGDPVSLAAAGDGSPDIGPTGELSGSLK  
IPNRDSGIDSPSSSVAGENFPCEEGLEAGPSPTVLGAHAEMALDSQVPKVTPEEADSDVGEEDSENTP  
QKADKDALAQHSGPQKLLHIAQELLHTEETYVKRLHLLDQVFCTRLTDAGIPPEVIMGIFSNISSIHRF  
HGQFLLPELKTRITEEWDTPRLGDILQKLAPFLKMYEYVKNFDRAGLVSTWTQSRPLFKDVVHSIQK  
QEVCGNLTQLQHMLEPVQVRPRYELLLKDYLRKPQDAPDRKDAERSLELISTAANHSNAAIRKVEKMHK  
50 LLEVYEQLGGEEDIVNPANELIKEGQIQKLSAKNGTPQDRHLFLFNSMILYCVPKRLMGQKFSVREKMD  
ISGLQVQDIVKPNTAHTFIITGRKRSLELQTRTEEEKKEWIIQIATIEKHKQNSETFKAFFGAFSODED  
PSLSPDMPITSTSPVEPVVTEGSSGAAGLEPRKLSSKTRRDKEKQSCKSCGETFNSITKRRHHCKLCGA  
VICGKSEFKAENSRQSRVCRDCFLTQPVAPESTEKTPTADPQPSLLCGPLRLSESGETWSEVWAAIPMS  
55 DPQVLHLQGGSDGRLPRTIPLPSCKLSVPDPEERLDSGHVWKLQWAKQSWYLSASSAELQQQWLETLS  
AAHGDTAQDSPGALQLQVPMGAAP
- 60 >DEX0360\_044.aa.2  
MPITSTSPVEPVVTEGSSGAAGLEPRKLSSKTRRDKEKQSCKSCGETFNSITKRRHHCKLCGAVICGK  
SEFKAENSRQSRVCRDCFLTQPVAPESTEVEGAPSSCSPGGAAEPDTCSCAPAALAASAFVSLGPG

DEX-0360

232

PATENT

>DEX0360\_045.aa.1  
SRGSRLPSPNFPDLYSLAHSYLGGGGRKGRTKREAAANTNRPSPGGHERKLVTKLQNSERKKRGARR

5 >DEX0360\_045.aa.2  
MGSHYVSQADPKFLGSSNSPALASQSABITGVSHPAQPTHPLANLFLGPSRHPCLIPYPRSAMLLSLGP  
HTHLGSHIPQRGSSRLPALPIPTTLNPLCLSSDRASHHAYAHFTSDSCLGYRRWRPERSHQERSCCQHQP  
PQPWRAREETGDQAAEFREEEARGTALRQSWRVRSRGAQRAQGASAMKDRPEGV

10 >DEX0360\_046.aa.1  
MKAKRSHQAIIMSTSLRVSPSIHGYPHFTASRKKAVGNIFENTDQESLERLFRNSGDKKAEERAKIIFAI  
DQDVEEKTRALMALKKRTKDKLFQFLKLRKYSIKVH

15 >DEX0360\_046.aa.2  
MKAKRSHQAIIMSTSLRVSPSIHGYPHFTASRKKAVGNIFENTDQESLERLFRNSGDKKAEERAKIIFAI  
DQDVEEKTRALMALKKRTKDKLFQFLKLRKYSIKVH

20 >DEX0360\_046.aa.3  
MLLERRSVMGQVSLGAEFRKIPTSMKAKRSHQAIIMSTSLRVSPSIHGYPHFTASRKKAVGNIFENTDQ  
ESLERLFRNSGDKKAEERAKIIFAI DQDVEEKTRALMALKKRTKCFQQGFENSSVPAGKD

25 >DEX0360\_047.aa.1  
DACRAGRSVDGYKAVRFSSPSRALLGTREIWLWSRWSSLTPHRANLNLVLEKAFSNSTPPYKMHMEVG

30 >DEX0360\_048.aa.1  
MGNSKKNTEGTGKTTFFTNELFIHFQWIQTKLQKTQRKSGQAKSLISYTCGKALSSVLTESRWGDFMTTIK  
KIQLLGNCFCCLDDVVQTRDKQLRNLRCIGKDTGLWHHKGTRILRVNAEGMIPIGGDPQVRLGCLCFRK  
AWAIGMQGSYDSMTPPPSNSVIATADGYLARWPQSTSLSESELLAVLSALSSGTSNLVVFVKDPKVLWG  
VITFFYNIPGSTSSATNSVMVVSAGPWSSEKAETNILEINEKLRPQLAENKQQFRNLKEKCFVTQLAGFL  
ANRQKKYKYECKDLIKFMLRNERQFKEEKLAELQKAEELRQYKVLVHSQERELTQLREKLREGDASC  
35 SLNQHLQALLTPDEPDKSQGDQLQELAEGCRLAQHLVQKLSPENDNDDDEDVQVEVAEKVQKSSAPREM  
PKAEKEVPEDSLEECATCSNSHGPYDSNQPHRKTITFEEDKVDSTLIGSSSHVEWEDAVHIIIPENES  
DDEEEEEKGPVSPRNLQSEEEEEVPQESWDEGYSTLSIPPEMLASYQSYSGTFHSLLEEQQVCMVDIGGH  
RWDQVKKEDQEATGPSQLSRELLDEKGPEVLQDSLDRCYSTPSGYLELTDSCQPYRSAFYILEQQRVGWA  
LDMDEIEKYQEVEEDQDPSCPRLSRELLDEKEPEVLQDSLDRCYSTPSGYLELPDLGQPYRSVAVHSLEE  
40 YLGLALDVEDRIKKDQEEEDQGPCCPRLSRELLAVEPEVLQDSLDRCYSTPSSCLEQPDSCLPYGSSFY  
ALEEKHVGFSLDVGEIEKKKGKRRGRSTTKRRRRRGRKEGEDQNPPCPRLSRELLDEKGPEVLQDSL  
DRCYSTPSGYLELTDSCQPYRSAFYILLEQQRVELRP

45 >DEX0360\_048.aa.2  
MLRCIGKDTGLWHHKGTRILRVNAEGMIPIGGDPQVRLGCLCFRKAWAIGMQGSYDSMTPPPSNSVIAT  
ADGYLARWPQSTSLSESELLAVLSALSSGTSNLVVFVKDPKVLWGVTFFYNIPGSTSSATNSVMVVS  
GPWSSEKAETNILEINEKLRPQLAENKQQFRNLKEKCFVTQLAGFLANRQKKYKYECKDLIKFMLRNER  
QFKEEKLAELQKAEELRQYKVLVHSQERELTQLREKLREGDASC SLNQHLQALLTPDEPDKSQGDQLQ  
EQLAEGCRLAQHLVQKLSPENDNDDDEDVQVEVAEKVQKSSAPREMPKAEKEVPEDSLEECATCSNSH  
45 GPYDSNQPHRKTITFEEDKVDSTLIGSSSHVEWEDAVHIIIPENESDDEEEEEKGPVSPRNLQSEEEEEV  
PQESWDEGYSTLSIPPEMLASYQSYSGTFHSLLEEQQVCMVDIGGHRWDQVKKEDQEATGPSQLSRELLD  
EKGPEVLQDSLDRCYSTPSGYLELTDSCQPYRSAFYILEQQRVGWALDMDEIEKYQEVEEDQDPSCPRLS  
RELLDEKEPEVLQDSLDRCYSTPSGYLELPDLGQPYRSVAVHSLEEQLGLALDVEDRIKKDQEEEDQGP  
50 CPRLSRELLAVEPEVLQDSLDRCYSTPSSCLEQPDSCLPYGSSFYALEEKHVGFSLDVGEIEKKKGK  
RRGRSTTKRRRRRGRKEGEDQNPPCPRLSRELLDEKGPEVLQDSLDRCYSTPSGYLELTDSCQPYRS  
FYILLEQQRVELRP

55 >DEX0360\_049.aa.1  
MAFARRLLRGPLSGPLLGRGVCAGAMAPRRFVLELPDCTLAHFALGADAPGDADAPDRLAALLGPPE  
RSYSLCVPVTPDAGCGARVRAARLHQRLHLQRRGPFQRCQLLRLLCYCPGGQAGGAQQGFLRLDPLDDP  
DTRQALLELLGACQEA PRPHLGEFEADPRGQLWQRLWEVQDGRRLQVGCAQVVPVPEPLHPVVPDLPS  
VVFPDREARAVLEECTSFIPPEARAVLDLVDQCPKQIQKGKQVVAIEGLDATGKTTVTQSVADSLKAVL  
LKSPPCIGQWRKIFDDEPTIIRRAFYSLGNIVASEIAKESAKSPVIVDRYWHSTATYAIATEVSGGLQ  
60 HLPPAHHPVYQWPEDLLKPDLLILLTVSPEERLQRLQGRGMEKTRREEAELEANSVFRQKVMSYQRMENP  
GCHVVDASPSREKVLQTVLSLIQNSFSEP

DEX-0360

233

PATENT

&gt;DEX0360\_050.aa.1

5 MQGSEKCPQKTTRRDETKPVPTSEVKRSKMATSVVPKKNEMKKS VHTQVNTNTTLPKSPQPSVPEQSDN  
ELEQAGKSKRGSI LQLCEEIAGEIESDNVEVKKESSQMESVKEEKPT EIKLEETSVERQILHOKETNQDV  
QCNRRFFPSRKTKPVKCI LNGINSSAKKNSNWKIKLSKFNSVQHNLDSQVSPKLG LLLTSFSPPALEMH  
HPVTQSTFLG TKLHNRNITCQQEKMKEINSEEVKINDITVEINKTTERAPENCHLANEIKPSDPPLDNQM  
KHSFDSASNKNFSQCLESKLENSPVENVTAASTLLSQAKIDTGENKFPGPSAPQQHSILSNQTSKSSDNRE  
TPRNHSLPKCNSHLEITIPKDLKLKEAEKTDEKQLIIDAGQKRFGAVSCNVCGMLYTASNPEDETQHLLF  
10 HNQFISAVKYV VLLINHHECGSEEEFITSLFLSMFNFRYTQRSFSFPIRFLEGWKKERILAEPDGRIM  
VLPEDPKYALKKVDEIREMVDNDLGFQQAPLMCYSRTKTLFISNDKKVVGCLIAEHQWGYRVIEEKL P  
VIRSEEEKVRFERQKAWCCSTLPEPAICGISRIWVFSMMRRKKIASRMIECLRSNFIYGSYLSKEEIAFS  
DPTPDGKLFATQYCGTGQFLVYNFINGQNST

&gt;DEX0360\_051.aa.1

15 MFSSCFWFKHAKMCNNYRGPAVLATKAAAGTKKYDLSKWKYAELRDTINTSCDIELLAACREEFHRLKV  
YHAWKSKNKKRNTETEQRAPKSVTDY AQQNPAQIPARQREIEMNRQORFFRIPIRPAQYKDPQSKKK  
GWWYAHFDGFPWIARQMELHPDKPILLVAGKDDMEMCELNLEETGLTRKRGAEILPRQFEEIWERCGGIQ  
YLQNAIESRQARPTYATAMLQSLLK

&gt;DEX0360\_052.aa.1

20 MTTVERGCGSGAAWRAVQCRAGVSQGLVATVERGCGSGGSPACSPVPGRSLAECSLTPPRGSPGPYRLPQ  
LQSWVPSDAVAGQREAEAGSPREAWAPSPGHGCPSPRSSSLQPQSQGDVGTGVKSGWSVALRPQERYGLKP  
AARACHTRVGPPLHILR

&gt;DEX0360\_053.aa.1

25 MDRPPGQVKAATSDLEHYDKTRHEEFKKYEMMKEHERREYLKTLNEEK RKEEESKFEE MKKHENHPKVN  
HPGSKDQLKEVWEETDGLDPNDFDPKTF FKLHDVNSDGLFDEQELEALFTKELEKVYDPKNEEDDMVEME  
EERLRMRHEVMNEVD TNKDRLV TLEEF LKATEKKEFLEPDSWETLDQQQFFTEELKEYENI IALQENEL  
KKKADELQKQKEELQRQHDQLEAQKLEYHQVIQQMEQKKLQQGIPPSGPAGELKFEPHI

&gt;DEX0360\_053.aa.2

30 MRWRTILLQYCFLLITCLLTALEAVPIDIDKTKVQNIHPVESAKIEPPDTGLYYDEYLKQVIDVLETDKH  
FREKLQKADIEEIKSGRLSKELDLVSHHVRTKLDELKRQEVGRLRLMIKAKLDSLQDIGMDHQALLKQFD  
HLNHLNPDKFESTDL DMLIKAATSDLEHYDKTRHEEFKKYEMMKEHERREYLKTLNEEK RKEEESKFEE M  
35 KKHENHPKVNHPGSKDQLKEVWEETDGLDPNDFDPKTF FKLHDVNSDGLFDEQELEALFTKELEKVYDP  
KNEEDDMVEMEEERLRMRHEVMNEVD TNKDRLV TLEEF LKATEKKEFLEPDSWEVIQQMEQKKLQQGIPP  
SGPAGELKFEPHI

&gt;DEX0360\_054.aa.1

40 MQTSVTWEIPFPTNSLVVKLHSMKDITYYHKIKKCIFSALRARNTRRSIKLDGKGEPKGAKRAKPVKYTA  
AKLHEKGVLLDIDDLQTNQFKNVTFDIIATEDVGFIDVRSKFLGVEMEKVQLNIQDLLQM QYEGVAVMKM  
FDKVKVNVNLLIYLLNKKFYGK

&gt;DEX0360\_055.aa.1

45 QSSAEAGGGDEREINTYGRWALMQCERRSVMDVRGRGTSELP

&gt;DEX0360\_056.aa.1

50 MRMAALPTFRKLFRKLYGHIRQGNYSAGLPRCVYCVNITYNYLGKKRNSTLYITMLLIVPVIVAGAIIVL  
LLYLKRLKIIIFPPIPDGKIFKEMFGDQND DTLHWKKYDIYEKQTKETDSVVL IENLKKASQ

&gt;DEX0360\_057.aa.1

55 MLMAGKGLKPTQNAS EKLQAPGKGLTSNKS KDDLVAEVEINDVPLTCRNLLTRGQTQDEISRLSGAAVS  
TRGRFMTTEEKAKVGPGRPLYLHVQGQTR ELVDRAVNRIKEITNGVVHQPAPIAQLSPAVSQKPPFQS  
GMHYVQDKL FVGLEHAVPTFNVKEKVEGPGCSYLQHIQIETGAKVFLRGKSGCIEPASGREAFEPMYIY  
ISHPKPEGLAAAKKL CENLLQTVHAEYSRFVNQINTAVPLPGYTQPSA ISSVPPQPPYPSNGYQSGYPV  
VPPQPPVQPPYGVPSIVPPAVSLAPGVLPALPTGVPPVPTQYPITQVQPPASTGQSPMGPPFIPAAPVK  
TALPAGPQPQPQPPLPSQFQAQKRRFTEELPDERESGLLYGYVK

&gt;DEX0360\_057.aa.2

60 MHYVQDKL FVGLEHAVPTFNVKEKVEGPGCSYLQHIQIETGAKVFLRGKSGCIEPASGREAFEPMYIYI

SHPKPEGLAAAKKLCENLLQTVHAEYSRFVNQINTAVPLPGYTQPSAISSVPPQPPYYPSNGYQSGYPVV  
PFPQPVQPPYGVPSIVPPAVSLAPGVLPALPTGVPPVPTQYPITQVQPPASTGQSPMGGPFIAPAPVKT  
ALPAGPQPQPQPPLPSQPQAQKRRFTEELPDERESGLLGYPVK

5 >DEX0360\_058.aa.1  
GKKKFNFGRLCYLESKFSLVKMDCIILLTKISRIMCGLLISGMLRSYSLTIKILN

>DEX0360\_059.aa.1  
10 MGRVRTLAGECSAQQAQSL LAVVLSAPPSGGTPSARLSVRSPSPRDPWGLWAPVLQMTGSNEFKLNQPP  
EDGISSVKFSPNTSQFLLVSSWDTSVRLYDVPANSMRLKYQHTGAVLDCAFYDPTHAWSGGLDHQMKMHD  
LNTDQENLVGTHDAPIRCVEYCPEVNVMTGSDQTVKLWDPRTPCNAGTFSQPEKVYTLVSGDRLIVG  
TAGRRVLVWDLRNMGYVQQRRESSLKYQTRCIRAFPNKQGYVLSSIEGRVAVEYLDPSPEVQKKKYAFKC  
HRLKENNIEQIYPVNAISFHNIHNTFATGGSDGFVNIWDPPNKKRLCQFHYPTSIA SLAFSNDGTTLAI  
15 ASSYMYEMDDTEHPEDGIFIRQVTD AETKPKSPCT

>DEX0360\_060.aa.1  
MARRPAGRENSGVPRGLPKFSPPTFSAATNVRAAQGRPRRAPDATRRRTARAGTTPPRHGQPPAHARAAP  
20 AHNRLPSCC SRCRAKARYARPRRAEAAAARARRATPAAPGWRGGGTATRPTRRRAGTNAHDPHRNGEQRP  
SGQRRPRRGSRRRRHETRESERPLRGAGPGVPGPTRGG

DEX-0360

235

PATENT

CLAIMS

We claim:

1. An isolated nucleic acid molecule comprising:
  - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 104-190;
  - (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103;
  - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
  - (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b).
2. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a cDNA.
3. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is an RNA.
5. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a mammalian nucleic acid molecule.
6. The nucleic acid molecule according to claim 5, wherein the nucleic acid molecule is a human nucleic acid molecule.
7. A method for determining the presence of a breast specific nucleic acid (BSNA) in a sample, comprising the steps of:
  - (a) contacting the sample with the nucleic acid molecule of SEQ ID NO: 1-103 under conditions in which the nucleic acid molecule will selectively hybridize to a breast specific nucleic acid; and

(b) detecting hybridization of the nucleic acid molecule to a BSNA in the sample, wherein the detection of the hybridization indicates the presence of a BSNA in the sample.

5 8. A vector comprising the nucleic acid molecule of claim 1.

9. A host cell comprising the vector according to claim 8.

10 10. A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of:

- (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and
- (b) incubating the host cell under conditions in which the polypeptide is produced.

15

11. A polypeptide encoded by the nucleic acid molecule according to claim 1.

12. An isolated polypeptide selected from the group consisting of:

- (a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 104-190 ; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103.

25 13. An antibody or fragment thereof that specifically binds to:

- (a) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 104-190 ; or
- (b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103.

30

14. A method for determining the presence of a breast specific protein in a sample, comprising the steps of:

- (a) contacting the sample with a suitable reagent under conditions in which the reagent will selectively interact with the breast specific protein comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 104-190; and
- 5 (b) detecting the interaction of the reagent with a breast specific protein in the sample, wherein the detection of binding indicates the presence of a breast specific protein in the sample.
15. A method for diagnosing or monitoring the presence and metastases of breast cancer in a patient, comprising the steps of:
- 10 (a) determining an amount of:
- (i) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 104-190;
- (ii) a nucleic acid molecule comprising a nucleic acid sequence of SEQ
- 15 ID NO: 1-103;
- (iii) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (i) or (ii);
- (iv) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (i) or (ii);
- 20 (v) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 104-190 ; or
- (vi) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103
- 25 and;
- (b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the breast specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the
- 30 presence of breast cancer.

16. A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence of:
- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 104-190;
  - 5 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103;
  - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
  - (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b); or
  - 10 (e) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 104-190 ; or
  - (f) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103.
  - 15
17. A method of treating a patient with breast cancer, comprising the step of administering a composition consisting of:
- (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes an amino acid sequence of SEQ ID NO: 104-190;
  - 20 (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103;
  - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b);
  - (d) a nucleic acid molecule having at least 95% sequence identity to the nucleic acid molecule of (a) or (b);
  - 25 (e) a polypeptide comprising an amino acid sequence with at least 95% sequence identity to of SEQ ID NO: 104-190 ; or
  - (f) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule having at least 95% sequence identity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1-103;
  - 30
- to a patient in need thereof, wherein said administration induces an immune response against the breast cancer cell expressing the nucleic acid molecule or polypeptide.



60451123-123532

DEX-0360

239

PATENT

18. A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 12.

DEX-0360

240

PATENT

## ABSTRACT OF THE INVENTION

The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to

5 antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying,

10 diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast, identifying breast tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**